Biosynthesis of Xenovulenes in Acremonium strictum by Schor, Raissa
		
	
	
	
Biosynthesis	of	Xenovulenes	in	Acremonium	strictum	
	
	
	
Von	der	Naturwissenschaftlichen	Fakultät	der		
Gottfried	Wilhelm	Leibniz	Universität	Hannover	
	
zur	Erlangung	des	Grades	
Doktorin	der	Naturwissenschaften	(Dr.	rer.	nat.)	
genehmigte	Dissertation	
	
	
	
von	
Raissa	Schor,	M.	Sc.	
	
	
	
2018	
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Referent:	Prof.	Dr.	Russell	Cox	
Korreferent:	Prof.	Dr.	Andreas	Kirschning	
Tag	der	Promotion:	16.	März	2018	
	
	 	 	 	 Abstract	
	 i	
Abstract	
Keywords:	natural	products,	biosynthesis,	ascomycetes,	meroterpenoids	
Xenovulenes	 (101,	 107,	 108	 and	 109)	 are	 a	 family	 of	 fungal	 meroterpenoids	 produced	 by	 the	
ascomycete	Acremonium	strictum.	Xenovulene	A	101	binds	the	g-butyric	acid	receptor	in	vitro.	The	
compound	exhibits	an	unusual	tetrahydrofuro-cyclopentenone	attached	to	a	humulene	ring,	which	
aroused	interest	in	its	biosynthesis.	In	a	combined	genetic	and	chemical	approach,	the	biosynthesis	
of	xenovulene	A	101	and	co-metabolites	107-109	was	investigated	in	this	work.	
	
The	A.	 strictum	 genome	 as	well	 as	 the	 transcriptome	 under	101	 producing	 and	 non-producing	
conditions	were	sequenced.	It	allowed	the	in	silico	prediction	of	biosynthetic	gene	clusters	(BGC)	
and	identified	the	aspks1	BGC	as	a	good	candidate	for	101	biosynthesis.	
This	was	confirmed	by	knockout	of	aspks1	in	A.	strictum.	Heterologous	co-expression	of	eight	genes	
of	 the	aspks1	 BGC	 led	 to	 the	 production	 of	 101	 in	Aspergillus	 oryzae.	 Four	 of	 the	 eight	 genes	
(Aspks1:	 NR-PKS,	 asL1:	 FAD	 dependent	 monooxygenase,	 asL3:	 non-heme	 FeII	 dependent	
dioxygenase,	 asR2:	 cytochrome	 P450)	 were	 shown	 to	 encode	 proteins	 homologous	 to	 the	
tropolone	pathway	in	Talaromyces	stipitatus.	
Two	genes	(asR5,	asR6)	encoding	proteins	of	unknown	function	were	identified	to	be	crucial	 for	
meroterpenoid	production.	In	vitro	assays	of	AsR6	identified	its	role	as	an	unprecedented	humulene	
synthase,	without	homologies	to	any	known	terpene	cyclase.	In	vivo	evidence	suggested	AsR5	to	
be	involved	in	the	joining	of	polyketide	and	terpene	precursors.	
For	the	two	ring	contraction	steps,	two	FAD	dependent	monooxygenases	encoded	by	asL4	and	asL6	
were	 discovered.	 In	 vivo	 evidence	 suggested	 these	 to	 be	 aromatic	 hydroxylases	with	 a	 distinct	
regioselectivity.	
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Zusammenfassung	
Schlagwörter:	Naturstoffe,	Biosynthese,	Ascomyceten,	Meroterpenoide	
Die	pilzlichen	Naturstoffe	der	Xenovulene	 (101,	107,	108	und	109),	produziert	von	Acremonium	
strictum,	 gehören	 zu	 den	 Meroterpenoiden.	 Für	 Xenovulen	 A	 101	 wurde	 eine	
In-vitro-Bindungsaffinität	 an	 den	 g-Aminobuttersäure	 Rezeptor	 gezeigt.	 Der	 Naturstoff	 besitzt	
einen	 seltenen	 Tetrahydrofurancyclopentenon	 Bizyklus,	 welcher	 über	 ein	 Tetrahydropyran	 mit	
Humulen	 verbunden	 ist.	 Diese	 ungewöhnlichen	 Strukturelemente	 erweckten	 Interesse	 an	 der	
Biosynthese	 dieses	 Naturstoffes,	 welche	 in	 dieser	 Arbeit	 mit	 chemischen	 und	
molekularbiologischen	Methoden	untersucht	wurde.	
	
Zunächst	 wurden	 das	 A.	 strictum	 Genom	 und	 Transkriptom	 (unter	 101	 produzierenden	 und	
nicht-produzierenden	 Bedingungen)	 sequenziert	 und	 analysiert.	 In	 silico	 wurde	 ein	
Biosynthesecluster	 (aspks1	 BGC)	 identifiziert,	 das	 für	 essentielle	 Proteine	 der	 101	 Biosynthese	
kodiert.	
Ein	Genknockout	von	aspks1	in	A.	strictum	bestätigte	die	bioinformatische	Hypothese	und	das	BGC.	
Die	 heterologe	 Koexpression	 von	 acht	 Genen	 des	 aspks1	 BGC	 in	 Aspergillus	 oryzae	 führte	 zur	
Produktion	 von	 101	 in	 A.	 oryzae.	 Für	 vier	 der	 acht	 Proteine	 (aspks1:	 NR-PKS,	 asL1:	 FAD	
Monooxygenase,	 asL3:	 Häm-unabhängige	 FeII	 Dioxygenase,	 asR2:	 Cytochrome	 P450)	 konnten	
Homolge	in	der	Talaromyces	stipitatus	Tropolonbiosynthese	identifiziert	werden.	
Zwei	 (asR5,	 asR6)	 der	 acht	 Gene	 kodieren	 für	 Proteine	 mit	 unbekannter	 Funktion.	 In	 vitro	
Untersuchungen	 von	 AsR6	 zeigten	 dessen	 Rolle	 als	 neue	 Humulensynthase.	 Im	 Vergleich	 mit	
anderen	Terpenzyklasen	konnten	keine	Ähnlichkeiten	mit	AsR6	 festgestellt	werden.	Damit	 stellt	
AsR6	eine	neue	Klasse	von	Terpenzyklasen	dar.	In-vivo-Experimente	weisen	darauf	hin,	dass	AsR5	
an	der	Kopplung	von	Polyketid	und	Humulen	beteiligt	ist.	
Für	die	zwei	Ringkontraktionen	zu	Cyclopentenon	wurden	zwei	FAD	abhängige	Monooxygenasen	
(AsL4	und	AsL6)	identifiziert.	In-vivo-Experimente	weisen	darauf	hin,	dass	beide	Enzyme	Aromaten	
mit	unterschiedlicher	Regioselektivität	hydroxylieren.
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Abbreviations	and	Units	
A	 	 adenine	
ACP	 	 acyl	carrier	protein	
Ago	 	 argonaute	
asRNA	 	 anti	sense	RNA	
aspks1	 	 A.	strictum	PKS1	gene	
ASPM	 	 A.	strictum	production	medium	
AMA1	 autonomous	maintaining	of	plasmids	in	
Aspergillus	
AMT	 A.	tumefaciens	mediated	
transformation	
ASSM	 	 A.	strictum	seed	medium	
AU	 	 absorption	unit	
BGC	 	 biosynthetic	gene	cluster	
BLAST	 	 basic	local	alignment	search	tool	
BLASTp/n	 	 BLASTprotein/nucleotide	
AT	 	 acyl	transferase	
bp	 	 base	pair	
C	 	 cystosine	
cDNA	 	 complementary	DNA	
CD	 	 conserved	domain	
CLC	 	 Claisen	cyclase	
C-MeT	 	 C-methyltransferase	
CoA	 	 Co-enzyme	A	
COSY	 	 correlation	spectroscopy	
CRISPR	 clustered	interspaced	short	palindromic	
repeats	
d	 day(s)	
DA(ase)	 	 Diels	Alder(ase)	
DAD	 	 diode	array	detector	
DAPI	 	 4,6-diamidino-2-phenlyindole	
dATP	 	 deoxyadenosine	triphosphate	
ddH2O	 	 double	distilled	H20	
dDNA	 	 donor	DNA	
DH	 	 dehydratase	
DNA	 	 deoxyribonucleic	acid	
DMAPP	 	 dimethylallyl	pyrophosphate	
DMOA	 	 3,5-dimethylorsellinic	acid	
DTT	 	 dithioeritol	
DSB	 	 double	strand	break	
dsRNA	 	 double	strand	RNA	
EDTA	 	 ethylenediaminetetraacetic	acid	
ER	 	 enoyl	reductase	
eGFP	 	 enhanced	green	fluorescent	protein	
ESI	 	 electron	spray	ionisation	
ELSD	 	 evaporative	light	scattering	detector	
FAD(H2)	 	 flavin	adenine	dinucleotide	
FAS	 	 fatty	acid	synthase	
FPP	 	 farnesyl	pyrophosphate	
G	 	 guanine	
GABA	 	 y-ammino	buturic	acid	
GC	 	 gas	chromatography	
genR	 	 geneticin	resistance	cassette	
GFPP	 	 geranylfarnesyl	pyrophosphate	
GGPP	 	 geranylgeranly	pyrophosphate	
GPP	 	 geranyl	pyrophosphate	
gDNA	 	 genomic	DNA	
GOI	 	 gene	of	interest	
gRNA	 	 guide	RNA	
hDA(ase)	 	 hetero	Diels	Alder(ase)	
HH	 	 hammer	head	
HDV	 	 hepatitis	delta	virus	ribozyme	
HMBC	 heteronuclear	multiple	bond	
correlation	
HPLC	 high	performance	liquid	
chromatography	
HR	 	 highly	reducing	
HR	 	 homologous	recombination	
h	 	 hour(s)	
	
	
	
HRMS	 	 high	resolution	mass	spectrometry	
HSQC	 heteronuclear	single	quantum	
correlation	
hygR	 	 hygromycin	B	resistance	cassette	
Hz	 	 hertz	
IPP	 	 isopentenyl	diphosphate	
kb	 	 kilo	base	pairs	
KR	 	 β-ketoreductase	
KS	 	 β-ketosynthase	
KO	 	 knock	out	
KOe	 	 knock	out	by	expression	
L	 	 litre	
LC	 	 liquid	chromatography	
M	 	 molar	
m/z	 	 mass	to	charge	ratio	
min	 	 minute	
mg	 	 milligram	
mL	 	 millilitre	
MOS	 	 3-methylorcinaldehyde	synthase	
mRNA	 	 messenger	RNA	
MS	 	 mass	spectrometry	
MS2	 	 MS/MS	
µL	 	 microliter	
NAD(P)(H)	 nicotinamide	adenine	dinucleotide	
(phosphate)	
NHEJ	 non-homologous	end-joining	
nm	 nanometre	
NMR	 nuclear	magnetic	resonance	
NOE	 nuclear	overhauser	effect	
NR	 	 non-reducing	
NRPS	 	 non-ribosomal	peptide	synthetase	
nt	 	 nucleotide(s)	
ORF	 	 open	reading	frame	
PAGE	 	 polyacrylamide	gel	electrophoresis	
PAM	 	 protospacer	adjacent	motif	
PCR	 	 polymerase	chain	reaction	
PEG	 	 polyethylene	glycol	
PKS	 	 polyketide	synthase	
PP	 	 pyrophosphate	
ppm	 	 parts	per	million	
PR	 	 partially	reducing	
PT	 	 product	template	
Q-TOF	 	 quadrupole	time-of-flight	
R	 	 reductive	release	domain	
RT-PCR	 	 reverse	transcriptase	PCR	
revGOI	 	 reverse	gene	of	interest	
RISC	 	 RNA-induced	silencing	complex	
RNA	 	 ribonucleic	acid	
rpm	 	 revolutions	per	minute	
SAM	 	 S-adenosyl	methionine	
SAT	 starter	unit	acyl	carrier	protein	
transferase	
SDR	 short	chain	dehydrogenase/reductase	
SDS	 sodium	dodecyl	sulphate	
sec	 second	(s)	
siRNA	 short	interfering	RNA	
sp.	 	 species	
USERTM	 	 uracil	specific	excision	reagent	
T	 	 thymine	
TAE	 	 tris-acetate-EDTA	
TE	buffer	 	 tris-EDTA	buffer	
TE	 	 thiolesterase	
THF	 	 tetrahydrofuran	
TMS	 	 trimethylsilyl	
U	 	 uracil	
UPLC	 ultra-performance	liquid	
chromatography	
UV	 	 ultra	violet	
WT	 	 wild-type	
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1 Introduction	
In	the	widest	definition,	natural	products	are	all	substances	produced	by	living	organisms.	Organic	
chemists,	however,	define	natural	products	as	small	molecules	relevant	for	primary	and	secondary	
metabolism.	While	primary	metabolites	are	essential	 for	 the	survival	of	an	organism,	secondary	
metabolites	are	regarded	as	an	accessory	that	often	provides	a	benefit	in	competition	with	other	
organisms.	In	contrast	to	primary	metabolites,	which	are	ubiquitously	produced	over	species	and	
kingdoms,	 secondary	metabolites	 are	 often	 exclusively	 produced	 by	 one	 or	 a	 family	 of	 related	
organisms.1	
Secondary	 metabolites	 often	 display	 antifungal,	 antibacterial	 or	 even	 more	 specific	 biological	
activity.1	 In	 fact,	 65%	 of	 all	 newly	 approved	 small	molecule	 drugs	 between	 1981	 and	 2014	 are	
derived	 from	 nature	 or	 have	 a	 natural	 origin.2	 Typical	 examples	 are	 the	 bacterial	 derived	
vancomycin	1	(antibiotic),3	the	fungal	compound	lovastatin	2	(cholesterol	lowering	agent),4,5	and	
plant	metabolites	like	morphine	3	(painkiller)6,7	and	menthol	4	(cough	suppressant)8	(Figure	1.1)	all	
of	which	are	of	pharmacological	significance.	
	
Figure	1.1	Natural	products	vancomycin	1,	lovastatin	2,	morphine	3	and	menthol	4	of	bacterial,	fungal	and	plant	origin.	
These	 four	substances	also	 represent	 the	 four	major	classes	of	natural	products:	non-ribosomal	
peptides	(1),	polyketides	(2),	alkaloids	(3)	and	terpenes	(4).1	These	groups	are	classified	according	
to	the	biosynthetic	precursors	that	build	up	the	complex	molecules	and	the	enzymes	involved.	The	
precursors	of	non-ribosomal	peptides	are	amino	acids	5	which	are	connected	by	non-ribosomal	
peptide	syntethases	(NRPS).9,10	The	polyketide	backbone	consists	of	formal	acetate	6	units	which	
are	 elongated	 by	 polyketide	 synthase	 (PKS)	 enzymes.11,12	 The	 two	 precursors	
dimethylallyl	pyrophosphate	7	(DMAPP)	and	isopentenyl	pyrophosphate	8	(IPP)	combine	to	form	
different	chain	 length	 terpenes	which	are	cyclised	 to	diverse	structures	by	 terpene	cyclases.13,14	
Alkaloids	are	nitrogen	containing	substances	normally	synthesised	from	amino	acids.	The	carbon	
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skeleton	often	originates	from	prenylation	with	the	terpene	precursor	DMAPP	7	such	as	in	indole	
alkaloids.15	
	
Figure	1.2	Small	building	blocks	for	natural	products.	
	
1.1 Fungal	Natural	Products	in	the	Genomic	Age	
Early	analysis	of	fungal	biosynthetic	pathways	was	mainly	based	on	feeding	studies	with	labelled	
precursor	 molecules.	 Even	 though	 labelling	 and	 novel	 nuclear	 magnetic	 resonance	 (NMR)	
spectroscopy	techniques	still	contribute	and	facilitate	the	understanding	of	natural	products	today,	
it	was	the	development	of	recombinant	deoxyribonucleic	acid	(DNA)	techniques	in	the	late	1980s	
which	promoted	the	elucidation	of	biosynthetic	pathways	at	the	genetic	 level.1	Today	molecular	
biology	 techniques	 including	 gene	 knockout,	 silencing	 and	heterologous	 expression	 are	 used	 to	
elucidate	 the	 function	 of	 encoded	 proteins	 and	 link	 them	 to	 the	 corresponding	 steps	 in	 the	
biosynthesis	of	secondary	metabolites.12	
With	the	development	of	fast	and	cheap	whole	genome	sequencing	and	computational	methods	
for	 data	 processing,	 the	 number	 of	 sequenced	 fungal	 genomes	 has	 increased	 rapidly.16,17	
Identification	of	secondary	metabolite	genes	has	thus	been	greatly	simplified	over	the	last	decade.	
Genes	required	for	the	biosynthesis	of	one	or	a	family	of	metabolites	are	very	frequently	co-located	
in	biosynthetic	gene	clusters	(BGC)	within	fungal	genomes.18,19	Usually	such	a	BGC	consists	of	a	core	
synthase	gene,	encoding	e.g.	a	PKS,	NRPS	or	terpene	cyclase,	and	a	number	of	tailoring	genes.	The	
latter	can	encode	a	series	of	proteins	such	as	cytochrome	P450s	or	methyltransferases	for	further	
tailoring	modifications	(Chapter	1.1.3).	In	addition,	genes	encoding	transporters	and	transcription	
regulators	are	also	often	clustered.	 In	 silico	analysis	of	 fungal	genomes	with	 the	antibiotics	and	
secondary	 metabolites	 analysis	 shell	 (antiSMASH)	 enables	 preliminary	 identification	 of	 those	
BGC.20–22	 However,	 limited	 knowledge	 especially	 in	 fungi,	 restricts	 the	 usefulness	 of	 purely	
bioinformatic	methods,	and	significant	experimental	work	is	still	often	required.	
1.1.1 Polyketide	and	Fatty	Acid	Biosynthesis	
Polyketides	form	a	major	class	of	fungal	metabolites.	Very	diverse	structural	polyketide	scaffolds	
such	as	lovastatin	2,	but	also	small	aromatic	compounds	such	as	3-methylorsellinic	acid	9	are	known	
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(Figure	1.3).	Although	diverse	in	structure,	these	molecules	are	built	up	by	one	class	of	enzymes,	
polyketide	synthases,	deploying	a	restricted	subset	of	reactions.12	
In	 the	1950s	Birch	and	 co-workers	demonstrated	 for	 the	 first	 time	 that	polyketides	are	 formed	
through	the	formal	condensation	of	acetates	6.23	This	confirmed	Collie’s	hypothesis	from	1907	of	
the	 eponymous	 polyketone	 intermediate	 (10)	 built	 from	 C2	 precursors	 and	 it	 also	 led	 to	 Birch	
realising	the	relationship	between	fatty	acid	and	polyketide	biosynthesis.24	
	
Figure	1.3	Polyketides	lovastatin	2	and	3-methylorsellinic	acid	9.	Pentaketone	10,	as	an	example	for	a	polyketone,	and	
fatty	acids	11.	Bold	bonds	resemble	acetate	C2	units.	
Fatty	 acids	 are	 synthesised	 by	 condensation	 and	 reduction	 of	 starter	 acetate	6	 and	 elongation	
malonate	13	 units	 through	multifunctional	 fatty	 acid	 synthase	 (FAS)	 enzymes.	 The	 acetate	 and	
malonate	units	are	activated	as	Co-enzyme	A	(18,	CoA)	thiolester	12	and	13a.	To	initiate	the	fatty	
acid	synthesis	these	activated	precursors	are	transferred	onto	the	acyl	carrier	protein	(ACP)	of	the	
FAS	by	an	acyltransferase	(AT)	enzyme	activity	(Scheme	1.1	Step	0).25	
The	 key	 step	 to	 build	 up	 the	 carbon	 backbone	 of	 fatty	 acids	 is	 a	 decarboxylative	 Claisen	
condensation	 of	 an	 acyl	 12a	 and	 a	 malonyl	 thiolester	 13b	 catalysed	 by	 the	 ketosynthase	 (KS)	
enzyme	 activity	 (Scheme	 1.1	 Step	 I).	 After	 chain	 extension	 the	 growing	 carbon	 backbone	 is	
covalently	bound	to	the	ACP	via	a	flexible	phosphopantetheine	arm	(Figure	1.4).	This	enables	the	
bound	 b-keto	 ester	 (14)	 to	 access	 all	 active	 sites	 of	 the	 FAS	 protein	 for	 further	 b-carbonyl	
modifications	(Figure	1.5).25	
	
Figure	1.4	Phosphopantetheine	arm	of	ACP.	
Ketoreductase	 (KR),	 dehydratase	 (DH)	 and	 enoylreductase	 (ER)	 catalytic	 domains	 then	 further	
modify	the	b-carbonyl	of	14	to	give	the	fully	saturated	thiolester	17	(Scheme	1.1	Steps	II-IV).	The	
carbon	chain	 is	 further	elongated	(and	reduced)	by	C2	units	until	 it	 reaches	a	 length	of	16	to	18	
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carbon	 atoms.	 The	 fully	 saturated	 carbon	 backbone	 is	 then	 released	 as	 a	 free	 acid	 11	 by	 a	
thiolesterase	(TE)	domain	(Scheme	1.1	Step	V).25	
All	known	FAS	produce	fatty	acids	in	an	iterative	process.	This	means	the	individual	b-processing	
domains	are	reused	in	each	elongation	step	until	the	full	length	fatty	acid	is	produced.26	
	
Scheme	1.1	Catalytic	cycle	of	fatty	acid	chain	elongation	and	structure	of	Co-enzyme	A	18.	
Depending	on	the	organism,	FAS	proteins	differ	in	structure	and	are	thus	divided	into	type	I	and	II	
systems.	Type	I	FAS	are	large	multifunctional	proteins	containing	all	domain	activities	for	fatty	acid	
biosynthesis	 in	 one	 megasynthase	 protein.26,27	 In	 contrast,	 type	 II	 FAS	 are	 formed	 by	 a	 set	 of	
dissociated	monofunctional	proteins,	which	most	likely	assemble	non-covalent	complexes	similar	
to	type	I	FAS.	However,	both	FAS	architectures	catalyse	the	same	set	of	reactions	to	build	up	fatty	
acids	11	(Scheme	1.1).28	
In	the	homodimer	crystal	structure	of	mammalian	type	I	FAS	a	spatial	division	into	condensing	and	
modifying	 parts	 of	 the	 enzyme	 is	 observed	 (Figure	 1.5).26	 KS	 and	 AT	 activities	 are	 essential	 for	
carbon-carbon	bond	formation.	For	further	processing	of	the	elongated	carbon	backbone	KR,	DH	
and	ER	domain	activities	are	 required.	The	essential	ACP	and	TE	domains	are	disordered	 in	 the	
model	and	hence	not	visible.26	
Polyketide	synthase	(PKS)	enzymes	not	only	employ	identical	chemistry	as	FAS	but	are	also	closely	
related	in	structure.12,31	PKS	proteins	are	also	divided	in	type	I	(multidomain	megasynthases)	and	
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type	II	systems	(sets	of	monofunctional	proteins).31,32	In	addition,	ACP-independent	type	III	PKS	are	
reported,	which	do	not	resemble	a	known	class	of	FAS.33	
	
	
Figure	1.5	Homodimer	crystal	structure	of	mammalian	FAS	at	3.22	Å	resolution.	PDB	entry	2VZ8.	Image	created	with	NGL	
viewer.29,30	
Most	fungal	PKS	are	iterative	type	I	megasynthases.34	Iterative	PKS	reuse	the	same	set	of	domains	
(like	FAS)	in	each	round	of	elongation	(Figure	1.6A).	In	FAS	all	b-processing	domains	are	active	after	
each	 extension	 step.	 However,	 in	 PKS	 the	b-processing	 is	 variable	 after	 each	 extension	 so	 that	
ketones,	alcohols,	alkenes	and	methylenes	can	be	formed.	This	flexibility	is	programmed	in	the	PKS	
protein	itself	(Figure	1.6A).	This	means	that	based	on	domain	organisation	only,	no	prediction	of	
chain	length,	degree	of	saturation	and	stereochemistry	of	the	final	product	can	be	made.	A	second	
important	class	of	type	I	PKS	are	bacterial	modular	PKS.35	The	major	difference	to	iterative	PKS	is	
that	domains	are	not	reused.	For	each	elongation	cycle	the	required	subset	of	domains	is	organised	
in	one	module	and	multiple	modules	are	present	(Figure	1.6B).	
Fungal	iterative	type	I	PKS	are	further	divided	into	three	functional	classes	based	on	the	presence	
or	absence	of	particular	catalytic	domains.12,34	PKS	producing	highly	 reduced	polyketides	 (highly	
reducing	PKS,	HR-PKS)	possess	 the	 full	 set	of	modifying	domains	 (KR,	ER,	DH)	and	are	known	to	
produce	 compounds	 such	 as	 squalestatin	 S1	 tetraketide	19	 (Figure	 1.7A	 and	B).36	 The	different	
degree	of	saturation	(alkene	at	C-2/3,	methylene	at	C-5,	C-7)	reflects	the	programmed	activity	of	
domains	 in	 each	 individual	 elongation	 cycle.37	 In	 addition,	 a	 common	 modification	 in	 fungal	
polyketides,	which	is	not	observed	in	fatty	acid	biosynthesis,	is	the	methylation	at	a-position	by	a	
S-adenosyl	methionine	(SAM,	20)	dependent	C-methyltransferase	(C-MeT)	(C-4	and	C-6	in	19).12,34	
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Figure	1.6	Type	I	PKS.	A,	Iterative	PKS.	B,	Modular	PKS.	
	
Figure	1.7	HR-PKS	and	C-MeT	domain.	A,	Domain	organisation	of	squalestatin	tetraketide	synthase	(SQTKS).	B,	Its	product	
tetraketide	19.	C,	SAM	20.	
PKS	producing	non	reduced	polyketides	(non-reducing	PKS,	NR-PKS)	are	more	different	to	FAS	than	
HR-PKS	as	they	are	lacking	the	whole	set	of	modifying	domains	(KR,	ER,	DH).	Instead	they	usually	
possess	 a	 starter	 unit	 acyl	 transferase	 (SAT)	 and	 a	 product	 template	 (PT)	 domain.12,34	 The	 SAT	
domain	transfers	more	advanced	precursors	such	as	the	tetraketide	21	 in	asperfuranone	22	and	
hexanoic	acid	23	in	aflatoxin	24	biosynthesis	to	the	ACP	(Schemes	1.2	and	1.3).38,39	The	PT	domain	
was	shown	to	control	the	regioselectivity	of	the	poly-b-keto	chain	cyclisations	(Scheme	1.2A:	C-2/7,	
1.2	 B:	 C-4/9	 27,	 1.2	 C:	 C-6/11)	 towards	 mono/mulitcyclic	 aromatic	 compounds	 such	 as	
intermediates	27,	28	and	29.40,41	
The	offloading	of	polyketides	from	PKS	can	occur	very	similar	as	in	FAS	by	hydrolysis	through	a	TE	
domain.	However,	in	NR-PKS	a	variety	of	different	reactions	are	reported.	Often	a	domain	showing	
similarities	 to	 known	 TE	 domains	 but	 catalysing	 an	 intramolecular	 Claisen	 cyclisation	 (TE/CLC	
domain)	is	involved.	This	usually	results	in	phenolic	compounds	such	as	the	observed	intermediate	
32	in	aflatoxin	biosynthesis.42	Reductive	release	domains	(R),	are	also	known.	R-domains	produce	
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aldehydes	such	as	the	intermediate	31	on	the	biosynthesis	towards	asperfuranone	22.39	In	emodin	
30	biosynthesis	the	NR-PKS	lacks	an	off-loading	domain.	Instead	a	trans	acting	hydrolase,	belonging	
to	the	b-lactamase	family,	releases	the	polyketide	upon	formation	of	the	cyclohexone	intermediate	
33.43	
	
Scheme	1.2	Regioselectivity	of	product	 template	domains.	A,	 In	 asperfuranone	22,	B,	 aflatoxin	24	 and	C,	 emodin	30	
biosynthesis.	
	
Scheme	1.3	NR-PKS	product	release.	A,	Reductive,	B,	Claisen-like	cyclisation	and	C,	by	a	trans	hydrolase.	
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Only	 a	 few	 PKS	 which	 produce	 partially	 reduced	 polyketides	 are	 reported	 (Scheme	 1.4,	
3-methylsalicylic	acid	35,	mellein	37).44,45	Partially	reducing	PKS	(PR-PKS)	possess	an	incomplete	set	
of	modifying	domains	and	often	no	known	off-loading	domain.12	Phylogenetic	analysis	linked	fungal	
PR-PKS	more	closely	to	bacterial	modular	type	I	PKS	rather	than	fungal	iterative	PKS.46,47	
	
Scheme	1.4	Partially	reduced	polyketides.	A,	3-Methylsalicylic	acid	35.	B,	Mellein	37.	
1.1.2 Terpene	Biosynthesis	and	Sesquiterpenes	
A	 variety	 of	 terpene	 scaffolds	 of	 different	 size	 and	 structural	 complexity	 such	 as	 menthol8	 4,	
aristolochene48	 38	 and	 ent-kaurene49	 39	 are	 known.13,14	 Although	 very	 diverse	 in	 structure,	 all	
compounds	are	built	up	from	C5	isoprene	40	building	blocks	(Figure	1.8).	According	to	the	number	
of	isoprene	units	incorporated	in	the	terpene	backbone	these	are	divided	into	mono-	(C10),		sesqui-	
(C15),	di-	(C20)	and	sesterterpenes	(C25).13,14	
	
Figure	1.8	Monoterpene	menthol	4,	sesquiterpene	aristolochene	38,	diterpene	ent-kaurene	39	and	isoprene	40.	
The	formal	C5	units	are	built	up	by	the	two	precursors	DMAPP	7	and	IPP	8,	which	are	produced	by	
the	 mevalonate	 pathway	 in	 fungi.50	 Isoprenyl	 pyrophosphate	 synthases	 catalyse	 multiple	
head-to-tail	condensations	of	IPP	7	and	DMAPP	8	to	yield	the	linear	precursor	molecules:	geranyl	
pyrophosphate	41	(GPP,	C10),	farnesyl	pyrophosphate	42	(FPP,	C15),	geranylgeranyl	pyrophosphate	
43	(GGPP,	C20)	and	geranylfarnesyl	pyrophosphate	44	(GFPP,	C25)	(Scheme	1.5).13,14	
Enzymes	known	as	terpene	cyclases	initiate	dephosphorylation	of	the	linear	precursors	41-44	and	
induce	a	cyclisation	cascade	yielding	very	structurally	diverse	terpene	scaffolds.	Depending	on	the	
employed	 cyclisation	 mechanism,	 terpene	 cyclases	 are	 divided	 into	 two	 types.	 Class	 I	 terpene	
cyclases	use	an	ionisation	dependent	mechanism	and	are	reported	to	cyclise	GPP	41,	FPP	42	as	well	
as	GGPP	43.	Class	II	terpene	cyclases,	in	contrast,	employ	a	deprotonation	dependent	mechanisms	
and	use	GGPP	43	or	GFPP	44	as	substrate.13,14	
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Scheme	1.5	Biosynthesis	of	different	length	linear	terpene	precursors.	
C15	 sesquiterpenes	 are	 usually	 formed	 by	 class	 I	 terpene	 cyclases.	 Four	 initial	 cyclisations	 are	
possible	 (Scheme	 1.6).	 Direct	 formation	 of	 the	 carbocation	 from	 FPP	 allows	 1,10	 or	 1,11	 ring	
formation	to	45	and	46,	respectively	(Scheme	1.6).	Some	enzymes,	however,	catalyse	a	trans-cis	
isomerisation	of	the	2,3-alkene	first,	to	give	the	FPP	isomer	42a	and	enable	an	initial	1,6	or	1,10	
cyclisation	to	carbocations	47	and	48	(Scheme	1.6).	Although	1,7	cyclisations	are	possible	(49),	no	
natural	 product	 arising	 from	 it	 has	been	 reported.14	 Formation	of	 diversified	 structures	 such	as	
aristolochene	38,51,52	presilphiperfolan-8b-ol	50,53,54	(-)-germacrene	D	5155,56	and	trichodiene	5257	
is	achieved	through	hydride	and	methyl	shifts	as	well	as	ring	rearrangements.	
Conserved	 active	 site	 motifs	 of	 class	 I	 terpene	 cyclases	 are	 DDxx(D,E)	 and	 NSE/DTE	 which	 are	
essential	 for	the	coordination	of	Mg2+.58–60	The	divalent	 ions	stabilise	the	pyrophosphate	 leaving	
group	within	the	active	site	cavity	and	 induce	the	 ionisation	of	the	substrate.	Aromatic	residues	
neighbouring	the	active	site	cavity	of	all	sesquiterpene	synthases	stabilise	reaction	intermediates	
before	the	reaction	sequence	is	completed	either	by	attack	of	water	or	deprotonation.14	
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Scheme	1.6	Possible	initial	FPP	42	cyclisations	and	examples	for	products	38,	50,	51	and	52.	AS	=	aristolochene	synthase,	
BcBOT2	=	Botrytis	cinera	botrydial	synthase,	Cop1/4	=	Coprinus	cinerus	terpene	cyclases	14/4,	TS	=	trichodiene	synthase.	
1.1.3 Tailoring	of	Secondary	Metabolites	
The	basic	natural	product	scaffolds	produced	by	core	secondary	metabolite	synthases	are	almost	
always	substrates	of	further	enzymatic	reactions.	These	transformations	are	referred	to	as	tailoring	
and	involve	a	wide	scope	of	reactions.	
Often	 O-methylation	 by	 SAM	 dependent	 methyltransferases,	 as	 in	 the	 biosynthesis	 of	
mycophenolic	acid	54	(Scheme	1.7A),61	or	O-acetylation	by	acyltransferases,	as	in	squalestatin	S1	57	
(Scheme	 1.7B)	 biosynthesis,	 are	 observed.	More	 complex	 compounds	 such	 as	 the	 squalestatin	
tetraketide	19	can	also	be	transferred	by	acyltransferases.62	
	
Scheme	1.7	Methylation	and	acetylation.	A,	In	mycophenolic	acid	54,	and	B,	squalestatin	S1	57	biosynthesis.	
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Another	 frequently	 seen	 class	 of	 enzymes	 are	 nicotinamide	 adenine	 dinucleotide	 (phosophate)	
(NAD(P)H	58,	59/NAD(P)+	60,	61)	dependent	proteins.	These	possess	a	characteristic	Rossman	fold	
to	bind	the	co-factor	which	serves	as	a	hydride	donor/acceptor	(Scheme	1.8).63	Depending	on	the	
substrates	 and	 conditions,	 these	 enzymes	 can	 catalyse	 reductions	 or	 oxidations	 of	 a	 variety	 of	
substrates.	
	
Scheme	1.8	Reduction	and	oxidation	of	NADPH/NADH	59/58.	
Often	carbonyl	to	alcohol	reductions	and	oxidations	are	catalysed.	In	the	biosynthesis	of	leporin	A	
64	the	short	chain	dehydrogenase/reductase	(SDR)	LepF	reduces	62	to	63	(Scheme	1.9A).64	In	the	
biosynthesis	of	terretonin	67,	in	contrast,	a	SDR	(Trt9)	is	reported	to	catalyse	the	oxidative	reaction	
of	65	to	66	(Scheme	1.9A).65	
	
Scheme	1.9	Two	examples	of	NAD(P)H	dependent	SDR	catalysing	the	respective	A,	Reduction	of	62	to	63	and	B,	oxidation	
of	65	to	66.	
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Activation	of	Atmospheric	Oxygen	
Oxidations	are	an	important	tool	of	fungal	tailoring	reactions.	Enzymes	that	typically	catalyse	these	
types	of	reactions	are	mono-	or	dioxygenases,	classified	according	to	the	number	of	oxygen	atoms	
which	are	 incorporated	 in	 the	 substrate.	As	atmospheric	O2	 is	 a	diradical	 a	direct	 reaction	with	
paired	electron	systems	is	spin-forbidden.	Thus,	oxygenases	usually	deploy	a	co-factor	to	activate	
the	oxygen	for	further	reactions.	Often	metal	ions	such	as	iron	or	copper,	as	well	as	flavin	adenine	
diphosphate	(FAD)	68	are	used	for	this	purpose.66	
In	FAD	dependent	monooxygenases	FADH2	69	binds	O2	and	forms	the	reactive	(hydro)peroxyflavin	
70a(b)	species	(Scheme	1.10).	70a	and	70b	can	transfer	oxygen	either	by	a	nuclephilic	attack	(71	to	
72)	to	the	substrate	or	by	a	nucleophilic	attack	(73	to	74)	of	the	substrate.	After	elimination	of	water	
from	75,	FAD	68	is	reduced	to	FADH2	69	by	consuming	reduced	NAD(P)H.67	
Heme	dependent	monooxygenases,	 known	as	 cytochrome	P450s,	 use	 the	metal	 FeII	 to	 activate	
oxygen	 (Scheme	 1.11A).68	 Upon	 addition	 of	 O2	 to	 FeII	 (76)	 it	 is	 oxidised	 to	 FeIII	 and	 the	 radical	
intermediate	78	 is	 formed.	 Reduction	 by	 an	 electron	 (79)	 and	 addition	 of	 two	 protons,	 induce	
cleavage	of	 the	oxygen	bond	upon	release	of	water.	This	 forms	the	reactive	oxo-FeV	81	 species,	
which	can	catalyse	hydroxylations	(82	to	83)	and	epoxidations	(73	to	74)	of	alkanes	and	alkenes	
(Scheme	1.11B).69	The	peroxo-FeIII	species	can	also	react	in	a	Baeyer-Villiger	mechanisms	(71	to	72)	
(Scheme	1.11B).68	
	
Scheme	1.10	Oxygen	activation	by	FADH2	69	and	regeneration.	
Heme	 provides	 an	 electron	 transfer	 system	 for	 cytochrome	 P450	 enzymes,	 however	 also	 a	
multitude	of	non-heme	oxygenases	are	known.	These	use	different	co-factors	such	as	Rieske-type	
ferredoxin	or	a-ketoglutarate	to	form	the	active	iron	species.68		
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Scheme	 1.11	Catalytic	 activity	 of	 cytochrome	 P450s.	A,	 Formation	 of	 the	 active	 oxo-FeV	 species.	B,	 Typical	 reaction	
catalysed	by	cytochrome	P450s.	
The	 scope	 of	 oxygenase	 reactions	 includes	 simple	 C-H	 hydroxylations	 or	 alkene	 epoxidations	
(Scheme	1.11B).	However,	also	more	complex	desaturations	and	skeletal	rearrangements	are	often	
observed.70	The	biosynthesis	of	austinol	84,	for	example,	involves	two	oxygenases:	a	Bayer-Villiger	
monooxygenase	 (AusC)	 and	 a	 non-heme	 iron	 dependent	 dioxygenase	 (NHI,	 AusE).	 These	 two	
proteins	catalyse	four	key	reactions	towards	84	(Scheme	1.12).65	After	AusE	oxidises	85	to	86,	AusC	
induces	the	formation	of	the	cyclic	lactone	87.	This	is	followed	by	two	additional	oxidations	by	AusE,	
including	the	rearrangement	of	the	cyclic	lactone	88	to	the	final	spirolactone	89	(Scheme	1.12).	
	
Scheme	1.12	Selected	 steps	 of	 austinol	84	 biosynthesis.	 AusC,	 Baeyer-Villiger,	monooxygenase;	AusE,	Non-heme	 FeII	
dependent	dioxygenase.	
	
1.2 Fungal	Meroterpenoids	
The	 Greek	 prefix	 mero	 means	 “part,	 partial”.	 Thus	 meroterpenoids	 are	 natural	 products	 of	
combined	biosynthetic	origin	but	partially	derived	 from	terpenoids.	Approximately	81%	of	2009	
reviewed	 fungal	meroterpenoids	 possessed	 a	 polyketide	 part,	 11%	 a	 shikimate	moiety	 and	 the	
origin	of	8%	remained	miscellaneous.71	
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Most	polyketide	terpenoids	(60%)	are	derived	(or	proposed	to	derive)	from	an	aromatic	tetraketide	
precursor	 such	 as	 orsellinic	 acid	 90,	 3-methylorsellinic	 acid	 9,	 5-methylorsellinic	 acid	 91	 or	
3,5-dimethylorsellinic	 acid	 92	 (DMOA)	 (Figure	 1.9A).71	 Often	 oxidations	 and	 complex	
rearrangements	occur	en-route	to	the	final	structures,	such	as	the	rearrangements	observed	during	
biosynthesis	 of	 andrastin	 94	 or	 terretonin	 95.72–75	 In	 these	 examples	 the	 original	 polyketide	
structure	cannot	be	deduced	easily	(Figure	1.9B).	
	
Figure	1.9	Polyketide	meroterpenoids.	A,	Tetraketide	precursors	for	meroterpenoids;	B,	Pyripyropene	93,	austinol	84,	
andrastin	94	and	terretonin	95.	
The	early-stage	biosynthetic	steps	of	DMOA	92	class	meroterpenoids	(e.g.	austinol	84,76	andrastin72	
84	 and	 terretonin73–75	95)	 are	 very	 similar	 and	 BGC	 have	 been	 reported	 for	 a	 number	 of	 these	
compounds	 (Figure	 1.9).	 A	 typical	 meroterpenoid	 BGC	 encodes	 a	 NR-PKS	 that	 produces	 the	
aromatic	 polyketide	 (92)	 and	 an	 aromatic	 prenyltransferase	 which	 attaches	 FPP	 42	 onto	 the	
polyketide	moiety	(92	to	96).	 In	a	subsequent	reaction	the	terminal	alkene	of	the	sesquiterpene	
moiety	is	epoxidised	(96	to	97)	by	an	FAD	dependent	monooxygenase.	Cylisation	is	then	catalysed	
by	an	integral	membrane	protein.	This	class	of	terpene	cyclase	was	first	reported	in	the	biosynthesis	
of	pyripyropene	A	93	(Scheme	1.13).77	Further	diversification	is	catalysed	by	the	set	of	clustered	
genes	encoding	proteins	for	tailoring	reactions.	
A	 NR-PKS/PR-PKS	 and	 an	 aromatic	 prenyltransferase	 are	 also	 encoded	 in	 the	 BGC	 for	 the	
biosynthesis	of	compounds	with	non-cyclic	terpene	moieties	such	as	mycophenolic	acid61,78	54	and	
yanuthone	D	99	(Scheme	1.14).79	As	no	cyclisation	of	the	sesquiterpene	scaffold	is	catalysed	in	these	
cases,	 the	respective	cyclase	genes	are	 lacking	 in	 the	BGC.	For	 the	biosynthesis	of	54,	however,	
further	degradation	of	the	C-15	to	C-7	terpene	chain	is	thought	to	be	catalysed	by	MpaH.61	
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Scheme	1.13	Early	steps	of	DMOA	92	derived	meroterpenoids	austinol	84,	andrastin	94	and	terretonin	95.	FAD	dependent	
monooxygenase	(FAD	MO).	
The	majority	of	fungal	meroterpenoids	(reviewed	in	2009	and	2014)71,80	are	formed	through	the	
attachment	of	a	linear	terpene	precursor	to	the	polyketide	moiety.	Few	examples	(fumagillin	100,81	
xenovulene	A	10182	and	related	structures,	Figures	1.10	and	1.11)	are	known	where	the	terpene	
scaffold	 is	proposed	 to	cyclise	 first.	Fumagillin	100	has	been	 linked	 to	a	BGC,	but	as	 its	 terpene	
moiety	is	attached	via	an	ester	linkage	rather	than	a	C-C	bond	its	biosynthesis	is	likely	to	be	different	
to	xenovulene	A	101.81	
	
Scheme	1.14	Biosynthesis	of	meroterpenoids	with	non-cyclic	terpene	moiety.	A,	Biosynthesis	of	mycophenolic	acid	54.	
MpaDE:	chimeric	P450	and	hydrolase,	MpaA:	prenyltransferase.	B,	Biosynthesis	of	yanuthone	D	99.	YanB:	decarboxylase,	
YanC:	P450,	YanD:	putative	dehydrogenase,	YanE:	unknown,	YanF:	dehydrogenase,	YanG:	prenyltransferase,	YanH:	P450.		
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Figure	1.10	Fumagillin	100	and	Xenovulene	A	101.	
During	 the	 biosynthesis	 of	 fumagillin	 100,	 an	 unusual	 membrane	 bound	 FPP	 cyclase	 forms	
b-trans-bergamotene	 102	 from	 FPP	 42	 (Scheme	 1.15).	 This	 protein	 shows	 homologies	 to	 the	
prenyltransferase	UbiA,83	but	not	 to	class	 I	 terpene	cyclase	or	 to	 the	membrane	bound	terpene	
cyclase	reported	in	pyripyropene	A	93	biosynthesis.77	Further	oxidation	and	rearrangements	yield	
the	fumagillol	103	scaffold	which	is	attached	to	the	HR-PKS	derived	dodecapentenoyl	skeleton	(104)	
by	trans-esterification	yielding	105.	Further	oxidation	gives	the	final	product	fumagillin	100.81	
	
Scheme	1.15	Fumagillin	100	biosynthesis.	Fma-TC,	terpene	cyclase;	Fma-C6H,	dioxygenase;	Fma-MT,	methyltransferase;	
Fma-KR,	ketoreductase;	Fma-AT,	acyltransferase;	Fma-ABM,	monooxygenase.	
	
1.3 Xenovulene	A	and	Related	Meroterpenoids	
Xenovulene	A	101	is	a	polyketide	meroterpenoid	that	was	isolated	from	Acremonium	strictum	in	
1995.	A.	strictum	is	still	the	only	known	producer	of	this	compound	(Figure	1.11).82	It	contains	an	
unusual	 polyketide-derived	 tetrahydro-furocyclopentenone	 moiety	 (red)	 that	 is	 fused	 via	 a	
tetrahydropyran	 (blue)	 to	 an	 11-membered	 cyclic	 sesquiterpene	 (green)	 which	 corresponds	 to	
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humulene	 106.	 Related	 tropolone	 and	 phenolic	 meroterpenoids	 107,	 108	 and	 109	 have	 been	
reported	to	be	produced	alongside	101.84	
Similar	meroterpenoids	have	also	been	reported	from	a	series	of	different	fungi	(Figure	1.12).	These	
include	 pycnidione	 110	 (Phoma	 	 sp.),85	 eupenifeldin	 111	 (Eupenicillium	 brefeldianum)86	 and	
noreupenifeldin	112	 (unidentified	 fungus),87	 epolones	 A	113	 and	 B	 114	 (unidentified	 fungus),88	
ramiferin	115	(Kionochaeta	ramifera),89	pughiinin	A	116	(Kionochaeta	pughii)90	and	phomanolides	
A	 117	 and	 B	 118	 (Phoma	 sp.).91	 These	 compounds	 all	 share	 the	 structural	 feature	 of	 the	
tetra/dihydropyran	that	bridges	the	terpene	and	polyketide	derived	moieties.	Disubstitution	and	
hydroxylation	of	the	humulene	ring	appear	to	be	common	modifications	of	the	system	but	have	
not	been	observed	with	xenovulene	A	101	and	its	congeners	107-109.	
	
Figure	1.11	Xenovulene	A	101	and	co-metabolites	107,	108	and	109.	
	
Figure	1.12	Meroterpenoids	related	to	xenovulene	A	101.	
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All	 of	 these	 compounds	 show	 interesting	 biological	 activites.	 Epolones	 (113,	 114)	 for	 example	
induce	 erythropoetin	 expression,88	 eupenifeldin	 (111)	 showed	 antiproliferative	 activity	 against	
human	glioma	cell	lines91	and	xenovulene	A	101	was	found	to	bind	the	gamma	aminobutyric	acid	
(GABA)	receptor.82,92	
1.3.1 Fungal	Tropolone	Biosynthesis	in	Talaromyces	stipitatus	
A	shared	structural	 feature	of	xenovulene	type	meroterpenoids	 (110-114)	 is	 the	often	observed	
tropolone	core.	Tropolones	like	stipitatic	acid	119	are	known	fungal	polyketide	metabolites.93	
	
Figure	1.13	Feeding	studies	and	deduced	labelling	patter	of	stiptitatic	acid	119.	
The	biosynthesis	of	stipitatic	acid	119	has	been	investigated	since	the	1950s.	Feeding	studies	using	
14C	labelled	precursors	showed	that	119	consisted	of	two	intact	C2	units	and	one	C1	unit	intercepting	
a	 third	 C2	 unit	 (Figure	 1.13).94	 Feeding	with	 18O2	 showed	 the	 incorporation	 of	 one	 atmospheric	
oxygen	 into	 the	 tropolone	 scaffold.95	 Additional	 feeding	 of	 the	 advanced	 precursors	
3-methylorsellinic	 acid	 9	 and	 3-methylorcinaldehyde	 120,	 showed	 that	 the	 aldehyde	 120	 is	
converted	 into	 tropolones	 more	 effectively	 than	 the	 acid	 9.96	 The	 molecular	 basis	 for	 119	
biosynthesis	 was	 dissected	 in	 Talaromyces	 stipitatus	 where	 gene	 knockout	 and	 heterologous	
expression	 experiments	 identified	 the	 BGC	 and	 elucidated	 the	 pathway	 of	 119	 biosynthesis	
(Scheme	1.16).97,98	
The	 PKS	 bound	 tetraketide	 precursor	 is	 reductively	 released	 by	 the	 NR-PKS	 TropA	 to	 give	
3-methylorcinaldehyde	 120.	 The	 FAD	 dependent	 salicylate	 monooxygenase	 TropB	 then	
dearomatises	the	aldehyde	120	to	give	enone	121	by	oxidation	at	C-3.	121	is	the	substrate	of	the	
non-heme	FeII	dependent	dioxygenase	TropC,	which	induces	a	ring	expansion	towards	tropolones	
by	 hydroxylation	 of	 the	methyl	 group	 at	 C-3	 (122).	 Rearrangement	 leads	 to	 the	 first	 tropolone	
stipitaldehyde	 123.	 Oxidation	 by	 the	 cytochrome	 P450	 TropD	 most	 likely	 produces	 124a	 in	
equilibrium	with	its	hemiacetal	124b,	but	this	intermediate	has	not	been	directly	observed.	Instead,	
stipitafuran	 125	 was	 accumulated	 upon	 knockout	 of	 the	 dehydrogenase	 TropE.	 Further	
transformations	 by	 TropE-J	 convert	 the	 likely	 hemiacetal	 intermediate	 124b	 into	 stipitatic	 acid	
119.97,98	Discovery	of	these	genes	has	allowed	the	identification	of	parallel	tropolone	pathways	in	
different	fungi.97	
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Scheme	1.16	Stipitatic	acid	119	biosynthesis	in	T.	stipitatus	and	BGC.	
1.3.2 Proposed	Xenovulene	A	Biosynthesis	and	Partial	aspks1	BGC	
For	 the	 elucidation	 of	 xenovulene	 A	 101	 biosynthesis	 feeding	 experiments	 with	 13C	 labelled	
precursors	 were	 analysed.	 13C-NMR	 of	 enriched	 101	 showed	 two	 intact	 acetate	 units	 in	 the	
polyketide	 moiety	 and	 one	 acetate	 unit	 disrupted	 by	 a	 methionine-derived	 methyl	 group,	
(Scheme	1.17).	The	labelling	pattern	of	the	humulene	ring	was	consistent	with	a	terpene	origin.84	
Although	nowadays	tropolone	biosynthesis	is	understood	on	a	genetic	level,	at	the	time	of	these	
feeding	studies	no	such	knowledge	was	available.	However,	from	previous	feeding	experiments	in	
Penicillium	stipitatum	 (a	tropolone	producer)	with	14C	 labelled	precursors	 it	was	known	that	the	
methionine	derived	methyl	group	is	incorporated	into	the	seven	membered	tropolone	core	upon	
disruption	 of	 an	 acetate	 unit	 (Chapter	 1.3.1).94	 Based	 on	 the	 observed	 labelling	 pattern	 in	
xenovulene	A	101,	and	knowledge	about	methyl	incorporation	in	tropolones,	a	ring	expansion-ring	
contraction	mechanism	was	proposed	to	generate	the	cyclopentenone	in	101	(Scheme	1.17).84	
For	 the	 two	 ring	 contractions	 from	107	 to	101	 an	 oxidation,	 rearrangement	 and	 deformylation	
cascade	was	proposed	(Scheme	1.18A).	Similar	ring	contractions	have	been	proposed	to	happen	
during	the	biosynthesis	of	terrein99	132	and	cryptosporiopsonol100	133	via	a	dihydroisocoumarin	
131	intermediate	(Scheme	1.18B).	Although	the	terrein	BGC	has	been	identified	no	mechanism	or	
proteins	for	this	chemistry	have	yet	been	characterised.101	
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Scheme	1.17	Proposed	biosynthesis	based	on	feeding	studies,	heterologous	gene	expression	of	aspks1	 (encoding	the	
NR-PKS	MOS)	and	tropolone	biosynthesis	in	T.	stipitatus.	
In	a	genetic	approach,	even	before	the	tropolone	BGC	was	discovered,	a	partial	gDNA	fragment	of	
the	xenovulene	A	101	producer	A.	strictum	strain	was	analysed	for	a	nrpks	gene	using	degenerate	
oligonucleotides.102	 Similar	 to	 tropolone	 biosynthesis,	 where	 3-methylorcinaldehyde	 120	 was	
shown	to	be	incorporated	into	stipitatic	acid,	it	was	assumed	that	an	aromatic	tetraketide	produced	
by	a	NR-PKS	should	be	a	likely	precursor	in	101	biosynthesis.96	The	aspks1	gene	encoding	a	NR-PKS	
was	identified	and	a	~22	kb	contig	was	sequenced	from	a	gDNA	library	and	analysed	for	further	
open	reading	frames	(ORF).	In	total,	nine	ORF	were	predicted	and	the	basic	local	alignment	search	
tool	 for	 proteins	 (BLASTp)103	 revealed	 the	 presence	 of	 two	 putative	 FAD	 dependent	
monooxygenases	 (AsL1,	 AsL4),	 one	 putative	 non-heme	 FeII	 dependent	 dioxygenase	 (AsL3),	 one	
short	 chain	 dehydrogenase	 (AsL5),	 one	 putative	 cytochrome	 P450	 (AsR2),	 one	 putative	
transcriptional	 regulator	 (AsR3),	 one	 putative	 transporter	 (AsR1)	 and	 one	 hypothetical	 protein	
(AsL2)	(Figure	1.14A).102,104,105	
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Scheme	1.18	Ring	contractions.	A,	Proposed	ring	contraction	in	xenovulene	A	101	biosynthesis.	B,	Ring	contractions	and	
labelling	 in	 terrein	 132.	 Cryptosporiopsonol	 133.	 TerB,	 DH-KR	 multidomain	 protein;	 TerC/TerD,	 FAD	 dependent	
monooxygenases;	TerE,	multicopper	oxidase;	TerF,	protein	with	kelch	motif.	
Heterologous	expression	of	aspks1	 in	A.	oryzae	 led	 to	 the	production	of	3-methylorcinaldehyde	
120,	which	made	 the	NR-PKS	encoded	 in	aspks1	 the	 first	 reported	PKS	with	a	 reductive	 release	
mechanism;	 it	 was	 named	 3-methylorcinaldehyde	 synthase	 (MOS).102	 Later	 the	 A.	 strictum	
aspks1	BGC	was	used	to	mine	the	available	T.	stipitatus	genome	for	a	homologous	BGC	that	could	
encode	proteins	for	stipitatic	acid	119	biosynthesis.	With	this	approach	the	now	fully-characterised	
stipitatic	acid	BGC	was	identified	(Chapter	1.3.1).	Pairwise	comparison	of	proteins	suggested	that	
with	MOS,	AsL1,	AsL3	and	AsR2	homologues	to	TropA,	TropB,	TropC	and	TropD	are	encoded	in	the	
aspks1	BGC	(Figure	1.14B).106		
The	22	kb	aspks1	BGC	as	reported	in	2007	encodes	homologues	for	tropolone	biosynthesis,	which	
suggested	it	as	a	promising	BGC	for	101	biosynthesis	as	tropolone	containing	metabolites	107	and	
108	were	isolated	alongside	101.	However,	it	lacks	an	encoded	terpene	cyclase	to	form	humulene	
106	from	FPP	42.	It	 is	assumed	that	the	previously	discovered	BGC	is	incomplete	and	that	genes	
encoding	proteins	for	terpene	biosynthesis	are	encoded	nearby,	but	have	not	yet	been	sequenced.	
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Figure	1.14	aspks1	BGC.	A,	Partial	aspks1	BGC.	(Major	facilitator	superfamily	(MFS);	Gal4,	galactose	induced	transcription	
factor	superfamiliy)	B,	Putative	homologous	proteins	in	the	stipitatic	acid	119	BGC.	
1.3.3 Humulene	Biosynthesis	in	Fungi	
The	 rather	 simple	 metabolite	 humulene	 160	 is	 usually	 formed	 by	 deprotonation	 of	 the	
trans-humuly	 cation	46	 after	 initial	 1,11-ring	 closure	 of	 FPP	42	 (Scheme	 1.19A).14	 Although	 the	
metabolite	 is	 a	 common	 component	 of	 plant	 essential	 oils	 only	 one	 plant	 terpene	 cyclase	
(Zingiber	zerumbet	Smith)	 is	reported	that	produces	106	as	a	major	product.107,108	Production	of	
humulene	106	in	fungi	has	only	been	reported	in	Fusarium	fujikorii,109	Colletotrichum	acutatum110	
and	 Stereum	 hirsutum.56	 The	 responsible	 class	 I	 terpene	 cyclases	 Ffsc4	 and	 CaTPS	 were	
characterised	 by	 heterologous	 expression.	 Both	 were	 found	 to	 produce	 106	 as	 well	 as	
b-caryophyllene	 134.	 Ffsc4	 also	 produces	 epi-b-caryophyllene	 135	 and	 koraiol	 136.	 CaTPS	
additionally	produces	an	unidentified	terpene	(Scheme	1.19B).109,110	No	fungal	cyclase	is	reported	
to	produce	exclusively	106.	
	
Scheme	1.19	A,	Biosynthesis	of	humulene	106.	B,	b-caryophyllene	134,	epi-b-caryophyllene	134	and	koraiol	136.	
1.3.4 Biomimetic	Experiments	and	Diels	Alderases	
Another	unknown	step	during	xenovulene	A	101	biosynthesis	is	the	attachment	of	the	polyketide	
and	 terpene	 moieties.	 Although	 only	 tropolone	 (107,	 108)	 and	 post-tropolone	 phenolic	 (109)	
meroterpenoids	 have	 been	 reported,	 it	 remains	 elusive	 which	 polyketide	 precursor	 adds	 to	
humulene	 106.	 A	 hetero	 Diels	 Alder	 (hDA)	 cycloaddition	 mechanism	 has	 been	 proposed	
(Scheme	1.17),	which	is	consistent	with	the	relative	stereochemistry.	However,	the	enantiopurity	
suggest	the	involvement	of	an	enzyme.84	
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In	a	biomimetic	approach,	tropolone-	and	benzo-ortho-quinone	methides	(138,	141)	were	tested	
for	their	reactivity	towards	humulene	106	by	Baldwin	and	co-workers	(Scheme	1.20A	and	B).111–113	
Both	quinone-methides	(138,	141)	reacted	with	106	leading	to	mono-	and	di-adducts	142	and	139	
under	 harsh	 reaction	 conditions	 (150	 –	 170	 °C,	 24	 h).	 This	 suggested	 that	 an	 inverse	 electron	
demand	 hetero	 Diels	 Alder	 (hDA)	 reaction	 is	 a	 feasible	 approach	 to	 form	 xenovulene	 class	
meroterpenoids.	However,	the	observed	reaction	conditions,	poor	yields	and	low	stereoselectivity	
suggest	that	an	enzyme	catalyses	the	formation	of	101	in	vivo.	
	
Scheme	1.20	Biomimetic	studies	showing	benzo-ortho-quinone	methide	(138,	A)	and	tropolone-ortho-quinone	methides	
(141,	B)	to	react	with	humulene	106	in	a	hetero	Diels	Alder	reaction.	
An	example	of	a	multi-function	Diels	Alderase	(DAase)	is	the	HR-PKS	lovastatin	2	synthase	(LovB).	It	
catalyses	 carbon	 chain	 elongation	 to	 build	 up	 the	 polyketide	 backbone	 and	 the	 subsequent	
intramolecular	decalin	144	formation	by	an	additional	DA	activity	(Scheme	1.21A).114	Two	individual	
bacterial	stand-alone	DAase	(PyrE3,	PyrI4)	each	catalysing	a	[4+2]	cyclisation	in	the	biosynthesis	of	
pyrroindomycin	149	(Scheme	1.21B)	were	reported.115,116	PyrE3	is	a	Rossman	fold	protein	while	the	
crystal	structure	of	PyrI4	showed	it	to	be	a	b-barrel.	
The	first	and	only	stand-alone	hetero	Diels	Alderase	(hDAase)	reported	shows	homologies	to	a	SAM	
dependent	 methyltransferase.	 This	 enzyme	 (LepI)	 forms	 the	 dihydropyran	 ring	 in	 the	 fungal	
metabolites	leporin	C	151	and	B	64	(Scheme	1.21C).64	A	similar	dihydropyran	ring	is	also	found	in	
the	xenovulene	class	meroterpenoids	(Figures	1.11	and	1.12).	
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The	structural	divergence	of	these	proteins	(LovB,	NR-PKS;	PyrE3,	Rossmann	fold;	PyrI4,	b-barrel;	
LepI,	SAM	dependent)	 indicates	that	nature	uses	different	tertiary	architectures	to	 induce	these	
[4+2]	cycloadditions,	which	results	in	difficulties	predicting	DAases	or	hDAases	in	silico.116,117	
	
Scheme	1.21	Examples	for	catalysed	Diels	Alder	reactions	by	a	A,	the	multifunctional	DAase	LovB;	B,	Two	stand-alone	
DAase	and	C,	one	stand-alone	hDAase.	
	
1.4 Project	Aims	
The	biosynthesis	of	xenovulene	A	101	in	A.	strictum	is	the	key	focus	of	this	project.	For	this	reason,	
the	secondary	metabolite	profile	of	A.	strictum	will	be	analysed	in	detail.	Previously	reported	107,	
108	 and	 109	 (Figure	 1.11)	 and	 putative	 novel	 compounds	 will	 be	 identified,	 purified	 and	 their	
structure	elucidated	by	subsequent	full	NMR	analysis.		
Sequencing	 of	 the	 whole	A.	 strictum	 genome	 will	 be	 attempted	 to	 enable	 a	 full	 bioinformatic	
analysis,	 prediction	 of	 all	 BGC	 and	 completion	 of	 the	 partial	 aspks1	 BGC.	 Comparison	 of	 the	
A.	strictum	 transcriptome	under	xenovulene	A	101	producing	and	non-producing	conditions	will	
help	 to	 identify	 the	BGC	responsible	 for	101	biosynthesis,	 to	set	neat	cluster	boundaries	and	 to	
verify	the	gene	model	as	well	as	exon/intron	predictions.	
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The	 best	 candidate	 BGC	 for	 101	 biosynthesis	 will	 be	 further	 analysed	 through	 gene	 knockout,	
editing	and	silencing	methods	in	A.	strictum.	Targeted	gene	inactivation	has	not	previously	been	
achieved	 in	 this	 organism	 and	 thus	 different	methods	will	 be	 tested.	 In	 addition,	 heterologous	
expression	of	selected	genes	of	the	candidate	BGC	in	A.	oryzae	and/or	E.	coli	will	be	performed	to	
characterise	 their	 role	 in	101	 biosynthesis.	 The	 identification	 of	 a	 humulene	106	 synthase,	 the	
proposed	hDA	catalyst	and	the	enzymes	involved	in	the	two	ring	contractions	to	cyclopentenone	
are	of	special	interest.	
Early	tropolone	biosynthesis	in	A.	strictum	has	already	been	proposed	to	be	similar	to	stipitatic	acid	
biosynthesis	in	T.	stipitatus.	It	will	be	of	interest	whether	the	entire	tropolone	pathway	is	identical	
in	A.	 strictum.	Apart	 from	3-methylorcinaldehyde	120,	 no	 tropolone	precursors	have	previously	
been	 identified	 in	A.	 strictum.104	 Therefore,	 crude	 extracts	will	 be	 analysed	 for	 the	presence	of	
possible	tropolone	polyketide	precursors.	
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2 Analysis	of	A.	strictum	Secondary	Metabolite	Production	
The	A.	strictum	 xenovulene	A	producing	strain	was	 first	 reported	 for	 the	production	of	101	and	
co-metabolites	 107-109	 (Figure	 2.1).82,84	 Extensive	 efforts	 were	 made	 to	 optimise	 the	 culture	
conditions	and	yield	for	101.118	Several	time	course	experiments	within	our	group104,105	and	also	by	
Blackburn	and	co-workers118	showed	initial	production	of	101	after	1-3	days	(d)	of	 liquid	culture	
followed	 by	 stagnation	 after	 6-8	 d.	 Similar	 results	were	 obtained	 in	 a	Master	 thesis	 by	Miriam	
Streeck,	but	as	often	observed	with	fungi,	yields	and	composition	of	actually	produced	secondary	
metabolites	were	inconsistent.119	
	
Figure	2.1	Metabolites	known	to	be	produced	by	A.	strictum.	
A.	strictum	was	typically	sub-cultured	in	101	production	media	(ASPM)	for	6-8	d	(25	°C,	200	rpm).	
Cells	were	removed	by	centrifugation	and	the	supernatant	was	acidified	to	pH	2	with	2	M	HCl	prior	
to	extraction	with	ethyl	acetate:hexane	(1:1).	Solvents	were	removed	in	vacuo	and	dried	extracts	
dissolved	 in	 methanol	 or	 acetonitrile:water	 (9:1)	 to	 a	 concertation	 of	 10	 mg/mL	 for	 analytical	
purposes,	 and	 50	 mg/mL	 for	 purification	 by	 high	 performance	 liquid	 chromatography	 (HPLC).	
Compounds	 purified	 by	 Miriam	 Streeck	 (107a	 and	 107b,	 108)	 were	 obtained	 from	 combined	
extracts	of	a	time	course	experiment,	where	extraction	was	carried	out	at	ten	consecutive	days.119	
A	 typical	 LCMS	 chromatogram	 of	 an	 A.	 strictum	 extract	 was	 analysed	 for	 the	 production	 of	
xenovulene	A	101	and	known	metabolites	107,	108	and	109.	Although	structures	for	107,	108	and	
109	 have	 been	 previously	 reported	 in	 the	 literature,84	 no	 spectroscopic	 (NMR	 or	 UV)	
characterisation	was	available.84	Extracted	ion	chromatograms	using	[M]H+	or	[M-H]-	corresponding	
to	101,	107,	108	or	109	led	to	the	identification	of	compounds	satisfying	the	nominal	mass	of	all	
previously	reported	compounds	(Figure	2.2).	Additionally,	two	compounds	satisfying	the	nominal	
mass	of	107	and	109	with	different	retention	times	(109a	tR	=	9.2	and	109b	9.4	min,	107a	tR	=	9.9	
and	107b	11.6	min)	were	observed	for	the	first	time.	Another	compound	(154)	eluting	at	tR	=	11.3	
with	 a	 nominal	mass	 of	 382	 and	 very	 similar	 UV	 absorption	 compared	 to	 the	 other	 tropolone	
compounds	 (107	 and	108)	was	 identified	 as	 a	 probably	 related	meroterpenoid	 (Figure	 2.2).	 All	
compounds	were	purified	by	HPLC	and	analysed	by	NMR	spectroscopy	(Chapters	2.1-2.7).	
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Figure	2.2	Analysis	of	A.	strictum	extract	for	known	metabolites	previously	observed	with	xenovulene	A	101.	Analysed	by	
LCMS	with	analytical	gradient	A1.	Top	trace	shows	Diode	array	detector	(DAD)	chromatogram.	Other	traces	show	the	
indicated	extracted	ion	chromatograms	corresponding	to	[M]H+	or	[M-H]-	for	compounds	101,	107-109.	
	
2.1 Identification	of	Xenovulene	A	101	
The	 UV	 spectrum	 of	 the	 compound	 eluting	 at	 tR	 =	 8.4	 with	 a	 nominal	 mass	 of	 358	 showed	 a	
maximum	absorption	 at	 276	nm,	which	 is	 consistent	with	 literature	data	 for	101	 (Figure	 2.3).82	
Subsequent	purification	of	4	mg	enabled	full	NMR	analysis.	
The	 acquired	 1H	 NMR	 data	 were	 identical	 to	 the	 literature	 data	 of	 101	 (Table	 2.1).	 However,	
chemical	shift	of	all	carbons	in	the	13C	NMR	were	observed	to	be	shifted	by	0.3	ppm	(C-2	by	0.4	ppm)	
upfield.	High	resolution	mass	spectrometry	(HRMS)	confirmed	the	molecular	formula	as	C22H30O4	
([M]Na+	C22H30O4Na	calculated	359.2222,	found	359.2219).	
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Figure	 2.3	 Xenovulene	 A	 101.	 A,	 Typical	 DAD	 chromatogram	 of	A.	 strictum	 extracts	 obtained	 under	 101	 producing	
conditions.	B,	Characterisation	of	xenovulene	A	101.	
Table	2.1	NMR	data	for	101	in	CD3OD	(500	MHz)	referenced	to	CD3OD.	Literature	data	was	measured	at	400	MHz.	
Position	 dC/ppm	101	
referenced	to	49.0	ppm	
measured/ppm	
dH/ppm	(J	in	Hz)	101	
referenced	to	3.31	ppm	
measured	
dC/ppm	101	
referenced	to	49.0	ppm	
literature/ppm82	
dH/ppm	(J	in	Hz)	101	
referenced	to	3.4	ppm	
literature/ppm82	
1	
2	
	
3	
4	
5	
6	
	
7	
8	
9	
	
10	
	
11	
12	
13	
14	
15	
16	
17	
18	
	
19	
20	
21	
22	
88.6	
44.8	
	
121.6	
144.4	
39.1	
42.8	
	
124.4	
137.1	
37.1	
	
31.9	
	
44.7	
83.4	
41.9	
166.7	
135.0	
200.7	
48.7	
70.6	
	
23.4	
24.6	
30.6	
17.4	
-	
2.26	(dd,	1H,	14.6,	10.3)	
2.61	(ddd,	1H,	14.7,	2.3,	1.6)	
5.22	(ddd,	1H,	15.9,	10.2,	2.4)	
5.15	(dd,	1H,	16.0,	1.6)	
-	
1.76	(br	dd,	1H,	12.8,	4.8)	
2.23	(br	dd,	1H,	12.1,	12.0)	
5.08	(m,	1H)	
-	
1.99	(br	dd,	1H,	12.5,	7.3)		
2.12	(m,	1H)	
1.29	(m,	1	H)	
1.49	(br	ddd,	1H,	13.5,	10.2,	7.1)	
2.13	(br	dd,	1H,	10.5,	4.6)	
3.74	(br	dd,	1H,	6.0,	4.9)	
3.59	(dd,	1H,	5.9,	5.9)	
-	
-	
-	
2.93	(ddd,	1H,	7.9,	5.6,	1.5)	
3.72	(dd,	1H,	9.4,	7.7)	
3.92	(br	dd,	1H,	9.3,	1.5)	
1.42	(s,	3H)		
1.05	(s,	3H)	
1.04	(s,	3H)	
1.63	(s,	3H)	
88.9	
45.2	
	
121.9	
144.7	
39.4	
43.1	
	
124.7	
137.4	
37.4	
	
32.2	
	
45.0	
83.7	
42.2	
167.0	
135.3	
201.0	
49.0	
70.9	
	
23.7	
24.9	
30.9	
17.7	
-	
2.38	(dd,	1H,	14.5,	9.9)	
2.70	(br	ddd,	1H,	14.5,	2.2,	1.6)	
5.32	(ddd,	1H,	15.9,	10.0,	2.2)	
5.24	(dd,	1H,	15.9,	1.5)	
-	
1.85	(br	dd,	1H,	13.0,	4.5)	
2.33	(br	dd,	1H,	12.7,	12.7)	
5.17	(m,	1H)	
-	
2.08	(br	dd,	1H,	12.5,	7.1)		
2.23	(br	dd,	1H,	11.6,	11.6)	
1.37	(m,	1H)	
1.58	(br	ddd,	13.2,	10.1,	6.8)	
2.22	(br	dd,	1H,	9.8,	5.2)	
3.83	(br	dd,	6,0,	6.0)	
3.67	(dd,	1H,	5.8,	5.8)	
-	
	
-	
3.02	(ddd,	1H,	7.8,	5.6,	1.5)	
3.80	(dd,	1H,	9.3,	7.9)	
4.03	(br	dd,	9.3,	1.5)	
1.51	(s,	3H)	
1.14	(s,	3H)	
1.13	(s,	3H)	
1.72	(s,	3H)	
	
2.2 Characterisation	of	the	Dihydroxytropolone	Meroterpenoid	108	
Although	the	structure	of	the	xenovulene	co-metabolite	108	with	the	molecular	formula	of	C24H30O6	
has	been	previously	reported	in	the	literature,	no	chemical	characterisation	was	available.84	The	
purified	 compound	 eluting	 at	 tR	 =	 9.5	min	was	 observed	 as	major	 product	 in	A.	 strictum	 liquid	
fermentation,	and	113	mg	were	isolated	(by	M.	Streeck)	from	2	L	extracted	culture.	This	compound	
Time
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
AU 0.0
2.0
9.50
8.40
9.16
9.90 11.6411.33
8.42
9.93 11.65
9.50
9.16 9.40
m/z
250 300 350
%
0
100 359
303263 341
360
381
383
10
m/z
250 300 350
%
0
100 357
313
293243 342
358
nm
250 300
AU
0.0
1.0
276
O
O
OH
O
H
H
H
H
101
MS	ES+ MS	ES-UV
AU
AU
time/min
A
B
n m/z /z
11
1
3
4
7
8
12
13 14
15
16
17
18
19
20
21
22
C22H30O4
M	=	358	g/mol
DAD
Analysis	of	A.	strictum	Secondary	Metabolite	Production	
	 29	
showed	 a	 nominal	mass	 of	 414,	 determined	 by	 low	 resolution	mass	 spectrometry	 and	 two	UV	
absorption	maxima	(273	nm,	365	nm)	(Figure	2.4).	
	
Figure	2.4	LCMS	analysis	for	108.	A,	Typical	DAD	chromatogram	of	A.	strictum	extracts	obtained	under	101	producing	
conditions.	B,	Characterisation	of	108.	
Analysis	of	 1H	and	 13C	NMR	data	 identified	24	 carbon	atoms	and	27	protons	 (Table	2.2).	HRMS	
confirmed	 a	molecular	 formula	 of	 C24H30O6	 ([M]H+	 calculated	 415.2121,	 found	 415.2119)	which	
suggested	three	exchangeable	protons.	The	HSQC	spectrum	revealed	four	–CH3,	five	diastereotopic	
–CH2,	five	–CH	and	ten	quaternary	carbon	atoms.		
Evaluation	of	HMBC	and	1H,1H	COSY	spectra	showed:	
• one	CH	(dC	40.9,	dH	2.05);	
• four	aliphatic	diastereotopic	CH2	(dC	43.6,	dH	2.40,	2.74;	dC	41.6,	dH	1.75,	2.16;	dC	37.9,	
dH	2.13,	2.31;	dC	28.4,	dH	1.38,	1.70);	
• four	CH3	groups	(dC	23.0,	dH	1.33;	dC	29.7,	dH	1.02;	dC	24-4,	dH	0.93;	dC	17.2,	dH	1.60);	
• two	quaternary	C	(dC	38.5,	87.1);	
• two	double	bond	systems	(dC	119.0,	dH	4.91;	dC	144.1,	dH	5.17;	dC	123.9,	dH	5.04;	dC	136.2).	
These	make	up	the	typical	humulene	106	scaffold	(Figure	2.5,	Carbon	positions	1-11	and	21-24;	
key	HMBC	couplings).	
The	chemical	shift	of	the	quaternary	C-1	(dC	87.1)	indicated	direct	attached	to	an	oxygen	atom.	By	
analysis	of	HMBC	and	1H,1H	COSY,	the	two	double	bond	systems	were	determined	at	positions	3/4	
(3:	dC	119.0,	dH	4.91;	4:	dC	144.1,	dH	5.17)	and	7/8	(dC	123.9,	dH	5.04;	dC	136.2).	The	3JHH	value	of	
15.8	Hz	indicates	a	trans	alkene	between	C-3	and	C-4.	The	geometry	of	the	C-6	and	C-7	alkene	could	
m/z
200 300 400
%
0
100 413
401345195 429
m/z
200 300 400
%
0
100 415
211
205 212 413343
437
nm
250 300 350 400
AU
0.0
1.0
273
365
Time
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
AU 0.0
2.0
9.50
8.40
9.16
9.90 11.6411.33
8.42
9.93 11.65
9.50
9.16 9.40
AU UV
O
O
OH
O
OH
H
H
HO
C24H30O6
M	=	414	g/mol
108
MS	ES+
MS	ES-
A B
AU
DAD
m/z
/z
Analysis	of	A.	strictum	Secondary	Metabolite	Production	
	 30	
not	be	determined,	but	it	was	assumed	to	be	trans	as	in	humulene	106	and	xenovulene	A	101.	This	
was	supported	by	very	similar	dC/dH	values.	
Table	2.2	NMR	data	for	108	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	
Position	 dC/ppm	108	 dH/ppm	(J	in	Hz)	108	 HMBC	(H	to	C)	
1	
2	
	
3	
4	
5	
6	
	
7	
8	
9	
	
10	
	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
	
21	
22	
23	
24	
87.1	
43.6	
	
119.0	
144.1	
38.5	
41.8	
	
123.9	
136.2	
37.9	
	
28.4	
	
40.9	
84.5	
123.5	
142.4	
144.6	
150.6	
160.3	
146.4	
127.4	
72.6	
	
23.0	
29.7	
24.4	
17.2	
-	
2.40	(dd,	1H,	14.8,	10.3)	
2.75	(d,	1H,	14.8)	
4.91	(m,	1H)	
5.17	(dd,	1H,	13.0,	4.9)	
-	
1.75	(dd,	1H,	13.0,	4.9)	
2.16	(m,	1H)	
5.04	(m,	1H)	
-	
2.13	(m,	1H)		
2.31	(m,	1H)	
1.38	(m,	1	H)	
1.70	(m,	1H)	
2.05	(br	dd,	1H,	10.8,	8.2)	
4.91	(m,	1H)	
-	
-	
-	
-	
-	
-	
-	
5.05	(m,	1H)	
5.21	(dd,	1H,	13.7,	1.1)	
1.33	(s,	3H)	
1.02	(s,	3H)	
0.93	(s,	3H)	
1.60	(s,	3H)	
-	
3,	4,	21	
1,	3,	4,	11,	21	
1,	2,	5	
2,	5,	22,	23	
-	
4,	5,	7,	8,	23	
4,	5,	7,	8,	22,	23	
5,	6,	24	
-	
7,	8,	10,	11,	24	
7,	8,	10,	11,	24	
1,	8,	9,	11,	12	
8,	9,	11,12	
1,	2,	9,	10,	12,	13,	21	
1,	11,	10,	13,	14,	15,	18,	19	
-	
-	
-	
-	
-	
-	
-	
13,	14,	17,	18,	19	
12,	13,	16,	17,	18,	19	
1,	2,	11	
4,	5,	6	23	
4,	5,	6,	22	
7,	9,	8	
	
	
Figure	2.5	HMBC	correlations	in	the	humulene	ring	in	108.	Arrow	direction	indicates	H	to	C.	
Consideration	 of	 chemical	 shift	 values	 also	 proposed	 a	 direct	 attachment	 to	 oxygen	 for	 C-20	
(dC	72.6,	dH	5.05,	5.23)	and	C-12	 (dC	84.5,	dH	4.91).	 3JCH	 coupling	between	C-12	 (dC	84)	and	H-20	
(dH	5.23)	 indicated	an	ether	 like	 linkage	at	 that	position.	Analysis	of	HMBC	correlations	of	H-12	
(dH	 4.91)	 identified	 the	 humulene	 carbons	 C-1,	 C-10,	 C-11	 as	 well	 as	 C-13	 (dC	 123.5)	 and	 C-19	
(dC	127.4)	in	coupling	distance.	3JHH	of	H-12	to	H-11	(dH	2.05)	confirmed	the	direct	attachment	to	
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humulene	and	determined	position	C-12	for	this	-CH-O-	group.	Further	HMBC	correlation	showed	
that	 the	ether	 linked	CH2	group	 (dC	72.6,	dH	5.05,	dH	5.23)	 is	 in	 coupling	distance	 to	quaternary	
carbons	C-13	(dC	123.5),	C-14	(dC	142.4),	C-17	(dC	160.3),	C-18	(dC	146.4)	and	C-19	(dC	127.4).	In	the	
1H,1H	COSY	spectrum	only	geminal	2JHH	coupling	of	dH	5.23	and	dH	5.05	was	detected	which	proposed	
its	position	at	C-20.	The	relative	stereochemistry	at	positions	C-1,	C-11	and	C-12	were	assumed	to	
be	identical	to	xenovulene	A	101,	but	not	further	determined.	
	
Figure	2.6	HMBC	correlations	of	108.	
Chemical	 shifts	 of	 the	 seven	 remaining	 quaternary	 carbons	 suggested	 their	 involvement	 in	 an	
aromatic	system	and	for	 five	of	 them	(dC	142.4.0,	dC	144.6,	dC	146.4,	dC	150.6	and	dC	160.3)	the	
attachment	to	an	oxygen.	HMBC	correlations	of	the	carbon	at	dC	123.5	to	protons	at	C-12,	C-20	and	
C-11	suggested	its	position	at	C-13.	Chemical	shift	and	3JCH	couplings	of	the	carbon	at	dC	127.4	to	
both	protons	(dH	5.23,	dH	5.05)	at	position	C-20	and	to	dH	4.9	at	C-12	suggested	it	to	be	at	position	
C-19.	The	carbon	at	dC	142.4	showed	a	 3JCH	 coupling	 to	 the	proton	at	C-12	and	 4JCH	couplings	 to	
dH	5.05	at	C-20	as	well	as	dH	2.40	at	C-2.	It	was	thus	assigned	at	position	C-14.	The	carbon	at	dC	144.6	
displays	a	4JCH	correlation	to	proton	dH	4.91	at	C-12,	but	not	to	protons	attached	at	C-20	and	was	
thus	assigned	at	C-15.	The	carbon	at	dC	146.4	couples	to	both	protons	at	C-20	and	to	the	one	proton	
at	C-12.	It	was	assigned	at	C-18.	The	carbon	at	dC	160.3	with	the	highest	chemical	shift	was	assigned	
as	a	carbonyl.	A	4JCH	coupling	to	dH	5.23	and	dH	5.05	at	C-20	suggested	its	position	at	C-17.	For	the	
carbon	at	dC	150.6	no	correlations	were	identified	in	the	HMBC	spectrum	which	strongly	indicates	
its	position	at	C-16	(Figure	2.6	for	key	HMBC	correlations).	
For	further	structure	validation	30	mg	of	108	were	methylated	with	an	excess	of	trimethylsilyl	(TMS)	
diazomethane	in	tetrahydrofuran	(THF)	/	methanol	(Figure	2.7A).120,121	LCMS	analysis	showed	the	
formation	four	major	compounds	with	tR	=	9.9	(I),	10.1	(II),	10.4	(III)	and	10.7	(IV)	min	(Figure	2.7B).	
The	nominal	mass	of	all	four	peaks	was	determined	by	low	resolution	mass	spectrometry	to	be	456,	
which	corresponds	to	108	methylated	at	three	sites.	Two	distinct	UV	absorption	maxima	(I	=	265,	
356,	II	=	270,	342,	III	=	264,	354,	IV	=	261,	351)	were	observed	for	all	compounds	(Figure	2.8).	
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Figure	2.7	Methylation	of	108	with	TMS-diazomethane	152.	A,	Formation	of	four	153	isomers.	B,	DAD	chromatogram	of	
reaction	mixture	after	3	h.	C	Extracted	ion	chromatogram	at	[M]H+	=	457.	
	
Figure	2.8	Detection	of	four	products	I-IV	upon	methylation	of	108.	
The	four	peaks	were	purified	by	LCMS	(I:	4.1	mg,	II:	2.5	mg,	III:	1.4	mg,	IV:	2.6	mg).	The	1H	NMR	
spectrum	of	 compound	 I	 showed	 two	new	singlets	with	a	 chemical	 shift	of	dH	3.85	and	dH	3.94	
integrating	for	respectively	three	and	six	protons.	1H	NMR	spectra	for	compounds	II-IV	showed	each	
three	new	singlets	between	dH	3.89	and	dH	3.99	integrating	for	three	protons	each	(Figure	2.9).	This	
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indicated	that	methylation	of	the	aromatic	alcohols	trapped	the	four	tautomers	of	compound	108	
(Figure	2.7A).	
	
Figure	2.9	1H	NMR	of	compounds	I	(153d),	II,	III	and	IV.	
Full	NMR	characterisation	and	HRMS	(C27H37O6,	[M]H+	calculated	457.2590,	found	457.2589)	was	
carried	out	for	compound	I	(compounds	II,	III	and	IV	degraded	before	data	was	acquired).	Protons	
and	carbons	 involved	 in	 the	humulene,	dihydropyran	and	 the	dihydrofuran	 rings	were	assigned	
according	 to	108,	as	chemical	 shifts	and	HMBC	couplings	were	very	similar	 (Table	2.3).	Carbons	
within	3JCH	distance	of	the	methyl	groups	were	identified	in	the	HMBC	(dC	157.3,	dC	157.1,	dC	146.8).	
Carbon	at	dC	146.8	showed	3JCH	to	dH	3.85	(at	dC	61.2)	and	dH	5.07	and	dH	4.91	(at	C-20).	An	additional	
4JCH	to	dH	4.75	(at	C-12)	proposed	its	position	at	C-18.	At	least	one	of	the	carbons	at	dC	157.1	and	dC	
157.3	couples	with	dH	5.07	and	dH	4.91	(at	C-20),	which	indicates	it	at	C-17.	Due	to	close	proximity	
of	the	chemical	shifts	the	correlating	carbon	could	not	be	assigned.	However,	it	was	assumed	that	
the	 other	 carbon	 has	 no	 correlations,	 which	 would	 propose	 it	 at	 position	 C-16.	 This	 is	 further	
underpinned	by	the	4JCH	coupling	of	carbon	dC	173.4	to	dH	4.75	(at	C-12)	which	indicates	its	position	
at	C-15.	Taken	together	these	data	strongly	suggest	that	compound	I	is	the	15-keto	isomer	153d	
(Figure	2.10).	
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Figure	2.10	Key	HMBC	correlations	for	assignments	of	tropolone	associated	carbon	atoms	in	153d.	
Table	2.3	NMR	data	for	153d	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	
Position	 dC/ppm	153d	 dH/ppm	(J	in	Hz)	153d	 HMBC	(H	to	C)	
1	
2	
	
3	
4	
5	
6	
	
7	
8	
9	
	
10	
	
11	
12	
13	
14	
15	
16,17	
18	
19	
20	
	
21	
22	
23	
24	
25,26	
27	
85.4	
43.0	
	
119.9	
143.2	
38.4	
41.8	
	
123.9	
136.3	
38.1	
	
28.5	
	
39.8	
84.5	
123.8	
152.6	
173.4	
157.1,	157.3	
146.8	
132.0	
71.8	
	
22.6	
30.1	
24.3	
17.1	
60.3,	61.9	
61.2	
-	
2.31	(m,	1H)	
2.88	(ddd,	1H,	14.7,	2.2,	2.2)	
4.99	(ddd,	1H,	15.9,	10.4,	2.5)	
5.12	(dd,	1H,	15.9,	1.7)	
-	
1.73	(dd,	1H,	12.9,	1.7)	
2.16	(m,	1H)	
5.06	(m,	1H)	
-	
2.11	(m,	1H)	
2.28	(m,	1H	
1.40	(m,	1H)	
1.61	(m,	1H)	
1.95	(dd,	1H,	10.6,	8.1)	
4.75	(dd,	1H,	10.6,	1.4)	
-	
-	
-	
-	
-	
-	
4.91	(dd,	1H,	13.9,	1.4)	
5.07	(d,	1H,	13.9)	
1.25	(s,	3H)	
1.03	(s,	3H)	
0.96	(s,	3H)	
1.61	(s,	3H)	
3.93,	3.94	(s,	6H)	
3.85	(s,	3H)	
-	
3,	4,	14	
1,	3,	4,	10,	11,	21	
4,	5,	6	
3,	5,	6,	22,	23	
-	
4,	5,	7,	8,	23	
5,	6,	7,	22,	23	
5,	24	
-	
1,	10,	24	
8,	10,	11,	13,	24	
1,	8,	9,	11,	12	
1,	8,	9,	11,	12	
1,	2,	9,	10,12,	13,	21	
10,	11,	13,	14,	17,	18,	19	
-	
-	
-	
-	
-	
-	
13,	14,	16/17,	18,	19	
12,	13,	16/17,	18,	19	
1,	2,	3,	11	
4,	5,	6,	23	
4,	5,	6,	22	
7,	8,	9	
16,	17	
18	
	
2.3 Characterisation	of	Hydroxytropolone	Meroterperpenoid	Isomers	107a/b	
Analysis	of	extracted	ion	chromatograms	of	A.	strictum	extracts	for	the	known	intermediate	107,	
with	the	molecular	formula	C24H30O5,	identified	two	compounds	satisfying	the	nominal	mass	of	398	
(determined	by	 low	resolutions	mass	 spectroscopy).	Both	compounds	 showed	characteristic	UV	
absorption	maxima	(107a	271,	363	and	107b	249,	330,	389)	but	different	retention	times	(107a	
tR	=	9.9	and	107b	tR	=	11.6)	(Figure	2.11A	and	B).	
Although	the	structure	of	107a	has	been	published	no	chemical	characterisation	was	available.84	
Purification	(by	M.	Streeck)	of	18	mg	107a	and	9	mg	107b	from	2	L	of	A.	strictum	culture	extracts	
enabled	full	NMR	characterisation.	Analysis	of	1H	and	13C	NMR	data	identified	24	carbon	atoms	and	
28	protons	for	each	107a	and	107b	(Table	2.4).	HRMS	confirmed	a	molecular	formula	of	C24H30O6	
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for	 both	 compounds	 ([M]-H+	 calculated	 399.2127,	 found	 107a:	 399.2168	 and	 107b:	 399.2166)	
which	suggested	two	exchangeable	protons.	
	
Figure	2.11	Compounds	107a	and	b.	A,	Typical	DAD	chromatogram	of	A.	strictum	extracts	obtained	under	101	producing	
conditions	 and	 extracted	 ion	 chromatograms	 corresponding	 to	 [M]H+	 =	 399.	 B,	 Chemical	 characterisation	 of	 two	
compounds	with	the	nominal	mass	of	398	eluting	at	tR	=	9.9	min	and	11.7	min.	
The	 HSQC	 spectrum	 revealed	 four	 –CH3,	 five	 diastereotopic	 –CH2,	 six	 –CH	 and	 nine	 quaternary	
carbon	atoms	for	both	compounds	(Table	2.4).	Comparison	with	1H	NMR,	1H,1H	COSY	and	HMBC	
spectra	obtained	for	108	enabled	rapid	verification	and	assignment	of	the	humulene,	dihydropyran	
and	dihydrofuran	proton	and	carbon	signals	to	the	respective	positions	in	107a	and	107b.	
	
Figure	2.12	Possible	structures	to	satisfy	the	HRMS	and	1H	NMR	results.	
O
O
OH
OH
O
H
107a
	C24H30O5
M	=	398	g/mol
H
O
O
O
OH
H
107b
	C24H30O5
M	=	398	g/mol
H
O
O
O
H
107c
	C24H30O5
M	=	398	g/mol
H
HO
OH
HO
1718
111
21
22
23
24
14 15
1619
20
12
13
Time
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
AU 0.0
2.0
9.50
8.40
9.16
9.90 11.6411.33
8.42
9.93 11.65
9.50
9.16 9.40
Time
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
%
0
100
8.00 9.00 10.00 11.00 12.00
AU 0.0
2.0
9.50
8.40
9.16
9.90 11.6411.33
8.42
9.93 11.65
9.50
9.16 9.40
m/z
200 300 400
%
0
100 399195
326196 249 369
400
401
/z
200 300 400
%
0
100 397
359315136 179
398
m/z
200 300 400
%
0
100 399
383211179 309
400
m/z
200 300 400
%
0
100 397
381
117 328277177
398
nm
250 300 350 400
AU
0.0
1.0
271
363
nm
250 300 350 400
AU
0.0
1.0 249
389
330
O
O
OH
OH
O
H
107a
	C24H30O5
M	=	398	g/mol
tR	=	9.9	min
tR	=	11.7	min
AU
AU
ES+	m/z	=	399
1.2	e8
DADAU
time/min
A
B
MS	ES+ MS	ES-UV
nm m/z m/z
MS	ES+ MS	ES-UV
nm /z
107a 107b
H
Analysis	of	A.	strictum	Secondary	Metabolite	Production	
	 36	
	
Figure	2.13	1H	NMR	of	purified	compounds	107a	and	107b.	
A	sharp	singlet	integrating	for	one	proton	was	identified	in	the	1H	NMR	data	for	107a	(dH	7.12	at	dC	
108.9)	and	107b	(dH	7.16	at	dC	112.3)	(Figure	2.13).	Consideration	of	chemical	shifts	proposed	the	
attachment	 to	 an	 aromatic	 system	 in	 both	 compounds,	 which	 led	 to	 the	 suggested	 possible	
structures	107a,	107b	or	107c	(Figure	2.12).	
Further	analysis	of	HMBC	correlation	data	of	107a	showed	a	3JCH	coupling	of	proton	dH	7.12	with	
C-20	(dC	72.5)	and	thus	the	proton	dH	7.12	was	proposed	to	be	at	position	C-18,	as	for	positions	C-15	
and	C-16	no	correlations	to	C-20	were	expected.	HMBC	data	of	compound	107b	showed	no	such	
correlation	between	proton	dH	7.16	and	C-20	(dC	72.5).	Instead	a	4JCH	interaction	between	proton	
dH	 7.16	 and	 C-12	 (dC	 84.3)	 was	 detected	 which	 suggested	 its	 attachment	 at	 position	 C-15	
(Figure	2.14).	Quaternary	tropolone	carbons	were	assigned	based	on	indicated	HMBC	correlations	
in	analogy	to	compound	108.	The	relative	stereochemistry	at	positions	C-1,	C-11	and	C-12	were	
assumed	to	be	identical	to	xenovulene	A	101,	but	not	further	determined.	
107b
107a
δ/ppm
CDCl3
CDCl3
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Figure	2.14	Key	HMBC	correlations	for	107a	and	107b.	
Table	2.4	NMR	data	for	107a	and	107b	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	
Position	 dC/ppm	
107a	
dH/ppm	(J	in	Hz)	107a	 HMBC	(H	to	C	107a)	 dC/ppm	
107b	
dH/ppm	(J	in	Hz)	107b	 HMBC	(C	to	H)	107b	
1	
2	
	
3	
4	
5	
6	
	
7	
8	
9	
	
10	
	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
	
21	
22	
23	
24	
87.5	
43.7	
	
119.4	
143.9	
38.5	
41.7	
	
124.0	
136.2	
38.0	
	
28.3	
	
41.1	
85.2	
127.7	
148.2	
149.3	
164.2	
159.8	
108.9	
138.2	
75.6	
	
23.1	
29.7	
24.4	
17.2	
-	
2.37	(dd,	1H,	14.7,	10.4)	
2.81	(d,	1H,	15.0)	
4.93	(ddd,	1H,	15.8,	10.3,	2.8)	
5.16	(dd,	1H,	15.8,	1.7)	
-	
1.75	(br	dd,	1H,	13.0,	4.9)	
2.16	(m,	1H)	
5.05	(m,	1H)	
-	
2.13	(m,	1H)		
2.30	(br	dd,	1H,	12.2,	12.2)	
1.41	(m,	1	H)	
1.68	(m,	1H)	
2.09	(m,	1H)	
4.99	(m,	1H)	
-	
-	
-	
-	
-	
7.12	(s,	1H)	
-	
5.00	(m,	1H)	
5.08	(dd,	1H,	13.3,	3.3)	
1.37	(s,	3H)	
1.02	(s,	3H)	
0.92	(s,	3H)	
1.61	(s,	3H)	
-	
3,	4,	14	
1,	3,	4,	5,	11,	21	
1,	2,	5	
1,	5,	22,	23	
-	
4,	5,	7,	8,	23	
4,	5,	7,	8,	22,	23	
5,	24	
-	
7,	8,	10,	11,	24	
7,	8,	10,	11,	24	
1,	8,	9,	11,	12	
8,	9,	11,	12	
1,	2,	9,	10,	12,	13,	21	
10,	11	
-	
-	
-	
-	
-	
13,	14,	16,	17,	19,	20	
-	
12,	13,	16,	18,	19	
13,	19	
1,	2,	11	
4,	6,	5,	23	
4,	6,	5,	22	
7,	9,	8	
85.8	
43.3	
	
119.2	
143.8	
38.5	
41.7	
	
123.8	
136.3	
38.0	
	
28.3	
	
40.5	
84.3	
122.8	
152.6	
112.3	
159.4	
165.9	
147.1	
134.5	
72.5	
	
22.8	
30.0	
24.3	
17.1	
-	
2.31	(m,	1H)	
2.60	(ddd,	1H,	14.9.,	3.9,	1.9)	
4.91	(ddd,	1H,	15.8,	10.5,	2.6)	
5.16	(dd,	1H,	15.8,	1.8)	
-	
1.75	(dd,	1H,	13.0,	4.7)	
2.16	(m,	1H)	
5.04	(m,	1H)	
-	
2.14	(m,	1H)		
2.28	(m,	1H)	
1.37	(m,	1	H)	
1.66	(m,	1H)	
1.96	(br	dd,	1H,	10.7,	8.2)	
4.85	(br	d,	1H,	10.7)	
-	
-	
7.16	(s,	1H)	
-	
-	
-	
-	
5.05	(dd,	1H,	14.1,	2.3)	
5.21	(dd,	1H,	14.1,	1.0)	
1.33	(s,	3H)	
1.02	(s,	3H)	
0.93	(s,	3H)	
1.60	(s,	3H)	
-	
3,	4,	14	
1,	3,	4,	5,	11,	21	
1,	2,	5	
2,	5,	22,	23	
-	
4,	5,	7,	8,	23	
5,	7,	8,	22,	23	
5,	6,	24	
-	
7,	8,	10,	11,	24	
7,	8,	10,	11,	24	
1,	8,	9,	11,	12	
8,	9,	11,	12	
1,	2,	9,	10,	12,	13,	21	
10,	11,	13,	15,	18,	19	
-	
-	
12,	13,	14,	16,	17,	19	
-	
-	
-	
-	
13,	14,	18	
12,	13,	17,	18,	19	
1,	2,	11	
4,	6,	5,	23	
4,	6,	5,	22	
7,	9,	8	
	
2.4 Characterisation	of	the	Tropolone	Meroterpenoid	154	
An	unknown	compound	with	the	nominal	mass	of	382	(determined	through	low	resolution	mass	
spectrometry)	 was	 frequently	 detected	 by	 LCMS	 of	 A.	 strictum	 culture	 extracts	 alongside	
xenovulene	 A	101.	 The	 compound	 eluted	 at	 tR	 =	 11.3	 and	 showed	 two	UV	 absorption	maxima	
(257	 nm,	 361	 nm),	 similar	 to	 compounds	 107,	 108	 and	 typical	 for	 tropolones	 (Figure	 2.15).122	
Purification	of	5	mg	of	this	compound	from	400	mL	A.	strictum	culture	extract	enabled	full	NMR	
characterisation.	
Analysis	of	1H	and	13C	NMR	data	 identified	24	carbon	atoms	and	29	protons.	HRMS	confirmed	a	
molecular	 formula	 of	 C24H30O4	 ([M-H]-	 C24H29O4	 calculated	 381.2066,	 found	 381.2062)	 which	
proposed	one	exchangeable	proton.	The	HSQC	spectrum	revealed	four	–CH3,	five	diastereotopic	–
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CH2,	seven	–CH	and	eight	quaternary	carbons	(Table	2.5).	Comparison	with	1H	NMR,	1H,1H	COSY	and	
HMBC	 spectra	 obtained	 for	 108	 enabled	 rapid	 verification	 and	 assignment	 of	 humulene,	
dihydropyran	and	dihydrofuran	proton	and	carbon	signals	to	the	respective	positions	in	154.	
	
Figure	 2.15	 Compound	 154.	 A,	 Typical	 DAD	 chromatogram	 of	 A.	 strictum	 extracts	 obtained	 under	 101	 producing	
conditions.	B,	Characterisation	of	compound	154	eluting	at	tR	=	11.3	min.	
Two	sharp	singlets	integrating	for	one	proton	each	were	identified	in	the	1H	NMR	data	(dH	6.96	at	
dC	 110.1,	dH	 6.91	 at	dC	 113.1).	 Consideration	 of	 chemical	 shifts	 indicated	 the	 attachment	 to	 an	
aromatic	system,	which	 led	to	the	proposal	of	a	 less	oxidised	tropolone	scaffold	(154,	154a	and	
154b).	The	three	proposed	structures	could	satisfy	the	molecular	formula	(Figure	2.16A).		
	
Figure	2.16	Compound	154.	A	Proposed	structures	to	satisfy	the	nominal	mass.	B	Key	HMBC	correlations	of	154.	
However,	 possible	 structure	 154b	was	 discarded	 as	 vicinal	 protons	would	 couple	 and	 result	 in	
doublets	in	the	1H	NMR	spectrum.	In	154	and	154a	a	3JCH	coupling	between	position	18	and	20	was	
expected.	And	indeed	for	proton	dH	6.91	a	coupling	to	dC	75.2	(C-20)	was	observed,	which	suggested	
its	attachment	at	C-18.	However,	to	satisfy	154a	further	3JCH	coupling	between	position	18	and	16	
were	expected,	but	not	observed.	Instead	a	4JCH	interaction	between	proton	dH	6.96	and	dC	84.2	(C-
12)	suggested	its	attachment	at	position	C-15.	Further	3JCH	correlation	of	the	two	aromatic	protons	
led	to	the	assignment	of	tropolone	carbons	as	indicated	(Figure	2.16B).	
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Table	2.5	NMR	data	for	154	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	
Position	 dC/ppm	154	 dH/ppm	(J	in	Hz)	154	 HMBC	(H	to	C)	
1	
2	
	
3	
4	
5	
6	
	
7	
8	
9	
	
10	
	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
	
21	
22	
23	
24	
86.7	
43.1	
	
119.2	
143.9	
38.5	
41.7	
	
123.8	
136.3	
38.0	
	
28.3	
	
40.5	
84.2	
121.3	
158.9	
111.0	
166.1	
173.5	
113.1	
152.1	
75.2	
	
22.7	
30.0	
24.3	
17.1	
-	
2.31	(dd,	1H,	14.6,	10.4)	
2.63	(ddd,	1H,	14.7,	3.9,	1.9)	
4.91	(m,	1H)	
5.17	(dd,	1H,	15.8,	1.8)	
-	
1.75	(dd,	1H,	12.9,	4.7)	
2.16	(m,	1H)	
5.05	(m,	1H)	
-	
2.12	(m,	1H)	
2.26	(m,	1H)	
1.35	(m,	1	H)	
1.64	(m,	1H)	
1.94	(br	dd,	1H,	10.7,	8.2)	
4.80	(dd,	1H,	10.6,	2.1)	
-	
-	
6.96	(s,	1H)	
-	
-	
6.91	(s,	1H)	
-	
4.90	(m,	1H)	
4.97	(m,	1H)	
1.26	(s,	3H)	
1.04	(s,	3H)	
0.97	(s,	3H)	
1.61	(s,	3H)	
-	
3,	4,	14	
1,	3,	4,	5,	11,	21	
2,	5	
1,	2,	5,	22,	23	
-	
4,	5,	7,	8,	22	
5,	7,	8,	22,	23	
5,	6,	24	
-	
7,	8,	10,	11,	24	
7,	8,	10,	11,	24	
1,	8,	9,	11,	12,	13	
8,	9,	11,	12	
1,	2,	9,	10,	12,	13,	21	
10,	11,	13,	14,	15,	18,	19	
-	
-	
12,	13,	14,	16,	17	
-	
-	
13,	16,	17,	19,	20		
-	
12,	13,	17,	18,	19	
13,	14,	17,	18,	19	
1,	2,	11	
4,	6,	5,	23	
4,	6,	5,	22	
7,	9,	8	
	
2.5 Characterisation	of	Phenolic	Meroterpenoids	109a	and	109b	
LCMS	analysis	of	A.	strictum	extracts	for	the	known	intermediate	109	 identified	two	compounds	
satisfying	 the	 nominal	 mass	 of	 370	 (determined	 by	 low	 resolutions	 mass	 spectrometry)	
(Figure	2.17).	
	
Figure	2.17	Typical	DAD	chromatogram	of	A.	strictum	extracts	obtained	under	101	producing	conditions	and	extracted	
ion	chromatogram	corresponding	to	[M-H]-	=	369.	
Both	compounds	showed	similar,	weak	UV	absorption	(Figure	2.18)	but	different	retention	times	
(109a	tR	=	9.2	and	109b	tR	=	9.4).	Although	the	structure	of	109a	has	been	published	no	chemical	
characterisation	 was	 available.84	 Purification	 of	 1.1	 mg	 109a	 and	 0.7	 mg	 109b	 from	 400	 mL	
A.	strictum	culture	extracts	enabled	full	NMR	characterisation	for	109a	but	only	1H	NMR	for	109b.	
Analysis	of	1H	and	13C	NMR	data	of	109a	 identified	23	carbon	atoms	and	28	protons	(Table	2.6).	
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HRMS	of	109a	confirmed	a	molecular	formula	of	C23H30O4	for	([M-H]-	calculated	369.2066,	found	
369.2065)	which	suggested	two	exchangeable	protons.	
	
Figure	2.18	Characterisation	of	two	compounds	eluting	at	tR	=	9.2	min	and	tR	=	9.4	min	with	a	nominal	mass	of	370.	
The	HSQC	 spectrum	 revealed	 four	 –CH3,	 five	 diastereotopic	 –CH2,	six	 –CH	 and	 eight	 quaternary	
carbon	 atoms	 for	 109a	 (Table	 2.6).	 Comparison	 with	 1H	 NMR,	 1H,1H	 COSY	 and	 HMBC	 spectra	
obtained	 for	108	enabled	rapid	verification	and	assignment	of	 the	humulene,	dihydropyran	and	
dihydrofuran	proton	and	carbon	signals	to	the	respective	positions	in	109a.	
	
Figure	2.19	Key	HMBC	correlations	for	compound	109a.	
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Table	2.6	NMR	data	for	109a	and	b	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	
Position	 dC/ppm	109a	 dH/ppm	(J	in	Hz)	109a	 HMBC	(H	to	C)	 dH/ppm	(J	in	Hz)	109b	
1	
2	
	
3	
4	
5	
6	
	
7	
8	
9	
	
10	
	
11	
12	
13	
14	
15	
16	
17	
18	
19	
	
20	
21	
22	
23	
86.8	
43.1	
	
119.7	
143.2	
38.4	
41.6	
	
123.4	
136.5	
37.9	
	
29.1	
	
43.4	
82.3	
118.7	
138.5	
128.8	
145.3	
100.7	
131.6	
73.4	
	
22.8	
30.3	
24.4	
17.1	
-	
2.34	(dd,	1H,	14.7,	10.5)	
2.60	(ddd,	1H,	14.7,	2.3,	2.3)	
4.93	(ddd,	1H,	15.8,	10.5,	2.5)	
5.13	(dd,	1H,	15.8,	1.8)	
-	
1.71	(m,	1H)	
2.15	(m,	1H)	
5.00	(m,	1H)	
-	
2.11	(m,	1H)		
2.22	(1H)	
1.29	(m,	1	H)	
1.65	(m,	1H)	
1.73	(m,	1H)	
4.78	(m,	1H)	
-	
-	
-	
-	
6.43	(s,	1H)	
-	
4.80	(m,	1H)	
5.01	(m,	1H)	
1.25	(s,	3H)	
1.03	(s,	3H)	
0.95	(s,	3H)	
1.59	(s,	3H)	
-	
3,	4,	5,	14	
1,	2,	3,	4,	21	
1,	2,	5	
2,	3,	5,	20,	21	
-	
4,	5,	7,	8,	20,	21	
5,	7,	8,	21	
5,	23	
	
7,	8,	10,	11,	23	
7,	8,	10,	11,	23	
1,	8,	9,	11,	12,	13	
8,	9,	11,	12	
1,	2,	9,	10,	12,	13	
10,	11,	13,	14,	18	
-	
-	
-	
-	
13,	15,	16,	19	
-	
12,	13,	17,	18	
13,	17,	18	
1,	2,	11	
4,	6,	5,	22	
4,	6,	5,	21	
7,	9,	8	
-	
2.28	(m)	
2.50	(ddd,	14.6,	2.3,	2.3)	
4.96	(m)	
5.10	(dd,	1H,	15.9,	1.7)	
-	
1.72	(m)	
2.07-2.22	(m)	
4.98-5.03	(m)	
-	
2.07-2.22	(m)		
2.07-2.22	(m)	
contamination	at	same	dH	
1.69	(m)	
contamination	at	same	dH	
4.75	(br	d)	
-	
-	
	
-	
-	
-	
4.98-5.03	(m)	
5.08		
1.25	(s)	
1.04	(s)	
0.95	(s)	
1.59	(s)	
	
A	sharp	singlet	integrating	for	one	proton	was	identified	in	the	1H	NMR	data	for	109a	(dH	6.43	at	
dC	100.7).	Consideration	of	 the	chemical	shift	proposed	the	attachment	to	an	aromatic	scaffold.	
HMBC	correlation	of	proton	dH	6.43	was	observed	with	dC	73.4	 (C-19),	dC	118.7	 (C-13),	dC	145.3	
(C-16)	 and	dC	 128.8	 (C-15),	which	 suggested	 its	 position	 at	 C-17.	 Chemical	 shift	 values	 of	 three	
quaternary	carbons	(dC	128.8,	dC	138.5	and	dC	145.3)	indicated	a	direct	attachment	to	an	oxygen.	
For	two	of	these	(dC	128.8,	dC	145.3)	a	correlation	to	the	proton	(dH	6.43)	at	C-17	was	identified.	
Consideration	of	HMBC	correlations	only	did	not	allow	differentiation	between	positions	C-15	and	
C-16	 for	 these	 carbons.	 However,	 simulation	 of	 chemical	 shifts	 (nmrdb.org)123–125	 suggested	
dC	 128.8	 (simulated	at	dC	 131.5)	 at	C-15	and	dC	 145.3	 (simulated	dC	 146.8)	 at	C-16.	One	 carbon	
(dC	138.5)	showed	no	correlation	to	the	proton	at	position	17,	instead	showing	a	correlation	to	a	
proton	 (dH	2.34)	 at	 C-2	 and	was	 thus	 assigned	 at	 C-14.	 The	 quaternary	 carbon	 at	dC	 131.6	 only	
couples	with	protons	at	C-19	and	was	thus	assigned	at	position	C-18.	
The	second	 isolated	compound	with	a	nominal	mass	of	370	was	only	analysed	by	 1H	NMR.	The	
collected	 spectroscopic	 information	 was	 relatively	 poor,	 but	 based	 on	 comparison,	 109b	 is	
proposed	to	be	a	related	compound	due	to	the	presence	of	key	humulene	signals	(Figure	2.20).	
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Figure	2.20	1H	NMR	of	compounds	109a	and	109b.	
Further	comparison	of	the	1H	NMR	identified	changes	in	chemical	shifts	of	the	two	protons	17	and	
2b.	The	aromatic	proton	(17)	in	109b	has	a	chemical	shift	of	dH	6.25,	instead	of	dH	6.43	in	109a.	This	
could	 indicate	 a	 differently	 substituted	 aromatic	 ring,	 similar	 to	 previously	 characterised	
compounds	107a	and	107b	 (Chapter	2.3).	 In	addition,	the	chemical	shift	of	proton	2b	(dH	2.5)	 is	
shifted	~0.1	ppm	upfield	in	109b	in	comparison	to	109a	(dH		2.6).	A	similar,	but	~0.2	ppm	upfield	
shift	of	proton	2b	(2b	dH	2.60)	is	observed	in	compound	107b,	where	position	C-15	is	substituted	
with	a	proton	instead	of	a	hydroxyl	function	in	107a	(2b	dH	2.81)	(Chapter	2.3).	In	addition,	for	the	
chemical	 shift	of	methylene	protons	at	position	C-19	a	downfield	 shift	 can	be	observed	 (dH	4.8,	
dH	5.01	in	107a	and	dH	4.98-5.03,	dH	5.08	in	107b).	Again	here	a	similar	shift	 is	observed	in	NMR	
data	of	the	structural	isomers	107a	and	107b	(dH	5.00,	dH	5.08	in	107a	and	dH	5.05,	dH	5.21	in	107b)	
(Table	2.7).	
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Table	2.7	Comparison	of	selected	1H	NMR	data.	
Position	 dH/ppm	
109a	
dH/ppm		
10b	
dH/ppm		
107a	
dH/ppm	
107b	
2b	
19/20	
	
2.60	
4.8	
5.01	
2.50	
4.98-5.03	
5.08	
2.81	
5.00	
5.21	
2.60	
5.05	
5.21	
	
HRMS	 of	 109b	 suggested	 a	 molecular	 formula	 of	 C23H30O4	 ([M-H]-	 calculated	 369.2066,	 found	
369.2066),	which	would	satisfy	the	proposed	structure	109b	and	109c	(Figure	2.21).	1H	NMR	spectra	
were	simulated	for	compounds	109b	and	109c.124–126	A	chemical	shift	of	dH	6.24	was	predicted	for	
the	isomer	109b,	and	dH	6.14	for	109c.	Comparison	of	predicted	and	measured	chemical	shift	of	
dH	6.25	suggested	that	the	isolated	compound	is	more	likely	the	109b	structural	isomer	of	109a.		
For	further	comparison	MS2	data	was	gathered	on	the	[M-H]-	m/z	=	369	peak	in	109a	and	109b/c.	
For	 both	 compounds	 one	 major	 fragmentation	 peak	 at	m/z	 =	 165	 was	 observed.	 This	 could	
correspond	 to	 the	 separation	of	 the	polyketide	and	humulene	moieties	 (Figure	2.21).	 Full	NMR	
characterisation	could	prove	this	theory,	but	109a	and	109b	are	not	always	produced	by	A.	strictum	
and	often	only	traces	are	observed.	
	
Figure	2.21	Proposed	fragmentation	ions	of	109a	(A)	and	109b	or	109c	(B).	
	
2.6 Characterisation	of	Meroterpenoid	156	
A	 compound	 with	 the	 nominal	 mass	 of	 362	 (determined	 through	 low	 resolution	 mass)	 was	
sometimes	detected	by	LCMS	in	A.	strictum	culture	alongside	xenovulene	A	101.	The	compound	
(156)	eluted	at	tR	=	8.4	and	showed	a	maximal	UV	absorption	at	211	nm	(Figure	2.22).	Purification	
of	1.7	mg	from	2	L	A.	strictum	wild-type	(WT)	culture	extract	enabled	full	NMR	characterisation.		
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Figure	2.22	Compound	156.	A	Structure	and	tR	=	8.4	min	of	purified	compound	156.	B,	Characterisation	of	compound	
156.	
Analysis	of	 1H	and	 13C	NMR	data	of	156	 identified	21	carbon	atoms	and	29	protons	 (Table	2.8).	
HRMS	 of	 156	 confirmed	 a	 molecular	 formula	 of	 C21H30O5	 ([M]H+	 calculated	 363.2171,	 found	
363.2179)	which	suggested	one	exchangeable	proton.	
Table	2.8	NMR	data	for	156	in	CD3OD		(500	MHz)	referenced	CD3OD.	
Position	 dC/ppm	156	 dH/ppm	(J	in	Hz)	156	 HMBC	(H	to	C)	
1	
2	
	
3	
4	
5	
6	
	
7	
8	
9	
	
10	
	
11	
12	
13	
	
14	
15	
16	
17	
18	
19	
20	
21	
88.6	
44.1	
	
120.7	
144.8	
39.2	
42.5	
	
124.1	
137.7	
37.9	
	
31.4	
	
43.4	
85.8	
70.7	
	
49.1	
47.8	
174.7	
175.9	
22.1	
24.6	
30.5	
17.3	
-	
2.33	(m,	1H)	
2.46	(ddd,	1H,	14.7,	2.2,	2.2)	
5.11	(m,	1H)	
5.23	(dd,	1H,	15.9,	1.8)	
-	
1.79	(br	dd,	1H,	13.0,	4.9)	
2.25	(m,	1H)	
5.09	(m,	1H)	
-	
2.04	(br	dd,	1H,	12.8,	7.2)	
2.28	(m,	1H)	
1.42	(m,	1	H)	
1.56	(m,	1H)	
1.96	(dd,	1H,	8.3,	8.3)	
4.21	(m,	1H)	
3.73	(m,	1H)	
4.23	(m,	1H)	
3.55	(ddd,	1H,	8.1,	8.1,	5.3)	
3.74	(m,	1H)	
-	
-	
1.37	(s,	3H)	
1.08	(s,	3H)	
1.07	(s,	3H)	
1.65	(s,	3H)	
-	
1,	3,	4,	5	
1,	3,	4,	11	
1,	2,	5	
2,	5,	19,	20	
-	
4,	5,	7,	8,	19	
4,	5,	7,	8,	19	
5,	21	
	
7,	8,	10,	11,	21	
7,	8,	10,	11,	21	
1,	8,	9,	11,	12,	13	
8,	9,	11,	12	
1,	2,	9,	10,	12,	13,	18	
10,	16	
12,	17	
12,	14	
13,	15,	16,	17	
16,	17	
-	
-	
1,	2	
4,	6,	5,	20	
4,	6,	5,	19	
7,	9,	8	
	
Acetonitril H2O 9:1
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The	HSQC	spectrum	showed	 four	–CH3,	 five	diastereotopic	–CH2,	seven	–CH	and	 five	quaternary	
carbon	atoms	(Table	2.8).	Comparison	with	1H	NMR,	1H,1H	COSY	and	HMBC	spectra	obtained	for	
108	 and	 101	 enabled	 rapid	 verification	 and	 assignment	 of	 humulene,	 tetrahydropyran	 and	
tetrahydrofuran	 proton	 and	 carbon	 signals	 to	 the	 respective	 positions	 in	 156.	 Relative	
stereochemistry	at	C-1,	C-11	and	C-12	was	assumed	to	be	identical	to	xenovulene	A	101,	but	not	
further	determined.	
The	two	newly	identified	carbon	signals	(dC	174.7,	dC	175.9	)	suggested	the	presence	of	carboxylic	
acid	and/or	ester	functional	group.	HMBC	correlations	led	to	the	proposal	of	structure	156,	which	
satisfies	the	HRMS	(Figure	2.23).	Strong	3JCH	correlations	observed	in	HMBC,	suggested	the	relative	
stereochemistry	at	C-12,	C-15	and	C-14	to	be	identical	to	xenovulene	A	101.	However,	for	further	
validation	of	the	stereochemistry	a	NOE	experiment	should	be	acquired.	
	
Figure	2.23	Key	HMBC	correlations	of	compound	156.	
	
2.7 Characterisation	of	the	Merotperpenoids	157	and	158	
A	compound	with	a	nominal	mass	of	360	(determined	through	low	resolution	mass	spetrometry)	
was	 rarely	 detected	 by	 LCMS	 of	A.	 strictum	 culture	 alongside	 xenovulene	 A	 101.	 2	 mg	 of	 the	
compound	 eluting	 at	 tR	 =	 9.2	 were	 purified	 by	 LCMS	 from	 1	 L	 A.	 strictum	 WT	 culture	 extract	
(Figure	2.24).	1H	NMR	spectrum	showed	characteristic	humulene	signals	and	thus	full	spectroscopic	
information	 was	 acquired	 (13C,	 1H,1H	 COSY,	 HMBC,	 HSQC).	 Further	 evaluation	 of	 NMR	 data	
suggested	the	presence	of	 two	co-eluting	meroterpenoid	compounds	(157	and	158)	 (Table	2.9).	
The	major	compound	157	was	determined	to	have	a	chemical	formula	of	C21H30O4	([M]H+	C21H30O4	
calculated	 347.2222,	 found	 347.2220)	 and	 for	 the	 minor	 158	 C21H28O5	 was	 found	 ([M]Na+	
C21H28O5Na	calculated	383.1834,	found	383.1827).	
The	HSQC	spectrum	of	compound	157	showed	four	–CH3,	six	diastereotopic	–CH2,	five	–CH	and	six	
quaternary	carbon	atoms	(Table	2.9).	The	HSQC	spectrum	of	compound	158	in	comparison	showed	
four	 –CH3,	 five	 diastereotopic	 –CH2,	 five	 –CH	 and	 seven	 quaternary	 carbon	 atoms	 (Table	 2.9).	
Comparison	 with	 1H	 NMR,	 1H,1H	 COSY	 and	 HMBC	 spectra	 obtained	 for	 108	 enabled	 rapid	
O
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verification	and	assignment	of	humulene	(C-1	to	C-11;	and	C-18	to	C-21)	and	bridging	proton	and	
carbon	signals	(C-12,	C-16)	to	the	respective	positions	in	157	and	158.	
In	contrast	to	previous	compounds	no	di-	or	tetrahydrofuran	ring	system	was	identified,	but	the	
ether	linkage	between	C-12	and	C-13	was	still	intact.	3JCH	and	2JCH	correlation	thus	strongly	proposed	
the	presence	of	a	six	membered	ring	with	an	a,b-unsaturated	carbonyl	functional	group	(dC	202.5	
in	157	 and	 dC	200.7	 in	158)	 in	 place	 of	 the	 former	 tetrahydrofuran.	 Vice	 versa,	 the	 original	 six	
membered	di-	or	tetrahydropyran	ring	could	not	be	detected,	but	a	furan	was	proposed	based	on	
HMBC	correlations	(Figure	2.25).	
	
Figure	2.24	Compounds	157	and	158.	A,	Purified	compounds	157	and	158	co-eluting	at	tR	=	9.2	min.	B,	Characterisation	
of	compound	157.	C,	Characterisation	of	compound	158.	
The	NMR	data	for	compound	157	showed	an	additional	-CH2-O	group	(dH	4.39,	dH	4.60	at	dC	58.9).	
A	 geminal	 coupling	 is	 observed	 for	 the	 two	 protons	 attached	 to	 C-17,	 which	 suggested	 its	
attachment	next	 to	a	quaternary	 carbon	such	as	C-15.	Close	analysis	of	 the	multiplet	of	proton	
dH	4.39	suggested	a	doublet	of	doublets	(dd)	with	a	large	(2JHH	=	13.8)	geminal	coupling	and	a	small	
(JHH	=	1.4)	long	range	coupling.	However,	in	the	1H,	1H	COSY	no	correlating	proton	was	identified,	
which	suggested	 the	presence	of	 two	conformers	 rather	 than	a	 long	 range	coupling.	The	minor	
compound	158	 lack	 these	methylene	protons,	but	 instead	a	weak	carbon	signal	at	dC	174.3	was	
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observed,	which	proposed	the	presence	of	a	carboxylic	acid.	No	3JCH	correlation	was	observed	for	
this	carbon,	which	justifies	it	at	position	C-17.	
	
Figure	2.25	Key	HMBC	correlations	A,	for	compound	157.	B,	Key	HMBC	correlations	for	compound	158.	
These	 two	 compounds	 display	 a	 novel	 arrangement	 of	 the	 original	 xenovulene	 scaffold,	 thus	
stereochemistry	at	positions	C-1,	C-11	and	C-12	is	not	indicated.	It	could	be	that	the	xenovulene	A	
101	stereochemistry	at	this	positions	are	not	retained	during	putative	5	and	6	ring	rearrangements.	
Table	2.9	NMR	data	for	157	and	158	in	CD3OD	(500	MHz)	referenced	to	CD3OD.	
Position	 dC/ppm	
157	
dH/ppm	(J	in	Hz)	
157	
HMBC	(H	to	C)		
157	
dC/ppm		
158	
dH/ppm	(J	in	Hz)		
158	
HMBC	(H	to	C)		
158	
1	
2	
	
3	
4	
5	
6	
	
7	
8	
9	
	
10	
	
11	
12	
13	
	
14	
15	
16	
17	
	
18	
19	
20	
21	
87.9	
43.2	
	
120.7	
144.5	
39.2	
42.6	
	
124.2	
137.7	
39.0	
	
29.6	
	
41.9	
82.7	
74.1	
	
202.5	
109.0	
164.5	
58.9	
	
21.8	
24.4	
30.5	
17.1	
-	
2.33	(m,	1H)	
2.58	(m,	1H)	
5.10	(ddd,	1H,	12.6,	10.8,	2.3)	
5.20	(dd,	1H,	15.9,	1.9)	
-	
1.75	(br	dd,	1H,	12.8,	4.4)	
2.23	(m,	1H)	
5.08	(m,	1H)	
-	
2.09	(br	dd,	1H,	12.2,	12.2)		
2.34	(m,	1H)	
1.44	(m,	1	H)	
1.57	(m,	1H)	
1.83	(m,	1H)	
4.57	(m,	1H)	
4.01	(m,	1H)	
4.06	(m,	1H)	
-	
-	
-	
4.39	(dd,	1H,	13.8,	1.4)	
4.60	(m,	1H)	
1.20	(s,	3H)	
1.04	(s,	3H)	
1.09	(s,	3H)	
1.61	(s,	3H)	
-	
3,	4,	16,	18	
1,	3,	4,	11,	12,	18	
2,	4,	5	
3,	5,	6,	19,	20	
-	
4,	5,	7,	8,	19	
5,	7,	8,	19,	20	
5,	21	
	
7,	8,	10,	11,	21	
7,	8,	10,	11,	21	
1,	8,	9,	11,	12	
8,	9,	11,	12	
1,	2,	9,	10,	12,	15,	18	
10,	11	
12,	14	
12,	14,	15	
-	
-	
-	
15,	16	
15,	16	
1,	2,	11	
4,	5,	6,	20	
4,	5,	6,	19	
7,	9,	8	
87.9	
43.4	
	
121.0	
144.2	
39.2	
42.5	
	
124.2	
137.6	
39.1	
	
30.0	
	
41.6	
82.8	
74.1	
	
200.7	
105.0	
159.8	
174.3	
-	
21.4	
30.5	
24.6	
17.1	
-	
2.33	(m,	1H)	
2.58	(m,	1H)	
4.91	(ddd,	1H,	15.8,	10.5,	
2.6)	
5.16	(dd,	1H,	15.8,	1.8)	
-	
1.75	(dd,	1H,	13.0,	4.7)	
2.16	(m,	1H)	
5.04	(m,	1H)	
-	
2.14	(m,	1H)		
2.28	(m,	1H)	
1.37	(m,	1	H)	
1.66	(m,	1H)	
1.87	(m,	1H)	
4.57	(m,	1H)	
3.96	(m,	1H)	
4.03	(m,	1H)	
-	
-	
-	
-	
-	
1.21	(s,	3H)	
1.04	(s,	3H)	
1.08	(s,	3H)	
1.60	(s,	3H)	
-	
3,	4,	16,	18	
1,	3,	4,	11,	12,	18	
2,	4,	5	
3,	5,	6,	19,	20	
-	
4,	5,	7,	8,	19	
5,	7,	8,	19,	20	
5,	21	
	
7,	8,	10,	11,	21	
7,	8,	10,	11,	21	
1,	8,	9,	11,	12	
8,	9,	11,	12	
1,	2,	9,	10,	12,	18	
10,	11	
12,	14	
12,	14,	15	
-	
-	
-	
-	
-	
1,	2,	11	
4,	5,	6,	20	
4,	5,	6,	19	
7,	9,	8	
	
2.8 Analysis	of	the	Production	of	Polyketide	Intermediates	
In	 addition	 to	 the	 described	 meroterpenoids	 (Chapters	 2.1-2.7),	 the	 A.	 strictum	 extracts	 were	
analysed	for	possible	polyketide	precursors.	The	proteins	encoded	in	the	aspks1	BGC	are	predicted	
homologues	 of	 those	 known	 from	 tropolone	 biosynthesis	 (Chapter	 1.3.1).	 Thus	 extracted	 ion	
chromatograms	were	analysed	for	the	presence	of	key	tropolone	biosynthesis	intermediates	such	
as:	3-methylorcinaldehyde	120;	the	enone	121;	stipitaldehyde	123	and	stipitafuran	125;	as	well	as	
cordytropolone	159	 (Figure	2.26A)	using	[M]H+	or	 [M-H]-.	As	no	standards	for	these	compounds	
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were	 available,	 the	 initial	 assignments	 were	 tentative	 (Figure	 2.26B).	 However,	 later	 gene	
expression	in	A.	oryzae	(Chapter	5)	enabled	the	isolation	and	detailed	characterisation	of	120,	121,	
123,	 125	 and	 159.	 Comparison	 of	 retention	 time	 tR,	 mass	 and	 UV	 spectra	 of	 A.	 strictum	 and	
compounds	 purified	 from	 A.	 oryzae	 confirmed	 their	 identity	 (Chapter	 5.2	 for	 detailed	
characterisation	of	these	compounds).		
	
Figure	2.26	Polyketide	intermediates	in	A.	strictum	WT	extracts.	A,	Proposed	polyketide	precursor	of	xenovulene	A	101.	
B,	Extracted	ion	chromatograms	for	the	analysis	of	production	of	the	indicated	intermediates.	
All	key	intermediates	(120,	121	and	125)	except	stipitaldehyde	123	were	observed	in	A.	strictum	
extracts.	It	is	likely	that	123	is	a	reactive	intermediate	which	is	prevented	from	accumulation	due	
to	fast	processing.	A	similar	observation	was	made	upon	heterologous	gene	expression	(Chapter	5):	
accumulation	of	stiptialdehyde	123	was	only	observed	when	downstream	processing	genes	were	
not	co-expressed	in	A.	oryzae	NSAR.	In	addition,	HRMS	analysis	of	the	A.	strictum	compound	eluting	
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at	tR	=	4.9	min	confirmed	its	molecular	formula	to	be	identical	to	stipitafuran	125	([M-H]-	C9H5O4	
calculated	177.0188,	found	177.0188).	
	
2.9 Non-Producing	Conditions	
For	the	differential	expression	analysis	(Chapter	3.2)	A.	strictum	was	grown	under	xenovulene	A	
producing	 (ASPM)	 and	 non-producing	 conditions	 (DPY).	 In	 order	 to	 establish	 non	 producing	
conditions	the	ascomycete	was	sub-cultured	in	a	series	of	different	liquid	media	(PDB,	YMG,	ME,	
DPY,	 CM,	 ASSA;	 Figure	 2.27).	 All	 media	 expect	 DPY	 showed	 at	 least	 trace	 production	 of	 101.	
However,	the	usual	secondary	metabolites	can	only	be	observed	in	A.	strictum	seed	medium	(ASSA)	
(101,	109a,	108,	107b).	In	three	other	cultures	a	compound	eluting	at	tR	=	9.6	(YMG,	DPY,	CM)	was	
observed.	In	PDB	medium	another	a	new	metabolite	is	produced	eluting	at	tR	=	9.5	min.		
	
Figure	 2.27	DAD	 chromatogram	of	 extracts	 obtained	 from	A.	 strictum	 liquid	 cultures	 grown	 for	 6	 d	 in	 the	 indicated	
different	media	(PDB,	YMG,	ME,	DPY,	CM,	ASSA).	
The	A.	strictum	xenovulene	producing	strain	was	exploited	for	101	production,	but	has	not	yet	been	
further	 analysed	 for	 the	production	of	metabolites	under	different	 growth	 conditions.	 This	 first	
screen	 showed	 that	 there	 is	 the	 potential	 to	 isolate	more	 putative	 new	metabolites	 from	 this	
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fungus.	 Analysis	 of	 UV	 and	 MS	 of	 the	 newly	 observed	 compounds,	 suggested	 no	 relation	 to	
xenovulenes	101,	107-109,	but	no	further	analysis	was	carried	out.	
	
2.10 	 Discussion	and	Outlook	
Xenovulene	A	101	was	 reported	alongside	co-metabolites	107,	108	 and	109.	However,	only	 full	
characterisation	for	101	was	available.	Purification	and	NMR	analysis	of	compounds	107a,	108	and	
109a	enabled	assignment	of	carbon	and	proton	signals	for	the	first	time.	In	addition,	with	107b,	
109b	and	154	three	similar	but	new	compounds	were	isolated	and	described.	
As	 it	 is	 not	 yet	 known	at	which	 stage	 the	polyketide	 and	 terpene	moiety	 in	101	 are	 fused,	 the	
identification	of	the	less	hydroxylated	tropolone	154	gives	the	first	indication	that	the	fusion	step	
could	 happen	 to	 a	 tropolone	 moiety	 (126)	 (Scheme	 2.1).	 No	 pre-tropolone	 (e.g.	 benzenoid)	
meroterpenoids	have	been	observed	 in	A.	strictum,	and	neither	reported	 in	fungi	producing	the	
related	compounds	eupenifeldin	111	or	epolone	A	113.86,88	Comparing	the	level	of	oxidation	in	154	
and	111	or	113,	the	oxidation	pattern	of	stipitaldehyde	123	or	stipitafuran	125	can	be	recognized.	
Stipitaldehyde	123	should	also	be	considered	as	final	polyketide	because	in	111	and	113	no	further	
hydroxylation	 of	 the	 6-methyl	 group	 is	 required	 to	 yield	 meroterpenoids.	 This,	 and	 the	
identification	 of	 125	 in	 extracts	 of	 A.	 strictum	 suggests	 either	 123	 or	 125	 as	 the	 most	 likely	
polyketides	for	humulene	106	attachment.	
For	both	compounds	107a	and	109a	structural	isomers	(107b	and	109b)	were	identified.	This	raises	
the	 question	 whether	 these	 compounds	 are	 true	 intermediates	 or	 shunts	 on	 the	 xenovulene	
pathway.	The	proposed	mechanism	for	the	two	consecutive	ring	contractions	requires	an	oxidative	
rearrangement/derformylation	cascade	(Scheme	1.18A).84	However,	starting	with	meroterpenoid	
154	oxidation	followed	by	ring	contraction	at	position	C-15	or	C-18	seems	equally	possible.	Later	
gene	expression	experiments	showed	the	involvement	of	two	FAD	dependent	monooxygenases	in	
the	ring	contraction	mechanism	(Chapter	5.7.4	for	discussion	of	a	more	detailed	mechanism).	
Isolation	 and	 structure	 elucidation	 of	 three	 further	 meroterpenoids	 156,	 157	 and	 158	 from	
A.	strictum	suggested	these	to	be	post-xenovulene	products,	which	most	 likely	arise	through	an	
unknown	degradation	process.	
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Scheme	2.1	Proposed	biosynthesis	for	101	in	regard	to	newly	isolated	compounds.	
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3 Genome	and	Transcriptome	of	A.	strictum	
In	 preliminary	 work,	 a	 potential	 partial	 xenovulene	 A	 101	 BCG	 was	 identified	 (aspks1	 BGC,	
Chapter	 1.3.2).102,127	 The	 BGC	 encodes	 the	 core	 tropolone	 forming	 homologues	 (aspks1/tspks1:	
NR-PKS,	 asL1/tsL1:	 FAD	 dependent	 monooxygenase,	 asL3/tsR5:	 NHI	 dioxygenase,	 asR2/tsL2:	
P450).97,98,102	In	addition,	two	oxidoreductases	are	encoded	(asL4/asL5)	(Figure	3.1).	These	could	be	
involved	 in	 the	 two	 oxidative	 ring	 contractions	 from	 seven	 membered	 tropolones	 to	
cyclopentenone	 in	 xenovulene	 A	101	 (Scheme	 1.17).	 However,	 the	 partial	 22	 kb	 BGC	 does	 not	
encode	a	terpene	cyclase	which	would	be	expected	for	humulene	106	biosynthesis.	In	addition,	no	
genes	 encoding	 proteins	 of	 unknown	 function	 for	 a	 putative	 hetero	 Diels	 Alder	 type	 fusion	 of	
polyketide	and	terpene	(Scheme	1.17)	are	present.	Thus	to	complete	the	partial	BGC	and	also	to	
enable	a	genome	wide	search	for	genes	that	could	be	involved	in	101	biosynthesis,	the	A.	strictum	
genome	was	sequenced.	
	
Figure	3.1	Comparison	of	partial	aspks1	BGC	and	stiptitatic	acid	19	BGC	from	T.	stipitatus.	Homologous	genes	are	marked	
by	arrows,	%	indicates	protein	identity.	
For	 further	 analysis	 of	 gene	 expression	 under	 xenovulene	 A	 101	 producing	 and	 non-producing	
conditions	the	respective	transcriptomes	(total	of	all	expressed	messenger	ribonucleic	acid,	mRNA)	
were	 sequenced.	 Fungal	 genomes	 usually	 encode	 several	 BGC	 but	 not	 all	 are	 expressed	
ubiquitously.	 In	 fact,	 BGC	 activation	 and	 secondary	 metabolite	 production	 is	 regulated	 by	
environmental	circumstances.	For	fungi,	different	secondary	metabolites	are	often	observed	when	
grown	 in	 different	 media	 or	 static/liquid	 culture.1	 In	 the	 end	 enzymes	 such	 as	 PKS	 or	 NRPS	
synthesise	 the	 secondary	 metabolite,	 but	 these	 proteins	 are	 only	 present	 in	 cells	 after	 gene	
expression.	Although	attempts	to	correlate	high	mRNA	levels	with	high	protein	concentrations	have	
not	been	consistent,128	increased	levels	of	mRNA	indicate	active	gene	expression.	By	comparison	of	
transcriptomes	collected	under	xenovulene	A	producing	and	non-producing	conditions	it	should	be	
possible	to	identify	genes	associated	with	xenovulene	A	101	production.	
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3.1 Whole	Genome	Sequencing	and	antiSMASH	Analysis	
Genomic	DNA	(gDNA)	of	A.	strictum	was	obtained	by	phenol	chloroform	extraction	of	freeze-dried	
fungal	mycelia	(taken	from	2.5	d	old	PDB	liquid	culture)	and	purified	by	caesium	chloride	gradient	
centrifugation	(Figure	3.2A).		
	
Figure	3.2	gDNA	purification	and	sequencing.	A,	A.	 strictum	 gDNA	1)	after	phenol	chloroform	extraction	and	2)	after	
caesium	chloride	centrifugation.	B,	Illumina	MiSeq	System	at	the	CeBiTec	in	Bielefeld	and	C,	Illumina	flow	cell	for	sample.	
The	sample	was	submitted	to	the	Center	for	Biotechnology	(CeBiTec,	University	of	Bielefeld)	 for	
Illumina	MiSeq	paired-end	 sequencing	 (Figure	3.2B	and	C).	 The	 raw	data	were	processed	by	Dr	
Daniel	Wibberg	 using	 an	 in-house	 software	 platform	 based	 on	 CASAVA	 1.8.2	 (Illumina).129	 The	
sequenced	300	bp	 reads	were	assembled	with	 gsAssembler	2.8129	with	default	 settings.	A	draft	
genome	 of	 33.8	Mb	 in	 51	 scaffolds	 with	 a	 N50	 scaffold	 length	 of	 1.3	Mb	was	 obtained.	 Gene	
prediction	and	annotation	was	performed	with	AUGUSTUS	3.0.3	and	the	GenDBE	platform.130,131	A	
total	number	of	10622	genes	were	predicted	(Table	3.1).	
Table	3.1	Statistics	of	draft	genome	assembly	and	gene	prediction	in	A.	strictum	genome.	
Assembly	statistics	 Gene	prediction	
Bases	in	Scaffolds	(bp)	
#	of	scaffolds	
#	of	contigs	
GC	content	(%)	
Avg.	scaffold	(bp)	
N50	scaffold	(bp)	
largest	scaffold	(bp)	
avg.	scaf.	contig	(bp)	
avg.	contig	(bp)	
N50	contig	(bp)	
Largest	contig	(bp)	
33,842,462	
51	
615	
52.28	
663,577	
1,366,384	
2,269,511	
90,075	
55,283	
196,596	
618,099	
#	of	predicted	genes	
avg.	gene	length	(bp)	
sense	strand	
antisense	strand	
avg.	#	of	exon	per	gene	
avg.	exon	length	(bp)	
largest	exon	(bp)	
smallest	exon	(bp)	
avg.	intron	length	(bp)	
largest	intron	(bp)	
smallest	intron	(bp)	
10622	
1788	
5268	
5394	
2.99	
535	
11915	
2	
93	
1887	
29	
	
AntiSMASH	is	a	platform	which	enables	a	genome	wide	search	for	BGC	within	a	genome	sequence.	
It	cross-links	the	output	with	either	characterised	or	in	silico	predicted	BGC.20–22	A	version	optimised	
for	fungal	genomes	(fungiSMASH)	predicted	118	BGC	in	the	A.	strictum	draft	genome.	Only	39	of	
these	BGC	were	matched	to	a	core	secondary	metabolite	encoding	gene	(PKS,	NRPS	or	terpene)	
and	these	were	further	investigated.	The	twelve	predicted	PKS	containing	BGC	formed	the	largest	
group,	but	also	eight	terpene	and	five	NRPS-containing	as	well	as	six	combined	BGC	were	identified.	
A B C1		2
20	kb	-
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Seven	of	the	predicted	clusters	showed	between	14-83%	genes	similar	to	previously	characterised	
BGC	(Figure	3.3).97,98,132–137		
	
Figure	3.3	Pie	chart	of	BGC	predicted	by	fungiSMASH	with	a	match	to	PKS,	NRPS	or	terpene	gene.	The	predicted	BGC	
assigned	 in	 ‘other’	 clade	were	 revised	and	all	were	 found	 to	encode	an	adenylation	domain	 containing	protein.	BGC	
numbers	are	denoted	as	well	as	the	core	gene	(encoding	PKS,	NRPS	and	terpene)	is	listed	with	gene	number.	Structures	
of	natural	products	are	shown	for	BGC	which	show	similarity	to	characterised	BGC.	
The	domain	organisations	of	 all	 predicted	PKS	genes	were	 further	 analysed	with	 the	 conserved	
domain	 (CD)	 analysis	 tool.	 Ten	 HR-PKS,	 one-PR-PKS,	 three	 NR-PKS	 and	 one	 type	 III	 PKS	 were	
annotated	(Figure	3.4).	138–141	Only	one	(Asg3673)	of	the	three	encoded	NR-PKS	was	found	to	have	
a	 C-Met	 and	 R	 domain,	 which,	 according	 to	 the	 biosynthetic	 hypothesis	 (Chapter	 1.3.2),	 are	
required	to	release	the	polyketide	precursor	3-methylorcinaldeyhde	120.	Sequence	alignment	of	
Asg3673	and	aspks1	(Figure	3.1)	confirmed	its	identity	(100%)	and	gave	first	in	silico	evidence	that	
BGC44	(referred	to	as	aspks1	BGC)	is	the	best	candidate	for	xenovulene	A	101	biosynthesis.	
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Figure	 3.4	 Conserved	 domain	 analysis	 of	 PKS	 genes	 in	 the	A.	 strictum	 genome.	 SAT	 =	 starter	 unit	 acyl	 transferase,	
KS	 =	 ketosynthase,	 AT	 =	 acyltransferase,	 PT	 =	 product	 template,	 DH	 =	 dehydratase,	 C-Met	 =	 C-methyl	 transferase,	
ER	 =	 enoylreductase,	 KR	 =	 ketoreductase,	 ACP	 =	 acyl	 carrier	 protein,	 TE	 =	 thiolesterase,	 R	 =	 reductive	 release,	
O-AT	=	O-acyltransferase.	
	
3.2 Transcriptome	Analysis	under	Producing	and	Non-Producing	Conditions	
Xenovulene	A	101	production	medium	(ASPM)	is	well	known	from	preliminary	experiments.118	To	
identify	 101	 non-producing	 conditions	 the	 secondary	 metabolite	 production	 was	 analysed	 in	
different	liquid	media	(Chapter	2.9).	DPY	medium	was	found	to	suppress	101	production	but	did	
not	 inhibit	 the	 growth	 of	A.	 strictum	 (Figure	 3.5).	 Therefore,	 it	 was	 selected	 as	 non-producing	
medium	for	comparative	transcriptome	analysis.	
Liquid	cultures	for	both	conditions	(ASPM,	DPY)	were	inoculated	with	an	A.	strictum	single	colony	
and	cultured	for	nine	days.	Samples	of	two	biological	replicates	for	each	condition	were	taken	at	
day	3,	6	and	9	and	combined	for	total	RNA	isolation	by	kit	(Zymo	Research).	The	RNA	samples	were	
submitted	to	CeBiTec	for	cDNA	library	preparation	and	Illumina	paired-end	sequencing.	
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Figure	 3.5	 DAD	 chromatograms	 of	 A.	 strictum	 extracts	 grown	 under	 producing	 (upper)	 and	 non-producing	 (lower)	
conditions.	Peaks	at	tR	=	8.4,	9.2,	9.6,	10.0	and	11.7	correspond	to	xenovulenes	101,	107a,	107b,	108	and	109a.	
The	 raw	data	were	 again	processed	by	Dr	Daniel	Wibberg	using	 an	 in-house	 software	platform	
based	on	CASAVA	1.8.2	(Illumina).142	The	75	bp	reads	were	mapped	on	the	A.	strictum	draft	genome	
with	 tophat2,143	after	 further	processing	by	 the	FASTX144	and	 trimmomatic145	 toolkits.	A	 total	of	
~80/120	million	 reads	were	 sequenced	under	 non-producing/producing	 conditions.	On	 average	
95%	of	those	were	mapped	to	the	A.	strictum	draft	genome	(Table	3.2).	
Table	3.2	Read	count	after	quality	control	and	unmapped	reads.	
conditions	 non-producing1	 non-producing2	 producing1	 producing2	
read	counts	after	filter	and	
trimming	
unmapped	reads	
%	
39.366.754	
	
2.431.118	
6.2%	
43.664.326	
	
2.731.955	
6.3%	
80.873.578	
	
4.407.226	
5.0%	
47.509.594	
	
1.223.507	
2.6%	
	
The	sequenced	transcriptomes	for	non-producing	(A)	and	producing	(B)	conditions	were	used	to	
perform	a	differential	expression	sequence	(DESeq)	analysis	by	Dr	Daniel	Wibberg.146	DESeq	 is	a	
software	package	 that	uses	 statistical	 testing	 and	a	negative	binominal	 distribution	 to	 compare	
differences	in	observed	read	counts.	It	evaluates	whether	the	observed	differences	in	two	biological	
samples	are	significant	or	in	the	range	of	natural	variation.	The	mean	expression	(meanA	or	meanB)	
of	non-producing	(A)	and	producing	(B)	conditions	is	calculated	from	the	normalized	read	counts	of	
biological	replicates	(in	this	work	two	per	condition).	The	normalized	read	count	 is	then	used	to	
calculate	the	relative	gene	expression	(fold	change,	meanB	over	meanA)	(Figure	3.6).	Comparing	
the	log2-fold	change	of	selected	genes	their	up-	(log2-fold	change>0)	and	downregulation	(log2-fold	
change<0)	can	be	determined.	If	a	log2-fold	change	of	>2	and	an	adjusted	p-value	>0.05	(significant	
differential	expression	determined	by	Benjamini-Höchberg147	testing	with	a	false	discovery	rate	of	
5%)	was	observed,	genes	were	regarded	as	differentially	expressed.	These	genes	are	displayed	in	
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red	(Figure	3.6);	genes	displayed	in	black	were	regarded	as	not	differently	expressed.	Genes	with	
large	or	infinite	log2-fold	change	are	displayed	at	the	borders	of	the	scatter	diagram.	
	
Figure	3.6	Scatter	diagram	shows	mean	expression	under	both	conditions	(mean(A+B)/2)	over	log2-fold	change.	Every	
dot	correlates	to	one	gene,	green	dots	represent	Asg3666-79	and	orange	dots	represent	Asg3663-5	+	Asg3680-82.	
The	expression	of	the	aspks1	gene	cluster	(green	dots,	Figure	3.6)	was	analysed	by	comparing	the	
log2-fold	 change	 of	 genes	 (Asg3663-Asg3682)	 encoded	 ~25	 kb	 up-	 and	 downstream	 of	 aspks1	
(Figure	3.6	and	Table	3.3).	The	log2-fold	change	of	genes	between	Asg3666-3679	was	found	to	be	
between	 6	 and	 16.	 For	Asg3674	 and	Asg3678,	 no	 reads	 under	 non-producing	 conditions	 were	
assembled	(meanA	=	0),	which	resulted	in	an	infinite	log2-fold	change.	This	analysis	allowed	to	set	
cluster	 boundaries	 of	 the	 aspks1	 BGC	 to	 a	 16	 (Asg3666-Asg3679)	 genes	 encoding,	 48922	 bp	
spanning	 genomic	 region.	 Three	 investigated	 genes	 adjacent	 to	 either	 5’	 (Asg3663-65)	 or	 3’	
(Asg3680-82)	 cluster	 borders	 (orange	 dots,	 Figure	 3.6),	 were	 found	 to	 be	 not	 differentially	
expressed.	
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Table	3.3	Data	calculated	with	DESeq	for	aspks1	BGC	and	boundaries	genes.	
gene	 mean	expression	(0.5*meanA+B)	 meanA	(non-producing)	 meanB	(producing)	 Log2-fold	change	
Asg3663	
Asg3664	
Asg3665	
Asg3666	
Asg3667	
Asg3668	
Asg3669	
Asg3670	
Asg3671	
Asg3672	
Asg3673	
Asg3674	
Asg3675	
Asg3676	
Asg3677	
Asg3678	
Asg3679	
Asg3680	
Asg3681	
Asg3682	
1496,91	
307,23	
64,10	
5635,53	
16885,47	
11284,07	
1899,60	
6046,69	
2385,73	
1231,79	
12300,95	
1960,75	
6674,83	
54766,45	
21058,44	
1962,28	
40698,49	
450,85	
254,08	
32,24	
1817,58	
426,31	
600,77	
13,79	
7,78	
27,13	
14,33	
196,08	
10,81	
1,09	
345,26	
0,00	
3,28	
63,89	
0,55	
0,00	
5,85	
46,27	
25,19	
32,40	
1176,24	
188,15	
707,42	
11257,28	
33763,17	
22541,01	
3784,87	
11897,30	
4760,64	
2462,48	
24256,64	
3921,51	
13346,38	
109469,01	
42116,34	
3924,56	
81391,12	
855,43	
482,98	
32,09	
-0,63	
-1,18	
0,24	
9,67	
12,08	
9,70	
8,04	
5,92	
8,78	
11,14	
6,13	
∞	
11,99	
10,74	
16,24	
∞	
13,76	
4,21	
4,26	
-0,01	
	
3.3 aspks1	BGC	Analysis	of	A.	strictum	
Analysis	 of	 the	A.	 strictum	 genome	 and	 comparison	 of	 the	 transcriptome	under	 producing	 and	
non-producing	conditions	strongly	suggested	that	the	aspks1	BGC	is	involved	in	xenovulene	A	101	
biosynthesis.	Predicted	ORFs	were	further	analysed	by	BLASTp103	and	annotation	as	well	as	intron	
prediction	was	manually	adjusted	based	on	the	transcriptomic	data	(Appendix	Table	9.1).	
	
Figure	3.7	The	~49	kb	aspks1	BGC.	Brackets	indicate	partial	BGC	as	published	2007.102	Not	to	scale.	
Based	 on	 the	 protein	 homology	 to	 tropolone	 biosynthetic	 enzymes	 from	 stipitatic	 acid	 119	
biosynthesis	 in	T.	 stipitatus,	aspks1,	asL1,	asL3	 and	aR2	 are	 assumed	 to	encode	homologues	 in	
A.	strictum.97	It	is	proposed	that	three	additional	transformations	have	to	take	place	to	form	101	
from	a	tropolone	or	phenolic	polyketide	core:	
• cyclisation	of	FPP	to	humulene	106,		
• fusion	of	106	with	the	polyketide	moiety	
• and	 two	 ring	 contraction	 steps	 to	 convert	 the	 seven	 membered	 tropolone	 to	 the	
cyclopentenone	in	101.	
aspks1
Asg3673
asL1
3674
asR2
3671
asR3
3670
asR4
3669
asR5
3668
asR6
3667
asR7
3666
asR1
3672
asL2
3675
asL3
3676
asL4
3676
asL5
3677
asL6
3678
asL7
3679
PKS oxidoreductase regulator transporter ferredoxin	like unknown
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The	identified	ORFs	also	encode	putative	transporters	(asL7,	asR1),	one	transcription	factor	(asR3),	
two	FAD	dependent	oxidoreductases	(asL4,	asL6),	and	one	SDR	(asL5).	In	addition,	a	ferredoxin	like	
protein	is	encoded	by	asL2	and	several	proteins	of	unknown	function	are	encoded	by	asR4,	asR5,	
asR6	and	asR7	(Table	3.4).	A	structural	prediction	of	AsR5	using	Phyre2148	revealed	its	homology	to	
a	Ca-dependent	phosphotriesterase.	
	
	
Scheme	3.1	Proposed	pathway	for	101	formation.	
Table	3.4	Aspks1	gene	cluster	analysis.	Transcriptome	analysis	confirmed	exon	and	intron	positions.	Proposed	function	
and	CD,	BLASTp103	or	Phyre2	analysis.	Grey	font	colour	indicates	weak	alignment	and	Phyre2	prediction.	
#	 gene,	protein	 bp,	aa	 Putative	
function	
BLASTpa,	Phyre2b	or	CDc	
Asg3679	
Asg3678	
Asg3677	
Asg3676	
Asg3676	
Asg3675	
Asg3674	
Asg3673	
Asg3672	
Asg3671	
Asg3670	
Asg3669	
Asg3668	
Asg3667	
Asg3666	
asL7,	AsL7	
asL6,	AsL6	
asL5,	AsL5	
asL4,	AsL4	
asL3,	AsL3	
asL2,	AsL2	
asL1,	AsL1	
aspks1,	MOS	
asR1,	AsR1	
asR2,	AsR2	
asR3,	AsR3	
asR4,	AsR4	
asR5,	AsR5	
asR6,	AsR6	
asR7,	AsR7	
4350,	1449	
1272,	423	
750,	249	
1293,	430	
1023,	340	
348,	115	
1443,	480	
8190,	2729	
1308,	435	
1551,	516	
2565,	854	
1899,	632	
1206,	401	
1293,	430	
2469,	822	
transporter	
oxidoreductase	
oxidoreductase	
oxidoreductase	
oxidoreductase	
hypothetical	
oxidoreductase	
NR-PKS	
transporter	
oxidoreductase	
regulation	
hypothetical	
hypothetical	
hypothetical	
hypothetical	
ABC	transportera	
FAD	binding,	2-polyprenyl	6-methoxyphenol	hydroxylasea,c	
NAD(P)-dependent	short-chain	dehydrogenasea,c	
FAD	binding,	2-polyprenyl	6-methoxyphenol	hydroxylasea,c	
Non-heme	FeII	dependent	dioxygenasea,c	
ferredoxin	like,	a+b	barrelb	
FAD	binding,	salicylate	monooxygenasea,c	
3-methylorcinaldehyde	synthasea,c	
MFS	transportera,c	
Cytochrome	P450a,c	
GAL4-like	Zn(II)2/Cys6	binuclear	cluster	DNA-binding	a,c	
Zn(II)2/Cys6	binuclear	cluster	DNA-binding	domain2	
Ca-dependent	phosphotriesterase	(six	bladed	propeller)b		
unknown	
Serine	protease	likeb	
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A	 gene	 encoding	 a	 terpene	 cyclase	 was	 expected	 to	 be	 clustered	 with	 aspks1	 to	 catalyse	 the	
cyclisation	 of	 FPP	42.	 However,	 analysis	 of	 all	 encoded	proteins	 did	 not	 identify	 a	 protein	with	
significant	 homology	 to	 known	 terpene	 cyclases.	 The	 intermolecular	 fusion	 of	 polyketide	 and	
terpene	precursor	is	proposed	to	be	catalysed	by	a	hetero	Diels	Alderase	type	of	enzyme.	A	few	
examples	of	intramolecular	Diels	Alderase	chemistry	have	been	characterised	(Chapter	1.3.4),	but	
proteins	 show	 little	 structural	 homology	 and	 thus	 BLASTp103	 results	 ore	 often	 inconclusive.116	
However,	within	the	aspks1	BGC	two	genes	encoding	proteins	of	unknown	function	(asR5,	asR6)	
and	 two	additional	genes	 (asR4,	asR7)	with	weak	protein	homology	alignments	were	 identified.	
These	were	regarded	as	possible	candidates	to	be	involved	in	a	hetero	Diels	Alder	type	reaction.	
The	 ring	 contraction	 is	 proposed	 to	 happen	 via	 an	 oxidative	 rearrangement/deformylation	
cascade.84	Thus	 it	 is	proposed	 to	 require	enzymes	 that	oxidise	aromatic	 ring	 structures,	 such	as	
tropolones	or	phenols.	Two	genes	(asL4,	asL6)	were	found	to	encode	two	putative	FAD	dependent	
monooxygenases	similar	to	the	2-polyprenyl	6-methoxyphenol	hydroxylase	UbiH	(COG0654),	which	
are	possible	candidates	for	this	kind	of	chemistry.	
Additionally,	a	gene	(asL5)	encoding	a	putative	short-chain	dehydrogenase	was	predicted.	These	
kinds	 of	 enzymes	 are	 known	 to	 catalyse	 epimerisations,	 decarboxylations	 and	 carbonyl-alcohol	
oxidoreductions	 (cd05233).138–141	However,	 the	proposed	biosynthesis	of	101	does	not	 include	a	
step	 in	which	an	SDR	 is	obviously	engaged.	Due	to	 its	co-expression	 it	 is	 likely	 to	be	 involved	 in	
either	 101	 biosynthesis	 or	 in	 a	 further	 transformation	 step	 of	 101.	 However,	 no	 intermediate	
proposing	such	a	reaction	of	101	has	yet	been	observed	in	A.	strictum	extracts.	
The	 in	 silico	 analysis	 of	 the	aspks1	 BGC	 showed	 that	 in	 addition	 to	 the	 core	 tropolone	 forming	
enzymes	(MOS,	AsL1,	AsL3	and	AsR2),	promising	candidates	for	the	ring	contraction	(AsL4,	AsL6)	as	
well	as	several	hypotheticals	(AsR4,	AsR5,	AsR6,	AsR7)	which	could	be	involved	in	the	hetero	Diels	
Alder	chemistry	are	encoded.		
The	absence	of	a	terpene	cyclase	encoding	gene	in	the	aspks1	BGC	led	to	the	hypothesis	of	a	split	
BGC	as	it	was	observed	in	the	biosynthesis	of	the	meroterpenoid	austinol	84	in	A.	nidulans.	In	this	
example	 the	 PKS	 encoding	 gene	 is	 located	 with	 four	 other	 genes	 in	 one	 BGC	 and	 the	
prenyltransferase	 encoding	 gene	 plus	 ten	 additional	 genes	 are	 encoded	 on	 a	 different	
chromosome.149	 In	order	 to	 identify	 the	 terpene	cyclase	 involved	 in	101	biosynthesis	 the	whole	
genome	was	screened	for	homologues	and	the	transcriptome	data	was	analysed	for	co-expression	
under	101	producing	conditions	(Chapter	3.3.1).	
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3.3.1 Terpene	Cyclase	Expression	Analysis	
Cyclisation	of	FPP	precursors	in	fungi	is	performed	by	two	types	of	terpene	cyclases.	‘Traditional’	
class	I	ionization	dependent	enzymes	with	a	characteristic	DDxxD	motif	for	coordination	of	metal	
ions57,150,151	(Mg2+).	In	addition,	a	class	of	integral	membrane	proteins,	which	were	first	described	in	
the	biosynthesis	of	pyripyropene	93,	are	also	 known.77	 For	 the	 latter,	 a	protonation-dependent	
cyclisation	mode	is	proposed,	but	has	not	yet	been	fully	elucidated	(Scheme	3.2).77	Classical	terpene	
cyclases	use	 free	 FPP	42	 as	 the	 substrate.	 The	 integral	membrane	proteins,	 however,	 cyclase	 a	
sesquiterpene	epoxide	166	which	is	pre-attached	to	a	cyclic	polyketide	precursor.80	
	
Scheme	3.2	Cyclisation	of	166	by	the	integral	membrane	protein	PyrG4	in	pyripyropene	A	93	biosynthesis.	
The	cyclase	involved	in	93	biosynthesis,	Pyr4,77	was	used	as	a	BLASTp103	template	and	one	putative	
homologue	encoded	by	Asg9222	was	identified	in	the	A.	strictum	genome.	Three	further	putative	
class	I	terpene	cyclases	(Asg5463,	Asg5501,	Asg10609)	were	identified	in	an	additional	BLASTp103	
homology	search	using	basidiomycetes	FPP	42	cyclases	(Stehi164702,	Stehi173029,	Stehi125180)56	
as	templates.	These	four	BLASTp-identified	together	with	nine	other	terpene	synthases	predicted	
by	 fungiSMASH	were	 further	analysed	 for	 their	 absolute	expression	and	 co-expression	with	 the	
aspks1	BGC	by	the	DESeq	tool	(orange	dots,	Figure	3.8).146	
In	 comparison	 to	 the	 aspks1	 BGC	 (green	 dots,	 Figure	 3.8)	 the	 terpene	 cyclases	 (orange	 dots,	
Figure	3.8)	show	a	low	mean	expression	and	no	differential	gene	expression	under	xenovulene	A	
producing	 and	 non-producing	 conditions	 is	 observed.	 For	 only	 one	 of	 the	 investigated	 genes	
(Asg7948)	 the	 calculated	 mean	 expression	 (1630)	 is	 comparable	 to	 the	 lower	 range	 of	 the	
aspks1	BGC,	where	the	lowest	mean	expression	was	observed	for	Asg3672	(1231)	(Tables	3.3	and	
3.5).	However,	a	BLASTp103	homology	search	suggests	it	to	be	a	squalene	synthase	rather	than	an	
FPP	processing	terpene	cyclase.	
The	analysis	of	all	putative	A.	strictum	terpene	cyclases	by	DESeq	analysis	showed	that	none	of	the	
13	 genes	 is	 co-regulated	 under	 101	 producing	 conditions.146	 However,	 some	 genes	 are	
constitutively	expressed	(Asg1730,	Asg7948,	Asg10608)	but,	compared	to	the	aspks1	BGC,	at	low	
levels.	Thus	with	 the	DESeq	analysis	 it	was	not	possible	 to	propose	a	candidate	 terpene	cyclase	
which	could	be	involved	in	101	biosynthesis.	
NO
OH
O NO
O
O
H
H
HO
O
Pyr4
integral	membrane	protein
NO
O
O
H
H
AcO
HO
OAc
OAc
166 167 93
Genome	and	Transcriptome	of	A.	strictum	
	 62	
	
	
Figure	3.8	Scatter	diagram	shows	mean	expression	under	both	conditions	over	log2-fold	change.	Every	dot	correlates	to	
one	gene,	green	dots	represent	the	aspks1	BGC	and	orange	dots	represent	terpene	genes.	
Table	3.5	Data	calculated	with	DESeq	for	terpene	genes.	Grey	font	colour	indicates	BLASTp103	alignment	scores	between	
80-200.	
Gene	 BLASTp	 mean	expression	 meanA	 meanB	 log2-fold	change	
Asg1730	
Asg2512	
Asg5501	
Asg5332	
Asg5463	
Asg5627	
Asg6941	
Asg7948	
Asg8228	
Asg9222	
Asg9750	
Asg10608	
Asg10609	
GGPP	synthase	
GGPP	synthase	
Terpenoid	synthase	
Aristolochene	like	cyclase	
Terpene	synthase	metal	binding	domain	
Pentalene	like	cyclase	
Persilphiperfolan-8beta-ol	like	synthase	
Squalene	synthase	
Lycopene	cyclase/phytoene	synthase	
Integral	membrane	protein	
FPP	synthase	
Pentalene	like	cyclase	
Terpenoid	synthase	
211,35	
1,39	
3,51	
7,53	
6,20	
17,86	
57,82	
1630,66	
39,28	
39,28	
0,57	
196,88	
3,50	
206,43	
0,00	
5,94	
14,48	
9,66	
30,44	
83,59	
1897,05	
33,86	
64,47	
0,00	
254,42	
3,67	
216,27	
2,79	
1,08	
0,57	
2,74	
5,28	
32,04	
1364,27	
44,69	
59,56	
1,14	
139,34	
3,33	
0,07	
0,00	
-2,45	
-4,67	
-1,82	
-2,53	
-1,38	
-0,48	
0,40	
-0,11	
0,00	
-0,87	
-0,14	
	
3.3.2 Homologous	BGC	in	Aspergillus	thermomutatus	
During	the	time	of	this	work	the	genome	of	Aspergillus	thermomutatus,	which	was	isolated	from	a	
human	nasal	sinus	abscess,	became	available	(NCBI:	GCA_002237265.1).	No	secondary	metabolites	
are	reported	from	this	isolated	strain.	The	species	is	also	known	as	Neosartorya	pseudofischeri	and	
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a	 strain	 isolated	 from	 a	 marine	 source	 is	 reported	 to	 produce	 several	 metabolites	 such	 as	
pyripyropene	 A	 93,	 several	 diketopiperazines	 and	 the	 alkaloid	 neosartin	 C.152	 However,	 no	
xenovulene	type	meroterpenoids	have	been	reported.	
	
Figure	 3.9	 Cluster	 comparison	 of	 aspks1	 BGC	 and	 one	 unknown	 homologous	 BGC	 from	 A.	 thermomutatus.	 Protein	
homologies	were	calculated	with	EMBOSS	Needle.153–155	
BLASTp103	homology	searches	with	the	hypothetical	proteins	AsR5	and	AsR6	of	the	aspks1	BGC	as	
templates	were	carried	out.	The	search	identified	two	putative	homologous	proteins	(60.3%	and	
58.0%	 amino	 acid	 identity)	 encoded	 by	 CDV56_06487	 and	 CDV56_06488	 which	 are	 located	
adjacent	to	each	other	 in	the	genome	of	A.	thermomutatus	 (Figure	3.9).	Further	analysis	of	 this	
genomic	locus	also	revealed	three	genes	encoding	a	NR-PKS,	an	FAD	dependent	monooxygenase	
and	a	transcription	factor	which	showed	57.9%,	68.1%	and	43%	amino	acid	identity	to	aspks1	BGC	
proteins	(Figure	3.9).	This	homologous	BGC	was	found	to	be	on	a	scaffold	with	a	total	 length	of	
76	kb.	Analysis	of	further	ORF	on	that	scaffold	only	identified	hypothetical	(encoded	by	atL2-atL6,	
atL12)	and	ion	transport	involved	proteins	(encoded	by	atL7-atL11)	(Table	3.6).	However,	the	whole	
genome	of	A.	thermomutatus	was	analysed	for	further	homologues	of	aspks1	BGC	proteins.	On	a	
second	 scaffold,	 with	 the	 total	 length	 of	 19	 kb,	 an	 AsL3	 homologous	 protein	 (encoded	 by	
CDV56_10047)	with	78.9%	amino	acid	identity	was	predicted.	The	genes	on	its	left	(CDV56_10046)	
and	 right	 (CDV56_10049)	 are	 predicted	 to	 encode	 a	 cytochrome	 P450	 and	 an	 SDR	 (Table	 3.6).	
Comparison	to	aspks1	BGC	proteins	(AsR2:	P450,	AsL5:	SDR),	however,	showed	only	minor	amino	
acid	identities	of	12.9%	and	23.3%	(Table	3.6).	Three	more	ORF	are	predicted	on	the	scaffold	which	
encode	hypothetical	proteins,	without	homologies	to	further	proteins	encoded	by	the	aspks1	BGC.	
In	total	six	proteins	of	the	aspks1	BGC	were	identified	to	have	a	homologue	in	A.	thermomutatus.	
The	fact	that	one	gene	(CDV56_10047)	is	located	on	a	different,	very	short	scaffold	indicates	that	
aspks1
Asg3673
asL1
3674
asR2
3671
asR3
3670
asR4
3669
asR5
3668
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3667
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atpks1
CDV56_06490
atL1
06491
atR2
06488
atR3
06487
atR4
06486
atR5
06485
atR1
06489
57.9%68.1%
58.0%60.3%
43.0%
atR6
10046
atR7
10047
78.9%
68.9%
Scaffold	149
76	kb
Scaffold	388
19	kb
atR8
10048
A.	thermomutatus
A.	strictum
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the	BGC	is	most	likely	not	sequenced	completely.	It	is	suggested	that	both	scaffolds	should	overlap,	
but	it	is	likely	that	due	to	missing	sequencing	data	the	assembly	is	incomplete	at	that	genomic	locus.	
However,	 with	 homologues	 of	 the	 core	 tropolone-forming	 enzymes	 (NR-PKS,	 FAD	 dependent	
monooxygenase,	NHI	dioxygenase)	the	A.	thermomutatus	BGC	encodes	all	necessary	enzymes	for	
tropolone	 (stipitaldehyde	 123)	 production	 (Scheme	 1.16).	 In	 addition,	 the	 two	 hypothetical	
proteins	AsR5	and	AsR6	are	highly	conserved	in	both	BGC	and	were	thus	analysed	in	more	detail.	
Table	3.6	Analysis	of	A.	thermomutatus	scaffolds	149	(79	kb)	and	388	(19	kb).		
#	 gene	 Putative	
function	
aspks1	BGC	 BLASTpa,	Phyre2b	or	CDc	
CDV56_06502	
CDV56_06501	
CDV56_06500	
CDV56_06499	
CDV56_06498	
CDV56_06497	
CDV56_06496	
CDV56_06495	
CDV56_06494	
CDV56_06493	
CDV56_06492	
CDV56_06491	
CDV56_06490	
CDV56_06489	
CDV56_06488	
CDV56_06487	
CDV56_06486	
CDV56_06485	
	
CDV56_10046	
CDV56_10047	
CDV56_10048	
CDV56_10049	
CDV56_10050	
CDV56_10051	
atL12	
atL11	
atL10	
atL9	
atL8		
atL7		
atL6		
atL5		
atL4	
atL3	
atL2		
atL1		
atpks1	
atR1		
atR2	
atR3	
atR4		
atR5		
	
atR6	
atR7	
atR8	
atR9	
atR10	
atR11	
hypothetical	
transporter	
transporter	
transporter	
transporter	
resistance	
hypothetical	
hypothetical	
hypothetical	
hypothetical	
hypothetical	
oxidoreductase	
NR-PKS	
regulation	
hypothetical	
hypothetical	
hypothetical	
transporter	
	
oxidoreductase	
oxidoreductase	
oxidoreductase	
hypothetical	
hypothetical	
hypothetical	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
AsL1	
MOS	
AsR3	
AsR6	
AsR5	
-	
AsL7	
	
-	
AsL3		
-	
-	
-	
-	
hypotheticala	
vacuolar	calcium	ion	transporter	a	
calcium/proton	exchanger	proteina	
vacuolar	calcium	ion	transporter	a	
sodium/calcium	exchanger	proteina	
cadmium	resistance	transporter	
hypotheticala	
hypotheticala	
hypotheticala	
hypotheticala	
hypotheticala	
FAD	binding,	salicylate	monooxygenasea,c	
3-methylorcinaldehyde	synthasea,c	
GAL4-like	Zn(II)2/Cys6	binuclear	cluster	DNA-bindinga,c	
hypotheticala	
hypotheticala	
hypotheticala	
ABC	transcportera	
	
cytochrome	P450	monooxygenasea,c	
Non-heme	FeII	dependent	dioxygenasea,c	
short-chain	dehydrogenasea,c	
hypotheticala	
Ribonuclease	likea,c	
hypotheticala	
	
AsR5	is	a	protein	of	401	aa	which	shows	very	few	good	(alignment	score	>200,	3	hits)	BLASTp103	
results,	but	was	found	to	be	a	structural	homologue	of	a	Ca2+	dependent	phosphotriesterase	with	
high	confidence	by	Phyre2.148	A	tertiary	structure	model	was	built	with	SWISS-MODEL155-157	for	AsR5	
and	its	A.	thermomutatus	homologue	(AtR3).	This	predicted	a	six-bladed	propeller	tertiary	structure	
for	both	proteins	(only	shown	for	AsR5)	(Figure	3.10).	
AsR6	 is	 a	 protein	 of	 430	 aa	 which	 also	 shows	 very	 few	 good	 (alignment	 score	 >200,	 11	 hits)	
BLASTp103	results.	Apart	from	the	A.	thermomutatus	homologue	AtR3	no	other	protein	was	found	
to	be	co-located	with	an	AsR5	homologue.	No	conserved	domains	or	structural	homologues	were	
identified	 using	 standard	 tools	 for	 AsR6	 or	 its	 A.	 thermomutatus	 homologue	 AtR3	 (CD,138–140	
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Phyre2148,	SWISS-MODEL156–158).	Later	in	this	work	the	in	vitro	activity	of	AsR6	was	investigated	and	
the	protein	was	shown	to	cyclise	FPP	42	to	humulene	106	in	the	presence	of	Mg2+	(Chapter	5.5).	
Typically,	class	I	terpene	cyclases	possess	two	conserved	aspartate	rich	motifs	to	coordinate	Mg2+:	
DDxxD/E	 and	 (N)DxxT/SxxxD/E.	 The	 alignment	 of	 the	 plant	 humulene	 106	 synthase	 from	
Z.	 zerumbet	 (AB247331.1),	 the	F.	 fujikorii	 koraiol	136	 synthase	Ffsc4	 (CCT72694.1),	C.	acutatum	
CaTPS	 (KP398851.1)	 and	 aristolochene	 38	 synthase	 from	 A.	 terreus	 (AAF13264.1)	 shows	 the	
conserved	Mg2+	binding	sites,	but	no	other	regions	of	significant	homology	(Figure	3.11).	
	
Figure	 3.10	Model	 of	 AsR5	 computed	 with	 SWISS-MODEL	 and	 template	 2p4o.1.A	 (hypothetical	 protein	 of	 Nostoc	
punctiforme	PCC	73102,	sequence	homology	21.22%	to	AsR5).	QMEAN	of	-3.79	indicates	reliable	quality	of	the	model	
(models	with	QMEAN	<-4	are	regarded	as	low	quality).	A,	Bottom	view	of	predicted	six-bladed	propeller.	B,	Side	view	of	
predicted	six-bladed	propeller.	Red	low	–	blue	high	confidence.	
	
	
Figure	 3.11	 Alignment	 of	 amino	 acid	 sequences	 of	 class	 I	 terpene	 cyclases	 to	 show	 conserved	motifs	 DDxxD/E	 and	
(N)DxxT/SxxxD/E.	 Humulene	 synthase	 from	 Z.	 zerumbet	 (AB247331.1),	 F.	 fujikorii	 koraiol	 136	 synthase	 Ffsc4	
(CCT72694.1),	C.	acutatum	CaTPS	(KP398851.1)	and	aristolochene	38	synthase	from	A.	terreus	(AAF13264.1).	Geneious	
7.1.9	was	used	for	the	alignment.	
A B
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A	 sequence	 alignment	 of	 AsR6	 and	 selected	 homologues	 could	 not	 identify	 either	 of	 these	
conserved	motifs	(Figure	3.12).	Bioinformatic	analysis	thus	showed	that	although	AsR6	was	shown	
to	 produce	 humulene	 106	 from	 FPP	 42	 in	 vitro	 (Chapter	 5.5),	 it	 has	 no	 conserved	 domain	 or	
sequence	homologies	to	any	other	known	terpene	cyclase.	
	
Figure	3.12	Protein	alignment	of	AsR6	and	homologous	sequences	identified	by	BLASTp.103	Geneious	7.1.9	was	used	for	
the	alignment.	
	
3.4 Other	BGC	in	A.	strictum	
The	antiSMASH	analysis	predicted	another	six	BGC	in	the	A.	strictum	genome	with	homologies	to	
literature	reported	BGC	(Chapter	3.1,	Figure	3.3).	These	were	 further	analysed	with	 the	artemis	
comparison	 tool.159	 Homologous	 protein	 sequences	 were	 pairwise	 compared	 using	 EMBOSS	
Needle.160	Two	of	the	analysed	A.	strictum	BGC	showed	high	homologies	to	the	literature	BGC	and	
are	further	described	in	more	detail	(viridicatumtoxin	160	and	aphidicolin	161).	The	remaining	four	
BGC	(depudecin	162,	clapurine	163,	aspyridone	164,	leucinostaatin	165:	Appendix	Tables	9.2-9.5)	
showed	low	homologies	(22-50%)	to	the	literature	BGC	and	are	not	further	discussed.	
3.4.1 Viridicatumtoxin	160	like	BGC	
The	 viridicatumtoxin	 160	 BGC	 from	 Penicillium	 aethiopicum	 was	 identified	 and	 a	 possible	
biosynthesis	was	proposed	by	Tang	and	co-workers	in	2010	(Scheme	3.3).133,161	Comparison	of	the	
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A.	strictum	homologous	BGC	with	the	original	BGC	showed	the	presence	of	all	genes.	Amino	acid	
identities	of	protein	sequences	were	found	to	be	between	39.1	–	77.9%	(Table	3.7).	This	strongly	
suggested	 that	 the	A.	 strictum	BGC	 is	 likely	 to	encode	proteins	 involved	 in	viridicatumtoxin	160	
biosynthesis.	However,	the	putative	transcription	factor	vrtR2	(Asg9751)	is	translocated.	While	in	
the	P.	aethiopicum	BGC	it	is	located	at	the	cluster	boarders,	it	is	found	in	the	middle	(between	vrtD	
and	vrtE	homologues)	of	the	BGC	in	A.	strictum.	In	addition,	this	putative	transcription	factor	shows	
the	 lowest	protein	 identities	(39.1%)	observed	for	the	whole	BGC.	Analysis	of	the	transcriptome	
data	 generated	 under	 xenovulene	 A	 101	 producing	 and	 non-producing	 conditions	 showed	 no	
abundant	 mRNA	 levels	 for	 the	 BGC.	 Attempts	 to	 identify	 virdicatumtoxin	 160	 in	 extracts	 of	
A.	strictum	grown	in	different	liquid	media	(Chapter	2.9)	were	unsuccessful.	
These	 findings	 suggest	 that	 the	 A.	 strictum	 putative	 viridicatumtoxin	 160	 BGC	 is	 inactive	 as	
transcription	is	repressed	under	the	investigated	conditions.	However,	it	is	also	possible	that	due	
to	the	transcription	factor	translocation	the	cluster	is	destroyed	and	cannot	be	expressed.	
	
Scheme	3.3	Proposed	biosynthesis	of	viridicatumtoxin	160	in	Penicllium	aethiopicum.	
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Table	3.7	Viridicatumtoxin	160	like	A.	strictum	BGC	with	54%	similarities	(antiSMASH).	
#	 Putative	function	 Homologue	 Identity/similarity	%	 BLASTp	and	CD	
Asg9743	
Asg9744	
Asg9745	
Asg9746	
Asg9747	
Asg9748	
Asg9749	
Asg9750	
Asg9751	
Asg9752	
Asg9753	
Asg9754	
Asg9755	
Asg9756	
transporter	
oxidoreductase	
transferase	
oxidoreductase	
NR-PKS	
acetoacetyl-CoA	synthetase	
prenyltransferase	
FPPS	
regulation	
oxidoreductase	
O-methyltransferase	
hypothetical	
oxidoreductase	
regulation	
VrtL	
VrtK	
VrtJ	
VrtI	
VrtA	
VrtB	
VrtC	
VrtD	
VrtR2	
VrtE	
VrtF	
VrtG	
VrtH	
VrtR1	
73.9/84.9	
77.0/85.9	
66.9/77.9	
53.6/62.0	
77.9/86.7	
58.4/71.5	
65.6/77.1	
57.9/67.3	
39.1/49.1	
67.0/73.8	
75.5/89.2	
63.8/75.3	
71.1/84.7	
53.2/67.8	
MFS	transporter	
cytochrome	P450	
PLP	dependent	transferase	
Fe	dependent	oxygenase	
polyketide	synthase,	SAT-KS-AT-PT-ACP	
acetoacetyl	CoA	synthetase	
aromatic	prenyltransferase	
FPP	synthase	
transcription	factor	
cytochrome	P450	
SAM-dependant	O-methyltransferase	
metallo-b-lactamase	superfamily	
FAD	dependant	monooxygenase	
transcription	factor	
	
3.4.2 Aphidicolin	161	like	BGC	
The	15	kb	BGC	of	the	diterpene	aphidicolin	161	was	identified	and	characterised	by	Oikawa	and	
co-workers	 from	 2001	 –	 2011	 (Scheme	 3.4).137,162,163	 The	 homologous	 BGC	 found	 in	A.	 strictum	
encodes	the	full	set	of	genes	necessary	for	aphidicolin	161	biosynthesis	(Table	8.3).	Pairwise	protein	
identities	were	found	to	be	between	25.2	–	64.8%.	Similar	to	the	viridicatumtoxin	160	homologous	
BGC	(Chapter	3.4.1),	the	transcription	factor	here	also	shows	the	lowest	homology	of	any	protein	
encoded	by	 the	BGC.	 In	 comparison	 to	 the	original	BGC	 from	Phoma	betae	 only	 two	genes	are	
translocated.	 The	 PbGGS	 and	 Pb450-1	 homologues	 encoding	 genes	 exchanged	 positions	 in	 the	
A.	 strictum	 BGC.	 Analysis	 of	 the	 transcriptome	 data	 suggested	 poor	 to	 no	 expression	 of	 the	
aphidicolin	161	BGC	genes	under	the	tested	A.	strictum	fermentation	conditions.	However,	this	was	
not	 further	 investigated	 and	 A.	 strictum	 extracts	 were	 not	 analysed	 for	 the	 presence	 of	
aphidicolin	161.	
Table	3.8	Aphidicolin	161	like	A.	strictum	BGC	with	83%	similarities	(antiSMASH).	
#	 Putative	function	 Homologue	 Identity/similarity	%	 BLASTp	and	CD	
Asg2509	
Asg2510	
Asg2511	
Asg2512	
Asg2513	
Asg2514	
regulation	
oxidoreductase	
transporter	
GGPP	synthase	
terpene	synthase	
oxidoreductase	
PbTF	
PbP450-2	
PbTP	
PbGGS	
ACS	
PbP450-1	
25.2/38.8	
64.8/72.9	
60.7/74.5	
57.9/68.9	
62.8/76.0	
61.0/72.9	
transcription	factor,	GAL4	
cytochrome	P450	
MFS	transporter	
polyprenyl	synthase	
copalyl	diphosphate	synthase	
cytochrome	P450	
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Scheme	3.4	Diterpene	aphidicolin	161	biosynthesis	in	Phoma	betae.	
3.4.3 Lactone	181	Biosynthesis	in	A.	strictum	
In	addition	to	xenovulene	A	101	and	related	compounds,	another	unrelated	putative	polyketide	
derived	 natural	 product	 was	 isolated	 from	 A.	 strictum	 cultures	 grown	 under	 101	 producing	
conditions	by	Simpson	and	co-workers.164	Attempts	to	identify	lactone	181	in	A.	strictum	extracts	
analysed	in	this	work	were	unsuccessful.	The	pentaketide	lactone	181	is	proposed	to	be	the	product	
of	a	HR-PKS	without	C-MeT.	Further	conversion	into	the	(Z,Z,E)-triene	by	a	cis-trans	double	bond	
isomerase	 like	 enzyme	 could	 yield	 a	 cytochrome	 P450	 substrate	 182.	 Epoxide	 formation	 and	
spontaneous	opening	could	give	the	final	lactone	181	(Scheme	3.5).164		
	
Scheme	3.5	Proposed	biosynthesis	and	putative	BGC	33	for	lactone	181	from	A.	strictum.	
Mining	the	A.	strictum	genome	identified	4	HR-PKS	encoded	by	Asg2657,	Asg6902,	Asg7194	and	
Asg8744	 with	 a	 matching	 domain	 architecture	 (Figure	 3.4).	 Analysis	 of	 the	 BGC	 predicted	 by	
fungiSMASH20–22	showed	that	only	one	BGC	(33,	Asg2657)	also	encodes	a	putative	P450	(Asg2661)	
and	a	putative	epimerase	(Asg2655).	In	total,	17	ORF	are	predicted	in	this	BGC.	BLASTp103	homology	
search	of	encoded	proteins	further	identified	a	putative	epoxide	hydrolase	(Asg2663),	a	lactonising	
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enzyme	(Asg2650),	an	SDR	(Asg2652)	and	an	aldolase	(Asg2652)	(Table	3.9)	which	might	be	involved	
in	further	biosynthetic	steps.	
Table	3.9	Analysis	of	predicted	ORF	of	BGC	33	by	BLASTp.103	
#	 Putative	function	 BLASTp	and	CD	
Asg2665	
Asg2664	
Asg2663	
Asg2662	
Asg2661	
Asg2660	
Asg2659	
Asg2658	
Asg2657	
Asg2656	
Asg2655	
Asg2654	
Asg2653	
Asg2652	
Asg2651	
Asg2650	
Asg2649	
transporter	
hypothetical	
hydrolase	
amino	acid	metabolism	
oxidoreductase	
hypothetical	
hypothetical	
hypothetical	
HR-PKS	
hypothetical	
cis-trans	isomerase	
amino	acid	transport	and	metabolism	
regulation	
Oxidoreductase,	aldolase	
reductase	
Racemase/lactonising	enzyme	
transporter	
glycosyl	hydrolase,	MFS	transporter	
Zn	peptidase	family	
epoxide	hydrolase	
asparagine	synthase,	glucosamine	6-phosphate	synthetase	
cytochrome	P450	
enamine	deaminase	like	
hypothetical	
pimeloyl-ACP	methyl	ester	carboxylesterase	
polyketide	synthase,	KS-AT-DH-ER-KR-ACP	
hypothetical	
NAD	dependent	epimerase/dehydratase	family	
Serine	dehydratase	
GAL4	Zn(2)	Cys(6)	transcription	factor	
short	chain	dehydrogenase/reductase,	aldolase	
NAD(P)(H)	Rossmann	fold	2-dehydrpantoate	2-reductase	
glucarate	dehydratase	
MFS/sugar	transporter	
	
3.5 Classification	of	A.	strictum	
An	 ascomycete	was	 first	 described	 in	 1995	 as	 the	 producer	 of	 xenovulene	A	101.	Based	 on	 its	
morphology	 it	was	classified	as	A.	 strictum.82	The	genomic	era	has	changed	 the	classification	of	
fungal	species.	Nowadays	a	barcoding	sequence	is	additionally	used	to	determine	the	taxonomy	of	
newly	discovered	strains.	For	fingerprinting	of	fungi	the	internal	transcribed	spacer	(ITS),	a	region	
between	 18S	 and	 28S	 ribosomal	 RNA	 (rRNA)	 including	 5.8S	 rRNA,	 is	 compared	 to	 other	 known	
sequences.	This	method	provides	rapid	confirmation	of	strain	identities	in	laboratory	use.165	The	
~600	bp	ITS	sequence	of	the	101	producer	strain	was	amplified	from	gDNA	with	oligonucleotides	
P11+12,	sequenced	(GATC,	Konstanz)	and	used	as	a	BLAST	nucleotide	(BLASTn)	search	template	in	
a	 homology	 103	 analysis.	 Best	 alignments	 were	 found	 to	 be	 with	 the	 Sarocladium	 kiliense	 ITS	
sequence,	rather	than	the	A.	strictum	ITS	sequences,	with	a	sequence	identity	of	98%.	The	genomes	
of	S.	kiliense166	and	A.	strictum	(isolate	DS1bioAYav1.0)	became	available	at	the	National	Center	for	
Biotechnology	 Information	 (NBCI)	and	the	 Joint	Genome	 Institute	 (JGI)	during	 the	period	of	 this	
work.	Pairwise	comparison	of	average	nucleotide	identities	(ANI)	with	the	A.	strictum	101	producing	
strain	by	Dr	Daniel	Wibberg	was	used	to	analyse	their	relationship.	The	comparison	showed	ANI	
values	to	be	~82%	for	all	three	compared	strains.	Isolates	representing	identical	species,	like	two	
strains	 of	 Aspergillus	 niger	 (SH2	 and	 ATCC2),	 Candida	 albicans	 (WO-1	 and	 A20)	 or	
Fusarium	oxysporum	(f.sp.	cubense	Race1	and	Race4),	were	found	to	have	ANI	value	of	97-99%.167	
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The	 calculated	 low	 pairwise	 identities	 of	 81%	 and	 83%	 of	 the	 101	 producer	 to	 S.	 kiliense	 and	
A.	strictum	indicate	that	it	is	a	novel	species	of	the	Acremonium/Sarocladium	family.	
Table	3.10	Pairwise	compared	ANI	for	A.	strictum	101	producer,	S.	kiliense	and	A.	strictum	DS1bioAYav1.0.	
ANI	in	%	 S.	kiliense	 A.	strictum	DS1bioAYav1.0	 A.	strictum	101	producer	
A.	strictum	101	producer	
A.	strictum	DS1bioAYav1.0	
S.	kiliense	
81.22	
83.18	
100	
83.13	
100	
100.00	
	
3.6 Discussion	
Analysis	 of	 the	 A.	 strictum	 whole	 genome	 identified	 a	 BGC	 which	 could	 be	 involved	 in	
xenovulene	A	101	biosynthesis.	In	addition,	the	101	producing	A.	strictum	strain	was	found	to	be	
wrongly	 classified	 as	 A.	 strictum	 and	 probably	 represents	 a	 novel	 member	 of	 the	
Acremonium/Sarcoladium	 family.	For	the	time	of	this	work	 it	will	nevertheless	be	referred	to	as	
A.	strictum,	but	for	the	future	the	proposal	of	a	novel	name	should	be	considered.	
The	A.	 strictum	 draft	 genome	of	33.8	Mb	was	assembled	 in	51	 scaffolds	by	Dr	Daniel	Wibberg.	
10622	genes	with	an	average	number	of	2.99	exons	per	ORF	were	predicted.	In	a	comparative	study	
of	82	ascomycete	draft	genomes	an	average	genome	size	of	36.8	Mb	was	calculated	and	predicted	
to	 encode	 an	 average	 of	 11129.45	 genes	 with	 an	 average	 2.58	 exons	 per	 gene.	 The	 genomes	
compared	 in	 this	 publication	 were	 assembled	 on	 7-3164	 scaffolds,	 but	 43%	 of	 those	 genomes	
consist	of	<100	scaffolds.168	The	A.	strictum	genome	as	proposed	in	this	work	thus	represents	an	
average	ascomycete	draft	genome,	with	a	reliable	assembly	in	51	scaffolds	which	enabled	further	
antiSMASH	 analysis	 for	 secondary	 metabolite	 BGC.20–22	 For	 the	 transcriptome	 analysis	 under	
producing/non-producing	conditions	~125/80	million	reads	were	sequenced	and	~95%	could	be	
mapped	to	the	A.	strictum	draft	genome.	For	comparison,	the	published	transcriptome	analysis	of	
Fusarium	 oxysporum	 (F.	 oxysporum)	 resulted	 in	 ~63	 million	 reads,	 with~91%	 located	 on	 the	
genome.	 This	 shows	 that	 quality	 and	 quantity	 of	 the	 transcriptomic	 data	 sequenced	 for	 either	
condition	of	A.	strictum	is	in	the	expected	range.	It	was	used	to	identify	differential	gene	expression	
with	the	DESeq	software	package.146,169	The	program	was	previously	used	to	successfully	analyse	
fungal	mRNA	expression	in	samples	from	Rhizoctonia	solani	taken	during	interaction	with	its	plant	
host	lettuce.142	
CD138–141	analysis	of	PKS	encoding	genes	showed	that	only	one	NR-PKS	(MOS	encoded	by	aspks1)102	
with	 a	 domain	 architecture	 suitable	 for	 production	 of	 the	 predicted	 precursor	 aldehyde	120	 of	
xenovulene	 A	 101	 is	 encoded	 in	 the	 entire	 A.	 strictum	 genome.	 Comparative	 gene	 expression	
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analysis	 (DESeq146)	 confirmed	 a	 distinct	 co-regulation	 of	 15	 genes	 accompanying	 aspks1	 under	
xenovulene	A	101	producing	conditions.	Further	BLASTp103	homology	searches	of	these	co-located,	
upregulated	 genes	 confirmed	 tropolone	 core	 genes	 (aspks1,	 asL1,	 asL3	 and	 asR2)97,102	 and	
identified	candidate	genes	for	further	transformation	steps.	Two	of	these	genes	encode	putative	
aromatic	 hydroxylases	 which	 could	 be	 involved	 in	 the	 two	 ring	 contraction	 steps	 (AsL4,	 AsL6).	
Several	(asR4,	asR5,	asR6,	asR7)	genes	encode	proteins	of	unknown	function	which	are	candidates	
to	be	involved	in	the	fusion	of	polyketide	and	terpene	moiety	(Scheme	3.6).	A	predicted	short-chain	
dehydrogenase	 (AsL5)	 was	 not	 directly	 assigned	 on	 the	 biosynthetic	 route	 towards	
xenovulene	A	101,	but	due	to	its	expression	it	is	assumed	to	further	modify	101.	
	
	
Scheme	3.6	Proposed	biosynthesis	of	101.	
A	known	gene	encoding	a	terpene	cyclase	to	synthesise	humulene	106	is	not	predicted	to	be	part	
of	the	upregulated	16	genes.	It	was	first	assumed	that	the	aspks1	BGC	could	be	split,	as	observed	
in	 the	 biosynthesis	 of	 the	meroterpenoid	 austinol	 84.76	 However,	 DESeq	 analysis	 did	 not	 yield	
terpene	cyclase	which	is	co-regulated	or	constitutively	expressed	but	located	at	a	different	genomic	
locus	under	101	producing	conditions.	At	this	point	it	was	further	hypothesised	that	the	terpene	
cyclisation	could	occur	similarly	to	viridicatumtoxin	160,	where	a	cytochrome	P450	oxygenase	was	
shown	 to	 serve	 as	 a	 terpene	 cyclase	 (Scheme	 3.7A).133	 A	 similar	 phenomenon	 has	 also	 been	
observed	in	the	biosynthesis	of	the	indol	terpenoid	teleocidin	186,	where	a	trans	located	C-methyl	
transferase	initiates	terpene	cyclisation	(Scheme	3.7B).170	However,	both	unusual	terpene	cyclases	
have	 in	 common	 that	 the	 precursor	 terpene	 is	 attached	 to	 the	 polyketide	 precursor	 by	 a	
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prenyltransferase	before	the	cyclisation	occurs	(similar	to	integral	membrane	protein	mediated	FPP	
cyclisation,	Chapter	1.2).	Although	a	cytochrome	P450	oxygenase	is	encoded	in	the	aspks1	BGC	no	
prenyltransferase	 is	 predicted.	 Additionally,	 the	 fusion	 pattern	 (Scheme	 3.6)	 of	 humulene	 and	
polyketide	 in	 154	 indicates	 a	 terpene	 cyclisation	 reaction	 to	 happen	 first	 followed	 by	 a	 [4+2]	
cycloaddition	to	fuse	humulene	and	polyketide	(Scheme	3.6).	This	mechanism	is	also	supported	by	
biomimetic	in	vitro	studies	towards	epolones	113/114	(Scheme	1.20).111,113	
	
Scheme	3.7	Unusual	terpene	cyclisation	in	the	biosynthesis	of	A,	viridicatumtoxin	160	and	B,	teleocidin	186.	
Although	the	obtained	genome	and	transcriptome	data	provided	a	good	platform	for	the	in	silico	
analysis	of	101	biosynthesis,	the	identification	of	a	humulene	synthase	remained	elusive.	It	was	first	
assumed	that	A.	strictum	provides	humulene	106	through	one	of	the	weakly	expressed	(Chapter	
3.3.1)	terpene	synthase	genes.	However,	later	in	this	work	AsR6	was	shown	to	produce	humulene	
106	in	vitro	(Chapter	5.5).	Bioinformatic	analysis	of	AsR6	and	known	terpene	cyclases	did	not	reveal	
homologies.	Thus,	with	AsR6,	the	aspks1	BGC	encodes	an	unknown	type	of	terpene	cyclase.	
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4 Targeted	Gene	Knockout	and	Knockdown	in	A.	strictum	
Gene	disruption	or	silencing	methods	are	widely	used	to	investigate	functions	of	encoded	proteins	
and	thus	are	a	practical	tool	to	elucidate	natural	product	biosynthesis.	Disrupting	or	silencing	genes	
from	a	BGC	and	analysing	the	changes	in	secondary	metabolite	production	links	genes	and	proteins	
with	 biosynthetic	 steps.	 For	 example,	 during	 the	 elucidation	 of	 tenellin	189	 biosynthesis	 in	 the	
filamentous	fungus	Beauveria	bassiana	both	strategies	were	used	successfully.	Targeted	knockout	
(KO)	of	tenS,	encoding	a	PKS-NRPS,	showed	total	deficiency	in	189	production.	Silencing	of	tenA	or	
tenB,	 encoding	 two	 P450s,	 led	 to	 the	 accumulation	 of	 intermediates	 pretenellin-A	 187	 and	
pretenellin-B	 188,	 respectively.	 Thus,	 it	 was	 possible	 to	 assign	 substrates,	 enzymes	 and	 the	
catalysed	reactions	in	the	biosynthetic	route	189.171,172	
	
Scheme	4.1	Biosynthesis	and	BGC	of	tenellin	189	in	B.	bassiana.	
The	two	strategies	have	 in	common	that	exogenous	DNA	targeting	 the	gene	of	 interest	 (GOI)	 is	
inserted	into	the	natural	product	producing	organism.	However,	gene	disruption	results	in	KO	of	
the	targeted	gene,	whereas	silencing	methods	rely	on	post-transcriptional	mRNA	degradation.	
Different	techniques	for	transformation	of	DNA	into	fungal	cells	have	been	proven	successful	in	a	
wide	range	of	filamentous	fungi:	Agrobacterium	tumefaciens	mediated	transformation	(AMT),173	
CaCl2/polyethylene	 glycol	 (PEG)	 treatment;174	 electroporation	 of	 protoplasts;175	 or	 particle	
bombardment	(biolistics),176	which	can	be	used	if	formation	of	protoplast	is	insufficient.		
Once	the	exogenous	DNA	is	inside	the	fungal	cell	it	is	integrated	into	the	genome.	In	order	to	disrupt	
the	targeted	gene,	the	transformed	DNA	is	designed	to	contain	two	sequences	homologous	to	the	
GOI	which	flank	a	selection	marker	on	either	side	(Figure	4.1).	By	homologous	integration	of	this	
KO	cassette	the	targeted	gene	is	 inactivated.	Transformants	are	then	selected	using	appropriate	
conditions,	for	example	use	of	the	E.	coli	gene	hph,	encoding	a	hygromycin	B	phosphotransferase177	
as	selection	marker	for	the	antibiotic	hygromycin	B.178	
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Figure	4.1	Gene	disruption	by	homologous	recombination	of	selection	marker	flanking	sites	and	GOI.	
KO	methods	exploit	 a	naturally	occurring	DNA	 repair	mechanism	of	 the	 cell,	which	mends	DNA	
lesions	caused	by	oxidative	and	mechanical	stress	or	ionizing	radiation.179	The	enzyme	Rad51	and	a	
number	 of	 associated	 proteins	 are	 involved	 in	 homologous	 recombination	 in	 yeast	
Saccharomyces	cerevisiae.	This	organism	was	 reported	 to	efficiently	 recombine	DNA	with	30	bp	
homology	sequence	(Figure	4.2).180,181,182,183	
Although	homologous	recombination	is	the	preferred	mechanism	of	DNA	repair	in	S.	cerevisiae,	it	
is	not	frequently	observed	in	most	ascomycetes	and	homologous	sequences	of	several	hundred	bp	
are	 often	 required	 for	 effective	 recombination.184	 Instead,	 a	 second	 DNA	 repair	 mechanism,	
non-homologous	 end	 joining	 (NHEJ),	 which	 is	 independent	 of	 sequence	 homology,	 is	 used	
ubiquitously.185	 The	 ku	 heterodimer,	 consisting	 of	 two	 DNA	 binding	 proteins	 (ku70	 and	 ku80),	
recognizes	 DNA	 double-strand	 breaks	 and	 recruits	 further	 enzymes	 such	 as	 a	 DNA-dependent	
protein	kinase	and	the	DNA	ligase	IV-XRCC4	complex.182,186,187	NHEJ	mediated	DNA	repair	is	error	
prone	 and	 the	 integration	 of	 exogenous	 DNA	 occurs	 at	 random	 genetic	 loci	 as	 no	 sequence	
homology	 is	 required	 (Figure	 4.2).	 This	 ectopic	 integration	 of	 KO	 cassettes	 by	 NHEJ	 results	 in	
transformants	with	undisrupted	GOI,	which	 are	 able	 to	 grow	under	 selective	 conditions.	Often,	
homologous	recombination	frequencies	of	<20%	are	observed	in	filamentous	fungi,	which	increases	
the	number	of	transformants	that	have	to	be	analysed.	It	was	shown	that	KO	of	ku70	or	ku80	results	
in	an	 increase	of	homologous	recombination	rates	up	to	100%	for	N.	crassa188	and	other	 fungal	
species.184	However,	 generating	∆ku70	or	∆ku80	 strains	must	 first	be	achieved,	 and	 this	 can	be	
difficult	in	itself.	
A	modified	gene	disruption	method,	known	as	 the	bipartite	marker	 strategy,	was	developed	by	
Nielsen	et	al.	in	A.	nidulans.	For	this	method	two	individual	DNA	fragments,	each	composed	of	a	
gene	targeting	sequence	and	a	non-functional	part	of	a	selection	marker	are	co-transformed.	Only	
when	 the	 selection	marker	 is	 recombined	 by	 three	 homologous	 recombination	 events	 will	 the	
resistance	cassette	be	reconstructed	and	colonies	be	formed	on	selective	medium	(Figure	4.3).	The	
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selection	marker,	usually	consisting	of	a	structural	resistance	gene	for	the	appropriate	antibiotic	
and	a	constitutive	fungal	promoter/terminator,	is	divided	within	the	structural	gene	onto	the	two	
DNA	fragments.	This	way	the	possibility	of	the	3’	bipartite	substrate	being	functional	if	integrated	
downstream	of	a	native	promoter	is	prevented.	Thus	ectopic	integration	of	either	DNA	fragment	
alone	cannot	result	in	the	formation	of	selectable	transformants.	It	is	hypothesized	that	this	initial	
essential	 homologous	 recombination	 event	 channels	 the	 entire	 recombination	 towards	
homologous	recombination	rather	than	ectopic	 integration.	This	method	was	shown	to	 increase	
gene	targeting	in	A.	nidulans	by	~40%.189	
	
Figure	4.2	Ectopic	DNA	integration	by	non-homologous	end	joining	(NHEJ)	and	targeted	gene	disruption	by	homologous	
recombination	(HR).	
The	 most	 recent	 developments	 in	 targeted	 gene	 disruption	 are	 genome-editing	 tools	 where	
engineered	nucleases	are	deployed	to	 insert,	 remove	or	 replace	DNA	 in	a	very	specific	manner.	
These	include	meganucleases,	zinc-finger	nucleases,	transcription	activator-like	nucleases	and	the	
currently	most	popular	CRISPR/Cas9	 (type	 II	clustered	regularly	 interspaced	palindromic	repeats	
with	 the	 CRISPR-associated	 protein	 9).	 190,191	 The	 multidomain	 nuclease	 Cas9	 from	
Streptocccus	pyogenes	induces	a	DNA	double-strand	break	at	the	locus	base	pairing	a	20	bp	guide	
RNA	(gRNA).	gRNA	sequences	can	be	adapted	for	the	GOI,	but	must	be	adjacent	to	a	downstream	
5’-NGG	motif	 (protospacer	 adjacent	motif,	 PAM).	 The	 double-strand	 breaks	 can	 be	 repaired	 by	
NHEJ	resulting	in	deletions	or	insertions	of	variable	length.	In	the	presence	of	a	homologous	donor	
DNA	 (dDNA)	 the	DNA	double	 strand	 break	 can	 also	 be	 repaired	 by	 homologous	 recombination	
(Figure	4.4).190	In	2015	this	technique	was	first	reportedly	used	in	Trichoderma	reesei,	where	it	was	
shown	to	improve	homologous	recombination	efficiency	to	almost	100%.192	
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Figure	 4.3	 Integration	 of	 two	 DNA	 fragments	 with	 three	 homologous	 recombination	 (HR)	 events	 to	 reduce	 ectopic	
integration	by	the	bipartite	marker	strategy.	
A	different	method	for	the	exploration	of	gene	function	is	post-transcriptional	gene	silencing	which	
often	 results	 in	 decreased	 yields	 rather	 than	 complete	 absence	 of	 the	 investigated	 secondary	
metabolite.	Introduction	of	antisense	RNA	(asRNA)	to	the	mRNA	of	the	GOI	induces	the	formation	
of	 aberrant	 double	 stranded	 RNA	 (dsRNA)	 by	 an	 RNA	 dependent	 RNA	 polymerase	 (RdRP).	 This	
initiates	 the	 endogenous	 silencing	 pathway	 in	 fungi	 which	 is	 involved	 in	 gene	 regulation	 and	
genome	stability.193,194	The	dsRNA	is	degraded	into	small	interfering	RNA	(siRNA)	of	~22	nt	by	the	
endoribonuclease	Dicer.	This	in	itself	results	in	the	destruction	of	much	mRNA,	but	in	a	second,	and	
amplifying,	 process	 these	 ~22	 nt	 fragments	 are	 recruited	 to	 the	 protein	 Argonaute	 (Ago)	 and	
assembled	into	an	RNA-induced	silencing	complex	(RISC).	
	
Figure	4.4	CRISPR/Cas9	mediated	gene	editing.	
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The	siRNA	guides	RISC	to	the	remaining	mRNA	which	is	then	degraded	by	Ago,	resulting	in	low	levels	
of	mRNA	and	thus	reducing	translation	to	protein	(Figure	4.5).193,195	This	approach	is	independent	
of	homologous	recombination,	because	the	reverse	GOI	(revGOI)	can	be	introduced	at	a	random	
locus	on	the	genome,	while	the	actual	targeting	occurs	in	the	cytosol.	Gene	silencing	in	B.	bassiana	
yielded	more	positive	transformants	and	resulted	in	the	same	phenotype	of	metabolite	production	
as	generated	KO	strains.	This	indicates	that	asRNA	mediated	gene	silencing,	in	this	case,	induced	
the	degradation	of	almost	100%	mRNA.172	
	
Figure	4.5	siRNA	induced	silencing	mechanism	in	eukaryotes.	
	
4.1 Transformation	of	A.	strictum	
The	xenovulene	producing	A.	strictum	strain	has	been	shown	to	efficiently	produce	protoplasts	and	
was	first	successfully	transformed	with	a	CaCl2/PEG	method	by	Dr	Kate	Harley	from	our	group.127	
The	 strain	 was	 found	 to	 be	 sensitive	 to	 the	 aminoglycoside	 antibiotic	 hygromycin	 B	 in	
concentrations	of	50	µg/mL	and	a	hygromycin	 resistance	cassette	was	shown	to	be	effective	as	
selection	marker	during	transformation.127	
4.1.1 Antibiotics	Screening	
During	transformation	the	selection	marker	is	stably	integrated	into	the	fungal	genome	and	cannot	
be	recycled.	For	multiple	rounds	of	transformation	and	selection	it	is	beneficial	to	have	more	than	
one	antibiotic	to	which	the	investigated	microorganism	shows	sensitivity.		
To	analyse	whether	A.	strictum	shows	sensitivity	to	an	additional	antibiotic	it	was	sub-cultured	on	
CD	 with	 sorbitol	 (CD+S)	 agar	 containing	 different	 concentrations	 (10,	 50,	 100,	 200	 µg/mL)	 of	
glufosinat,	geneticin,	neomycin	or	zeocin,	respectively.	Observation	of	the	colonies	at	25	°C	for	16	d	
and	105	d	showed	that	A.	strictum	is	able	to	grow	on	all	antibiotics	at	a	concentration	of	10	µg/mL.	
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However,	geneticin	effectively	inhibits	the	growth	at	a	concentration	of	50	µg/mL	for	16	d,	whereas	
colonies	were	observed	for	all	other	tested	selection	reagents.	At	a	concentration	of	100	µg/mL	
geneticin	 induced	growth	 inhibition	 is	 stable	 for	 at	 least	 105	d	 (Figure	4.6).	 These	observations	
suggest	that	geneticin	could	be	used	as	an	antibiotic	for	selection	in	a	second	round	of	A.	strictum	
transformations.	
	
Figure	4.6	A.	strictum	CD+S	agar	plates	with	different	concentrations	of	antibiotics	at	two	time	points.	
4.1.2 Transformation	of	A.	strictum	with	pTH-GS-egfp		
A	 reliable	 transformation	method	 enables	 further	 genetic	manipulation	 of	A.	 strictum	 and	was	
re-established	 and	 optimised	 using	 the	 vector	 pTH-GS-egfp.	 The	 vector	 contains	 a	 resistance	
cassette	(hygR)	for	selection	with	hygromycin	B	and	the	egfp	gene,	encoding	an	enhanced	green	
fluorescent	protein	(eGFP),	as	visible	marker.	The	egfp	gene	is	expressed	under	the	control	of	the	
starch	or	maltose	inducible	PamyB	promoter	and	terminator	from	A.	oryzae	(Figure	4.7).196,197	
A.	 strictum	 PEG/CaCl2	 mediated	 protoplast	 (Figure	 4.7B)	 transformation	 with	 pTH-GS-egfp	
(Figure	4.7A)	resulted	in	12	colonies	growing	on	tertiary	selection	plates.	For	fluorescence	analysis	
6	transformants	were	sub-cultured	in	ASPM	liquid	medium,	which	contains	maltose	as	the	carbon	
source	 for	 the	 induction	 of	 PamyB.	 Samples	 of	 4	 d	 old	 transformants	 and	 A.	 strictum	WT	 were	
microscopically	 analysed.	Upon	 excitation	 (450	 –	 490	 nm)	 the	 transformants	 displayed	 a	 green	
fluorescence	correlating	to	the	expression	of	egfp	and	translation	into	protein,	whereas	wildtype	
control	does	not	emit	green	light	(Figure	4.7C	I-IV).	This	confirms	the	successful	transformation	and	
selection	 method	 as	 well	 as	 the	 effective	 initiation	 of	 transcription	 downstream	 of	 PamyB	 in	
A.	 strictum.	 These	 findings	 confirm	 previous	 results	 of	 Dr	 Jack	 Davison	 from	 our	 group,	 who	
previously	showed	that	efpg	was	expressed	in	A.	strictum	downstream	of	PamyB.104	
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Figure	 4.7	 A.	 strictum	 transformation.	 A,	 Vector	 map	 of	 pTH-GS-egfp;	 B,	 A.	 strictum	 protoplasts;	 C,	 A.	 strictum	
transformed	with	pTH-GS-egfp	(I+II)	and	WT	(III+IV),	I+III)	upon	excitation	and	II+IV)	bright-field.	
Although	the	transformation	method	was	successfully	re-established	with	pTH-GS-egfp,	recovering	
A.	 strictum	 transformants	 was	 difficult.	 Of	 18	 further	 transformations	 targeting	 aspks1	
(Chapter	4.3.2)	only	four	yielded	a	reasonable	number	of	transformants	(8	to	14),	indicating	a	major	
selection	issue,	as	14	transformations	yielded	no	colonies	at	all.	Two	main	observations	were	made:	
either	the	transformation	plates	were	overgrown	after	three	to	five	days;	or	no	colonies	could	be	
recovered	 at	 all.	 To	 address	 this,	 several	 changes	 to	 the	 original	 transformation	 protocol	were	
made.	 Firstly,	 to	 remove	 spores	 causing	 a	 high	 background,	 cells	 were	 collected	 by	 miracloth	
instead	of	centrifugation.	Secondly,	different	molecular	weights	PEG	(3350,	4000)	were	tested,	but	
gave	inconclusive	results.	And	finally,	instead	of	overlaying	the	plates	16	h	after	transformation,	the	
protoplasts	were	directly	plated	onto	solid	media	containing	50-100	µg/mL	hygromycin	B.	
These	changes	improved	the	process	but	still	did	not	result	in	a	reliable	transformation	efficiency	
of	A.	strictum.	In	a	comparison	experiment,	selection	agar	was	prepared	with	tap,	millipore	or	VE	
water	 and	 used	 for	 transformation.	 Tap	 water	 resulted	 in	 overgrown	 plates	 after	 three	 days,	
millipore	water	 yielded	 no	 colonies	 and	 VE	water	 resulted	 in	 colonies	 growing	 after	 10	 d.	 This	
sensitivity	 towards	 the	water	quality	does	not	affect	 the	positive	control,	where	untransformed	
protoplasts	 are	 plated	 on	 selection	 agar	 without	 antibiotics.	 For	 those	 protoplasts	 recovery	 is	
observed	after	16	h	under	all	tested	conditions.	This	experiment	showed	that	A.	strictum	protoplast	
recovery	in	the	presence	of	hygromycin	B	is	depending	on	the	water	quality	and	has	a	great	impact	
on	the	success	rate	of	the	transformation.	
4.1.3 Nuclei	Staining	of	A.	strictum	
Fungal	protoplasts	are	generated	through	the	incubation	of	freshly	grown	mycelia	with	a	cell	wall	
degrading	 enzyme	 mixture.	 Usually	 one	 protoplast	 contains	 an	 uncertain	 number	 of	 nuclei.	
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Therefore,	primary	transformants	are	often	heterokaryons	and	have	to	be	genetically	purified	by	
re-streaking	of	conidiaspores.	Depending	on	the	number	of	nuclei	per	conidiaspore	the	efficiency	
of	this	process	can	vary.198	The	fluorescent	dye	4’,6-diamidino-2-phenylindole	(DAPI)	binds	AT	rich	
regions	 of	 DNA	 in	 the	 minor	 groove	 and	 can	 be	 visualized	 upon	 excitation	 (358	 nm)	 by	
microscopy.199	It	was	used	to	stain	a	2	d	old	sporulating	A.	strictum	sample	obtained	from	liquid	
culture.	 Excitation	 and	 microscope	 analysis	 showed	 that	 every	 conidiaspore	 harbours	 a	 single	
nucleus	 (Figure	 4.8B).	 These	 findings	 facilitated	 genetic	 purification	 of	 A.	 strictum	 in	 further	
experiments.	
	
Figure	4.8	A.	strictum	spores	with	DAPI	stained	nuclei,	A,	bright-field	B,	DAPI	and	C,	overlay	of	A+B.	
4.1.4 Assembly	of	Vector	Constructs	by	Homologous	Recombination	in	S.	cerevisiae	
For	targeted	gene	disruption	a	KO	cassette	consisting	of	a	selection	marker	(hygR	or	the	geneticin	
resistance	cassette	genR)	flanked	by	arms	homologous	to	the	GOI	has	to	be	assembled.	S.	cerevisiae	
can	recombine	DNA	fragments	by	homologous	recombination	with	an	overlap	sequence	of	30	bp.	
It	has	been	used	extensively	to	build	up	vector	constructs	through	PEG	mediated	co-transformation	
of	individual	DNA	fragments	and	a	vector	backbone	(Figure	4.9).180,200	
In	 this	work	pE-YA201	was	used	 as	 vector	 for	 the	 assembly	 of	 all	 KO	 and	 silencing	 constructs	 of	
Chapter	 4.	 This	 vector	 contains	 the	 2µ	 origin	 of	 replication	 (ori)	 and	 ura3	 gene	 (encoding	 an	
orotidine	5’-phopsphate	decarboxylase)	to	select	uracil	auxotroph	S.	cerevisiae	in	uracil	and	uridine	
free	 medium.	 All	 DNA	 fragments	 for	 yeast	 assembly	 were	 amplified	 by	 PCR	 using	 gDNA	 of	
A.	strictum	as	gene	specific	template.	For	amplification	of	the	fungal	selection	marker	appropriate	
vector	DNA	(pTH-GS-egfp,	pTYG-genR)	was	used	as	the	PCR	template	(Figure	4.10).	The	necessary	
30	 bp	 sequence	 overlap	 for	 homologous	 recombination	 of	 the	 individual	 DNA	 fragments	 was	
introduced	 by	 PCR	 through	 tails	 on	 the	 designed	 oligonucleotides.	 pE-YA	 was	 linearized	 by	
restriction	 hydrolysis	 with	 either	 AscI,	 NotI	 or	 both	 enzymes	 prior	 to	 PEG	 mediated	
co-transformation	with	the	PCR	amplified	DNA	fragments.	Assembled	vector	DNA	was	isolated	from	
S.	cerevisiae	by	kit	and	directly	used	to	transform	competent	E.	coli.	For	propagation	in	E.	coli	pE-YA	
has	an	additional	ori	(pUC)	and	the	nptII	gene,	encoding	the	neomycin	phosphotransferase	II,	which	
A B C
20	µm 20	µm 20	µm
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also	confers	resistance	to	kanamycin	(kanR).	Obtained	E.	coli	colonies	were	screened	by	PCR	and	
confirmed	by	sequencing	(Eurofins,	Ebersberg).	
	
Figure	4.9	Yeast	homologous	recombination	(HR)	cloning	strategy.	
The	 selection	 marker	 for	 hygromycin	 B	 (hygR)	 and	 geneticin	 (genR)	 consists	 of	 the	 respective	
bacterial	 resistance	 gene	 hph	 or	 nptII	 (also	 confers	 resistance	 to	 geneticin)	 (Figure	 4.10).	 The	
resistance	genes	are	expressed	under	the	control	of	the	A.	nidulans	promoter/terminator	PgpdA/TtrpC.	
	
Figure	4.10	Selection	genes	under	the	control	of	the	fungal	PgpdA	and	TtrpC	and	vector	map	of	pTYG-gen
R.	
	
4.2 Attempted	Targeting	of	asl4,	asL5	and	asL6	
All	previous	attempts	for	gene	disruption	or	silencing	(Chapter	4.3)	in	A.	strictum	within	our	group	
were	 targeting	 aspks1.	 It	 has	 never	 been	 attempted	 to	 target	 any	 of	 the	 clustered	 genes	 for	
disruption.	In	other	filamentous	fungi,	e.g.	Magnaporthe	grisea	and	A.	nidulans	it	was	shown	that	
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gene	disruption	is	locus	dependent.202,203	In	M.	grisea	the	secondary	metabolite	ACE1	gene	cluster,	
involved	in	avirulence	signalling	during	rice	infection,	was	targeted	for	different	gene	disruptions.	
However,	it	was	only	possible	to	disrupt	3	of	15	genes	at	this	genetic	locus.202	A	similar	phenomenon	
was	observed	in	A.	nidulans,	where	disruption	of	two	genes	(niaD,	encoding	a	nitrate	reductase,	
and	 amdS,	 encoding	 an	 acetamidase)	 showed	 that	 targeting	 of	 one	 (niaD)	 genetic	 locus	 was	
five-fold	 more	 efficient	 than	 the	 other.203	 By	 targeting	 aspks1	 clustered	 genes	 it	 should	 be	
investigated	whether	disruption	of	genes	other	than	aspks1	is	more	efficient.	In	addition,	successful	
KO	of	a	putative	tailoring	enzyme	encoding	gene	could	elucidate	its	role	during	the	biosynthesis	of	
xenovulene	A	101.	
4.2.1 Attempted	Bipartite	Knockouts	of	asL4,	asL5	and	asL6	
The	 genes	 asL4	 and	 asL6,	 both	 encoding	 putative	 FAD	 dependent	monooxygenases,	 and	 asL5,	
encoding	a	putative	short-chain	dehydrogenase/reductase,	were	selected	for	gene	knockouts	with	
the	bipartite	method	(Figure	4.11).189		
	
Figure	4.11	aspks1	BGC.	
The	KO	cassettes	(RSI77	1-6)	for	each	gene	were	constructed	by	in	vivo	homologous	recombination	
in	S.	cerevisiae	with	selection	markers	for	hygromycin	B	(RSI77	2,	4	and	6)	and	geneticin	(RSI77	1,	3	
and	5),	respectively	(Figure	4.12	and	Table	7.7).	DNA	fragments	for	assembly	were	amplified	by	PCR	
using	oligonucleotides	Pa-Pf	(Figure	4.12	and	Table	7.7,	Chapter	4.1.4).	
Table	4.1	Overview	of	transformants	obtained	by	bipartite	substrate	KO	and	chemical	or	genetic	analysis.	
Transformation	
Experiment	
GOI	 Resistance	
cassette	
Plasmid	ID	
for	PCR	
#transformants	 #	of	chemically	
analysed	
transformants	
#	of	genetically	
analysed	
transformants	
RSI93	3	
RSI93	5	
asL5	
asL6	
genR	
genR	
RSI77	3	
RSI77	5	
8	
8	
8	
8	
-	
-	
RSI103/104	2	
RSI103/104	4	
RSI103/104	6	
asL4	
asL5	
asL6	
hygR	
hygR	
hygR	
RSI77	2	
RSI77	4	
RSI77	6	
1	
3	
18	
-	
-	
-	
1	
3	
18	
	
The	 5’	 and	 3’	 bipartite	 substrates	 for	 asL4,	 asL5	 or	 asL6	 were	 amplified	 by	 PCR	 using	
oligonucleotides	Pg+h	and	Pi+j	from	the	corresponding	template	vector	DNA	(RSI77	1–6,	Figure	4.12).	
The	 DNA	 was	 purified	 and	 directly	 used	 for	 PEG/CaCl2	mediated	 protoplast	 transformation	 of	
aspks1asL1 asR2 asR3 asR4 asR5 asR6 asR7asR1asL2asL3asL4asL5asL6asL7
PKS oxidoreductase regulator transporter ferredoxin	like unknown
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A.	 strictum.	 In	 total	 1	 transformant	 targeting	 asL4,	 11	 transformants	 targeting	 asL5	 and	 26	
transformants	targeting	asL6	were	obtained	from	three	rounds	of	transformations	(Table	4.1).	
	
Figure	 4.12	 General	 method	 for	 assembly	 of	 KO	 cassettes	 for	 asL4,	 asL5	 and	 asL6	 in	 pE-YA	 by	 yeast	 homologous	
recombination	(HR).	
For	chemical	analysis	the	16	transformants	obtained	from	transformation	RSI93	(Table	4.1)	were	
grown	 under	 xenovulene	 A	 101	 producing	 conditions,	 extracted	 following	 a	 small	 scale	 (1	mL)	
protocol	and	analysed	by	analytical	LCMS.	Production	of	xenovulene	A	101	was	observed	by	UV	
absorption,	mass	and	tR	in	all	chromatograms	(Figure	4.13).	
For	 genetic	 testing	 of	 the	 22	 transformants	 obtained	 from	 transformations	 RSI103	 and	 RSI104	
(Table	4.1)	gDNA	was	extracted	and	used	as	PCR	template.	Disruption	of	genes	was	analysed	with	
oligonucleotides	 specific	 for	 the	 targeted	 genes	 and	 compared	 to	 A.	 strictum	 WT	 gDNA	
(Figure	4.14).	A	DNA	fragment	corresponding	to	the	size	of	non-disrupted	GOI	was	amplified	for	all	
tested	transformants,	rather	than	the	~3	kb	longer	KO	cassette.	
All	chemically	analysed	transformants	still	produced	101	and	all	genetically	tested	transformants	
possessed	a	non-disrupted	GOI.	This	indicates	that	the	bipartite	substrate	cassette	has	ectopically	
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integrated	within	the	genome	for	all	targeted	genes	(asL4,	asL5,	asL6).	These	findings	suggets	that	
either	the	genetic	locus	of	the	whole	aspks1	BGC	is	protected	from	gene	disruptions	by	homologous	
recombination	or	non-homologous	end	joining	is	much	more	effective	in	A.	strictum.	
	
	
Figure	4.13	LCMS	analysis	of	two	transformants	obtained	with	the	bipartite	marker	strategy	by	analytical	LCMS.	Extracted	
ion	(ES+)	chromatograms	at	m/z	=	359	and	tR	=	8.4	min	show	the	presence	of	101	in	the	extracts.	
	
Figure	4.14	Genetic	analysis	of	transformants	obtained	with	bipartite	marker	strategy	by	PCR.	
4.2.2 Attempted	Silencing	of	asL4,	asL5	and	asL6	
The	 attempted	 targeted	 knockouts	 (asL4,	asL5,	asL6;	 Chapter	 4.2.1)	 showed	 that	A.	 strictum	 is	
proficient	in	ectopic	integration	but	not	in	homologous	recombination	of	DNA.	This	suggests	that	
targeted	gene	knockouts	which	rely	on	gene	disruption	by	homologous	site	specific	integration	are	
not	promising	in	this	organism.	However,	ectopic	integration	of	exogenous	DNA	has	been	shown	to	
be	successful	(Chapters	4.1.2,	4.21)	and	should	hence	be	used	to	silence	asL4,	asL5	or	asL6.	Previous	
attempts	to	silence	aspks1	by	Dr	Elizabeth	Skellam	and	Dr	Jack	Davison	using	exogenous	promoters	
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to	drive	transcription	of	different	length	asRNA	were	unsuccessful	(Chapter	4.3).104,105	However,	in	
these	 experiments	 heterologous	 promoters	 were	 used	 and	 it	 was	 not	 clear	 if	 they	 promoted	
effective	gene	expression	in	A.	strictum.	The	genome	sequence	of	A.	strictum	enabled	the	use	of	an	
endogenous	promoter	to	drive	the	expression	of	asRNA.	For	this	experiment	the	promoter	of	the	
strongly	 expressed	 primary	 metabolism	 gene	 gpdA	 (encoding	 glyceraldehyde-3-phosphate	
dehydrogenase	A)	was	selected.	
	
Figure	4.15	Assembly	of	silencing	cassettes	for	asL4,	asL5	and	asL6	in	pE-YA	by	yeast	homologous	recombination	(HR).	
Assembly	of	 the	 silencing	vectors	 containing	asRNA	of	 the	GOI	downstream	of	A.	 strictum	 PgdpA	
(asPgdpA)	 and	 next	 to	 a	 hygromycin	 resistance	 cassette	 was	 achieved	 by	 in	 vivo	 homologous	
recombination	in	S.	cerevisiae	(RSI95	2:	asL4,	RSI95	4:	asL5	or	RSI95	6:	asL6).	DNA	fragments	for	
assembly	 were	 amplified	 with	 the	 denoted	 oligonucleotides	 Pa–Pf	 by	 PCR	 (Table	 7.8	 for	 used	
oligonucleotides	and	Chapter	4.1.4	for	experimental	details).	
The	silencing	vectors	for	asL4,	asL5	or	asL6	(RSI95	2,	RSI95	4	and	RSI95	6)	were	directly	used	for	
PEG/CaCl2	mediated	 protoplast	 vector	 transformation	 of	A.	 strictum.	 In	 total,	 25	 transformants	
targeting	 asL4,	 16	 targeting	 asL5	 and	 12	 targeting	 asL6	 were	 obtained	 from	 two	 rounds	 of	
transformations	 (RSI106,	 RSI101,	 Table	 9.5).	 For	 chemical	 analysis	 11	 asL4,	 5	 asL5	 and	 8	 asL6	
transformants	were	 selected,	 grown	under	101	producing	 conditions	 and	 extracted	 following	 a	
large	scale	(50	mL)	protocol.	Analytical	LCMS	analysis	and	interpretation	of	the	chromatograms	did	
not	show	any	distinct	changes	in	the	production	of	secondary	metabolites	(Figure	4.16).	
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To	confirm	the	vector	integration	two	transformants	of	each	targeted	gene	(asL4:	RSI101B2-5	and	
B2-6,	 asL5:	 RSI101B4-3	 and	 B4-4,	 asL6,	 RSI106	 6-1	 and	 6-2)	 were	 selected	 for	 gDNA	 isolation.	
Transformants	were	genetically	analysed	by	PCR	using	oligonucleotides	P686+Pa	and	the	respective	
gDNA	templates	(Figure	4.17).	A	~2800	bp	(asL4,	asL6)	or	a	~2300	bp	(asL5)	DNA	fragment	were	
amplified	from	gDNA	of	both	(asL4,	asL5)	and	from	one	(asL6)	tested	transformant,	but	not	from	
A.	strictum	WT	gDNA	(Figure	4.17).	This	confirms	the	ectopic	integration	of	the	silencing	vector	and	
the	 presence	 of	 asGOI	 downstream	 of	 asPgpdA	 in	 all	 but	 one	 (RSI106	 6-2)	 of	 the	 tranformants	
transformants	(Figure	4.17).	Further	PCR	analysis	for	the	integration	of	the	hygromycin	resistance	
cassette	using	P419+420,	resulted	in	the	amplification	of	~600	bp	for	all	gDNA	templates,	but	not	
for	 A.	 strictum	 WT	 gDNA.	 This	 indicates	 that	 upon	 integration	 of	 the	 silencing	 construct	 in	
transformant	RSI106	6-2	(targeting	asL6)	asPgdpA	was	separated	from	asGOI.	
	
Figure	4.16	Chemical	analysis	of	A.	strictum	transformants	obtained	through	transformation	of	silencing	vector	(RSI95)	
by	analytical	LCMS	(Gradient	A1).	DAD	of	selected	transformants	RSI101	B2-5,	101	B4-3	and	106	6-1.	
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Although	genetic	analysis	confirmed	the	correct	integration	of	the	silencing	construct	in	5	out	of	6	
transformants	tested,	the	secondary	metabolite	production	did	not	show	distinct	changes.	These	
findings	suggest	that	either	the	attempted	gene	silencing	in	A.	strictum	is	unsuccessful	or	that	the	
targeted	 genes	 of	 the	 aspks1	BGC	 are	 not	 involved	 in	 101	 biosynthesis.	 However,	 the	 in	 silico	
evidence	(Chapter	3.2)	strongly	suggests	that	the	aspks1	BGC	is	responsible	for	101	biosynthesis.	
	
	
Figure	4.17	Genetic	analysis	of	transformants	obtained	with	transformation	of	silencing	vectors	(RSI95)	by	PCR.	
	
4.3 aspks1	Knockout	
All	 previous	 unsuccessful	 attempts	 in	 our	 group	 to	 link	 the	aspks1	BGC	 and	 xenovulene	 A	101	
production	targeted	the	aspks1	gene.	Traditional	KO	as	well	as	RNA	induced	silencing	experiments	
by	Dr	Kate	Harley,127	Dr	Elizabeth	Skellam105	and	Dr	Jack	Davison104	showed	no	loss	or	significant	
decrease	in	xenovulene	A	101	production.	For	the	disruption	of	aspks1	a	vector	(AsPKS1KO-2,	Figure	
4.18A)	 containing	 a	 KO	 cassette	with	 the	 hygromycin	marker	hygR	was	 constructed	 by	 Dr	 Kate	
Harley	and	transformed	by	Dr	Elizabeth	Skellam.	In	a	total	of	14	transformations	84	transformants	
were	generated,	extracted	and	analysed	for	their	secondary	metabolite	production	by	LCMS.	All	
showed	production	of	101	and	the	genetic	analysis	by	Southern	Blots	showed	non-disrupted	aspks1	
(Figure	4.18).	Additional	gene	silencing	experiments	were	conducted	by	Dr	Elizabeth	Skellam	and	
Dr	 Jack	Davison	using	different	promoters	and	antisense	RNA	 (AsSil	 and	pUC18+hph,	pAsSilPKS,	
pTAex3-hph-aspks1AS;	 Figure	 4.18B-D),	 but	 none	 of	 the	 42	 analysed	 transformants	 showed	 a	
significant	decrease	in	xenovulene	A	101	production.	
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The	 development	 of	 the	 bipartite	 marker	 strategy189	 as	 well	 as	 the	 implementation	 of	 a	
CRISPR/Cas9192,198	system	for	ascomycetes	provided	two	new	approaches	which	should	be	used	to	
generate	targeted	gene	knockouts	of	aspks1.	Although	the	KO	of	aspks1	proved	difficult	in	previous	
experiments	it	was	selected	as	targeted	gene	as	its	disruption	would	give	clear	evidence	that	the	
BGC	is	involved	in	101	biosynthesis.	
	
Figure	4.18	Vectors	used	 to	 transform	A.	strictum	 in	previous	experiments	A,	 traditional	KO	of	aspks1,	B-D,	silencing	
attempts	with	different	length	of	asRNA	and	promoters.	
4.3.1 Attempted	Gene	Editing	of	aspks1	by	CRISPR/Cas9	
During	 the	 time	of	 this	work	 several	 strategies	 to	apply	CRISPR/Cas9	 technology	 in	 filamentous	
fungi	have	been	published.192,198,204	Amongst	the	first	is	a	single	vector	based	method	developed	by	
Nødvig	et	 al.	 This	 strategy	was	 selected	 for	 application	 in	A.	 strictum	due	 to	 facile	 cloning	 and	
transformation	methodology.198	
A	single	fungal	CRISPR	vector	(pFC332)	is	used	to	introduce	a	codon	optimized	cas9	with	an	SV40	
nuclear	 localization	 signal	 and	 a	 gRNA	 cassette	 (Figure	 4.19)	 into	 the	 fungal	 host	 in	 one	
transformation	 step.	 The	 gene	 encoding	 the	 Cas9-SV40	 fusion	 protein	 is	 expressed	 under	 the	
control	of	the	A.	nidulans	constitutive	promoter	and	terminator	Ptef1/Ttef1.	Stable	integration	and	
expression	of	cas9	might	cause	off	target	effects.	This	is	prevented	through	a	nucleotide	sequence	
that	induces	autonomous	maintaining	of	plasmids	in	Aspergillus	(AMA1).205,206	The	gRNA	cassette	
(Figure	 4.19	 and	 4.20)	 to	 target	 individual	 genes	 can	 be	 introduced	 by	 uracil-specific	 excision	
reagent	cloning	(USERTM	Enzyme,	New	England	Biolabs)	into	a	PacI/Nt.BbvCI	site.207	
Short	 RNA	 without	 a	 cap	 structure	 and	 poly(A)	 tail,	 such	 as	 gRNA,	 are	 transcribed	 by	 RNA	
polymerase	III	in	other	CRISPR/Cas9	systems.	However,	RNA	Polymerase	III	promoters	are	poorly	
defined	 in	 filamentous	fungi	and	hence	Nødvig	et	al.	embedded	the	gRNA	 in	a	 longer	transcript	
which	 is	 transcribed	 by	 RNA	 Polymerase	 II	 under	 the	 control	 of	 the	 constitutive	 PgpdA/TtrpC	
(Figure	4.20).	This	 transcript	encodes	 two	ribozyme	sequences,	a	5’	hammerhead	 (HH)	and	a	3’	
hepatitis	 delta	 virus	 (HDV)	 (Figure	 4.20,	 black).	 The	 autocatalytic	 RNA	 cleaving	 activity	 of	 these	
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ribozymes	frees	the	gRNA	in	the	fungal	host.	The	gene	targeting	gRNA	leads	the	Cas9-SV40	fusion	
protein	to	the	targeted	sequence	by	nucleotide	base	pairing	(Figure	4.20,	blue	and	red).198,208	
	
Figure	4.19	Fungal	CRSIPR/Cas9	plasmid	pFC332.	
	
Figure	4.20	gRNA	cassette	design	used	for	the	CRISPR/Cas9	system	developed	by	Nodvig	et	al.	
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The	 individual	 gRNA	 sequence	 as	 well	 as	 the	 6	 bp	 inverted	 repeat	 (Figure	 4.20,	 green)	 for	 HH	
cleavage	 are	 introduced	 through	 oligonucleotides	 in	 PCR	 (Pa	 and	 Pb)	 using	 pFC334	 as	 template	
(Figure	4.21).	pFC334	is	a	vector	containing	a	gRNA	cassette	with	a	protospacer	(Figure	4.20,	red)	
to	target	yA	(p-diphenol	oxidase)	in	A.	nidulans,	but	can	be	used	as	a	PCR	template	for	any	gRNA	
cassette.	 The	 two	amplified	DNA	 fragments	 (F1	andF2)	 can	 then	be	directionally	 fused	 into	 the	
fungal	CRISPR	(pFC)	vector	by	USER	cloning	(Figure	4.21	and	4.25).	
	
Figure	4.21	Amplification	of	gRNA	cassette	fragments	F1	and	F2	from	pFC334	for	USER	cloning.	
To	target	aspks1	the	CRIPSR/Cas9	plasmid	pFC332	was	sub-cloned	with	a	gRNA	cassette	to	induce	
a	DSB	within	aspks1	after	transformation	of	the	vector	into	A.	strictum.	Repair	of	the	DSB	should	
lead	to	an	insertion	or	deletion	at	the	cut	DNA	site	through	non-homologous	end	joining	and	result	
in	a	frameshift	within	the	aspks1	gene	(Figure	4.22).	
	
Figure	4.22	CRISPR/Cas9	induced	targeted	DSB	and	repair	by	non-homologous	end	joining	(NHEJ)	resulting	in	random	
insertions	or	deletions	within	aspks1.	
Therefore,	the	gRNA	cassette	targeting	aspks1	was	amplified	in	two	individual	PCRs	using	pFC334	
as	template	and	oligonucleotides	P559+562	(F1)	and	P561+560	(F2)	(Figure	4.20	and	4.25).	USER	
cloning	 was	 used	 to	 fuse	 PacI/Nt.BbvCI	 hydrolysed	 pFC332,	 F1	 (544	 bp)	 and	 F2	 (424	 bp)	 in	 a	
directional	manner.	Transformants	were	screened	with	colony	PCR	and	positives	were	confirmed	
by	sequencing	(Eurofins,	Ebersberg).	
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The	protospacer	was	selected	on	exon	1	of	aspks1	adjacent	to	a	5’-TGG	PAM	motif	(Figure	4.23).	It	
was	chosen	to	be	close	to	the	5’	end	of	aspks1	so	the	intended	frameshift	would	affect	the	function	
of	the	entire	translated	protein.		
	
Figure	4.23	Protospacer	position	on	exon1	directly	upstream	to	5’-TGG	PAM	at	aspks1.	
The	 obtained	 plasmid	 (RSI59B2)	 was	 used	 to	 transform	 A.	 strictum	 by	 CaCl2/PEG	 mediated	
protoplast	 transformation.	 This	 yielded	 45	 colonies	 from	 two	 rounds	 of	 transformations.	 15	
colonies	 were	 selected	 for	 analysis	 of	 secondary	 metabolite	 production	 under	 101	 producing	
conditions	(ASPM)	in	liquid	fermentation.	Cell	free	cultures	were	extracted	following	a	small	scale	
protocol	(1	mL)	and	analysed	by	LCMS.	The	chromatograms	showed	production	of	101,	deduced	by	
UV	absorption,	mass	and	tR	in	all	screened	transformants	(Figure	4.24).	Further	genetic	analysis	was	
not	carried	out,	as	the	production	of	101	clearly	indicated	that	the	applied	CRISPR/Cas9	system	in	
combination	with	the	selected	gRNA	is	not	effective	in	A.	strictum.	
	
Figure	4.24	Chemical	analysis	of	transformants	obtained	through	transformation	of	A.	strictum	with	the	CRIPSR	plasmid	
targeting	aspks1	(RSI59B2)	on	analytical	LCMS.	Extracted	ion	(ES+)	chromatograms	at	m/z	=	359	and	tR	=	8.4	min	show	the	
presence	of	101	in	the	extracts.	
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Figure	4.25	gRNA	cloning	strategy	and	used	oligonucleotides	for	USER	cloning.	Uracil	containing	tails	were	introduced	
trough	tails	at	the	oligonucleotides	(P559-562).	Overlapping	and	complementing	sequences	are	coloured	accordingly.	
4.3.2 aspks1	Disruption	by	Bipartite	Marker	Strategy	
As	a	second	approach	to	disrupt	aspks1	in	A.	strictum	the	bipartite	marker	strategy	was	applied.189	
The	5’	and	3’	bipartite	substrate	were	assembled	in	two	separate	constructs	(RSI21A1,	RSI21B5)	by	
in	 vivo	 homologous	 recombination	 in	 S.	 cerevisiae	 (Figure	 4.26,	 Chapter	 4.1.4	 for	 experimental	
details).	The	aspks1	 targeting	sequences	and	the	two	hygromycin	resistance	cassette	containing	
fragments	were	amplified	by	PCR	using	the	indicated	oligonucleotides	(Figure	4.26).		
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Figure	4.26	Assembly	of	bipartite	substrates	for	aspks1	in	pE-YA	by	yeast	HR. 
The	bipartite	substrates	were	PCR	amplified	with	P83+22	and	P23+86	using	RSI21B5/RSI21A1	as	
PCR	 template.	 The	 DNA	 fragments	 were	 purified	 and	 used	 directly	 for	 CaCl2/PEG	 mediated	
protoplast	 transformation	 of	 A.	 strictum.	 In	 4	 rounds	 of	 transformations	 43	 colonies	 were	
generated	and	analysed	for	their	secondary	metabolite	production	(Appendix	Table	9.6).	
The	 43	 putative	 Daspks1	 colonies	 were	 grown	 under	 xenovulene	 A	 101	 producing	 conditions	
(ASPM),	cell	free	culture	broth	was	extracted	following	small	scale	extraction	(1	mL)	and	analysed	
by	analytical	 LCMS.	The	chromatograms	showed	production	of	101,	deduced	by	UV	absorption,	
mass	and	tR	in	all	but	one	(RSI58	1-1)	analysed	transformants.	The	remaining	cell	free	culture	broth	
(49	 mL)	 of	 RSI58	 1-1	 was	 extracted	 and	 LCMS	 analysis	 confirmed	 the	 lack	 of	 101	 or	 related	
compounds	107-108	(Figure	4.27).	
Genomic	 DNA	 of	 transformants	 RSI58	 1-1	 –	 1-9	 was	 isolated	 and	 used	 for	 further	 genetic	
characterisation	by	PCR.	Correct	integration	of	the	KO	cassette	was	investigated	at	the	5’	and	3’	site	
of	aspks1.	For	this	purpose,	five	different	sets	of	oligonucleotides	were	designed	(Figure	4.28A):	
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1)	P323+322	amplifying	a	2400	bp	fragment	at	5’	aspks1	from	non-disrupted	A.	strictum	gDNA	only.	
With	 gDNA	of	RSI58	1-1	 –	 1-9	 as	 template	 a	 2400	bp	DNA	 fragment	was	 amplified	 for	 all	 used	
templates,	but	RSI58	1-1,	indicating	a	5’	disruption	of	aspks1	(Figure	4.28A1).	
2)	P323+618	amplifying	a	1291	bp	 fragment	at	5’	aspks1	 if	 the	5’	bipartite	 substrate	 integrated	
correctly.	With	gDNA	of	RSI58	1-1	as	template	a	1291	bp	DNA	fragment	was	amplified,	but	not	from	
A.	strictum	WT	gDNA,	suggesting	correct	integration	of	the	5’	bipartite	substrate	(Figure	4.28B2).	
3)	 P419+420	 amplifying	 a	 710	 bp	 fragment	 only	 if	 the	 hygromycin	 cassette	 (hygR)	 recombined	
accordingly.	 With	 gDNA	 of	 RSI58	 1-1	 a	 710	 bp	 DNA	 fragment	 was	 amplified,	 confirming	 the	
recombination	of	the	hygromycin	selection	marker	(Figure	4.28B3).	
4)	P81+557	amplifying	a	2047	bp	fragment	at	3’	aspks1	from	non-disrupted	A.	strictum	gDNA	only.	
With	gDNA	of	RSI58	1-1	as	well	as	A.	strictum	WT	a	2047	bp	DNA	fragment	was	amplified,	indicating	
no	disruption	of	3’	aspks1	(Figure	4.28B4).	
5)	P619+557	amplifying	a	1652	bp	 fragment	at	3’	aspsk1	 if	 the	3’	bipartite	 substrate	 integrated	
correctly.	With	gDNA	of	RSI58	1-1	no	DNA	fragment	of	the	expected	size	(1652	bp)	was	amplified,	
but	instead	a	~4	kb	band	was	detected.	The	~4	kb	DNA	fragment	was	not	amplified	from	A.	strictum	
WT	 gDNA	 confirming	 an	 unpredicted	 integration	 of	 the	 3’	 bipartite	 substrate.	 Any	 attempts	 to	
sequence	the	~4	kb	DNA	fragment	were	unsuccessful	(Figure	4.28B5).	
	
Figure	4.27	Chemical	analysis	of	RSI58	1-1	by	analytical	LCMS.	DAD	of	RSI58	1-1	and	A.	strictum	WT	extracts.	
Time
2.00 4.00 6.00 8.00 10.00 12.00 14.00
AU
0.0
2.0
9.55
8.45
4.09
2.95
1.43 3.20
5.84
4.94 7.90 9.21
13.36
9.95 11.69
11.38pure 1
Time
2.00 4.00 6.00 8.00 10.00 12.00 14.00
AU
0.0
2.0
4.74
1.38
2.78 4.203.91
4.87
10.38
time/min
DAD
A.	strictum	WT
AU
AU
DAD
RSI58	1-1
101
108
107b
107a
Targeted	Gene	Knockout	and	Knockdown	in	A.	strictum	
	 96	
	
Figure	4.28	Genetic	analysis	of	A,	RSI58	1-1	–	1-9	and	B,	RSI58	1-1	by	PCR.	Negative	controls	are	labelled	with	–ve.	
Further	analysis	of	5’	substrate	integration	in	RSI58	1-1	with	P83+322	(Figure	4.29)	resulted	in	the	
amplification	 of	 a	 2163	 bp	 DNA	 fragment.	 The	 amplification	 of	 a	 DNA	 fragment	 with	 this	
oligonucleotide	combination	was	unexpected,	as	correct	integration	of	the	5’	KO	substrate	should	
have	removed	the	annealing	site	of	P322	(Figure	4.29).	At	this	point	it	was	hypothesized	that	5’	and	
3’	substrates	were	recombined	by	homologous	recombination	first	and	random	integration	at	the	
5’	 site	 of	 aspks1	 led	 to	 the	 displacement	 of	 the	 promoter	 region	 and	 the	 inability	 to	 initiate	
downstream	 transcription	 at	 that	 site.	 Oligonucleotides	 P826+899	 were	 designed	 to	 amplify	 a	
139	 bp	 DNA	 fragment	 spanning	 3’	 aspks1	 (introduced	 through	 bipartite	 substrates)	 and	
endogenous	5’	aspks1	 (Figure	4.29).	Gel	electrophoresis	of	 the	DNA	 fragment	amplified	by	PCR	
using	 P826+899	 suggested	 it	 to	 be	 approximately	 600	 bp	 larger	 than	 predicted	 (Figure	 4.29).	
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Sequencing	confirmed	an	 insertion	of	590	bp	between	3’	bipartite	substrate	and	5’	endogenous	
aspks1.	By	 sequence	alignment	 the	 inserted	 fragment	was	 found	 to	be	 the	590	bp	homologous	
recombination	site	(red)	of	the	hygromycin	resistance	gene	hph	with	three	T®C	point	mutations	
(Figure	4.29).	
	
Figure	4.29	Further	genetic	analysis	RSI58	1-1	by	PCR.	Negative	controls	are	labelled	with	–ve.	
Genetic	 analysis	 of	 RSI58	 1-1	 showed	 that	 aspks1	 was	 displaced	 from	 its	 promoter	 by	 the	
recombined	bipartite	substrates	and	a	590	bp	insertion.	This	probably	led	to	the	inability	to	express	
aspks1	 which	 would	 explain	 the	 lack	 of	 xenovulene	 A	 101	 and	 related	 compounds	 107-109	
production.	 This	 strongly	 suggests	 that	aspks1	 is	 involved	 in	101	 biosynthesis	 (Figures	4.27	and	
4.28).	However,	as	the	targeted	gene	disruption	did	not	occur	as	intended	it	is	also	posssible	that	
disruption	of	aspks1	and	deletion	of	101	production	is	still	a	coincidence.	The	bipartite	substrates	
could	have	integrated	elsewhere	in	the	genome	and	disrupted	a	random	gene	at	the	same	time.	A	
complementation	 experiment,	 where	 aspks1	 is	 reintroduced	 in	 the	 Daspks1	 strain	 (RSI58	 1-1)	
should	re-establish	101	biosynthesis	and	give	final	confirmation	that	aspks1	encodes	the	protein	
that	produces	the	polyketide	precursor	for	xenovulene	A	101.	
Therefore,	 aspks1	 was	 inserted	 into	 the	 fungal	 expression	 vector	 pTYG-genR	 (Figure	 4.10)	 by	
LR	recombination	(RSI74,	Figure	4.31,	for	experimental	details	Chapter	5.1.1).	The	vector	contains	
the	geneticin	resistance	marker	genR	and	a	fungal	expression	cassette.	Gene	expression	under	the	
control	of	the	inducible	promoter	PamyB,	which	was	shown	to	induce	downstream	transcription	in	
A.	 strictum	 (Chapter	 4.1.2).104	 CaCl2/PEG	 mediated	 protoplast	 transformation	 (RSI79)	 of	 the	
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A.	strictum	Daspks1	(RSI58	1-1)	strain	with	the	vector	RSI74	(aspks1	in	pTYG-genR)	resulted	in	one	
A.	 strictum	Daspks1+aspks1	 (RSI79	 6)	 colony	 growing	on	 tertiary	 plates	with	 hygromycin	B	 and	
geneticin.	The	transformant	was	grown	under	101	producing	conditions,	extracted	following	a	large	
scale	protocol	(50	mL)	and	analysed	by	analytical	LCMS.	The	chromatogram	showed	low	production	
of	101,	deduced	by	UV	absorption,	mass	and	tR	=	8.4	min.	HRMS	(C22H31O4,	calculated	359.2214,	
found	359.2222	[M-H]+)	confirmed	the	production	of	101.	
	
Figure	4.30	Chemical	analysis	of	RSI79	6-1	by	analytical	LCMS.	Extracted	ion	(ES+)	chromatogram	at	m/z	=	359,	tR	=	8.4	min	
and	DAD	of	RSI79	6-1	show	the	presence	of	101	in	the	extracts.	
Genomic	DNA	of	A.	strictum	Daspks1+aspks1	(RSI79	6)	was	isolated	and	analysed	for	the	integration	
of	aspks1	(RSI74)	by	PCR.	As	controls	also	gDNA	of	A.	strictum	WT	and	A.	strictum	Daspks1	(RSI58	
1-1)	were	analysed	using	four	pairs	of	oligonucleotides	(Figure	4.31):	
1)	P660+659	amplifying	543	bp	of	the	geneticin	resistance	gene	if	the	vector	integrated	successfully.	
Only	with	gDNA	of	A.	strictum	Daspks1+aspks1	(RSI79	6)	as	PCR	template	a	543	bp	fragment	was	
amplified.	This	confirms	the	integration	of	the	geneticin	resistance	(genR)	(Figure	4.31	1).	
2)	 P147+322	 amplifying	 a	 2279	 bp	of	 aspks1	 under	 the	 control	 of	 PamyB.	 Only	 with	A.	 strictum	
Daspks1+aspks1	(RSI79	6)	gDNA	as	PCR	template	a	2279	bp	was	amplified.	This	shows	that	aspks1	
downstream	PamyB	is	present	after	transformation	of	RSI74	(aspks1	in	pTYG-genR)	(Figure	4.31	2).	
3)	P323+618	amplifying	a	1291	bp	 fragment	at	5’	aspks1	 if	 the	5’	bipartite	 substrate	 integrated	
correctly	 to	 prove	 that	 the	Daspks1	 strain	 RSI58	 1-1	was	 further	 transformed.	 A	 1291	bp	DNA	
fragment	 was	 amplified	 from	 A.	 strictum	 Daspks1+aspks1	 (RSI79	 6)	 and	 A.	 strictum	 Daspks1	
(RSI58	1-1)	gDNA.	This	confirms	the	disruption	of	endogenous	aspks1	in	A.	strictum	Daspks1+aspks1	
(RSI79	6)	(Figure	4.31	3).	
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4)	P323+322	amplifying	a	2400	bp	fragment	at	5’	aspks1	 from	A.	strictum	WT	gDNA.	This	PCR	is	
designed	to	identify	a	possible	A.	strictum	WT	contamination.	Only	a	2400	bp	DNA	fragment	from	
A.	 strictum	 WT	 gDNA	 was	 amplified.	 This	 confirms	 the	 lack	 of	 endogenous	 aspks1	 and	 thus	
contamination	free	transformants	A.	strictum	Daspks1+aspks1	(RSI79	6)	and	A.	strictum	Daspks1	
(RSI58	1-1)	(Figure	4.31	4).	
Genetic	 and	 chemical	 analysis	 of	 aspks1	 deletion	 A.	 strictum	 Daspks1	 (RSI58	 1-1)	 and	
complementation	A.	strictum	Daspks1+aspks1	 (RSI79	6)	strains	confirmed	that	aspks1,	encoding	
the	NR-PKS	MOS,	is	essential	for	the	biosynthesis	of	meroterpenoids	101,	107-109.	However,	the	
unexpected	integration	of	the	bipartite	substrates,	which	resulted	in	the	displacement	of	aspks1	
from	 its	 promoter,	 indicates	 that	 the	 applied	 bipartite	 method	 is	 not	 efficient	 in	 the	
non-homologous	end	joining	proficient	A.	strictum	strain.	
	
Figure	4.31	Genetic	analysis	RSI79	1-6	by	PCR.	Negative	controls	are	labelled	with	–ve.	
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4.4 	 Discussion	and	Outlook	
Targeted	gene	KO	and	isolation	of	accumulating	intermediates	is	a	powerful	tool	to	elucidate	the	
biosynthesis	 of	 natural	 products.	 Xenovulene	 A	 101	 belongs	 to	 a	 rare	 family	 of	 secondary	
metabolites	 from	ascomycetes	and	 the	A.	 strictum	producer	 is	 the	only	 strain	with	an	available	
sequenced	 genome	 that	 can	 be	 exploited	 for	 genetic	 manipulation.	 Abundant	 protoplasts	
formation	 as	 well	 as	 successful	 vector	 transformation	 provided	 a	 basis	 for	 further	 genetic	
manipulations.104,105,127		
The	previously	used	traditional	KO	strategy104,105,127	as	well	as	the	bipartite	strategy189	applied	 in	
this	work	showed	that	targeted	gene	disruption	in	A.	strictum	at	the	aspks1	BGC	genetic	locus	is	
very	inefficient.	Of	90	transformants	generated	with	bipartite	substrates	targeting	different	genes	
(aspks1,	asL4,	asL5	 and	asL6)	none	was	 shown	 to	have	 integrated	 the	KO	cassette	as	 intended.	
Reconstitution	of	the	selection	gene	(hph	or	nptII)	proved	that	A.	strictum	is	able	to	homologously	
recombine	 DNA	 fragments,	 but	 appears	 to	 be	 barely	 deploying	 it.	 However,	 with	 RSI58	 1-1	
(A.	strictum	Daspks1),	a	transformant	unable	to	produce	101	was	generated	by	transformation	of	
the	 bipartite	 substrates	 targeting	 aspks1.	 Genetic	 analysis	 by	 PCR	 revealed	 an	 unexpected	
integration/insertion	event	(Figure	4.29)	that	separated	the	promoter	from	aspks1	and	resulted	in	
loss	 of	 mRNA	 transcription.	 A	 subsequent	 complementation	 experiment	 with	 aspks1	 (RSI79,	
A.	 strictum	 Daspks1+aspks1)	 confirmed	 that	 the	 aspks1	 BGC	 is	 involved	 in	 xenovulene	 A	 101	
production.	These	findings	are	further	supported	by	heterologous	gene	expression	of	the	aspks1	
BGC	 genes	 which	 led	 to	 the	 isolation	 of	 101	 from	 A.	 oryzae	 NSAR1	 (Chapter	 5).	 This	 work	
demonstrated	that	although	the	bipartite	strategy	improves	targeted	gene	disruptions	in	a	variety	
of	other	fungi,62,209,210	it	is	not	applicable	for	the	aspks1	BGC	genetic	locus	of	A.	strictum.	KO	of	the	
non-homologous	 end	 joining	 involved	 genes	 ku80	 or	 ku70	 in	 A.	 strictum	 could	 improve	 gene	
targeting	as	ectopic	 integration	should	be	 less	efficient	 in	the	mutant	strain.	However,	although	
Dku80	mutants	were	shown	to	improve	gene	targeting	rates	in	N.	crassa	and	M.	ruber,188,211it	did	
not	improve	gene	targeting	at	the	ACE1	genetic	locus	in	M.	grisea.202	
With	 attempted	 gene	 silencing	 and	 CRISPR/Cas9	 two	 strategies	 independent	 of	 homologous	
recombination	were	 deployed	 to	 explore	 further	 gene	 functions	 of	 the	aspks1	 BGC.	 The	 LCMS	
analysis	of	24	putative	silenced	and	15	 transformants	generated	with	CRISPR/Cas9	gene	editing	
showed	that	both	methods	did	not	have	the	intended	effect	in	A.	strictum.		
The	gene	silencing	strategy	was	based	on	previous	experiments	where	silencing	of	tenA	or	tenB	was	
achieved	through	the	introduction	of	full	length	tenA	or	tenB	antisense	RNA	in	B.	bassiana.172	Full	
length	asGOI	(asL4,	asL5	or	asL6)	was	assembled	3’	of	~1.5	kb	A.	strictum	endogenous	promoter	
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asPgpdpA.	 It	 was	 assumed	 that	 1.5	 kb	 promoter	 length	 are	 sufficient,	 however	 it	 has	 not	 been	
analysed	whether	 the	promoter	 sequence	 is	 long	enough	 to	drive	gene	expression.	 In	addition,	
expressing	 full	 length	 asRNA	 was	 shown	 to	 be	 successful	 in	 B.	 bassiana,172	 but	 in	 several	
experiments	hairpin	RNA	(hpRNA)212–214	with	targeting	sequence	was	found	to	be	more	efficient	in	
stable	gene	silencing.	
In	 the	model	organism	N.	crassa	 two	silencing	pathways	have	been	described:	meiotic	silencing	
during	the	sexual	cycle	and	quelling	during	the	vegetative	cycle.	For	each	pathways	one	set	of	RNA	
silencing	genes	is	conserved	(Table	4.2).194	A	BLASTp103	analysis	of	the	A.	strictum	genome	using	the	
corresponding	RdRP,	Ago	and	Dicer	protein	sequences	as	search	templates	identified	A.	strictum	
homologues	 (Table	 4.2).	 Dicer	 DCL-2	 involved	 in	 meiotic	 silencing	 was	 found	 to	 have	 one	
homologue	 in	 A.	 strictum,	 but	 not	 its	 quelling	 homologue	 DCL-1.	 A	 similar	 phenomenon	 was	
observed	in	A.	nidulans,	where	only	one	set	of	homologues	of	RNA	silencing	proteins	(involved	in	
quelling)	is	encoded.	Upon	KO	of	those	genes	no	changes	in	viability	was	observed.	This	suggested	
that	RNA	silencing	proteins	have	a	‘non-housekeeping’	function	such	as	defence	against	viral	dsRNA	
rather	than	being	involved	in	gene	regulation	and	genome	stability.215	If	this	was	also	the	case	for	
A.	 strictum	 a	 less	abundant	expression	of	genes	 involved	 in	 silencing	would	be	expected,	which	
could	explain	the	observed	inefficiency	of	gene	silencing.	To	analyse	the	efficiency	of	RNA	silencing	
in	A.	strictum	a	reporter	gene	such	as	egfp	could	be	used	to	visualize	the	silencing	effect.	A	construct	
where	antisense	egfp	(asegfp)	is	located	downstream	of	asPgpdpA	could	be	inserted	into	A.	strictum	
transformed	with	pTH-GS-egfp	(RSI16,	Chapter	4.1.2).	Subsequent	microscopic	analysis	should	give	
evidence	about	 the	 functionality	of	 gene	 silencing	 in	A.	 strictum	 and	 the	 corresponding	vectors	
designed	in	this	work.	
Table	4.2	Overview	of	protein	homologues	predicted	to	be	involved	in	RNA	silencing	in	A.	strictum.	
	
For	gene	editing	with	CRISPR/Cas9198	a	vector	based	strategy	optimised	for	 the	model	organism	
Aspergillus	 was	 selected	 due	 to	 facile	 cloning	 and	 transformation.	 Despite	 successful	
N		crassa	 NCBI	Accession	 A.	strictum	 E	value	
meiotic	silencing	
QDE-1	(RdRP)	 XM_953954.2	 Asg2314	 5e-147	
QDE-2	(Ago)	 AF217760.1	 Asg4864	 0	
DCL-2	(Dicer)	 XM_958445.3	 Asg5496	 0	
quelling	
SAD-1	(RdRP)	 XM_959155.3	 Asg850	 0	
SMS-2	(Ago)	 AF508210.1	 Asg4581	 0	
DCL-1	(Dicer)	 XM_956805.2	 Asg5496	 4e-40	
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transformation	of	A.	strictum,	no	Daspks1	strain	could	be	generated	with	this	method.	With	the	
used	vector	(RSI59B2),	cas9	is	transcribed	from	A.	nidulans	constitutive	Pteft,	but	this	promoter	has	
not	 previously	 been	 tested	 for	 its	 activity	 in	A.	 strictum.	 To	 analyse	 the	 ability	 of	 Pteft	 to	 drive	
transcription	in	A.	strictum	cas9	should	be	expressed	alongside	egfp.	The	resulting	fusion	protein	
could	be	visualized	by	microscopy	and	the	cellular	 localisation	could	be	determined.	 If	 the	gene	
expression	 and	 nuclear	 protein	 localisation	 can	 be	 confirmed,	 different	 protospacer	 sequences	
should	be	tested	to	improve	gene	targeting.	In	this	work	the	protospacer	was	selected	manually.	In	
order	 to	 reduce	 off	 target	 effects,	 which	 have	 been	 observed	 with	 CRISPR/Cas9,216	 a	 software	
package,	such	as	sgRNAcas217,	should	be	used.	At	the	time	when	the	experiment	was	set	up	for	
A.	 strictum	 only	 two	 CRIPSR/Cas9	 strategies	 were	 available	 for	 filamentous	 fungi,	 but	 in	 the	
meanwhile	 further	 strategies	 have	 been	 published	 and	 should	 be	 considered	 for	 future	
experiments.218
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5 Heterologous	Expression	of	the	A.	strictum	aspks1	BGC	in	A.	oryzae	
Heterologous	expression	of	 single	genes	or	entire	BGC	 is	used	 to	analyse	biosynthetic	 routes	of	
microorganisms	 where	 targeted	 gene	 disruption	 or	 transformation	 methods	 are	 ineffective.	
Beyond	that	it	offers	many	engineering	possibilities	such	as	co-expression	of	genes	from	different	
biosynthetic	 pathways	 to	 produce	 novel	 hybride	 secondary	 metabolites.	 Gene	 expression	 in	
Escherichia	coli	and	recombinant	protein	purification	allows	the	study	of	reactions	in	vitro.	
The	 arginine	 auxotroph	A.	 oryzae	M2-3	 strain	 has	 previously	 been	used	 successfully	 to	 express	
single	genes	or	entire	BGC.	For	example,	the	four	genes	which	encode	the	tenellin	189	BGC	make	
up	 the	 first	 complete	 fungal	 BGC	 to	 be	 expressed	 heterologously.219	 The	 biosynthesis	 of	 more	
complex	 fungal	 metabolites,	 such	 as	 the	meroterpenoids	 pyripyropene	 93	 and	 anditomin	 190,	
where	 up	 to	 eleven	 genes	 have	 been	 expressed	 simultaneously,	 have	 also	 been	 elucidated	 by	
heterologous	expression	studies	(Figure	5.1).77,220		
	
Figure	5.1	Tenellin	189,	pyripyropene	93	and	anditomin	190.	
For	the	reconstitution	of	the	desired	biosynthetic	pathway	the	genes	can	be	directly	amplified	by	
PCR	 from	g-	or	 cDNA	of	 the	producing	ascomycete.	For	 closely	 related	species	 intron	splicing	 is	
usually	not	problematic,	however	when	expressing	genes	from	distantly	related	fungi	intron	free	
clones	are	advantageous.	Due	to	similar	codon	usage	between	the	fungal	strains	no	optimisation	is	
generally	 required	 for	 gene	 expression	 in	 A.	 oryzae.	 However,	 to	 activate	 transcription	 it	 is	
important	to	insert	the	GOI	downstream	of	an	A.	oryzae	promoter.	
	
5.1 Yeast	Recombination,	Gateway	Cloning	and	Transformation	of	A.	oryzae	
The	 quadruple	 auxotroph	 A.	 oryzae	 NSAR1	 is	 deficient	 in	 arginine	 (DargB),	 methionine	 (sC-),	
adenine	 (adeA-)	 and	 ammonium	 (niaD-)	 metabolism	 which	 enables	 its	 use	 as	 a	 host-vector	
system.221	The	four	auxotrophies	can	be	exploited	for	transformation	of	fungal	expression	vectors	
by	complementation	with	the	four	different	selection	markers	(argB,	sC,	adeA,	niaD).	Additionally,	
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the	 natural	 sensitivity	 of	A.	 oryzae	 NSAR1	 towards	 the	 antibiotics	 bleomycin	 and	 the	 herbicide	
glufosinate	(bleR,	bar)	enables	the	use	of	two	more	selection	markers.		
The	 pTYGS	 fungal	 expression	 vectors,	 which	 are	 available	 with	 selection	 markers	 for	 all	
auxotrophies	 and	 sensitivities	 (argB,	 sC,	 adeA,	 niaD,	 bleR,	 bar),	 contain	 four	 fungal	
promoter/terminator	(P/TamyB,	P/Tadh,	P/TgpdA,	P/Teno)	gene	cloning	sites	(Figure	5.2A).	In	theory,	the	
simultaneous	 expression	of	 24	 genes	 is	 possible.201	 Three	of	 these	 cloning	 sites	 include	 an	AscI	
restriction	sequence	(P/Tadh,	P/TgpdA,	P/Teno)	and	are	designed	for	in	vivo	homologous	recombination	
by	S.	cerevisiae.	For	this,	the	desired	vector	is	cut	into	three	parts	and	co-transformed	with	up	to	
three	PCR	amplified	DNA	fragments	(genes)	(Figure	5.2B).	S.	cerevisiae	assembles	the	vector	and	
genes	by	homologous	recombination	in	the	desired	order	as	long	as	the	DNA	fragments	include	at	
least	30	bp	unique	homologous	overlap	sequence.	These	can	be	introduced	by	PCR	through	tails	at	
the	designed	oligonucleotides.180	The	vector	also	contains	ura3,	encoding	orotidine	5’-phopsphate	
decarboxylase,	and	the	2µ	ori	for	selection	and	propagation	in	uracil	deficient	S.	cerevisiae	strains.	
Colonies	able	to	grow	on	uracil-	and	uridine-free	medium	contain	vector	DNA	which	can	be	isolated	
and	 further	 transformed	 into	 E.	 coli	 for	 facile	 screening	 of	 colonies	 by	 PCR.	 For	 selection	 and	
propagation	 in	 E.	 coli	 the	 vector	 contains	 an	 appropriate	 ori	 (colE1)	 and	 confers	 resistance	 to	
chloramphenicol	(camR)	as	well	as	ampicillin	(ampR).	
	
Figure	5.2	Fungal	expression	vectors	used	in	this	work.	A,	pTYGS	vector	family.	B,	Cloning	of	up	to	3	genes	into	pTYGS	
vectors	by	in	vivo	HR	in	S.	cerevisiae.		
The	P/TamyB	cloning	site	contains	recombination	sequences	(attR1	and	attR2)	 flanking	a	gateway	
cassette	(ccdB	gene,	encoding	the	CcdB	killer	protein,	and	chloramphenicol	resistance,	camR)	for	
use	with	an	in	vitro	gateway	cloning	kit	(LR	recombinase,	Invitrogen).	The	kit	consists	of	an	enzyme	
argB:	pTYGSarg,	15171	bp
adeA:	pTYGSade,	15045	bp
sC:	pTYGSmet,	16628	bp
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URA3
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attR1 attR2
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X
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B
Heterologous	Expression	of	the	A.	strictum	aspks1	BGC	in	A.	oryzae	
	 105	
mixture	 containing	 bacteriophage	 l	 integrase	 proteins	 (integrase,	 integration	 host	 factor,	
excisionase)	 which	 interchange	 DNA	 flanked	 by	 attR	 sites	 with	 DNA	 flanked	 by	 attL	 sites	
(Figure	5.2A).222	attL	recombination	sequences	are	included	in	the	E.	coli-S.	cerevisiae	shuttle	vector	
pE-YA	 (entry	 clone),	 which	 also	 contains	 ORI	 (2µ,	 pUC)	 and	 selection	 markers	 (ura3,	 kanR)	 for	
selection	and	propagation	in	S.	cerevisiae	and	E.	coli	(Figure	5.3A).	
	
Figure	5.3	Gateway	cloning.	A,	Assembly	of	large	synthase	gene	(aspks1)	by	in	vivo	HR	recombination	(S.	cerevisiae)	in	
the	 gateway	 entry	 clone	 pE-YA.	 B,	 Gateway	 cloning	 by	 LR	 recombination	 between	 pE-YA	 (entry	 clone)	 and	 pTYGS	
(destination	vector)	yielding	in	expression	clone	(pTYGS)	and	donor	vector	(pE-YA).	
pE-YA	can	be	used	for	HR	by	S.	cerevisiae	to	assemble	large	synthase	genes,	such	as	pks,	in	multiple	
fragments,	 but	 it	 is	 also	 useful	 for	 small	 genes	 (Figure	 5.3A).	 By	 incubation	 of	 the	 entry	 vector	
(pE-YA)	 containing	 a	 GOI	 and	 a	 vector	 of	 the	 pTYGS	 family	 (destination	 vector)	 with	 the	
LR	recombinase	enzyme	mixture	two	new	plasmids	are	formed:	the	expression	clone	containing	
the	GOI	and	the	donor	vector	containing	the	gateway	cassette	(ccdB,	camR)	(Figure	5.2B).	Double	
selection	is	used	to	 isolate	the	expression	clone	only.	Destination	vectors	with	gateway	cassette	
have	to	be	propagated	in	E.	coli	ccdB	survival	cells,	which	are	resistant	to	the	ccdB	gene	product.	
Thus	 for	 selection	 of	 the	 expression	 clones	 only,	 an	 E.	 coli	 TOP10	 strain	 as	 well	 as	 a	 different	
antibiotic	(ampicillin)	is	used.	
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5.1.1 Gene	Selection	and	Vector	Construction	
KO	of	aspks1	(Chapter	4.3.2)	in	A.	strictum	confirmed	the	involvement	of	the	aspks1	BGC	in	101	
biosynthesis.	Differential	expression	analysis	(Chapter	3.2)	showed	the	upregulation	of	15	genes	
(asL1-7,	asR1-7	and	aspks1).	For	heterologous	co-expression	12	genes	were	selected,	omitting	only	
transporters	(asR1,	asL7)	and	transcription	factors	(asR3)	(Figure	5.4).	
	
Figure	5.4	aspks1	BGC,	framed	genes	were	selected	for	heterologous	expression	in	A.	oryzae	NSAR1.	
The	 biosynthetic	 hypothesis	 suggested	 that	 early	 tropolone	 formation	 is	 similar	 to	T.	 stipitatus	
(Chapter	1.3.2).	Thus,	for	co-expression	of	aspks1,	asL1,	asL3	and	asR2,	the	genes	were	cloned	into	
the	pTYGSarg	vector.	For	sequential	co-expression	of	these	genes,	different	combinations	(aspks1,	
aspks1+asL1,	aspks1+asL1+asL3	and	aspks1+asL1+asL3+asR2)	were	also	cloned	into	pTYGSarg.	The	
three	additional	oxidoreductases	encoded	by	asL4,	asL5	and	asL6,	which	could	be	involved	in	the	
ring	contraction,	were	cloned	into	the	pTYGSmet	vector.	The	genes	encoding	proteins	of	unknown	
function	(asL2,	asR4,	asR5	and	asR6)	were	cloned	into	the	pTYGSade	vector.	For	co-expression	of	
different	sub-sets	of	genes,	combinations	of	two	genes	each	(asL4,	asL5	and	asL6	or	asL2,	asR4	and	
asR6)	were	cloned	into	pTYGSmet	and	pTYGSade	(Figure	5.5).	
All	pE-YA	entry	and	pTYGS(arg/ade/met)	vectors	for	expression	of	the	aspks1	BGC	were	constructed	
by	in	vivo	homologous	recombination	in	S.	cerevisiae	and	in	vitro	recombination	(Figure	5.5).	Genes	
were	amplified	by	PCR	using	A.	 strictum	 c-	or	 gDNA	as	 template	with	denoted	oligonucleotides	
(Table	7.9),	which	were	designed	to	 introduce	the	30	bp	homologous	overlaps	(Chapter	5.1	and	
4.1.4	for	experimental	details).	Only	the	8190	bp	aspks1	gene	was	amplified	in	two	fragments	(each	
~4100	bp)	with	70	bp	overlap	from	A.	strictum	gDNA	and	assembled	in	the	gateway	entry	vector	
pE-YA	(Figure	5.3A).		
Genes	 amplified	 from	 cDNA	 (asL1,	 asL3	 and	 asR2)	 were	 initially	 sub-cloned	 in	 pCR2.1	 by	 the	
TOPO	 TA	 cloning	 kit	 (Invitrogen).	 Correct	 splicing	 was	 confirmed	 by	 sequencing	 (Eurofins,	
Ebersberg)	and	the	vector	used	as	template	in	further	PCR	reactions.	Assembly	of	1	or	2	genes	in	
pTYGS	expression	vectors	was	achieved	by	designing	oligonucleotides	with	an	overlap	to	Tadh/PgpdA	
or	 TgpdA/Peno	 and	Peno,	which	 resulted	 in	 the	 removal	 of	 the	 2480	bp	 Tadh/PgpdA	or	 the	 respective	
800	bp	TgpdA/Peno	DNA	fragment.	All	entry	and	expression	clones	used	 for	LR	recombination	and	
subsequent	A.	oryzae	NSAR1	transformation	are	displayed	in	Figure	5.5.	Additional	vectors	which	
aspks1asL1 asR2 asR3 asR4 asR5 asR6 asR7asR1asL2asL3asL4asL5asL6asL7
NR-PKS oxidoreductase regulator transporter ferredoxin	like unknown
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were	constructed	in	this	work	but	have	not	yet	been	used	for	fungal	transformations	are	displayed	
in	Appendix	Figure	9.41.	
	
Figure	5.5	Overview	of	constructed	in	this	work	used	gateway	entry	and	fungal	expression	(pTYGSarg,	met,	ade)	vectors.	
5.1.2 A.	oryzae	Transformation	and	Gene	Combinations	
Different	combinations	of	the	constructed	vectors	(Chapter	5.1.1)	were	used	to	transform	A.	oryzae	
NSAR1	 by	 a	 CaCl2/PEG	 mediated	 protoplast	 protocol.	 Usually	 two	 or	 three	 fungal	 expression	
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vectors,	with	different	selection	markers	(pTYGSarg,	-met,	-ade)	were	co-transformed	in	a	single	
transformation.	 The	 selection	 medium	 was	 adapted	 to	 the	 vectors	 used	 in	 the	 individual	
transformation.	
In	experiment	RSI105,	for	example,	the	three	vectors	RSI96	1-6	(pTYGSarg),	RSI96	5-1	(pTYGSmet)	
and	RSI100	2-16	 (pTYGSade)	were	co-transformed	 in	A.	oryzae	NSAR1.	As	each	of	 these	vectors	
complements	 a	 different	 auxotrophy,	 the	 protoplasts	were	 recovered	 and	 selected	 on	minimal	
medium	(Chapter	7.4.3)	without	arginine,	methionine	or	adenine	(Table	7.1).	Colonies	which	grew	
on	selection	medium	were	picked	onto	secondary	selection	plates	and	 further	growing	colonies	
were	genetically	purified	by	streaking	for	single	colonies	on	a	third	selection	plate.	
In	total,	16	different	combinations	of	fungal	expression	vectors	were	used	to	co-transform	A.	oryzae	
NSAR1.	This	lead	to	the	isolation	of	16	different	A.	oryzae	NSAR1	strains,	each	expressing	a	different	
sub-set	of	genes	of	the	A.	strictum	aspks1	BGC	(Table	5.1).	
Table	5.1	Overview	of	A.	oryzae	NSAR1	transformations	with	different	combinations	of	genes.	Chromatograms	of	grey	
labelled	experiments	are	included	in	the	Appendix	Figure	9.42,	as	no	additional	information	about	the	biosynthesis	of	
xenovulene	A	101	was	gained	from	these	combinations	of	genes.	
Transfor-
mation	
ID	
Transformed	vector	constructs	
vector	backbone	pTYGSarg,	-met,	-ade	
Genes	as	 #	
colon-
ies	PKS	 L1	 L2	 L3	 L4	 L5	 L6	 R2	 R4	 R5	 R6	
RSI80	1	
RSI70	1	
RSI72	2	
RSI80	2	
RSI98	1	
RSI105	
RSI107	
RSI109	
RSI110	
RSI111	1	
RSI111	2	
RSI111	3	
RSI113	
RSI114	B1	
RSI114	B2	
RSI114	B3	
RSI42A1LR4C,	pTYGSmet,	-	
RSI63	1-12,	RSI63	5-1,	-	
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Genomic	 DNA	 of	 selected	A.	 oryzae	 NSAR1	 colonies	was	 isolated	 and	 analysed	 by	 PCR	 for	 the	
intended	integration	of	genes	with	gene	specific	oligonucleotides	(Figure	5.6).	A.	strictum	WT	gDNA	
served	as	positive,	and	gDNA	of	an	A.	oryzae	NSAR1	strain	(RSI74	2)	transformed	with	pTYGSarg,	
pTYGSmet	 and	 pTYGSade	 empty	 vectors	 as	 negative,	 control	 (Figure	 5.6).	 Comparison	 of	 DNA	
fragment	 sizes	 amplified	 from	 the	 different	A.	 oryzae	 NSAR1	 gDNAs	 and	A.	 strictum	WT	 gDNA	
confirmed	the	intended	integration	of	genes	within	the	respective	A.	oryzae	NSAR1	genome.	
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Figure	5.6	PCR	analysis	of	A.	oryzae	NSAR1	transformants,	negative	control	with	RSI74	2	(transformed	with	pTYGSarg,	
met	and	ade	empty	vectors)	and	positive	control	with	A.	strictum	WT	gDNA.	Oligonucleotides:	aspks1	(P83+322),	asL1	
(P421+423),	asL2	(P755+756),	asL3	(P424+426),	asL4	(P645+706),	asL5	(P421+423),	asL6	(P707+708),	asR2	(P709+650),	
asR4	(P757+758),	asR5	(P761+762),	asR6	(P759+760).	
The	 secondary	 metabolite	 production	 of	 all	 transformants	 was	 analysed	 by	 sub-culturing	 the	
colonies	in	PamyB	induction	medium	(Starch	M	+	0.15%	methionine	or	DPY)	for	3-6	d	at	28	°C	and	
120	rpm.	The	cultures	were	acidified	with	HCl	(2	M),	the	cells	homogenised	and	the	solids	removed	
by	Buchner	 filtration.	The	cleared	culture	broth	was	extracted	 twice	with	ethyl	acetate	or	ethyl	
acetate:hexane	(1:1).	The	organics	were	dried	over	MgSO4,	concentrated	in	vacuuo	and	dissolved	
in	methanol	or	acetonitrile:	water	(9:1)	to	a	concentration	of	10	mg/mL.	The	extracts	were	then	
analysed	for	their	secondary	metabolite	production	by	LCMS.	
5.2 Early	steps	of	Xenovulene	Biosynthesis:	Tropolone	Formation	
Tropolone	biosynthesis	 (Scheme	5.1)	 in	T.	 stipitatus	 is	achieved	by	3	core	enzymes:	 the	NR-PKS	
TropA,	 releasing	 120;	 the	 FAD	 dependent	 monooxygenase	 TropB,	 which	 hydroxylates	 and	
dearomatizes	 120	 to	 121;	 and	 hydroxylation	 of	 121	 to	 122	 by	 the	 non-heme	 FeII	 dependent	
dioxygenase	TropC	followed	by	ring	expansion	to	give	the	first	tropolone	123.97	
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In	the	next	step	the	cytochrome	P450	monooxygenase	TropD	hydroxylates	123	at	C-9	to	give	the	
primary	alcohol	124a,	which	most	likely	is	in	equilibrium	with	its	hemiacetal	form	124b.	However,	
neither	124a	nor	124b	have	been	observed	upon	KO	of	tsL2	(encoding	TropD)	in	T.	stipitatus,	but	
instead	the	shunt	products	stipitafuran	125	and	cordytropolone	were	observed.98	
	
Scheme	5.1	Tropolone	biosynthesis	in	T.	stipitatus.	
Within	 the	 aspks1	 BGC	 genes	 encoding	 homologous	 proteins	 were	 predicted	 (Figure	 1.14	 B).	
Previously	reported	heterologous	expression	of	aspks1	as	well	as	co-expression	of	aspks1+asL1	in	
A.	oryzae	M2-3	led	to	the	production	of	120	and	121,	respectivly.102,104	This	confirmed	the	homology	
to	TropA	and	TropB	encoding	genes	tspks1	and	tsL1.	 In	order	to	express	the	entire	aspks1	BGC,	
these	 initial	 steps	 had	 to	 be	 re-established	 in	 the	 fungal	 host	 A.	 oryzae	 NSAR1.	 In	 addition,	
A.	 strictum	 asL3	 and	 asR2	 (homologues	 tropC	 and	 tropD)	 were	 heterologously	 expressed	 in	
A.	oryzae	NSAR1	for	the	first	time.	
5.2.1 Expression	of	aspks1	in	A.	oryzae	
Transformation	of	A.	oryzae	NSAR1	with	aspks1	alone	yielded	6	colonies	that	were	grown	in	PamyB	
induction	 medium.	 The	 obtained	 extracts	 (Chapter	 5.1.2)	 were	 submitted	 to	 LCMS	 and	 the	
chromatograms	were	analysed	for	the	production	of	3-methylorcinaldehyde	120.	In	comparison	to	
an	A.	oryzae	NSAR1	chromatogram	obtained	under	identical	conditions,	several	new	peaks	were	
detected	in	the	DAD	chromatogram	(Figure	5.7C)	mainly	eluting	between	tR	=	5	-	8	min.	
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Figure	5.7	Expression	of	aspks1.	A,	Domain	organisation	of	aspks1	encoding	 the	NR-PKS	MOS	 (SAT:	 starter	 unit	 acyl	
transferase,	 KS:	 ketosynthase,	AT:	Acyl	 transferase,	 PT:	 product	 template,	ACP:	 acyl	 carrier	 protein,	C-Met:	C-methyl	
transferase,	 R:	 reductive	 release).	 B,	 A.	 oryzae	 NSAR1	 WT	 and	 A.	 oryzae	 NSAR1	 +aspks1	 on	 DPY	 agar.	 C,	 DAD	
chromatogram	of	an	A.	oryzae	WT	and	ab	A.	oryzae	 +aspks1	 sample	measured	with	analytical	gradient	A1	on	LCMS.	
Extracts	were	obtained	from	cultures	grown	in	Starch	M	+	0.15%	methionine	for	6	d.	
Production	 of	 a	 compound	 with	 the	 nominal	 mass	 of	 166	 corresponding	 to	 120	 eluting	 at	
tR	=	5.9	min	was	observed	in	all	6	transformants.	The	UV	spectrum	showed	an	absorption	maxima	
at	297	nm,	which	is	consistent	with	literature	data	for	120	(Figure	5.8).102	A	molecular	formula	of	
C9H10O3	([M-H]-	C9H9O3	calculated	165.0552,	found	165.0551)	was	confirmed	for	this	peak	by	HRMS.	
	
Figure	5.8	Chemical	characterisation	of	120	(tR	=	5.9	min)	by	UV	and	mass	spectrum	obtained	from	ES
+	and	ES-.	
	
Figure	5.9	Chemical	characterisation	of	191	(tR	=	3.0	min)	by	UV	and	mass	spectrum	obtained	from	ES
+	and	ES-.	
In	addition,	a	compound	with	the	nominal	mass	of	140	corresponding	to	191,	which	was	previously	
observed	upon	aspks1	expression,	was	identified	in	all	chromatograms	at	tR	=	3.0	min	(Figure	5.9).102	
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This	compound	(3	mg)	was	purified	from	a	1	L	Starch	M	culture	extract	and	the	structure	confirmed	
by	1H	NMR	as	well	as	HRMS	([M]Na+	C7H8O3Na	calculated	163.0371,	found	163.0371)	(Chapter	7.5.6	
for	NMR	data).	
5.2.2 Co-Expression	of	aspks1+asL1		
Transformation	 of	A.	 oryzae	 NSAR1	with	aspks1+asL1	 yielded	 11	 colonies.	 For	 analysis	 of	 their	
secondary	metabolite	profile	the	transformants	were	sub-cultured	in	PamyB	induction	medium.	The	
obtained	extracts	(Chapter	5.1.2)	were	submitted	to	LCMS	and	the	chromatograms	were	analysed	
for	the	production	of	121	(Figure	5.10).	
	
Figure	 5.10	 Co-expression	 of	 two	 genes.	 A,	 Co-expression	 of	 aspks1	 and	 asL1.	 B,	 A.	 oryzae	 NSAR1	 +aspks1	 and	 A.	
oryzae	NSAR1	+aspks1+asL1	on	DPY	agar.	C,	DAD	chromatogram	of	an	A.	oryzae	NSAR1	+aspks1	and	an	A.	oryzae		NSAR1	
+aspks1+asL1	sample	measured	with	analytical	gradient	A2	on	LCMS.	Extracts	were	obtained	from	cultures	grown	in	DPY	
for	4	d.	
In	 ten	extracts	a	new	compound	eluting	at	 tR	=	2.9	min	with	a	nominal	mass	of	182	and	an	UV	
absorption	maximum	of	308	nm	(Figure	5.11)	was	detected.	Purification	of	15	mg	as	a	dark	brown	
oil	from	1	L	Starch	M	culture	extract	enabled	subsequent	1H	NMR	analysis	(Chapter	7.5.6	for	NMR	
data).	The	NMR	results,	as	well	as	HRMS	were	consistent	with	literature	data	of	enone	121	([M]Na+	
calculated	205.0477,	found	205.0477).97	
Three	additional	new	peaks	were	observed	at	tR	=	2.3,	3.3	and	4.3	min	which	showed	a	maximum	
UV	absorption	of	303	nm	similar	to	121.	Three	characteristic	ions	(m/z	=	415,	197	and	179)	in	ES+	
were	found	for	all	peaks	(Figure	5.13A).	Any	attempts	to	purify	either	of	these	compounds	yielded	
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enone	compound	121.	This	supports	the	idea	that	these	are	unstable	methanol	adducts	192a-c	of	
121	that	could	be	reversibly	formed	due	to	methanol	present	in	the	sample	(Figure	5.13B).	
	
Figure	5.11	Chemical	characterisation	of	121	(tR	=	2.9	min)	by	UV	and	mass	spectrum	obtained	from	ES
+	and	ES-.	
Another	 rarely	 detected	 compound	 was	 purified	 (4	 mg)	 from	 a	 1	 L	 Starch	 M	 culture	 extract	
(Figure	5.14A).	The	compound	193	eluting	at	tR	=	7.4	min	showed	a	characteristic	UV	absorption	of	
294	nm	and	a	nominal	mass	of	210	was	determined	by	low	resolution	mass	(Figure	5.14B).	Analysis	
of	1H	and	13C	NMR	data	identified	11	carbon	atoms	and	14	protons	(Table	5.2).	HRMS	confirmed	a	
molecular	formula	of	C11H14O4	([M]Na+	calculated	233.0790,	found	233.0787).	
	
Figure	5.12	Structural	proposal	for	193	(arrows	indicate	key	HMBC	correlations)	and	120	for	comparison.	
Table	5.2	NMR	data	for	193	in	CDCl3	(400	MHz)	referenced	to	CDCl3.	
Position	 dC/ppm	193	 dH/ppm	(J	in	Hz)	193	 HMBC	(H	to	C)	 dC/ppm	120102	 dH/ppm	(J	in	Hz)	120102	
1	
2	
	2’	
3	
4	
5	
6	
7	
8	
9	
10	
11	
140.7	
163.2	
-	
113.6	
163.8	
104.3	
112.8	
193.9	
7.4	
72.2	
56.0	
58.2	
-	
-	
12.40	(s,	1H,	O-H)	
-	
-	
6.47	(s,	1H)	
-	
10.14	(s,	1H)	
2.08	(s,	3H)	
4.67	(s,	2H)	
3.92	(s,	3H)	
3.41	(s,	3H)	
-	
-	
2,	3,	6,	7	
-	
-	
1,	3,	4,	6,	7,	8,	9	
-	
2,	3,	6		
1,	2,	3,	4,	5,	6	
1,	5,	6,	11	
4,	5	
9	
141.4	
161.0	
	
108.9	
164.1	
109.9	
113.3	
193.0	
6.8	
17.9	
-	
-	
-	
	
12.65	(s,	1H,	OH)	
-	
-	
6.20	(s,	1	H)	
-	
10.07	(s,	1H)	
2.08	(s,	3H)	
2.50	(s,	3H)	
-	
-	
	
NMR	data	of	193	and	120	were	 found	 to	be	almost	 identical.	Apart	 from	 two	additional	O-CH3	
chemical	shifts,	 they	are	very	similar	 (Table	5.2,	Figure	5.16)).	However,	 the	6-CH3	group	of	120	
does	 not	 appear	 in	 NMR	 data	 collected	 for	 193,	 but	 instead	 an	 O-CH2-group,	 proposing	
hydroxylation	and	methylation	at	this	position.	Evaluation	of	HMBC	couplings	led	to	the	structural	
proposal	of	193	(Figure	5.12).	
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Figure	5.13	Compounds	192a-c.	A,	Extracted	ion	chromatogram	(ES+	at	m/z	=	415)	(tR	=	2.3,	3.3	and	4.3	min).	UV	and	
mass	spectrum	obtained	from	ES+	is	identical	for	the	three	observed	compounds.	B,	Proposed	methanol	adducts	of	121.	
	
Figure	5.14	Compound	193.	A,	DAD	chromatogram	of	purified	compound	193	analysed	with	analytical	gradient	A1.	B,	
Chemical	characterisation	of	193	(tR	=	7.5	min)	by	UV	and	mass	spectrum	obtained	from	ES
+.	
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5.2.3 Co-Expression	of	aspks1+asL1+asL3	
Transformation	of	A.	oryzae	NSAR1	with	aspks1+asL1+asL3	yielded	6	colonies.	For	analysis	of	their	
secondary	 metabolite	 profile	 the	 transformants	 were	 sub-cultured	 in	 PamyB	 induction	 medium.	
Liquid	cultures	and	plates	of	these	transformants	displayed	a	bright	yellow	colour	(Figure	5.15B).	
The	 obtained	 extracts	 (Chapter	 5.1.2)	 were	 submitted	 to	 LCMS	 and	 the	 chromatograms	 were	
analysed	for	the	production	of	stipitaldeyhde	123	(Figure	5.15C).	
In	four	extracts	a	new	compound	eluting	at	tR	=	7.4	min	was	identified.	It	was	determined	to	have	
a	nominal	mass	of	180	and	displayed	three	characteristic	UV	absorption	maxima	(Figure	5.16)	(246,	
271,	377	nm).	These	characteristics	are	consistent	with	literature	data	for	123.97,223	
	
Figure	 5.15	 Expression	 of	 three	 genes.	 A	Co-expression	 of	aspks1+asL1+asL3.	 B	A.	 oryzae	 NSAR1	 +aspks1+asL1	 and	
A.	 oryzae	 NSAR1	 +aspks1+asL1+asL3	 on	 DPY	 agar.	 C	 DAD	 chromatogram	 of	 an	 A.	 oryzae	 NSAR1	 +aspks1	 and	 an	
A.	 oryzae	NSAR1	 +aspks1+asL1	 sample	measured	with	 analytical	 gradient	A2	on	 LCMS.	 Extracts	were	 obtained	 from	
cultures	grown	in	DPY	for	4	d.	
Purification	of	this	compound	(0.6	mg)	from	1	L	Starch	M	culture	extract,	showed	the	compound	to	
have	1H	NMR	data	which	is	highly	similar	to	123	(Table	5.3).	The	small	differences	in	chemical	shifts	
compared	 to	 literature	 data	 could	 be	 explained	 due	 to	 a	 pH	 dependent	 different	 resonance	
structure.	 HRMS	 confirmed	 a	molecular	 formula	 of	 C9H8O4	 ([M-H]-	C9H7O4	 calculated	 179.0344,	
found	179.0344).	
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Figure	5.16	Chemical	characterisation	of	123	(tR	=	7.4	min)	by	UV	and	mass	spectrum	obtained	from	ES
+	and	ES-.	
Table	5.3	1H	NMR	data	for	123	in	d6-DMSO	(500	MHz)	referenced	to	d6-DMSO.	
Position	 dH	Literature97	 dH	Purified	
3	
6	
8	
9	
6.75	(s,	1H)	
6.69	(s,	1H)	
2.57	(s,	3H)	
10.01	(s,	1H)	
6.28	(s,	1H)	
6.37	(s,	1H)	
2.46	(s,	3H)	
9.82	(s,	1H)	
	
In	addition,	a	compound	with	the	nominal	mass	of	152	corresponding	to	194,	which	previously	was	
observed	upon	KO	of	tropD	 in	T.	stipitatus,	was	identified.	The	compound	eluting	at	tR	=	5.6	min	
showed	two	characteristic	UV	absorption	maxima	(250	nm,	343	nm)	consistent	with	literature	data	
for	194	(Figure	5.17).97,224	This	compound	(4	mg)	was	purified	from	a	1	L	Starch	M	culture	extract	
and	the	structure	confirmed	by	NMR	as	well	as	HRMS	([M]-H+	C8H9O3	calculated	153.0552,	found	
153.0553)	(Chapter	7.5.6	for	NMR	data).	
	
Figure	5.17	Chemical	characterisation	of	194	(tR	=	5.6	min)	by	UV	and	mass	spectrum	obtained	from	ES
+	and	ES-.	
5.2.4 Co-Expression	of	aspks1+asL1+asL3+asR2	
Transformation	of	A.	oryzae	NSAR1	with	aspks1+asL1+asL3+asR2	yielded	11	colonies.	For	analysis	
of	 their	 secondary	 metabolite	 profile	 the	 transformants	 were	 sub-cultured	 in	 PamyB	 induction	
medium.	 Liquid	 cultures	 and	 plates	 of	 these	 transformants	 displayed	 a	 bright	 yellow	 colour	
(Figure	 5.18B).	 The	 obtained	 extracts	 (Chapter	 5.1.2)	 were	 submitted	 to	 LCMS	 and	 the	
chromatograms	were	analysed	(Figure	5.18C).	Several	new	compounds	eluting	at	tR	=	4.7,	5.5,	7.3	
and	 8.4	 min	 were	 observed	 in	 comparison	 to	 an	 extract	 of	 a	 transformant	 expressing	
aspks1+asL1+asL3	only.	
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Figure	 5.18	 Expression	 of	 four	 genes.	 A,	 Co-expression	 of	 aspks1+asL1+asL3+asR2.	 B,	 A.	 oryzae	 NSAR1	
+aspks1+asL1+asL3	 and	 A.	 oryzae	 NSAR1	 +aspks1+asL1+asL3+asR2	 on	 DPY	 agar.	 C,	 DAD	 chromatogram	 of	 an	
A.	oryzae	NSAR1	+aspks1+asL1+asL3	and	A.	oryzae	NSAR1	+aspks1+asL1+asL3+asR2	sample	measured	with	analytical	
gradient	A2	on	LCMS.	Extracts	were	obtained	from	cultures	grown	in	DPY	for	4	d.	
The	compound	eluting	at	tR	=	7.3	min	was	determined	to	have	a	nominal	mass	of	178	and	displayed	
three	characteristic	UV	absorption	maxima	(261,	272,	317	nm)	(Figure	5.19).	These	characteristics	
are	consistent	with	literature	data	for	125.98	Purification	of	4	mg	from	1	L	DPY	culture,	subsequent	
NMR	(1H,	HMBC,	HSQC)	analysis	and	HRMS	([M]-H+	C9H6O4	calculated	179.0344,	found	179.0344)	
confirmed	the	structure	(Chapter	7.5.6	for	NMR	data).	
	
Figure	5.19	Chemical	characterisation	of	123	(tR	=	7.3	min)	by	UV	and	mass	spectrum	obtained	from	ES
+	and	ES-.	
In	 addition,	 a	 compound	 eluting	 at	 tR	 =	 5.5	 min	 with	 highly	 similar	 maximum	 UV	 absorption	
spectrum	was	detected	alongside	125	(Figure	5.20).	It	was	determined	to	have	a	nominal	mass	of	
192,	which	could	correspond	to	a	methylated	shunt,	195a	or	195b.	
Analysis	of	1H	and	13C	NMR	data	of	the	isolated	compound	(4	mg,	1	L	DPY	culture)	showed	10	carbon	
atoms	 and	 7	 protons.	 HRMS	 of	 195	 confirmed	 a	molecular	 formula	 of	 C10H8O4	 ([M]H+	 C10H9O4	
calculated	193.0501,	found	193.0502)	which	suggested	one	exchangeable	proton.	Comparison	of	
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the	NMR	data	obtained	for	195a	or	195b	and	125,	showed	highly	similar	signals,	with	one	additional	
methyl	group	at	dH	3.65	(dC	56.3)	in	the	data	for	195	(Table	5.4).	
	
Figure	5.20	Chemical	characterisation	of	195	(tR	=	5.5	min)	by	UV	and	mass	spectrum	obtained	from	ES
+	and	ES-		
The	 chemical	 shift	 of	 this	 methyl	 group	 strongly	 suggests	 the	 attachment	 to	 an	 oxygen	 atom.	
Analysis	of	HMBC	correlations	and	an	unusual	5JH,H	coupling	of	the	methyl	protons	at	dH	3.65	and	
the	proton	at	dH	6.64	suggested	the	methylation	of	the	2-OH	group	in	195a	(Figure	5.21).	The	5JH,H		
coupling	was	observed	in	the	1H,1H	COSY	only.	In	1H	NMR	signals	of	protons	H-2	and	H-10	appeared	
as	singlets,	suggesting	a	5JH,H	<	1	Hz	which	supports	the	correlation	over	five	bonds.	
Table	5.4	NMR	data	for	195a	in	d6-DMSO	(500	MHz)	referenced	to	d6-DMSO	in	comparison	to	literature	data	for	125.	
Position	 dC/ppm	195a	 dH/ppm	(J	in	Hz)	195a	 HMBC	(H	to	C)	 dC/ppm	125
98	 dH/ppm	125
98	
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
176.9	
152.6	
100.8	
119.1	
122.4	
165.1	
109.7	
143.0	
144.0	
56.3	
-	
-	
6.64	(s,	1	H)	
-	
-	
-	
5.86	(s,	1	H)	
8.14	(d,	1	H,	1.9)	
8.17	(d,	1	H,	1.9)	
3.65	(s,	3H)	
-	
-	
1,	2,	5,	8	
-	
-	
-	
1,	2,	5,	6,	9	
2,	3,	4,	5,	9		
4,	5,	7,	8	
2,	3	
180.0	
149.3	
102.0	
119.6	
119.4	
161.4	
106.9	
142.7	
144.3	
-	
-	
-	
6.86	(s,	1	H)	
-	
-	
-	
6.16	(s,	1H)	
8.34	(d,	1	H,	1.8)	
8.22	(d,	1	H,	1.8)	
-	
	
Analysis	of	the	compound	eluting	at	tR	=	8.4	min	(nominal	mass	356,	maximal	UV	absorption	257,	
321)	suggested	it	to	be	the	previously	identified	talaroditroplone	196	(Figure	5.22).	This	compound	
is	known	from	T.	stipitatus	and	is	thought	to	be	formed	by	a	spontaneous	[4+2]	addition,	followed	
by	rearrangement,	of	2	molecules	of	125.98	Purification	of	2	mg	from	1	L	DPY	culture	extract	and	
subsequent	 full	 NMR	 analysis	 as	 well	 as	 HRMS	 ([M-H]-	 C18H11O8	 calculated	 355.0454,	 found	
355.0452)	confirmed	this	observation	(Chapter	7.5.6	for	NMR	data).	
The	final	newly	observed	peak	at	tR	=	4.7	showed	two	distinct	UV	absorption	maxima	and	a	nominal	
mass	of	180,	which	 is	consistent	with	 literature	data	of	cordytropolone	159	 (Figure	5.23).98	This	
compound	was	observed	previously	 in	T.	 stipitatus	upon	KO	of	 tropD	 and	 is	most	 likely	a	 shunt	
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product	arising	from	reduction	of	stipitafuran	125.98	HRMS	confirmed	the	molecular	formula	for	
this	peak	([M]H+	C9H9O4	calculated	181.0501,	found	181.0502).	
	
Figure	5.21	Compound	195a.	A,	Key	HMBC	correlations	observed	for	195a.	B,	1H,1H	COSY	spectrum	of	195a	showing	5JH,H	
coupling.	
	
Figure	5.22	Chemical	characterisation	of	196	(tR	=	8.4	min)	by	UV	and	mass	spectrum	obtained	from	ES
+	and	ES-.		
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Figure	5.23	Chemical	characterisation	of	159	(tR	=	4.7	min)	by	UV	and	mass	spectrum	obtained	from	ES
+	and	ES-.	
5.2.5 Summary	of	Heterologous	Tropolone	production	in	A.	oryzae	
The	sequential	expression	of	aspks1,	asL1,	asL3	and	asR2	in	A.	oryzae	NSAR1	led	to	the	isolation	
and	 characterisation	of	 the	 expected	 intermediates	 (120,	121,	123)	which	have	been	described	
previously	 in	the	biosynthesis	of	stipitatic	acid	119.97,98	This	showed	that	aspks1,102	asL1,104	asL3	
and	asR2	encode	true	tropolone	forming	proteins	(Scheme	5.2).	The	direct	intermediates	(120,	121,	
123)	were	observed,	as	well	as	previously	observed	shunt	products	(191,	194,	125,	159,	196).	 In	
addition,	two	compounds	(193,	195a)	probably	forming	through	spontaneous	addition	of	methanol	
(used	in	the	preparation	of	LCMS	samples)	were	isolated	and	fully	characterised	for	the	first	time.	
However,	the	proposed	product	124a/b	of	AsR2	was	not	observed.	
	
Scheme	5.2	Tropolone	biosynthesis	 in	A.	oryzae	NSAR1	by	expressing	A.	 strictum	aspks1	BGC	genes.	Scheme	5.7	 for	
proposed	mechanism	of	formation	of	193	and	195a.	
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5.3 Simultaneous	Expression	of	11	genes	of	the	aspks1	BGC	
The	observation	that	four	core	genes	of	the	A.	strictum	aspks1	BGC	encode	proteins	for	tropolone	
biosynthesis	confirmed	the	initial	bioinformatic	hypothesis	and	led	to	the	isolation	of	stipitafuran	
125.	 For	 the	 following	 required	 three	processes	 (humulene	 formation,	 fusion	of	polyketide	and	
terpene,	and	the	two	ring	contractions)	no	logical	prediction	could	be	made	from	in	silico	analysis	
of	 the	 BGC.	 This	 is	 due	 to	 the	 lack	 of	 a	 suitable	 terpene	 cyclase	 encoding	 gene	 and	 to	 the	
biosynthetically	 unprecedented	 steps	 of	 a	 proposed	 hetero	 Diels	 Alder	 reaction	 as	well	 as	 two	
unusual	ring	contractions	(Scheme	5.3).	
In	an	attempt	to	express	as	many	genes	as	possible	from	the	aspks1	BGC,	12	genes	were	initially	
selected	 (aspks1,	asL1-6,	asR2,	asR4-7),	 omitting	only	 the	 two	 transporter	 (asL7,	asR1)	 and	 the	
transcription	factor	(asR3)	encoding	genes.	However,	due	to	initial	difficulties	in	cloning	asR7	it	was	
not	included	in	the	first	expression	experiments.	
	
	
Scheme	5.3	Biosynthetic	proposal	for	the	formation	of	xenovulene	A	101.	
	
Figure	5.24	Eleven	genes	of	the	aspks1	BGC	selected	for	expression	in	A.	oryzae	NSAR1.	
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Transformation	of	A.	oryzae	NSAR1	with	aspks1,	asL1-6,	asR2	and	asR4-6	yielded	28	colonies.	For	
analysis	 of	 their	 secondary	 metabolite	 profile	 the	 transformants	 were	 sub-cultured	 in	 PamyB	
induction	medium.	Liquid	cultures	and	plates	of	these	transformants	did	appear	slightly	darker	than	
those	of	previous	experiments	expressing	tropolone	forming	genes	only	(Figure	5.25).	
	
Figure	5.25	DPY	agar	plates	of	A.	oryzae	NSAR1	WT,	A.	oryzae	NSAR1	+aspks1+asL1+asL3+asR2	and	A.	oryzae	NSAR1	
+aspks1+asL1-6+asR2+asR4-6.	
The	 obtained	 extracts	 (Chapter	 5.1.2)	 were	 submitted	 to	 LCMS	 and	 the	 chromatograms	 were	
analysed.	 Apart	 from	 the	 previously	 characterised	 intermediates	 and	 shunts	 (Chapter	 5.2),	 no	
distinct	new	peaks	were	detected	in	the	DAD	chromatogram	(Figure	5.26).		
	
Figure	5.26	DAD	chromatogram	of	an	A.	oryzae	NSAR1	WT	and	an	A.	oryzae	NSAR1	+aspks1+asL1-asL6+asR2+asR4-6	
sample	measured	with	analytical	gradient	A1	on	LCMS.	Extracts	were	obtained	from	cultures	grown	in	Starch	M	+	0.15%	
methionine	for	6	d.	
However,	a	trace	compound	with	the	nominal	mass	of	358	was	detected	in	ES-	and	ES+	at	tR	=	8.4	in	
16	transformants,	which	corresponds	to	the	retention	time	of	xenovulene	A	101.	This	peak	was	
shown	to	have	a	characteristic	UV	absorption	maximum	at	276	nm.	These	findings	are	consistent	
with	literature	data	as	well	as	previously	purified	(Chapter	2.1)	xenovulene	A	101.82	Further	HRMS	
([M]Na+,	C22H30O4Na,	calculated	381.2042,	found	381.2041)	and	MS2	(Appendix	9.4.4)	of	[M]H+	359	
strongly	suggested	it	to	be	101.	
A.	oryzae	NSAR1
+aspks1+asL1+asL3+asR2
A.	oryzae	NSAR1	WT A.	oryzae	NSAR1
+aspks1+asL1+asL3+asR2
+asL2+asL4+asL5+asL6
+asR4+asR5+asR6
Time
2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00
AU
0.0
2.0
4.0
4.773.082.02
2.78
2.37
3.59
4.00
6.605.12 6.10 8.10 9.45
Time
2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00
AU
0.0
2.0
4.0 2.78
2.00
2.35
3.53
3.07
4.113.72
5.14
4.80
4.46
5.35
5.75 6.36
6.02 6.95 7.91 8.60
AU
AU
A.	oryzae	NSAR1	WT
A.	oryzae	NSAR1
+aspks1+asL1+asL3+asR2
+asL2+asL4+asL5+asL6
+asR4+asR5+asR6
time/min
121
159
191
192c
Heterologous	Expression	of	the	A.	strictum	aspks1	BGC	in	A.	oryzae	
	 123	
In	 order	 to	 improve	 the	 titres	 of	101,	 four	 different	media	 (ASPM,	 DPY,	 Starch	M,	 CMP)	were	
extracted	at	three	different	time	points	(day	3,	6,	10).	Titres	were	improved	in	DPY	medium	after	
3	d	and	101	was	detected	by	DAD	(Figure	5.28).	Purification	of	1	mg	of	this	compound	from	a	1	L	
DPY	culture	extract,	and	subsequent	NMR	analysis	(1H,	1H,1H	COSY,	HMBC,	HSQC)	confirmed	the	
structural	identity	of	the	compound	produced	by	A.	oryzae	NSAR1	as	101	(Chapter	7.5.6	for	NMR	
data).	
	
Figure	5.27	Xenovulene	A	101.	A,	Extracted	ion	chromatograms	(ES+	m/z	=	359)	of	samples	of	A.	oryzae	NSAR1	+11	genes,	
A.	 oryzae	NSAR1	WT	 and	A.	 strictum.	B,	 Chemical	 characterisation	 of	101	 isolated	 from	A.	 strictum	WT	 and	C,	 101	
produced	by	A.	oryzae	NSAR1	transformed	with	11	genes	from	the	aspks1	BGC.	
	
Figure	 5.28	 DAD	 chromatogram	 of	 an	 A.	 oryzae	 +aspks1+asL1-asL6+asR2+asR4-6	 sample	 measured	 with	 analytical	
gradient	A1	on	LCMS.	Extracts	were	obtained	from	cultures	grown	in	DPY	for	6	d.	
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In	the	DAD	chromatogram	an	additional	peak	(197)	at	tR	=	7.9	min	was	detected.	The	retention	time	
suggested	it	to	be	a	compound	related	to	101	and	was	thus	targeted	for	purification.	Approximately	
1	 mg	 was	 obtained	 from	 2	 L	 of	 DPY	 culture	 extracts.	 Subsequent	 1H	 NMR	 analysis	 showed	
characteristic	humulene	signals.	Thus	full	NMR	was	acquired	and	analysis	of	1H	and	13C	NMR	data	
of	197	identified	23	carbon	atoms	and	30	protons	(Table	5.5).	HRMS	of	197	confirmed	a	molecular	
formula	 of	 C23H31O6	 ([M-H]-	 calculated	 403.2121,	 found	 403.2129)	 which	 suggested	 two	
exchangeable	protons.		
	
Figure	5.29	Chemical	characterisation	of	197	 (tR	=	7.9	min)	by	UV	and	mass	spectrum	obtained	from	ES
+	and	ES-.	Key	
HMBC	correlations	are	indicated.	
Chemical	 shifts	 of	 the	 humulene	 skeleton	 were	 assigned	 according	 to	 previously	 isolated	
A.	strictum	WT	compounds	(Chapter	2.1-2.7).	In	addition,	the	characteristic	ether	linkage	of	C-12	
(dC	 84.3)	 to	 C-13	 (dC	 72.5)	 was	 identified.	 For	 the	 usually	 observed	 tetrahydrofuran	 ring	 in	
xenovulene	 A	101	 only	 one	 additional	 CH	 (dC	53.7)	 group	 could	 be	 detected.	 This	 proposed	 an	
unsaturated	system	at	C-15,	which	was	in	accordance	with	the	chemical	shift	of	dC	116.9.	Further	
consideration	of	the	chemical	shifts	led	to	the	proposal	of	a	carbonyl	(dC	211.2),	a	carboxylic	acid	
(dC	170.3)	and	a	CH2-OH	(dC	67.3)	group.	The	methylene	protons	at	dC	67.3	only	displayed	germinal	
coupling,	which	indicated	the	attachment	next	to	quaternary	carbon	like	the	carbonyl	functional	
group	(dC	211.2).	Further	HMBC	correlations	(Figure	5.29)	strongly	proposed	structure	197,	which	
is	in	accordance	with	the	HRMS	result.	Relative	stereochemistry	at	C-1,	C-11	and	C-12	was	assumed	
to	be	identical	to	xenovulene	A	101,	but	not	further	determined.	
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Table	5.5	NMR	data	for	197	in	CD3OD	(500	MHz)	referenced	to	CD3OD.	
Position	 dC/ppm	197	 dH/ppm	(J	in	Hz)	197	 HMBC	(H	to	C)	
1	
2	
	
3	
4	
5	
6	
	
7	
8	
9	
	
10	
	
11	
12	
13	
	
14	
15	
16	
17	
18	
19	
	
20	
21	
22	
23	
83.3	
43.6	
	
122.5	
143.1	
39.3	
42.8	
	
124.3	
137.7	
39.2	
	
29.6	
	
41.0	
84.3	
72.5	
	
53.7	
116.9	
143.2	
170.3	
211.2	
67.3	
	
22.4	
24.6	
30.8	
17.2	
-	
2.25	(m,	1H)	
2.60	(bd,	1H,	14.2)	
5.16	(m,	1H)	
5.15	(m,	1H)	
-	
1.75	(dd,	1H,	12.6,	4.6)	
2.20	(m,	1H)	
5.10	(m,	1H)	
-	
2.01	(m,	1H)	
2.32	(m,	1H)	
1.40	(m,	1	H)	
1.49	(m,	1H)	
1.87	(m,	1H)	
4.12	(dd,	1H,	10.0,	1.7)	
3.91	(m,	1H)	
3.93	(m,	1H)	
4.09	(m,	1H)	
-	
-	
-	
-	
4.17	(d,	1H,	18.1)	
4.31	(d,	1H,	18.1)	
1.14	(s,	3H)	
1.09	(s,	3H)	
1.04	(s,	3H)	
1.62	(s,	3H)	
-	
3,	11	
1,	3,	4,	11	
2,	5,	21	
2,	3,	5,	21	
-	
4,	5,	7,	8,	21	
4,	7,	21,	22	
6,	9,	23	
-	
7,	8,	10,	11,	23	
7,	8,	10,	11,	23	
8,	9		
8,	9,	12	
1,	2,	9,	10,	12,	20	
10,	11,	15,	16	
12,	15,	18	
12,	15,	18	
13,	15,	18	
-	
-	
-	
-	
18	
18	
1,	2,	11	
4,	5,	6,	22	
4,	5,	6,	21	
6,	7,	9	
	
5.4 Defining	the	Minimal	aspks1	BGC	
Although	the	simultaneous	expression	of	eleven	genes	led	to	the	production	of	xenovulene	A	101,	
it	is	possible	that	not	all	genes	are	essential	for	the	biosynthesis.	Four	core	proteins	(MOS,	AsL1,	
AsL3,	AsR2)	were	shown	to	be	necessary	for	tropolone	production.	But	for	the	remaining	proposed	
four	chemical	transformations	(humulene	formation,	fusion	of	terpene	and	polyketide	moiety,	two	
ring	contractions)	 it	 is	 likely	 that	 fewer	 than	seven	proteins	are	 required.	 In	a	KO	by	expression	
(KOe)	experiment,	eight	different	A.	oryzae	NSAR1	strains	were	generated.	Seven	of	those	included	
sets	of	ten	genes	(Figure	5.30	1-7)	and	one	included	a	set	of	eight	genes	(Figure	5.30	8).	
For	 every	 set	 of	 genes,	 several	 transformants	 (Table	 5.1)	 were	 sub-cultured	 in	 PamyB	 induction	
medium.	Extracts	(Chapter	5.2.1)	were	analysed	for	their	production	of	xenovulene	A	101	or	any	
related	meroterpenoids	 observed	 in	A.	 strictum.	 In	 all	 experiments	 the	 previously	 isolated	 and	
characterised	polyketide	tropolone	(Chapter	5.2)	intermediates	121,	191,	192c,	159,	194,	195a,	125	
and	196	were	observed.	
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Figure	5.30	Overview	of	the	genes	simultaneously	expressed	in	A.	oryzae	NSAR1.	
For	xenovulene	A	101	production	the	extracted	ion	chromatogram	at	m/z	=	359	[M]H+	was	analysed	
(Figure	 5.33).	 In	 extracts	where	asL2,	asL5	 or	asR4	were	not	 expressed,	 xenovulene	A	101	was	
clearly	detected	(Figure	5.33).	This	indicates	that	proteins	encoded	by	these	genes	are	not	essential	
for	101	production.	On	the	contrary,	when	asR5	or	asR6	were	not	expressed,	no	xenovulene	or	
other	 meroterpenoids	 were	 observed.	 This	 shows	 that	 these	 genes	 are	 essential	 for	 the	
biosynthesis	(Figure	5.33).	When	omitting	either	asL4	or	asL6	only	traces	of	xenovulene	101	are	
observed	(Figure	5.33).	In	a	separate	experiment,	expressing	aspks1,	asL1,	asL2,	asR4,	asR5,	asR6	
in	A.	oryzae	NSAR1,	but	neither	asL4,	asL5	or	asL6,	no	101	production	was	observed	(Figure	5.33,	
Chapters	5.6	for	further	analysis	of	these	transformants).	
	
aspks1asL1 asR2 asR4 asR5 asR6asL3asL4asL5asL6
aspks1:	NR-PKS
asL1:	FAD-dependent	monooxygenase
asL3:	non-heme	iron	dependent	dioxygenase
asR2:	cytochrome	P450	monooxygenase
asL4:	FAD-dependent	monooxygenase
asL5:	short	chain	dehydrogenase/reductase
asL6:	FAD-dependent	monooxygenase
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Figure	5.31	DAD	chromatogram	of	A.	oryzae	NSAR1	extracts	measured	with	analytical	gradient	A2	on	LCMS.	Extracts	were	
obtained	from	transformants	(DPY,	4	d)	expressing	different	set	of	genes	as	indicated	(Figure	5.30).	
These	findings	strongly	suggested	that	the	minimal	xenovulene	A	BGC	is	composed	of	eight	genes	
(aspks1,	 asl1,	 asL3,	 asL4,	 asL6,	 asR2,	 asR5,	 and	 asR6).	 Subsequent	 transformation	 of	
A.	oryzae	NSAR	1	with	these	eight	genes	and	analysis	of	the	secondary	metabolite	production	by	
Carsten	 Schotte	 showed	 the	 production	 of	 101	 (Figure	 5.32).	 This	 confirmed	 the	 minimal	
xenovulene	aspks1	BGC.	
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Figure	5.32	DAD	chromatogram	of	an	A.	oryzae	NSAR1	expressing	the	minimal	BGC	sample	measured	with	analytical	
gradient	A1	on	LCMS.	Extracts	were	obtained	from	cultures	grown	in	DPY	for	5	d	by	Carsten	Schotte.	Data	by	courtesy	of	
Carsten	Schotte.	
	
Figure	5.33	Extracted	ion	chromatograms	ES+	m/z	=	179	for	125	and	m/z	=	359	for	101	for	all	extracts	obtained	through	
KOe	experiments.	Compound	125	shows	the	production	of	polyketide	precursor	and	serves	as	an	internal	control.	All	data	
for	m/z	=	359	are	shown	at	equivalent	scales	(9.72	e7).	Experiment	–asL4	is	additionally	shown	at	1.92e6	to	show	traces	
of	101.	
DPY 5 days
Time
2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00
AU
0.0
2.0
3.542.65
2.48 3.12
3.33
4.66
4.27
4.093.79
4.89
8.425.54
8.02
AU A.	oryzae	NSAR1
+aspks1+asL1+asL3+asR2
+asL4+asL6
+asR5+asR6
time/min
125 101
3-3
Time
8.00 9.00
%
0
100
3
Time
4.00 6.00
%
0
100 4.85
5.11
2-4
Time
4.00 6.00
%
0
100 4.83
5.01
3-3
Time
4.00 6.00
%
0
100 4.86
3
Time
8.00 9.00
%
0
100
2-4
Time
8.00 9.00
%
0
100
8.42
Time
2.00 4.00
%
0
100
Time
8.00 9.00
%
0
100
1-5
Time
4.00 6.00
%
0
100 4.86
B2-2
Time
4.00 6.00
%
0
100 4.76
5.33
B3-3
Time
4.00 6.00
%
0
100 4.83
1-5
Time
8.00 9.00
%
0
100 8.42
B2-2
Time
8.00 9.00
%
0
100 8.41
B3-3
Time
8.00 9.00
%
0
100
8.42
Time
4.00 6.00
%
0
100 4.87
Time
8.00 9.00
%
0
100 8.43
B4
Time
4.00 6.00
%
0
100 4.78
4.97
B1-2
Time
4.00 6.00
%
0
100 4.74
5.33
B4
Time
8.00 9.00
%
0
100
B1-2
Time
8.00 9.00
%
0
100
3-3
Time
8.00 9.00
%
0
100 8.42
7.97 8.68 9.48
101
ES+	m/z	=	359
9.72e7
A.	oryzae	NSAR1
+10	genes
-asL2
ES+	m/z	=	179
1.14e8
A.	oryzae	NSAR1
+11	genes
A.	oryzae	NSAR1	WT
A.	oryzae	NSAR1
+10	genes
-asL5
A.	oryzae	NSAR1
+10	genes
-asR4
A.	oryzae	NSAR1
+10	genes
-asR5
A.	oryzae	NSAR1
+10	genes
-asR6
A.	oryzae	NSAR1
+10	genes
-asL4
A.	oryzae	NSAR1
+10	genes
-asL6
A.	oryzae	NSAR1
+8	genes
-asL4	-asL5	-asL6
ES+	m/z	=	359
1.92e6
125
time/mintime/min
zoom	in
Heterologous	Expression	of	the	A.	strictum	aspks1	BGC	in	A.	oryzae	
	 129	
5.5 Formation	and	Attachment	of	Humulene	
Four	(aspks1,	asL1,	asL3	and	asR2)	of	the	eight	genes	of	the	minimal	BGC	were	assigned	to	their	
role	 in	 biosynthesis	 (Chapter	 5.2).	 Of	 the	 four	 remaining	 genes,	 two	 encode	 putative	 FAD	
dependent	 oxidoreductases	 (asL4,	 asL6)	 and	 two	 showed	 very	 weak	 bioinformatic	 functional	
predictions	 (asR5,	 asR6).	 The	 KO	 by	 expression	 (KOe)	 experiments	 (Chapter	 5.3)	 showed	 that	
omission	 of	 either	 asL4	 or	 asL6	 still	 led	 to	 the	 production	 of	 traces	 of	 101	 (Figure	 5.33).	 This	
indicates	that	these	transformants	express	all	genes	necessary	for	meroterpenoid	production.	 It	
was	thus	concluded	that	proteins	encoded	by	asL4	and	asL6	are	most	likely	involved	in	the	later	
ring	 contractions	 (Chapter	 5.6).	 KOe	 of	 either	 asR5	 or	 asR6	 only	 yielded	 polyketide	 precursors	
(Figure	5.33).	The	genes	asR5	and	asR6,	both	encoding	proteins	of	unknown	function,	were	thus	
proposed	to	be	involved	in	meroterpenoid	formation	(Scheme	5.4).	
	
Scheme	5.4	Biosynthetic	proposal	for	proteins	of	unknown	function	encoded	in	asR5	and	asR6.	
Transformation	of	A.	oryzae	NSAR1	with	6	genes	(aspks1,	asL1,	asL3,	asR2,	asR5,	asR6)	and	analysis	
of	 the	 secondary	metabolite	 production	 by	 Carsten	 Schotte	 showed	 the	 production	 of	 a	 novel	
compound	at	tR	=	11.2	min	(Figure	5.34).	UV	absorption,	tR	and	the	determined	low	resolution	mass	
of	382	were	consistent	with	the	A.	strictum	WT	meroterpenoid	154	described	earlier	in	this	thesis	
(Chapter	 2.4).	 The	 molecular	 formula	 was	 confirmed	 by	 HRMS	 ([M]H+,	 C24H31O4,	 calculated	
383.2222,	found	383.2223).	This	gave	further	evidence	that	unknown	proteins	AsR5	and/or	AsR6	
must	be	involved	in	humulene	106	production	and	its	fusion	to	the	polyketide	moiety.	
The	asR5	and	asR6	genes	were	obtained	as	E.	coli	codon	optimised	N-terminal	his6	tagged	clones,	
solubly	 expressed	 (AsR5:	 Raissa	 Schor,	 AsR6:	 Carsten	 Schotte)	 and	 purified	 by	 Ni-NTA	 affinity	
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purification	(by	Carsten	Schotte)	(Figure	3.35).	Protein	sequences	of	AsR5	and	AsR6	were	confirmed	
by	mass	 spectrometry	 (Dr.	 Jennifer	 Senkler,	AG	Braun,	 Leibniz	Universität	Hannover)	 (Appendix	
9.4.5).	
	
Figure	5.34	DAD	chromatogram	of	A.	oryzae	NSAR1	transformed	with	six	genes	showing	the	tropolone	meroterpenoid	
154.	Data	by	courtesy	of	Carsten	Schotte.	
In	vitro	assays	of	the	individual	enzymes	with	FPP	42	and	Mg2+	were	carried	out	by	Carsten	Schotte.	
The	assays	(500	µL)	were	extracted	with	n-pentane	(300	µL)	and	analysed	by	gas	chromatography	
coupled	to	MS	(GCMS).	Incubation	of	FPP	42	and	Mg2+	with	AsR6,	but	not	AsR5	(data	not	shown),	
resulted	 in	 the	detection	of	a	major	novel	peak	eluting	at	 tR	=	8.7	 (Figure	5.36A	and	5.36B).	As	
negative	 control	 heat	 inactivated	 protein	 was	 incubated	 with	 FPP	 42	 and	 Mg2+	 under	 assay	
conditions,	which	did	not	lead	to	the	production	of	this	novel	peak	(Figure	5.36B).	This	peak	was	
identified	as	humulene	by	comparison	of	retention	time	and	mass	fragmentation	(Figure	5.36B	and	
5.36C)	with	a	humulene	standard	(purchased	at	Sigma-Aldrich,	96%	purity).	The	observed	minor	
peaks	in	assay	and	standard	were	not	further	characterised.	
	
Figure	5.35	12%	SDS-PAGE	of	Ni-NTA	purified	AsR5	and	AsR6.	Picture	by	courtesy	of	Carsten	Schotte.	
Further	in	vitro	assays	(conducted	by	Carsten	Schotte)	using	AsR6,	stipitafuran	125	and	humulene	
106	(Figure	5.5A)	or	AsR5,	AsR6,	FPP	42	and	stipitafuran	125	(Figure	5.5B)	were	designed	to	produce	
meroterpenoid	154.	However,	these	experiments	have	not	yet	shown	any	conversion.	
The	heterologous	expression	of	aspks1,	asL1,	asL3,	asR2,	asR5	and	asR6	led	to	the	production	of	
meroterpenoid	154.	These	results	showed	that	AsR5	and	AsR6	are	involved	in	humulene	formation	
and	its	fusion	to	the	polyketide	moiety.	Further	in	vitro	assays	of	AsR6	identified	its	role	as	a	novel	
humulene	106	synthase.	This	strongly	suggests	that	AsR5	must	be	involved	in	joining	humulene	to	
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a	tropolone	precursor	to	form	154.	However,	first	in	vitro	assays	with	stipitafuran	125	as	polyketide	
precursor	and	humulene	106	did	not	give	further	evidence	for	this.	
	
Figure	5.36	AsR6	in	vitro	assay.	A,	Assay	conditions.	B,	TIC	of	assay	extract,	negative	control	(heat	inactivated	AsR6)	and	
standard	humulene	106.	C,	MS	(electron	impact	ionisation)	of	humulene	106	produced	by	AsR6	and	standard.	GCMS	data	
by	courtesy	of	Carsten	Schotte.	
	
Scheme	5.5	Attempted	in	vitro	assays	to	investigate	a	hetero	Diels	Alder	activity	of	AsR5.	A,	Providing	humulene	106.	B,	
Adding	AsR6,	42	and	Mg2+	for	humulene	106	production	in	vitro.	
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5.6 Ring	Contraction:	from	Tropolone	towards	the	Cyclopentenone	
For	five	of	the	eight	proteins	encoded	by	the	minimal	aspks1	BGC	a	role	during	biosynthesis	was	
assigned	 (Chapter	 5.2:	aspks1,	asL1,	asL3,	asR2;	 Chapter	 5.5:	asR6).	 For	AsR5	 (Chapter	 5.5)	 the	
gathered	experimental	data	 strongly	proposes	 the	 involvement	 in	 the	attachment	of	polyketide	
precursor	and	humulene.	
For	the	two	remaining	putative	FAD	dependent	monooxygenases	AsL4	and	AsL6	a	role	in	the	ring	
contraction	of	tropolones	to	cyclopentenone	in	101	was	proposed.	The	analysis	of	fungal	extracts	
lacking	 either	 expression	 of	 asL4	 or	 asL6	 still	 showed	 trace	 production	 of	 Xenovulene	 A	 101	
(Figure	5.33).	However,	analysis	of	fungal	extracts	lacking	expression	of	both	asL4	and	asL6	only	
yielded	the	meroterpenoid	154	(Figure	5.34).	These	results	strongly	proposed	that	AsL4	and	AsL6	
are	involved	in	the	two	ring	contraction	steps	from	tropolone	to	xenovulene	A	101	and	that	they	
can	partially	complement	each	other	(Scheme	5.6).	
Further	analysis	of	the	chromatograms	of	extracts	 lacking	asL4	or	asL6	expression	 identified	the	
presence	 of	 two	 compounds	 with	 a	 nominal	 mass	 of	 370	 at	 tR	 =	 9.2	 min	 and	 tR	 =	 9.4	 min	
(Figure	5.37).	
	
Scheme	5.6	Biosynthetic	proposal	for	the	ring	contraction	of	meroterpenoid	154	to	xenovulene	A	101.	
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Figure	5.37	Extracted	 ion	chromatograms	ES-	m/z	=	369	for	109a/b,	ES+	m/z	=	179	for	125	and	m/z	=	359	for	101	 for	
extracts	obtained	through	KOe	experiments.	Compound	125	shows	the	production	of	polyketide	precursor	and	serves	as	
an	internal	control.	
The	 compound	with	 tR	 =	 9.2	min	was	 only	 observed	 in	 fungal	 extracts	 lacking	 asL4	 expression	
whereas	 the	 compound	 eluting	 at	 tR	 =	 9.4	 min	 was	 only	 traceable	 in	 extracts	 lacking	 asL6	
expression.	 Retention	 time,	 HRMS	 and	MS2	 (Appendix	 9.4.6)	 identified	 the	 two	 compounds	 as	
phenolic	meroterpenoids	109a	([M-H]-	,	C23H29O4,	calculated	369.2066,	found	369.2066)	and	109b	
([M-H]-,	 C23H29O4,	 calculated	 369.2066,	 found	 369.2065),	 which	 were	 previously	 observed	 in	
A.	strictum	WT	(Figure	5.37,	Chapter	2.5).	These	compounds	were	not	observed	in	fungal	extracts	
obtained	from	transformants	lacking	asL4	and	asL6	expression	at	the	same	time	(Figure	5.37).	
These	results	strongly	propose	that	the	two	FAD	dependent	monooxygenases	AsL4	and	AsL6	are	
involved	in	two	the	ring	contraction	steps.	The	observation	of	traces	of	xenovulene	A	101	detected	
when	either	asL4	or	asL6	is	KOe,	but	no	detection	of	101	when	both	genes	are	lacking,	indicates	
that	the	encoded	proteins	can	at	least	partially	complement	one	another.	
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5.7 Discussion	
Elucidation	of	the	biosynthesis	of	xenovulene	A	101	in	A.	strictum	with	attempted	KO,	CRISPR/Cas9	
and	 silencing	 strategies	 proved	 very	 difficult	 (Chapter	 4).	 However,	 transcriptomic	 data	
(Chapter	3.2)	allowed	neat	BGC	cluster	boundaries	to	be	set	and	thus	enabled	the	heterologous	
expression	of	the	whole	aspks1	BGC.	
All	genes	of	the	aspks1	BGC,	except	transporters	and	transcription	factors,	were	successfully	cloned	
from	 A.	 strictum	 g-	 and	 cDNA	 into	 several	 vectors	 of	 the	 pTYGS	 family.	 Through	 subsequent	
protoplast	transformation	of	A.	oryzae	NSAR1	with	16	different	vector	combinations	the	secondary	
metabolite	 production	 of	 transformants	 harbouring	 16	 different	 combinations	 of	 genes	 was	
analysed.	
5.7.1 Tropolone	Biosynthesis	in	A.	strictum	
Sequential	 transformation	and	expression	of	aspks1,	asL1,	asL3	and	asR2	 led	 to	 the	 isolation	of	
intermediates	 (120,	 121,	 123)	 and	 shunt	 products	 (191,	 193,	 194,	 125,	 159,	 196)	 which	 were	
previously	observed	in	tropolone	biosynthesis	in	T.	stipitatus	(Chapter	5.2).97,98	Proteins	encoded	
by	these	four	genes	were	predicted	in	silico	to	be	homologous	to	the	tropolone	forming	enzymes	
TropA	(NR-PKS),	TopB	(salicylate	monooxygenase),	TropC	(non-heme	FeII	dependent	dioxygenase)	
and	TropD	(P450)	from	T.	stipitatus.97	Previous	expression	of	aspks1102	and	aspks1+asL1104	already	
confirmed	this	homology	and	was	re-established	in	this	work.		
Further	co-expression	of	asL3	and	asR2	and	isolation	of	intermediate	123	and	shunt	125	confirmed	
these	protein	homologies	for	the	first	time.	Thus,	the	aspks1	BGC	encodes	a	full	set	of	tropolone	
forming	 proteins.	 MOS	 (NR-PKS,	 encoded	 by	 aspks1)	 releases	 120,	 which	 is	 oxidatively	
dearomatised	 by	 the	 salicylate	 monooxygenase	 AsL1	 to	 give	 enone	 121	 (Scheme	 5.7A).	 This	
intermediate	undergoes	further	hydroxylation	(122)	and	ring	expansion	to	stipitaldeyhde	123	by	
AsL3,	a	non-heme	FeII	dependent	dioxygenase.	The	P450	monooxygenase	AsR2	hydroxylates	the	
methyl	 group	 and	 most	 likely	 forms	 124a,	 which	 is	 in	 equilibrium	 with	 its	 hemiacetal	 124b.	
However,	this	compound	was	not	directly	observed,	but	instead	three	previously	reported	shunts	
(125,	159,	196)	probably	arising	 from	it.	The	two	newly	observed	compounds	193	and	195a	are	
most	likely	adducts	formed	with	methanol	as	solvent	(Scheme	5.7B	and	5.7C).	
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Scheme	 5.7	 Tropolone	 biosynthesis	 in	 A.	 oryzae	 NSAR1	 by	 expression	 of	 genes	 encoded	 in	 the	 aspks1	 BGC	 from	
A.	strictum.	A,	Porposed	biosynthetic	pathway.	B,	Proposed	addition	of	 two	molecules	methanol	 to	121.	C,	Proposed	
addition	of	methanol	to	125.	
5.7.2 Heterologous	Production	of	Xenovulene	A	101	and	Minimal	aspks1	BGC	
In	a	further	experiment	an	additional	seven	genes	from	the	aspks1	BGC	(eleven	genes	in	total)	were	
co-expressed	which	led	to	the	production	of	xenovulene	A	101	and	compound	197	(Figure	5.38A).	
The	latter,	197,	most	likely	arises	as	degradation	product	of	phenolic	meroterpenoids	rather	than	
as	a	product	of	xenovulene	A	101	itself	as	it	has	23	carbon	atoms,	one	more	than	101	(Figure	5.38B).		
This	 result	 confirmed	 that	 although	 the	aspks1	 BGC	does	not	encode	a	 known	class	of	 terpene	
cyclase,	it	encodes	all	proteins	to	form	the	merotperpenoid	101.	This	is	consistent	with	previous	
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in	silico	analysis	of	the	A.	strictum	 transcriptome,	where	no	co-regulated	terpene	gene	could	be	
identified	 (Chapter	 3.3.1).	 In	 order	 to	 determine	 the	 minimal	 aspks1	 BGC	 a	 KO	 by	 expression	
method	 was	 employed	 and	 this	 identified	 four	 additional	 genes	 which	 are	 crucial	 for	 101	
biosynthesis:	asL4,	asL6,	asR5	and	asR6.		
	
Scheme	5.8	Xenovulene	A	101	biosynthesis	in	A.	oryzae	NSAR1.	A,	Xenovulene	A	101	minimal	BGC.	B,	Proposed	oxidative	
degradation	of	128	to	shunt	197,	observed	in	A.	oryzae	NSAR1	only.	
5.7.3 Humulene	Production	and	Joining	to	Polyketide	
Co-expression	of	core	tropolone	encoding	genes	(aspks1,	asL1,	asL3	and	asR2)	with	asR5	and	asR6	
in	 A.	 oryzae	 NSAR1,	 both	 encoding	 proteins	 of	 unknown	 function,	 led	 to	 the	 production	 of	
meroterpenoid	154.	This	strongly	suggested	that	these	novel	proteins	catalyse	the	two	cryptic	steps	
in	meroterpenoid	formation:	cyclisation	of	FPP	42	to	106	and	attachment	of	humulene	106	to	the	
polyketide	precursor.	
To	probe	 this	hypothesise,	both	proteins	 (AsR5	and	AsR6)	were	solubly	expressed	 in	E.	 coli	 and	
in	vitro	assays	were	conducted	(by	Carsten	Schotte).	In	the	presence	of	Mg2+	AsR6	was	shown	to	
cyclise	FPP	42	to	humulene	106.	AsR6	is	a	protein	that	possesses	no	DDxxD	or	NSE	motif,	which	is	
characteristic	 for	 class	 I	 terpene	 cyclases.	 It	 furthermore	 shows	 no	 homologies	 to	 any	 known	
terpene	cyclase	(Chapter	3.3.2).	Thus	AsR6	represents	an	unprecedented	terpene	cyclase	that	 is	
first	described	in	xenovulene	A	101	biosynthesis.	Further	mechanistic	studies	and	identification	of	
active	site	residues	have	to	await	the	crystallographic	analysis	of	the	protein.	
In	a	further	attempt	to	characterise	AsR5,	another	protein	of	unknown	function,	 in	vitro	enzyme	
assays	 were	 carried	 out.	 Incubation	 of	 neither	 AsR5,	 AsR6,	 FPP,	 125	 and	 Mg2+/Ca2+	 or	 AsR5,	
humulene	106	 and	125	 showed	 conversion	 to	 the	 tropolone	meroterpenoid	154	 (Scheme	 5.5).	
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Although	the	protein	was	expressed	and	purified	in	soluble	form,	the	obtained	yields	were	poor	
and	 the	activity	 could	not	be	confirmed.	This	 could	be	due	 to	 several	 reasons	 such	as	 lacking	a	
co-factor	or	the	presence	of	incorrect	substrates.	
This	suggests	that	reaction	conditions	for	AsR5	in	in	vitro	assays	need	further	optimisation.	Testing	
different	co-factors	and	polyketide	precursors	could	identify	the	true	substrates	and	reconstitute	
the	biosynthesis	of	meroterpenoid	154	 in	vitro.	Comparison	of	xenovulene	A	101	and	epolone	B	
114	suggests	stipitaldehyde	123	as	the	likely	polyketide	substrate.	In	parallel	systems	the	related	
meroterpenoids	110-116	are	formed	despite	the	lack	of	the	cytochrome	P450	oxygenase	catalysed	
hydroxylation	at	the	methyl	group	in	123.	Further,	A.	oryzae	NSAR1	expression	studies	lacking	asR2	
(P450)	could	also	help	to	elucidate	the	polyketide	precursor.	
	
Scheme	5.9	Proposed	in	vitro	assay	with	123	as	substrate.	
AsR5	was	predicted	to	be	a	Ca2+	dependent	phosphotriesterase	homologue	and	a	model	proposed	
the	tertiary	structure	of	a	six	bladed	propeller	protein	(Figure	3.10,	Chapter	3.3.2).	Strictosidine	204	
synthase,	a	plant	enzyme	that	catalyses	an	intermolecular	Pictet-Spengler	reaction	of	tryptamine	
202	and	secologanin	203,	was	shown	to	crystallise	as	a	similar	six	bladed	propeller.225	
	
Scheme	5.10	Pictet-Spengler	reaction	catalysed	by	strictosidine	synthase.	
Protein	homology	modelling	of	AsR5	and	strictosidine	synthase	using	SWISS-MODEL	showed	that	
substrate	bindings	sites	are	not	conserved.156–158	However,	six	bladed	propeller	proteins	are	known	
to	mediate	protein-protein	 interaction	and	to	display	diverse	 functions.	These	proteins	can	trap	
substrates	at	their	top	face	or	between	domains.226	During	the	biosynthesis	of	xenovulene	A	101	
two	advanced	biosynthetic	precursors	have	to	react.	It	is	possible	that	the	tertiary	structure	of	an	
AsR5	 six	 bladed	 propeller	 traps	 humulene	 106	 and	 the	 required	 polyketide	 precursor	 in	 close	
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proximity	and	 induces	a	conformational	organisation	to	enable	 the	proposed	hetero	Diels	Alder	
reaction.		
5.7.4 Ring	Contraction	from	Tropolone	to	Cyclopentenone	
The	 final	 steps	 of	 101	 biosynthesis	 are	 two	 ring	 contractions	 to	 form	 a	 cyclopentenone	 from	
tropolone	meroterpenoids	(Scheme	1.18A).	The	A.	oryzae	NSAR1	expression	studies	showed	that	
asL4	 and	 asL6,	 both	 encoding	 FAD	 dependent	monooxygenases,	 are	 crucial	 for	 this	 chemistry.	
When	both	are	not	expressed	only	meroterpenoid	154	 can	be	observed.	However,	when	either	
asL4	or	asL6	are	KOe,	traces	of	101	and	the	two	different	phenolic	structural	isomers	109a	and	109b	
are	 observed.	 These	 findings	 strongly	 suggest	 that	 AsL4	 and	 AsL6,	 which	 share	 33.4%	 protein	
sequence	identity,	catalyse	the	two	ring	contractions	and	can,	at	least	partially,	complement	each	
other.	
Conserved	domain	analysis141	of	AsL4	and	AsL6	showed	a	high	similarity	to	UbiH,	an	FAD	dependent	
monooxygenase	involved	in	ubiquinone	8	211	formation	(Scheme	5.11).	UbiH,	UbiI	and	UbiF	belong	
to	a	family	of	regioselective	aromatic	hydroxlyases.	In	E.	coli	UbiI	hydroxylates	the	aromatic	core	at	
C-6,	UbiH	at	C-4	and	UbiF	at	C-5	 (Scheme	5.11).	Although,	 catalysing	very	 similar	 chemistry	 the	
overall	sequence	identity	of	these	proteins	is	only	between	29	–	38%.83,227	
	
Scheme	5.11	Regioselective	aromatic	hydroxylations	catalysed	by	UbiI,	UBiH	and	UbiF.	
The	 isolated	A.	strictum	WT	compounds	107a	 and	107b,	as	well	as	 the	exclusive	observation	of	
meroterpenoid	 109a	 or	 109b,	 when	 either	 asL4	 or	 asL6	 is	 KOe	 in	 A	 oryzae	NSAR1	 support	 a	
regioselective	oxidation	mechanism	for	the	two	monooxygenases	AsL4	and	AsL6	(Scheme	5.12).	In	
regard	to	observed	phenolic	meroterpenoid	109a	upon	KOe	of	asL4,	it	could	be	proposed	that	the	
enzymatically	less	preferred	intermediate	109a	accumulates,	which	would	lead	to	the	conclusion	
that	AsL4	could	oxidise	C-15.	Vice	versa,	when	asL6	is	KOe,	phenolic	compound	109b	accumulates	
and	suggests	AsL6	to	oxidise	C-18.	
Mechanism	and	enzymes	for	similar	ring	contractions	are	unknown,	but	aromatic	hydroxylations	
and	mechanisms	of	FAD	dependent	monooxygenases	have	been	reported.228	A	detailed	mechanism	
was	 investigated	 for	 p-hydroxybenzoate	 3-hydroxylase.229	 The	 direct	 hydroxylation	 by	 a	
nucleophilic	 attack	 of	 the	 activated	 p-hydroxybenzoic	 acid	 212	 to	 the	 hydroperoxoflavin	 70b	
resulted	in	the	respective	dihydroxylated	compound	214	via	a	cyclohexadieneone	intermediate	213	
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(Scheme	 5.13A).230	 This	 direct	 hydroxylation	 would	 explain	 the	 intermediates	 107a	 and	 107b	
observed	in	A.	strictum	WT.	In	addition,	it	is	in	accordance	with	Simpson’s	previously	proposed	ring	
contraction	mechanism	for	xenovulene	A	101	and	supported	by	the	feeding	experiments	(Scheme	
5.13B).84	
	
Scheme	5.12	Regioselective	hydroxylation	and	ring	contraction	by	AsL4	and	AsL6.	Framed	compounds	are	characterised	
in	Chapter	2.	
FAD	dependent	monooxygenases	are	also	often	linked	to	epoxidations	of	alkenes	such	as	reported	
for	 austinol	 84	 and	 related	 meroterpenoids	 93-95	 (Chapter	 1.2,	 Scheme	 1.13).72,76,77	 In	 the	
biosynthesis	of	aspyrone	218	and	asperlactone	219	such	an	epoxide	216	is	proposed	to	rearrange	
via	an	1,2	alkyl	migration	to	217	(Scheme	5.14).231	
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Scheme	 5.13	 FAD	 dependent	 aromatic	 hydroxylation.	 A,	 Hydroxylation	 of	 p-hydroxybenzoic	 acid	 212.	 B,	 Simpson’s	
proposed	hydroxylation	and	ring	contraction	of	tropolone	meroterpenoid	154.84	
An	alternative	epoxidation	dependent	oxidation	of	154	to	107a	or	107b,	could	also	explain	the	ring	
contraction	 towards	 phenolic	 compounds	 109a	 and	 109b	 through	 1,2	 alkenyl	 migration	
(Scheme	5.15A).	The	corresponding	1,2	hydride	migration,	known	as	the	NIH	shift,	would	explain	
and	define	compounds	107a	and	107b	as	shunts	(Scheme	5.15B).232	The	NIH	shift	 is	observed	in	
hydroxylations	 of	 a	 variety	 of	 aromatic	 compounds	 by	 phenylalanine-,	 tryptophan	 or	 tyrosine	
hydroxylases	(Scheme	5.15C).232,233	
	
Scheme	5.14	Porposed	epoxide	rearrangement	in	the	biosynthesis	of	aspyrone	218	and	asperlactone	219.	
However,	 attempts	 to	 correlate	 a	 possible	 epoxide	mechanism	with	 the	 results	 of	 the	 feeding	
experiments	of	xenovulene	A	101	resulted	in	either	incorrect	labelling	of	101	or	in	the	requirement	
of	one	or	two	additional	oxidations.	
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Scheme	5.15	Proposed	FAD	dependent	epoxidation.	A,	Ring	contraction	and	B,	NIH	1,2	hydride	shift.	C,	Classic	NIH	shift	
of	phenylalanine	hydroxylase	on	4-tritiophenylalanine	223.232	
A	 similar	 ring	 contraction	 mechanism	 is	 proposed	 in	 terrein	 132	 biosynthesis	 (Scheme	 5.16).	
Although	 the	 molecular	 steps	 have	 not	 yet	 been	 characterised,	 a	 BGC	 responsible	 for	 132	
biosynthesis	 has	 been	 reported.101	 Protein	 sequences	 of	 two	 putative	 FAD	 dependent	
monooxygenases	(encoded	by	terC	and	terD)	essential	for	132	biosynthesis,	were	compared	to	AsL4	
and	AsL6	using	EMBOSS	Needle.153	Pairwise	protein	identity	was	between	14-17	%	and	similarity	
less	then	27%	of	all	compared	sequences,	thus	indicating	no	close	relation	for	ring	contractions	in	
101	and	132.	
	
Scheme	5.16	Terrein	132	biosynthesis	in	A.	terreus.	
Taken	together	these	findings	suggest	that	AsL4	and	AsL6	are	regioselective	aromatic	hydroxylases.	
In	vivo	evidence	showed	that	the	order	of	oxidations	can	alter.	This	indicates	that	AsL4	and	AsL6	
can	hydroxylate	both	 tropolones	and	phenolic	 compounds,	 even	 though	a	 reduced	efficiency	 is	
observed.	However,	mechanistic	studies	of	a	possible	ring	contraction	mechanism	have	to	await	
recombinant	protein	production	to	enable	in	vitro	assays	and	crystallisation	experiments.	
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6 Conclusion	and	Outlook	
The	 major	 focus	 of	 this	 project	 was	 the	 identification	 and	 investigation	 of	 a	 BGC	 involved	 in	
xenovulene	 A	 101	 biosynthesis.	 For	 this	 reason,	 genome,	 transcriptome	 and	 secondary	
metabolomes	of	A.	strictum	were	analysed	in	detail.	
By	KO	of	the	core	PKS	encoding-gene	in	A.	strictum	the	49	kb	large	aspks1	BGC	was	confirmed	as	
responsible	for	xenovulene	A	101	production	(Chapter	4).	By	heterologous	co-expression	all	genes	
crucial	for	101	biosynthesis	were	identified	and	further	characterised	(Chapter	5).	
	
Figure	6.1	aspks1	BGC,	encoding	xenovulene	A	101	biosynthesis.	
Heterologous	co-expression	of	xenovulene	A	101	early	genes	(aspks1,	asL1,	asL3,	asR2)	and	also	
tropolone	precursor	120,	121	and	125	in	A.	strictum	WT	chromatograms	showed	for	the	first	time	
that	the	aspks1	BGC	encodes	a	tropolone	pathway	homologous	to	T.	stipitatus	(Chapter	2.8	and	5).	
The	 direct	 intermediate	 produced	 by	 the	 cyctochrome	 P450	 monooxygenase	 AsR2,	 which	 is	
proposed	to	be	compound	124a	in	equilibrium	with	its	hemiacetal	124b,	was	not	observed.	Also	in	
the	 T.	 stipitatus	 pathway	 this	 likely	 intermediate	 is	 shunted	 to	 125	 probably	 very	 quickly	
(Scheme	6.1).98	Expression	of	 the	T.	 stipitatus	AsR2	homologue	yielded	 insoluble	protein,	which	
made	 in	 vitro	 assays	 impossible.97	 However,	 in	 order	 to	 identify	 the	 true	 AsR2	 product	 in	 vitro	
enzyme	assays	are	most	promising.	
	
Scheme	6.1	Proposed	hemiacetal	124a	intermediate	upon	cytochrome	P450	monooxygenase	hydroxylation	of	the	methyl	
group.	
Further	 heterologous	 expression	 of	 different	 gene	 sets	 of	 the	 aspks1	 BGC	 in	A.	 oryzae	NSAR1	
identified	 two	 genes	 encoding	 proteins	 of	 unknown	 function,	 which	 are	 essential	 for	
meroterpenoid	production.	In	vitro	enzyme	assay	confirmed	one	(AsR6)	as	unprecendent	humulene	
synthase	(Chapter	5.5).	Although,	this	work	showed	that	the	protein	is	Mg2+	dependent,	such	as	
classical	 terpene	cyclases,	no	active	site	 residues	 for	Mg2+	coordination	were	 identified	 in	 silico.	
Future	crystallisation	of	this	protein	will	identify	active	site	residues	and	possibly	reveal	more	about	
a	structural	relationship	to	classical	terpene	cyclases.	
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The	other	unknown	protein	(AsR5)	is	very	likely	involved	in	the	fusion	of	polyketide	and	terpene	
moiety	 (Chapter	5.5).	 For	 this	 reaction	a	hetero	Diels	Alder	 reaction	has	been	proposed	and	 its	
feasibility	was	shown	in	vitro	by	Baldwin	and	co-workers	(Chapter	1.3.4).111,113	Only	a	few	examples	
of	enzymes	catalysing	a	DA	or	hDA	reaction	are	reported	in	the	literature	and	a	variety	of	protein	
tertiary	 structures	are	used.117	However,	 the	 structural	prediction	of	 this	protein	 is	 a	 six-bladed	
propeller	and	these	are	known	for	the	capacity	to	trap	compounds.226	This	enzyme	could	trap	a	
polyketide	and	a	terpene	moiety	in	close	proximity	and	conformation	to	induce	the	hDA	reaction.	
To	prove	a	hetero	Diels	Alder	mechanism,	the	true	polyketide	substrate	would	have	to	be	identified	
and	the	protein	activity	confirmed	in	vitro	(Scheme	6.2).	However,	protein	kinetics	alone	will	not	
show	 the	nature	of	 a	 concerted	Diels	Alder	 reaction.	Additional	molecular	 dynamic	 simulations	
under	consideration	of	a	protein	crystal	structure	or	substrate	transitions	states,	which	were	used	
to	 show	 the	 concerted	Diels	Alder	 reaction	 in	abyssomicin	and	 leporin	B	64	 biosynthesis,	 could	
finally	confirm	the	mechanism.64,234	
The	two	FAD	dependent	monooxygenases	AsL4	and	AsL6	were	identified	as	crucial	for	the	proposed	
ring	 contractions	 (Chapter	 5.4	 and	 5.6).	 It	 is	 likely	 that	 both	 enzymes	 catalyse	 regioselective	
aromatic	 hydroxylations	 or	 epoxidations	 and	 a	 subsequent	 ring	 contraction	 each	 (Scheme	 6.2).	
However,	no	similar	mechanism	is	elucidated	on	a	molecular	level.	It	was	initially	proposed	that	the	
mechanism	and	enzymes	involved	in	xenovulene	A	101	ring	contractions	are	similar	to	those	from	
terrein	 132	 biosynthesis,	 but	 sequence	 comparison	 of	 encoded	 protein	 did	 not	 identify	 close	
homologues.	For	further	elucidation	of	a	mechanism,	substrates,	intermediates	and	shunt	products	
these	proteins	should	be	recombinantly	expressed	and	in	vitro	assays	conducted.	
In	addition,	one	gene,	asL5,	encoding	a	short	chain	dehydrogenase	is	part	of	the	aspks1	BGC	and	
its	 expression	 is	 up-regulated	 under	 101	 producing	 conditions	 (Chapter	 3.2).	 Nevertheless,	 the	
protein	was	found	to	be	unnecessary	for	101	biosynthesis.	Short	chain	dehydrogenases	can	catalyse	
oxidations	and	reductions	of	a	variety	of	substrates	(Chapter	1.1.3).63	Often	ketone	to	alcohol	and	
vice	 versa	 reactions	 are	 observed.	 In	 order	 to	 identify	 its	 activity	 in	 vitro	 assays	 with	 different	
intermediates	from	the	xenovulene	pathway	could	be	conducted.	Maybe	xenovulene	A	101	itself	
is	the	subject	of	a	further	transformation	(Scheme	6.2).	
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Scheme	6.2	Proposed	xenovulene	A	101	biosynthesis	based	on	results	gained	this	work.	
Taken	together,	we	were	able	to	identify	a	BGC	for	xenovulene	type	meroterpenoids	for	the	first	
time.	Even	beyond	that	we	could	assign	likely	functions	for	the	individual	proteins	and	propose	a	
more	detailed	biosynthetic	route	(Scheme	6.2).	
These	results	will	simplify	the	identification	of	similar	BGC	in	different	fungi	as	we	showed	by	the	
identification	of	a	homologous	BGC	 in	A.	thermomutaus	 (Chapter	3.3.2).	Genome	sequencing	of	
fungal	 strains	 producing	 similar	 meroterpenoids	 (Chapter	 1.3)	 and	 in	 silico	 identification	 of	
homologous	 aspks1	 BGC	 will	 enable	 the	 elucidation	 of	 the	 biosynthesis	 of	 an	 entire	 class	 of	
meroterpenoids.	Of	special	interest	hereby	is,	how	or	whether	the	stereoselectivity	of	the	addition	
of	 the	 second	 tropolone	 is	 controlled.	 Although,	 the	 two	 diastereomers	 pycnidione	 110	 and	
eupenifeldin	111	are	reported	these	compounds	have	been	isolated	from	different	fungi,	indicating	
an	enzyme	controlled	reaction.	
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Figure	6.2	The	diastereomers	pyndidione	110	and	eupenifeldin	111.	
A	 rational	 genetic	 engineering	 strategy	 where	 genes	 of	 the	 xenovulene	 A	 101	 pathway	 are	
co-expressed	with	those	of	related	meroterpenoids	such	as	the	epolone	A	113	pathway	could	lead	
to	 novel	 compounds.	 A	 similar	 approach	 by	 expressing	 chimeric	 PKS-NRPS	 hybride	 system	was	
successfully	used	to	produced	novel	cytochalasins.235	 If	successfully	employed	in	the	xenovulene	
meroterpenoids	case,	this	could	expand	the	chemical	diversity	of	these	natural	products	and	may	
grant	access	to	novel	bioactive	compounds.	
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7 Experimental	
All	 chemicals	 and	 media	 ingredients	 used	 in	 this	 work	 were	 purchased	 from	 Carl	 Roth,	
Sigma-Aldrich,	VWR,	Merck,	Duchefa	Biochemie,	Formedium,	Acros,	Alfa	Aesar,	abcr	and	Thermo	
Fisher	Scientific	unless	denoted	differently.	
7.1 Media,	Antibiotics,	Buffers	
Deionised	 water	 was	 further	 purified	 by	 a	 GenPure	 Pro	 UV/UF	 milipore	 device	 from	
Thermo	Scientific	and	used	to	prepare	all	media,	antibiotics	and	buffers	unless	denoted	differently.	
Media	and	Buffers	were	sterilised	at	120	°C	for	15	min	using	a	Systec	VX150	or	a	Classic	Prestige	
Medical	 2100	 autoclave.	 Antibiotics	 were	 prepared	 at	 concentrated	 stock	 solutions	 and	 filter	
sterilised	using	a	45	µM	syringe	filter	with	a	cellulose	acetate	membrane.	
7.1.1 Media	
Table	7.1	Components	of	media	and	agar	used	in	this	work	are	listed.	
Media	and	Agar	 Concentration/%	(w/v)	 Ingredient	
2	tryptone	yeast	medium	(2TY)	 1.6	
1.0	
0.5	
tryptone	
yeast	extract	
NaCl	
A.	strictum	seed	agar	(ASSA)	 1.10	
1.50	
1.50	
0.30	
0.50	
0.10	
1.50	
D(+)-glucose	monohydrate	
glycerol	
polypeptone	
sodium	chloride	
malt	extract	
Tween	80	
agar	
pH	6.0	with	H2SO4	
A.	strictum	seed	medium	(ASSM)	 1.10	
1.50	
1.50	
0.30	
0.50	
0.10	
0.10	
D(+)-glucose	monohydrate	
glycerol	
polypeptone	
sodium	chloride	
malt	extract	
Tween	80	
Junlon	PW110	
pH	6.0	with	H2SO4	
A.	strictum	production	medium	(ASPM)	 4.74	
0.70	
0.10	
D(+)-maltose	monohydrate	
yeast	extract	
Tween	80	
pH	6.0	with	H2SO4	
CM	 2.00	
10.0	
Cottonseed	flour	
Lactose	monohydrate	
Czapek	Dox	with	sorbitol,	soft	agar	(CD+S	soft	agar)	 3.50	
18.22	
0.80	
Czapek	Dox	broth	
D-sorbitol	
Agar	
prepare	with	deionised	water	for	
A.	strictum	transformation	
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Media	and	Agar	 Concentration/%	(w/v)	 Ingredient	
Czapek	Dox	with	sorbitol	(CD+S)	 3.50	
18.22	
1.50	
Czapek	Dox	broth	
D-sorbitol	
Agar	
prepare	with	deionised	water	for	
A.	strictum	transformation	
Czapek	Dox	with	supplements	(CZD)	 3.50	
4.68	
0.10	
0.05	
0.15	
1.50	
Czapek	Dox	broth	
sodium	chloride	
ammonium	sulfate	
adenine	
L-methionine	
agar	
Czapek	Dox	with	sorbitol	and	supplements	(CZD+S)	 3.50	
18.22	
0.10	
0.05	
0.15	
1.50	
Czapek	Dox	broth	
D-sorbitol	
ammonium	sulfate	
adenine	
L-methionine	
agar	
Czapek	Dox	with	 sorbitol	 and	 supplements	 soft	 agar	
(CZD+S	soft	agar)	
3.50	
18.22	
0.10	
0.05	
0.15	
0.80	
Czapek	Dox	broth	
D-sorbitol	
ammonium	sulfate	
adenine	
L-methionine	
agar	
CZD	without	methionine	(CZD1)	 3.50	
4.68	
0.10	
0.05	
1.50	
Czapek	Dox	broth	
sodium	chloride	
ammonium	sulfate	
adenine	
agar	
CZD+S	without	methionine	(CZD1+S)	 3.50	
18.22	
0.10	
0.05	
1.50	
Czapek	Dox	broth	
D-sorbitol	
ammonium	sulfate	
adenine	
agar	
CZD+S	 soft	 agar	 without	 methionine	 (CZD1+S	 soft	
agar)	
3.50	
18.22	
0.10	
0.05	
0.08	
Czapek	Dox	broth	
D-sorbitol	
ammonium	sulfate	
adenine	
agar	
CZD1	without	adenine	(CZD2)	 3.50	
4.68	
0.10	
1.50	
Czapek	Dox	broth	
sodium	chloride	
ammonium	sulfate	
agar	
CZD1+S	without	adenine	(CZD2+S)	 3.50	
18.22	
0.10	
1.50	
Czapek	Dox	broth	
D-sorbitol	
ammonium	sulfate	
agar	
CZD1+S	soft	agar	without	adenine	(CZD2+S	soft	agar)	 3.50	
18.22	
0.10	
0.08	
Czapek	Dox	broth	
D-sorbitol	
ammonium	sulfate	
agar	
DPY	 2.00	
1.00	
0.50	
0.50	
0.05	
2.50	
dextrin	from	potato	starch	
polypeptone	
yeast	extract	
KH2PO4	
MgSO4	
agar	
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Media	and	Agar	 Concentration/%	(w/v)	 Ingredient	
Lysogeny	broth	(LB)	 0.50	
1.00	
0.50	
yeast	extract	
tryptone	
NaCl	
LB	agar	 0.50	
1.00	
0.50	
1.50	
yeast	extract	
tryptone	
NaCl	
agar	
Malt	extract	agar	(MEA)	 1.28	
0.08	
0.24	
0.28	
1.50	
malt	extract	
peptone	ex	soya	
glycerol	
dextrin	from	potato	starch	
agar	
Malt	extract	media	(ME)	 1.28	
0.08	
0.24	
0.28	
malt	extract	
peptone	ex	soya	
glycerol	
dextrin	from	potato	starch	
Potato	dextrose	broth	agar	(PDA)	 2.40	
1.50	
potato	dextrose	broth	
agar	
Potato	dextrose	broth	(PDB)	 2.40	 potato	dextrose	broth	
Supplement	mixture	minus	uracil	(SM-URA)	 0.17	
0.50	
2.00	
0.077	
1.50	
yeast	nitrogen	base	
(NH4)2SO4	
D(+)-glucose	monohydrate	
complete	supplement	mixture	minus	uracil	
agar	
Super	optimal	broth	(SOB)	 0.5	
2.00	
0.06	
0.02	
yeast	extract	
tryptone	
NaCl	
KCl	
SOB	with	magnesium	chloride	and	glucose	(SOC)	 93.75	(v/v)	
1.25	(v/v)	
5.00	(v/v)	
SOB	
MgCl2	x	6	H2O	(2M)	
D(+)-glucose	(20%)	
Solution	A	 4.00	
4.00	
1.00	
0.02	
NaNO3	
KCl	
MgSO4		
FeSO4	x	7	H2O	
Solution	B	 2.00	 K2HPO4	
Starch	M	 2.00	
1.00	
5.00	
5.00	
starch	from	potato	
polypeptone	
solution	A	
solution	B	
Yeast	maltose	glucose	media	(YMG)	 0.40	
0.40	
1.00	
D(+)-glucose	monohydrate	
yeast	extract	
malt	extract	
YPAD	 1.00	
2.00	
2.00	
0.03	
yeast	extract	
tryptone	
D(+)-glucose	monohydrate	
adenine	
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7.1.2 Antibiotics	
Table	7.2	Concentrations	of	stock	solutions	and	working	concentrations	of	used	antibiotics.	
Antibiotic	 Stock	concentration	in	mg/mL	 Final	concentration	in	µg/mL	
Kanamycin	 50	in	ddH2O	 50	
Carbenicillin	 50	in	ddH2O	 50	
Chloramphenicol	 34	in	undenatured	ethanol	 34	
Hygromycin	B	 50	in	ddH2O	 50-150	
Geneticin	 50	in	ddH2O	 50-150	
	
7.1.3 Buffers	and	Solutions	
Table	7.3	Components	of	buffers	and	solutions	used	in	this	work	are	listed.	
Buffer	 Concentration	 Components	
gDNA	extraction	buffer	 10	mM	
10	mM	
0.5%	
Tris-HCl,	pH	8	
EDTA,	pH	8	
SDS	(w/v)	
50x	Tris-Acetate-EDTA	(TAE)	 2	M	
1	M	
50	mM	
Tris-HCl	
Acetic	acid	
EDTA	
6x	DNA	Loading	Dye	 0.1%	(w/v)	
0.1%	(w/v)	
30%	(v/v)	
bromophenol	blue	
xylene	cyanol	
glycerol	
Coomassie	Bleach	 25%	(v/v)	
10%	(v/v)	
acetic	acid	
isopropanol	
Coomassie	Dying	Solution	 25%	(v/v)	
10%	(v/v)	
0.1%	(w/v)	
acetic	acid	
isopropanol	
Coomassie	Brilliant	Blue	
Fungal	transformation	solution	I	 10	mM	
0.8	M	NaCl	
50	mM	
CaCl2	
NaCl	
Tris-HCl,	pH	7.5	
Fungal	transformation	solution	II	 50	mM	
0.8	M	
50	mM	
60%	
CaCl2	
NaCl	
Tris-HCl,	pH	7.5	
PEG3350	(w/v)	
Protein	Elution	Buffer	 50	mM	
150	mM	
50	-	500	mM	
10%	
Tris-HCl,	pH	8.0	
NaCl	
imidazole	
glycerol	
Protein	Resuspension	Buffer	 50	mM	
150	mM	
20	mM	
10%	
Tris-HCl,	pH	8.0	
NaCl	
imidazole	
glycerol	
Protein	Storage	Buffer	 50	mM	
150	mM	
10%	
Tris-HCl,	pH	8.0	
NaCl	
glycerol	
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Buffer	 Concentration	 Components	
4x	SDS	Loading	Buffer	 250	mM	
8%	(w/v)	
40%	(v/v)	
10%	(v/v)	
2.5	mg/L	
Tris-HCl,	pH	6.8	
sodium	dodecyl	sulfate	(SDS)	
glycerol	
b-mercaptoethanol	
bromophenol	blue	
10x	SDS	Running	Buffer	 25	mM	
192	mM	
1%	(w/v)	
Tris	
gylcerole	
SDS	
pH	8.4-8.9	
50x	TAE	 2	M	
50	mM	
Tris	acetate	
EDTA	
pH	8.3	
10xTE	 100	mM	
10	mM	
Tris-HCl,	pH	8	
EDTA	
A.	oryzae	NSAR1	protoplasting	solution	 10	mg/mL	
	
0.8	M	
lysing	enzyme	from	Trichoderma	harzianum	
(Sigma-Aldrich)	
NaCl	
A.	strictum	protoplasting	solution	 20	mg/mL	
	
10	mg/mL	
0.8	M	
10	mM		
lysing	enzyme	from	Trichoderma	harzianum	
(Sigma-Aldrich)	
driselase	from	Basidiomycetes	sp.	(Sigma-Aldrich)	
NaCl	
K2HPO4/KH2PO4,	pH	6	
	
7.2 Molecular	Biology	
Standard	restrictions	enzymes	and	size	standards	were	purchased	from	New	England	Biolabs	(NEB)	
unless	denoted	differently.	
7.2.1 Agarose	Gel	Electrophoresis	
Quality	 and	 quantity	 of	 DNA	 and	 RNA	 samples	 were	 analysed	 by	 horizontal	 agarose	 gel	
electrophoresis.	Depending	on	the	samples	the	agarose	concentration	was	adjusted	in	a	range	of	
0.8	–	2.0%	(w/v)	agarose	in	0.5x	TAE	buffer.	Agarose	and	buffer	were	molten	in	a	microwave,	gel	
stain	(1	µL/25	mL,	Roti-GelStain,	Roth)	was	added	and	poured	on	a	tray	with	comb	fixed	in	a	gel	
caster	system	(Bio-Rad).	For	the	analysis	of	RNA	samples,	all	buffers	were	prepared	freshly	with	
double	 distilled	 water.	 After	 solidifying	 of	 the	 agarose,	 combs	 were	 removed	 and	 the	 tray	
transferred	to	a	Sub-Cell	GT	agarose	gel	electrophoresis	system	(Bio-Rad).	6x	DNA	loading	dye	was	
added	to	samples	to	a	final	concentration	of	1x	prior	to	transferring	it	to	the	gel.	1	µL	of	1	kb	or	
100	bp	DNA	ladder	was	loaded	alongside	and	the	gel	was	run	for	30-90	min	at	100	V	using	1x	TAE	
as	running	buffer.	DNA	bands	were	analysed	under	UV	light	with	a	gel	documentation	system	(Gel	
Doc	XR+,	Bio-Rad)	and	the	software	Image	Lab	(Bio-Rad).	
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7.2.2 PCR	
For	DNA	amplification	two	types	of	polymerases	were	available.	The	proofreading	Q5	High	Fidelity	
2x	Master	Mix	was	used	when	sequence	identity	was	crucial,	for	other	applications	the	One	Taq	
Quick-Load	2x	Master	Mix	was	sufficient.	Reactions	were	carried	out	 in	volumes	of	10	–	100	µL	
according	to	the	manufacturer’s	protocol	and	diluted	with	double	distilled	millipore	water	(ddH2O).	
Depending	 on	 the	 sample	 gDNA,	 complementary	 DNA	 (cDNA)	 or	 plasmid	 DNA	 was	 used	 as	
template.	For	E.	coli	colony	screening	the	PCR	template	was	obtained	by	picking	a	single	colony	
with	a	toothpick	and	transferring	it	directly	to	a	10	µL	PCR	reaction.	Annealing	temperatures	were	
adjusted	to	the	oligonucleotides.	For	All	PCR	reactions	a	Bio-Rad	T100	thermal	cycler	was	used.	
Table	7.4	Pipetting	scheme	for	standard	PCR	reactions.		
Component	 50	µL	Reaction		 Final	concentration	
Q5	High	Fidelity	2x	Master	Mix	
10	µM	forward	primer	
10	µL	reverse	primer	
template	DNA	
ddH2O	
25	µL	
2.5	µL	
2.5	µL		
variable	
to	50	µL	
1x	
0.5	µM	
0.5	µM	
>	1000	ng	
One	Taq	Quick-Load	2x	Master	Mix	
10	µM	forward	primer	
10	µL	reverse	primer	
template	DNA	
ddH2O	
25	µL	
1	µL	
1	µL		
variable	
to	50	µL	
1x	
0.2	µM	
0.2	µM	
>	1000	ng	
	
Table	7.5	Standard	PCR	programs	for	the	two	different	polymerases	used.	
Program	 Step	 Temperature	 Time	
Q5	High-Fidelity	2x	Master	Mix	 Initial	Denaturation	
	
30	cycles	
	
Final	Extension	
Hold	
98	°C	
98	°C	
50	–	72	°C	
72	°C	
72	°C	
8	°C	
2	min	gDNA,	cDNA;	30	sec	vector	DNA	
5	–	10	sec	
10	–	30	
20	–	30	sec/kb	
2	min	
∞	
One	 Taq	 Quick-Load	
2x	Master	Mix	
Initial	Denaturation	
	
30	cycles	
	
Final	Extension	
Hold	
94	°C	
94	°C	
50	–	72	°C	
72	°C	
72	°C	
8	°C	
2	min	gDNA;	30	sec	vector	DNA;	10	min	colony	
PCR	
15	–	30	sec	
10	–	30	
20	–	30	sec/kb	
2	min	
∞	
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7.2.3 Oligonucleotides	
All	oligonucleotides	used	in	this	work	were	designed	using	the	software	geneious	and	purchased	at	
Sigma	Aldrich.	
Table	7.6	All	oligonucleotides	used	in	this	work	are	listed	with	their	corresponding	cox	group	ID.	
Cox	group	ID	 Sequence	5’-3’	
11	 TCCGTAGGTGAACCTGCGG	
12	 TCCTCCGCTTATTGATATGC	
22	 CTAGAAAGAAGGATTACCTC	
23	 CTGTCGAGAAGTTTCTGATCG	
37	 GCAAAGTACATCTGCGAGCG	
38	 CAAGAACCCCACCTCCTTCC	
81	 GCTCAGCAAGGTTGGGTTTG	
82	 CGTTGTGGATGATGTGCGTC	
83	 ATGGCAGCTCATGGGCAAAC	
84	 CACTAGAGGATCCCCATCATGCGTGTTCATGTAACGAACCCTG	
85	 CACATCTCCACTCGACCTGGCTCTGGCCAAGATTACCG	
86	 TCACAACAAGAACCCCACCTCC	
124	 CAGGGTTCGTTACATGAACACGCATGATGGGGATCCTCTAGTG	
125	 CGGTAATCTTGGCCAGAGCCAGGTCGAGTGGAGATGTG	
145	 CAGGAAACAGCTATGACC	
146	 TGTAAAACGACGGCCAGT	
147	 TGCTTGGAGGATAGCAACCG	
148	 GGGGATGACAGCAGTAACGA	
179	 GCCAACTTTGTACAAAAAAGCAGGCTCCGCGGAATTCATGGCAGCTCATGGGCAAAC	
180	 TGCCAACTTTGTACAAGAAAGCTGGGTCGGGAATTCCGTCAGGACATTGTTGGAG	
181	 GCCAACTTTGTACAAAAAAGCAGGCTCCGCGAATTCCTGTCGAGAAGTTTCTGATCG	
182	 TGCCAACTTTGTACAAGAAAGCTGGGTCGGGAATTCTCACAACAAGAACCCCACCTCC	
200	 CGTTCCTCGTTAAATCATCACA	
201	 CAATCTCTACCAGCCCACGA	
202	 CATTGATGAACACGCCCTTGC	
203	 GACGAGGATTCTGGTCGAGG	
204	 CCATGAAGGTCAAGATCATTGC	
205	 CTCGTCGTACTCCTGCTTGG	
206	 GTCCGTCTTCGACCACTGG	
207	 CGTAGTAGTTCTCGACACCAGG	
318	 GCCAACTTTGTACAAAAAAGCAGGCTCCGCATGGCAGCTCATGGGCAAAC	
319	 CATGTGTCCTCGCAGAAGTTG	
320	 CACAGAAGCAAGCACGATTC	
321	 TGCCAACTTTGTACAAGAAAGCTGGGTCGGTCACAACAAGAACCCCACCTC	
322	 CTGCTGGCTTAACACGTGC	
323	 GACTGGAGATAGCCGTGTGC	
406	 CCAGTTCTTCTCGGCGTTC	
419	 CCACTTCATCGCAGCTTGAC	
420	 AACATCGCCTCGCTCCAG	
421	 TTCTTTCAACACAAGATCCCAAAGTCAAAGATGGACAGCCCAGAAGTAT	
422	 CAGGTTGGCTGGTAGACGTCATATAATCATTTAAAGAGTATAGCCGCC	
423	 TTTCATTCTATGCGTTATGAACATGTTCCCTTAAAGAGTATAGCCGCC	
425	 CAGGTTGGCTGGTAGACGTCATATAATCATCTATGGTAGCACTACTGGC	
424	 ACAGCTACCCCGCTTGAGCAGACATCACCGATGGGCAGCCTCACTGAT	
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Cox	group	ID	 Sequence	5’-3’	
426	 TACGACAATGTCCATATCATCAATCATGACCTATGGTAGCACTACTGGC	
427	 CGACTGACCAATTCCGCAGCTCGTCAAAGGATGGCTCTCGCACAGCAA	
428	 CAGGTTGGCTGGTAGACGTCATATAATCATTCATTCTTTGTCCGAGCG	
434	 GCGGCCGCATACCTAGACGCATG	
435	 GGTACCAGGACTTTGAAGCAGCCCT	
436	 GCGGCCGCATCCAACATAAGAATAA	
437	 GGTACCTGTGGAGGTTTGCTACTGG	
555	 CCTTAAAGGGACGCTGGAGG	
556	 CCTCCAGTTCTTCTCGGCGTTCTGG	
557	 CTATCGCCCATCACCCTCAC	
558	 CGAGACTGAGGAATCCGCTC	
559	 GGGTTTAAUGCGTAAGCTCCCTAATTGGC	
560	 GGTCTTAAUGAGCCAAGAGCGGATTCCTC	
561	 AGTAAGCUCGTCACCGATCTGTGAGCGCCGGCGTTTTAGAGCTAGAAATAGCAAGTTAAA	
562	 AGCTTACUCGTTTCGTCCTCACGGACTCATCAGACCGATCGGTGATGTCTGCTCAAGCG	
563	 GTGAAGGAGATGGAGCCGTC	
564	 GTTGCTTGATCCACAGCGTC	
601	 AGCTTACUCGTTTCGTCCTCACGGACTCATCAGCGCCTACGGTGATGTCTGCTCAAGCG	
602	 AGTAAGCUCGTCCGCCTACCTTTTCCGCCTGAGTTTTAGAGCTAGAAATAGCAAGTTAAA	
603	 TTTCTTTCAACACAAGATCCCAAAGTCAAAATGGCTCTCGCACAGCAATT	
604	 GGTTGGCTGGTAGACGTCATATAATCATACTCATTCTTTGTCCGAGCGGC	
618	 GCTCGACGTATTTCAGTGTC	
619	 GCTCCGTAACACCCAATACG	
621	 GCCAACTTTGTACAAAAAAGCAGGCTCCGCATGCCGCAACTAAAGGTTCT	
622	 CACTAGAGGATCCCCATCATGATGAGGAGCTTGCTACCGG	
623	 CCGGTAGCAAGCTCCTCATCATGATGGGGATCCTCTAGTG	
624	 GGGTTGTCCCTGCGTGTCTCAGAAGAACTCGTCAAGAAGG	
625	 CCTTCTTGACGAGTTCTTCTGAGACACGCAGGGACAACCC	
626	 TGCCAACTTTGTACAAGAAAGCTGGGTCGGTCACTCCTTGAGAAGCTCTG	
627	 CTGGGTTGTCCCTGCGTGTCCTATTCCTTTGCCCTCGGAC	
628	 GTCCGAGGGCAAAGGAATAGGACACGCAGGGACAACCCAG	
629	 GCCAACTTTGTACAAAAAAGCAGGCTCCGCATCAAGCGATCGTTGTAATT	
630	 CACTAGAGGATCCCCATCATGGCCAAGGGGAGTGGCCATT	
631	 AATGGCCACTCCCCTTGGCCATGATGGGGATCCTCTAGTG	
632	 CTGCTCGCCGGTGATCTTTCAGAAGAACTCGTCAAGAAGG	
633	 CCTTCTTGACGAGTTCTTCTGAAAGATCACCGGCGAGCAG	
634	 TGCCAACTTTGTACAAGAAAGCTGGGTCGGTTGTGTGTAGACGGACGC	
635	 CACTGCTCGCCGGTGATCTTCTATTCCTTTGCCCTCGGAC	
636	 GTCCGAGGGCAAAGGAATAGAAGATCACCGGCGAGCAGTG	
637	 GCCAACTTTGTACAAAAAAGCAGGCTCCGCATGACTGTGAAGATCCTTGT	
638	 CACTAGAGGATCCCCATCATGTCCGCTTCATCCTCAGACTT	
639	 AAGTCTGAGGATGAAGCGGACATGATGGGGATCCTCTAGTG	
640	 TTCTTGAACAGCGTGCTGTCAGAAGAACTCGTCAAGAAGG	
641	 CCTTCTTGACGAGTTCTTCTGACAGCACGCTGTTCAAGAA	
642	 TGCCAACTTTGTACAAGAAAGCTGGGTCGGTCATGCCTCAAACTCCAGCT	
643	 AATTCTTGAACAGCGTGCTGCTATTCCTTTGCCCTCGGAC	
644	 GTCCGAGGGCAAAGGAATAGCAGCACGCTGTTCAAGAATT	
645	 TTTCTTTCAACACAAGATCCCAAAGTCAAAATGCCGCAACTAAAGGTTCT	
646	 GGTTGGCTGGTAGACGTCATATAATCATACTCACTCCTTGAGAAGCTCTG	
647	 TTTCTTTCAACACAAGATCCCAAAGTCAAAATGAGCGCCATTCAAAGACT	
648	 GGTTGGCTGGTAGACGTCATATAATCATACTTAGATCTGAGCAAGGCCAC	
649	 TTTCTTTCAACACAAGATCCCAAAGTCAAAATGACTGTGAAGATCCTTGT	
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Cox	group	ID	 Sequence	5’-3’	
650	 GGTTGGCTGGTAGACGTCATATAATCATACTCATGCCTCAAACTCCAGCT	
653	 ATGCCGCAACTAAAGGTTCT	
654	 TCACTCCTTGAGAAGCTCTG	
655	 ATCAAGCGATCGTTGTAATT	
656	 TTGTGTGTAGACGGACGC	
657	 ATGACTGTGAAGATCCTTGT	
658	 TCATGCCTCAAACTCCAGCT	
659	 AGAGGCTATTCGGCTATGAC	
660	 CCATGATATTCGGCAAGCAG	
684	 GCCAACTTTGTACAAAAAAGCAGGCTCCGCCAGGTCGAGTGGAGATGTGG	
685	 TAATCGCTCACCTCAACAGCATGATGGGGATCCTCTAGTG	
686	 CACTAGAGGATCCCCATCATGCTGTTGAGGTGAGCGATTA	
687	 CAGAGCTTCTCAAGGAGTGATGTGAAAGATCTAGACAAGA	
688	 TCTTGTCTAGATCTTTCACATCACTCCTTGAGAAGCTCTG	
689	 TGCCAACTTTGTACAAGAAAGCTGGGTCGGATGCCGCAACTAAAGGTTCT	
690	 GTGGCCTTGCTCAGATCTAATGTGAAAGATCTAGACAAGA	
691	 TCTTGTCTAGATCTTTCACATTAGATCTGAGCAAGGCCAC	
692	 TGCCAACTTTGTACAAGAAAGCTGGGTCGGATGAGCGCCATTCAAAGACT	
693	 AGCTGGAGTTTGAGGCATGATGTGAAAGATCTAGACAAGA	
694	 TCTTGTCTAGATCTTTCACATCATGCCTCAAACTCCAGCT	
695	 TGCCAACTTTGTACAAGAAAGCTGGGTCGGATGACTGTGAAGATCCTTGT	
706	 TTTCATTCTATGCGTTATGAACATGTTCCCTCACTCCTTGAGAAGCTCTG	
707	 ACAGCTACCCCGCTTGAGCAGACATCACCGATGAGCGCCATTCAAAGACT	
708	 TACGACAATGTCCATATCATCAATCATGACTTAGATCTGAGCAAGGCCAC	
709	 CGACTGACCAATTCCGCAGCTCGTCAAAGGATGACTGTGAAGATCCTTGT	
710	 TACGACAATGTCCATATCATCAATCATGACTCACTCCTTGAGAAGCTCTG	
711	 CGACTGACCAATTCCGCAGCTCGTCAAAGGATGAGCGCCATTCAAAGACT	
755	 TTCTTTCAACACAAGATCCCAAAGTCAAAATGGCTGCTCCATCACTCGAA	
756	 TTTCATTCTATGCGTTATGAACATGTTCCCTTTACAGTCCCTTTCTAACG	
756	 AACAGCTACCCCGCTTGAGCAGACATCACCATGCCTGCCTCACTCCCAGG	
758	 ACGACAATGTCCATATCATCAATCATGACCCTATCGCCAGTCAAAATTCG	
759	 GTCGACTGACCAATTCCGCAGCTCGTCAAAATGCCCGTTACTACCCCCAC	
760	 GGTTGGCTGGTAGACGTCATATAATCATACTTACCCAACAGCAGTTGTTA	
761	 GCCAACTTTGTACAAAAAAGCAGGCTCCGCATGCGTCGCAGTTTTCTTAT	
762	 TGCCAACTTTGTACAAGAAAGCTGGGTCGGCTAGAAGTGAAAGCCAGTCG	
763	 GCCAACTTTGTACAAAAAAGCAGGCTCCGCATGGGCGAGGCGTGCTCAAA	
764	 TGCCAACTTTGTACAAGAAAGCTGGGTCGGCTAGGCGATTTCCGCACGCT	
771	 GCCAACTTTGTACAAAAAAGCAGGCTCCGCATGGGCGAGGCGTGCTCAAAG	
772	 TGCCAACTTTGTACAAGAAAGCTGGGTCGGCTAGGCGATTTCCGCACGCTGC	
787	 TACGACAATGTCCATATCATCAATCATGACTTACAGTCCCTTTCTAACGC	
788	 CGACTGACCAATTCCGCAGCTCGTCAAAGGATGCCTGCCTCACTCCCAGG	
789	 CAGGTTGGCTGGTAGACGTCATATAATCATACCTATCGCCAGTCAAAATT	
790	 CGACTGACCAATTCCGCAGCTCGTCAAAGGATGCCCGTTACTACCCCCAC	
791	 TTTCTTTCAACACAAGATCCCAAAGTCAAAATGCCTGCCTCACTCCCAGG	
792	 TACGACAATGTCCATATCATCAATCATGACCTATCGCCAGTCAAAATTCG	
793	 TTTCTTTCAACACAAGATCCCAAAGTCAAAATGGGCGAGGCGTGCTCAAA	
794	 GGTTGGCTGGTAGACGTCATATAATCATACTAGGCGATTTCCGCACGCTG	
795	 GCCAACTTTGTACAAAAAAGCAGGCTCCGCATGCCTGCCTCACTCCCAGG	
796	 TGCCAACTTTGTACAAGAAAGCTGGGTCGGCCTATCGCCAGTCAAAATTC	
799	 ATGGGCGAGGCGTGCTCAAAG	
800	 CTAGGCGATTTCCGCACGCTGC	
816	 GAGGTCAGGGACTCGGGCATCGTCATTGGATGTGGTAACG	
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Cox	group	ID	 Sequence	5’-3’	
817	 CGTTACCACATCCAATGACGATGCCCGAGTCCCTGACCTC	
824	 GGTTGGCTGGTAGACGTCATATAATCATACTTACAGTCCCTTTCTAACGC	
825	 TTTCTTTCAACACAAGATCCCAAAGTCAAAATGCCCGTTACTACCCCCAC	
826	 GCTTAGATTGTTTGTTAGAAGC	
	
Table	7.7	Overview	of	used	oligonucleotides	used	for	PCR	amplification	of	DNA	fragments	to	build	KO	cassettes	for	asL4,	
asL5	and	asL6.	For	oligonucleotides	binding	sites	a-f	Figure	4.2.	
Construct	ID	 GOI	 Selection	marker	and	oligonucleotides	for	amplification	
of	KO	fragments	
Oligonucleotides	for	construction	
in	S.	cerevisiae	
RSI77	1	 asL4	 genR	
Pg+h:P653+660	
Pi+j:	P659+654	
Pa+b:	P621+622	
Pc+d:	P623+624	
Pe+f:	P625+626	
RSI77	2	 asL4	 hygR	
Pg+h:	P653+22	
Pi+j:	P23+654	
Pa+b:	P621+622	
Pc+d:	P623+627	
Pe+f:	P928+626	
RSI77	3	 asL5	 genR	
Pg+h:	P655+660	
Pi+j:	P659+656	
Pa+b:	P629+630	
Pc+d:	P631+632	
Pe+f:	P633+634	
RSI77	4	 asL5	
	
hygR	
Pg+h:	P655+22	
Pi+j:	P23+656	
Pa+b:	P629+630	
Pc+d:	P631+635	
Pe+f:	P636+634	
RSI77	5	 asL6	 genR	
Pg+h:	P657+660	
Pi+j:	P659+658	
Pa+b:	P637+638	
Pc+d:	P639+640	
Pe+f:	P641+642	
RSI77	6	 asL6	 hygR	
Pg+h:	P657+22	
Pi+j:	P23+658	
Pa+b:	P637+638	
Pc+d:	P639+643	
Pe+f:	P644+642	
	
Table	7.8	Overview	of	used	oligonucleotides	used	for	PCR	amplification	of	DNA	fragments	to	build	silencing	cassettes	for	
asL4,	asL5	and	asL6.	For	oligonucleotides	binding	sites	a-f	see	Figure	4.15.	
Construct	ID	 GOI	 Resistance	cassette	 Oligonucleotides	for	construction	in	S.	cerevisiae	
RSI95	1	
RSI95	2	
asL4	 genR	
hygR	
Pa+b:	P684+685	
Pc+d:	P686+687	
Pe+f:	P688+689	
RSI95	2	
RSI95	4	
asL5	 genR	
hygR	
	
Pa+b:	P684+985	
Pc+d:	P868+690	
Pe+f:	P691+692	
RSI95	5	
RSI95	6	
asL6	 genR	
hygR	
	
Pa+b:	P684+985	
Pc+d:	P686+693	
Pe+f:	P694+695	
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Table	7.9	Overview	of	used	oligonucleotides	used	for	PCR	amplification	of	DNA	fragments	to	build	fungal	expression	and	
LR	entry	clones.	
Construct	ID	 Vector	backbone	 Template	 Oligonucleotides	for	construction	in	S.	cerevisiae	
RSI63	1-12	
RSI63	2-5	
RSI63	4-2	
RSI96	1-6	
RSI96	2-9	
RSI42A1LR4C	(pTYGSarg)	
RSI42A1LR4C	(pTYGSarg)	
RSI42A1LR4C	(pTYGSarg)	
RSI42A1LR4C	(pTYGSarg)	
RSI42A1LR4C	(pTYGSarg)	
RSI67-4	
RSI67-4,	RSI67-2	
RSI67-1	
RSI67-4,	RSI67-2,	RSI67-1	
gDNA	
asL1:	P421+422	
asL1:	P421+423	asL3:	P425+425	
asR2:	P603+604	
asL1:	P421+423	asL3:	P424+426	asR2:	P427+428	
asL4:	P645+706	asL5:	P707+708	asL6:	P709+650	
RSI63	5-1	
RSI63	6-4	
RSI96	4-2	
RSI96	5-9	
RSI100	1-9	
RSI97	1-1	
RSI97	2-2	
RSI97	3-1	
RSI112	1-1	1	
RSI112	1-2	1	
RSI112	1-3	1	
pTYGSmet	
pTYGSmet	
pTYGSmet	
pTYGSmet	
pTYGSmet	
pTYGSmet	
pTYGSmet	
pTYGSmet	
pTYGSmet	
pTYGSmet	
pTYGSmet	
RSI67-4	
RSI67-4,	RSI67-2	
RSI67-4,	RSI67-2,	RSI67-1	
gDNA	
gDNA	
gDNA	
gDNA	
gDNA	
gDNA	
gDNA	
gDNA	
asL1:	P421+422	
asL1:	P421+423	asL3:	P425+425	
asL1:	P421+423	asL3:	P424+426	asR2:	P427+428	
asL4:	P645+706	asL5:	P707+708	asL6:	P709+650	
asL2:	P755+756	asR4:	P757+758	asR6:	P759+760	
asL4:	P645+710	asL6:	P709+650	
asL4:	P645+710	asL5:	P648+711	
asL5:	P647+708	asL6:	P709+650	
asL2:	P755+824	
asR4:	P791+789	
asR6:	P825+760	
RSI76	1-5	
RSI76	2-3	
RSI76	3-3	
RSI100	2-16	
RSI102	1-10	
RSI102	2-5	
RSI102	3-5	
RSI112	2-1	1	
RSI112	2-2	1	
RSI112	2-3	1	
pTYGSade	
pTYGSade	
pTYGSade	
pTYGSade	
pTYGSade	
pTYGSade	
pTYGSade	
pTYGSade	
pTYGSade	
pTYGSade	
gDNA	
gDNA	
gDNA	
gDNA	
gDNA	
gDNA	
gDNA	
gDNA	
gDNA	
gDNA	
asL4:	P645+646	
asL5:	P647+648	
asL6:	P649+650	
asL2:	P755+756	asR4:	P757+758	asR6:	P759+760	
asL2:	P755+P787	asR4:	P788+789	
asL2:	P755+787	asR6:	P790+760	
asR4:	P791+792	asR6:	P790+760	
asL2:	P755+824	
asR4:	P791+789	
asR6:	P825+760	
RSI42A1LR4C	
RSI100	9-1	
RSI108	1-1	
RSI108	2-1	
RSI108	3-1	
RSI100	6-1	
pTYGSarg	
RSI96	5-9	(pTYGSmet)	
RSI96	4-2	(pTYGSmet)	
RSI96	5-9	(pTYGSmet)	
RSI63	4-2	(pTYGSmet)	
RSI100	2-16	(pTYGSade)	
-	
-	
-	
-	
-	
-	
LR	with	RSI42A1	
LR	with	RSI100	4-1	
LR	with	RSI100	3-1	
LR	with	RSI100	3-1	
LR	with	RSI100	3-1	
LR	with	RSI100	3-1	
RSI42A1	
RSI100	3-1	
RSI100	4-1	
RSI100	8-1	
pE-YA	
pE-YA	
pE-YA	
pE-YA	
gDNA	
gDNA	
RSI100	7-9	
gDNA	
aspks1:	P318+319,	P320+321	
asR5:	P761+762	
asR7:	P771+P772	
asR4:	P795+816,	P817+796	
RSI67	1	
RSI67	2	
RSI67	4	
RSI100	7-9	
pCR2.1	
pCR2.1	
pCR2.1	
pCR2.1	
cDNA	
cDNA	
cDNA	
gDNA	
gDNA	
asR2:	P427+428	
asL3:	P424+425	
asL1:	P421+423	
asR7:	P799+800	
	
7.2.4 Extraction,	Purification,	Concentration	and	Sequencing	of	DNA	
For	downstream	processes	PCR	amplified	DNA	and	vector	DNA	were	purified	by	kit	according	to	
the	 manufacturer’s	 protocol.	 For	 linear	 DNA	 the	 NucleoSpin	 Gel	 and	 PCR	 Clean-up	 kit	
(Macherey-Nagel)	was	used.	Vector	DNA	was	extracted	from	a	3-5	mL	E.	coli	overnight	culture	using	
the	NucleoSpin	Plasmid	kit	(Macherey-Nagel).	The	LB	overnight	culture	containing	the	appropriate	
antibiotic	was	 inoculated	 from	either	a	 fresh	plate	or	a	25%	glycerol	 stock	and	grown	at	37	 °C,	
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180	rpm	for	12-16	hours.	The	quality	of	purified	DNA	samples	was	determined	on	agarose	gels	and	
the	 concentration	 measured	 on	 a	 spectrophotometer	 (DeNovix	 DS-11+	 Spectrophotometer).	
Sequencing	 of	 DNA	 samples	 was	 carried	 out	 through	 Eurofins	 Genomics	 with	 custom	
oligonucleotides.	
7.2.5 Restriction	Hydrolysis	and	Cloning	
Standard	restriction	hydrolysis	and	 ligation	with	T4	DNA	Ligase	was	performed	according	to	the	
manufacturer’s	protocol.	
7.2.5.1 TOPO-TA	cloning	
The	Invitrogen	TOPO-TA	cloning	kit	was	used	according	to	the	provided	protocol	to	directly	ligate	
Taq	amplified	linear	DNA	fragments.	To	ligate	Q5	amplified	DNA	it	was	first	kit	purified	and	then	
incubated	10	min	at	68	°C	with	Taq	polymerase	to	introduce	A-overhangs.	
Table	7.10	Pipetting	scheme	to	introduce	A-overhangs	on	Q5	purified	amplified	PCR	products.	
Component	 10	µL	reaction	 Final	concentration	
Taq	DNA	Polymerase	
10x	Standard	Taq	reaction	buffer	
2.5	mM	dATP	
DNA	fragment	
0.2	µL	
1	µL	
0.5	µL	
to	10	µL	
	
1x	
125	µM	
7.2.5.2 Gateway	Cloning	
The	Invitrogen	Gateway	LR	Clonase	II	enzyme	mix	was	used	for	in	vitro	recombination	from	pE-YA	
entry	clones	 into	pTYGS	family	destinations	vectors.	The	manufacturer’s	protocol	was	optimised	
and	a	reduced	reaction	scale	was	used.	
Table	7.11	Pipetting	scheme	of	the	optimised	recombination	reaction.		
Component	 5	µL	reaction	 Concentration	
Entry	clone	
Destination	vector	
TE	buffer,	pH	8.0	
Gateway	LR	Clonase	II	
	
2	µg/µL	Proteinase	K	
0.5-3.5	µL	
0.5	µL	
to	4	µL	
1	µL	
incubation	at	25	°C	for	1-12	h	
0.5	µL	
50-150	ng	
150	ng	
1x	
0.2	µg/µL	
	
7.2.5.3 USER	Cloning	
DNA	for	USER	cloning	was	amplified	with	Phusion	U	polymerase	(Thermo	Scientific),	which	is	not	
inhibited	by	dU	containing	 templates.	The	procedure	was	carried	out	according	to	 the	provided	
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protocol.	PCR	amplified	DNA	was	gel	purified	to	remove	template	DNA.	Vector	DNA	was	hydrolysed	
with	PacI	and	Nt.BbvCI.	Restriction	hydrolases	were	heat	 inactivated.	USER	cloning	kit	was	used	
according	to	the	provided	protocol	and	2-12	µL	reaction	mixture	were	used	to	transform	competent	
E.	coli.	
Table	7.12	Pipetting	scheme	for	USER	cloning.	
Component	 12	µL	reaction	 Final	concentration	
Purified	PCR	product	
linearized	vector	
USER	enzyme	
	
10	µL	
1	µL	
01	µL	
to	12	µL	
	
20	ng	
1	U	
	
7.2.6 Extraction	of	fungal	gDNA	and	RNA	and	Reverse	Transcription	into	cDNA	
gDNA	
For	small-scale	gDNA	isolation	the	GenElute	Plant	Genomic	DNA	Miniprep	kit	(Sigma-Aldrich)	was	
used.	Fungal	material	was	obtained	from	liquid	culture	or	agar	plates	and	was	either	directly	used	
or	stored	at	-20	°C	prior	to	gDNA	extraction.	When	needed	as	PCR	template	only,	grinding	in	liquid	
nitrogen	was	omitted	and	for	elution	1x	100	µL	TE	buffer	(pH	8.0)	was	sufficient.	
For	large-scale	gDNA	isolation	300	mg	of	freeze	dried	fungal	material	(obtained	from	a	3	d	old	PDB	
culture	of	A.	strictum)	was	grinded	with	mortar	and	pistil	in	liquid	nitrogen.	20	mL	gDNA	extraction	
buffer	was	added	to	the	disrupted	cells	 in	a	50	mL	tube	and	mixed	gently	on	a	vertical	carousel	
(25	rpm,	15	min).	20	mL	phenol:chloroform:isoamyl	alcohol	(PCI)	was	added	and	mixed	gently	on	a	
vertical	 carousel	 (25	 rpm,	 15	 min).	 Aqueous	 phase	 was	 recovered	 by	 centrifugation	 (10	 min,	
maximal	speed)	and	extraction	with	20	mL	PCI	was	repeated	(6-7	times)	until	interphase	was	clear.	
10	mL	chloroform:isoamyl	alcohol	(24:1)	was	added	to	the	aqueous	phase	and	mixed	on	a	vertical	
carousel	(15	min,	25	rpm).	Centrifugation	(10	min,	maximal	speed)	recovered	the	aqueous	phase,	
which	was	subsequently	added	to	0.7-1	volumes	of	isopropanol	(100%).	The	mixture	was	inverted	
carefully	 until	 gDNA	 precipitation	 was	 observed.	 gDNA	 was	 pelleted	 by	 centrifugation	 (5	 min,	
4000	rpm),	washed	with	75%	ethanol	and	left	to	dry	until	the	pellet	was	clear.	500	μL	TE	pH	8.0	was	
used	to	suspend	the	pellet	over	night	at	4	°C.	For	caesium	chloride	gradient	centrifugation	3.2	g	
caesium	chloride	was	balanced	in	a	15	mL	tube	and	tared.	160	μL	ethidiumbromide	(10	mg/mL),	
500	μL	gDNA	in	TE	and	TE	buffer	was	added	to	3.2	g.	The	solution	was	carefully	transferred	to	a	
Beckman	Coulter	Polyallomer	tube	(326819)	with	a	Pasteur	pipette.	Centrifugation	was	carried	out	
at	45000	rpm	for	24	h	using	a	Beckman	SW	55	Ti	 rotor	and	UZ	Maxima	XP-80	Beckman	Coulter	
ultracentrifuge.	gDNA	band	was	detected	under	UV	light.	Fractions	(400	μL)	were	collected	by	hand.	
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A	5	μL	sample	of	each	fraction	was	analysed	on	a	0.8%	agarose	gel	(130	V,	30	min).	gDNA	containing	
fractions	were	combined,	diluted	in	2.5	volumes	of	water	and	gDNA	precipitated	with	0.7-1	volume	
of	isopropanol.	After	incubation	on	ice	for	5	min,	the	gDNA	was	pelleted	by	centrifugation	(10	min,	
maximal	speed).	Pelleted	DNA	was	dried	and	suspended	in	100	μL	ddH2O.	Sodium	acetate	(3	M)	
was	 added	 to	 a	 final	 concentration	 of	 0.3	 M	 and	 2.5	 volumes	 of	 96%	 ethanol	 were	 used	 to	
precipitate	gDNA.	After	incubation	on	ice	for	10	min,	gDNA	was	pelleted	by	centrifugation	(10	min,	
maximum	speed).	gDNA	was	washed	with	75%	ethanol	and	centrifuged	(10	min,	maximum	speed)	
again.	 Pellet	was	 left	 to	 dry	 before	 resuspension	 in	 50	μL	 ddH2O	overnight.	 For	whole	 genome	
sequencing	a	concentration	of	100	ng/μL	in	a	total	volume	of	100	μL	ddH2O	or	100	mM	Tris-HCl	
pH	8.0	is	required.	Concentration	was	determined	on	a	spectrophotometer	prior	to	dilution	to	the	
required	concentration.	
RNA	and	cDNA	
The	ZR	Fungal	Bacterial	RNA	MiniPrep	kit	(Zymo	Research)	was	used	to	isolate	total	RNA	according	
to	the	provided	protocol.	RNase	free	tubes	and	plugged	pipet	tips	were	used	to	avoid	degradation	
of	RNA.	cDNA	was	prepared	from	total	RNA	using	oligo(dT)	nucleotides	and	the	RevertAid	Premium	
Transcriptase	kit	(Thermo	Scientific)	according	to	protocol.	
Yeast	Vector	DNA	extraction	
Yeast	vector	DNA	was	extracted	with	 the	Yeast	Plasmid	Miniprep	 II	 kit	 (Zymoprep).	Cells	of	 the	
quarter	of	a	plate	 (Chapter	7.4.2)	were	collected	with	a	 toothpick	and	directly	 suspended	 in	kit	
solution	I.	DNA	was	purified	according	to	protocol	and	eluted	in	10	µL	sterile	ddH2O.	2-5	µL	DNA	
were	directly	used	for	transformation	of	competent	E.	coli	cells.	
7.3 Biochemistry	
Clones	for	E.	coli	codon	optimised	asR5	and	asR6	were	purchased	with	an	N-terminal	6xhis	tag	in	
pET100	at	Invitrogen	(Darmstadt,	Germany).	AsR5	was	first	solubly	produced	by	Raissa	Schor,	but	
later	 purification	 optimised	 by	 Carsten	 Schotte.	 AsR6	 was	 solublly	 produced	 and	 optimised	 by	
Carsten	 Schotte.	 Both	 vectors	 were	 used	 to	 transform	 E.	 coli	 BL21	 (DE3),	 which	 was	 used	 as	
heterologous	gene	expression	host	for	protein	production.	
7.3.1 Protein	Expression	and	Cell	Lysis	
An	E.	coli	BL21(DE3)	overnight	LB	culture	was	used	 to	 inoculate	100-1000	mL	2TY	medium.	The	
culture	 was	 incubated	 at	 37	 °C	 and	 200	 rpm	 until	 an	 OD600	 of	 0.4-0.8	 was	 reached.	 The	 gene	
expression	 and	 protein	 production	 was	 induced	 with	 0.1	 mM	 isopropyl	 b-D-1-
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thiogalactopyranoside	 (IPTG)	 for	16	h	at	16,	20	or	25	 °C.	 The	cells	were	used	directly	or	 stored	
at	-20	°C	for	later	protein	purification.	All	following	steps	were	carried	out	on	ice	or	at	4	°C.	
The	pellet	was	suspended	in	10-50	mL	pre	cooled	protein	resuspension	buffer	and	cells	lysed	by	
sonication	(pulse	program	7x	30	s,	7x	30	s	cool	down).	Cell	debris	were	removed	by	centrifugation	
(8500	rpm,	45	min,	4	°C)	and	supernatant	used	for	affinity	purification.	
7.3.2 Affinity	Purification	by	Gravity	Column	
Up	to	1	mL	Ni-NTA	Agarose	(Macherey-Nagel,	Düren)	was	equilibrated	with	protein	resuspension	
buffer	(2	x	1	mL,	2000	g,	2	min,	4	°C)	prior	to	incubation	with	supernatant	obtained	in	Chapter	7.3.1.	
After	up	to	1.5	h	at	4	°C	on	an	agitator	the	Ni-NTA	agarose	was	collected	by	gravity,	washed	with	
protein	 resuspension	 buffer	 (10	 mL)	 and	 protein	 eluted	 with	 an	 imidazole	 gradient	 in	 protein	
elution	 buffer	 (50-500	 mM	 imidazole).	 Three	 fractions	 each	 500	 µL	 were	 taken	 per	 imidazole	
concentration.	Carsten	Schotte	optimised	protein	production	and	purification	for	fast	protein	liquid	
chromatography	(FPLC).	
7.3.3 Polyacrylamide	Gel	Electrophoresis	
Protein	samples	were	analysed	by	vertical	SDS	polyacrylamide	gel	electrophoresis	(SDS-PAGE).	Gels	
were	casted	with	the	Mini-PROTEAN	Tetra	Handcast	system	and	run	in	Mini-PROTEAN	Tetra	vertical	
electrophoresis	 cell	 (Bio-Rad).	First	 the	separating	gel	was	casted	and	overlaid	with	 isopropanol	
until	 solidification.	 In	 a	 next	 step	 isopropanol	 was	 removed,	 stacking	 gel	 was	 casted	 and	
polymerised.	
15	µL	protein	sample	and	5	µL	4x	SDS	loading	buffer	were	denatured	at	95	°C	for	5	min.	Up	to	20	µL	
were	loaded	on	a	12%	polyacrylamide	gel	alongside	with	5	µL	prestained	standard	(Broad	Range,	
NEB)	and	separated	for	50-90	min	at	20-40	mA.	Gels	were	stained	in	coomassie	dying	solution	(1	h,	
agitator)	 and	 destained	 with	 coomassie	 bleach	 (1	 h,	 agitator).	 Gels	 were	 scanned	 with	 gel	
documentation	system	(Gel	Doc	XR+,	Bio-Rad)	and	the	software	Image	Lab	(Bio-Rad).	
Table	7.13	Components	of	a	12%	polyacrylamide	gel.	
Component	 12%	separating	gel	 5%	stacking	gel	
30%	acrylamide/bisacryamide	(37,5:1)	
1.5	M	Tris-HCl,	pH	8.8	
0.5	M	Tris-HCl,	pH	6.8	
10%	(w/v)	SDS	
10%	(w/v)	APS	
TEMED	
ddH2O	
3.00	mL	
1.90	mL	
-	
75.0	µL	
75.0	µL	
3.00	µL	
2.45	mL	
535	µL	
-	
250	µL	
20.0	µL	
20.0	µL	
2.00	µL	
1.70	mL	
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7.4 Microbiology	
Table	7.14	Strains	and	origin.	
Strain	 Genotype	 Phylum	 Origin	
Acremonium	strictum	 wildtype	 Ascomycete	 Cox	group,	
Bristol	
Aspergillus	oryzae	NSAR1		 DargB	sC-	adeA	niaD-	 Ascomycete	 Lazarus	group	
Bristol	
Saccharomyces	cerevisiae	CEN.PK	 MATa/α	ura3-52/ura3-52	trp1-289/trp1-289	
leu2-3_112/leu2-3_112	his3	Δ1/his3	Δ1	
MAL2-8C/MAL2-8C	SUC2/SUC2	
Ascomycetes	 Lazarus	group	
Bristol	
Escherichia	coli	OneShot	TOP10	 F-mcrA	 Δ(mrr-hsdRMS-mcrBC)	 Φ80lacZΔM15	
Δ	 lacX74	recA1	araD139	Δ(	araleu)7697	galU	
galK	rpsL	(StrR)	endA1	nupG	
Proteobacteria	 Thermo	Fisher	
Scientific	
Escherichia	coli	OneShot	ccdB	
survival	2T1R	
F-mcrA	 Δ(mrr-hsdRMS-mcrBC)	 Φ80lacZΔM15	
ΔlacX74	 recA1	 araΔ139	 Δ(ara-leu)7697	 galU	
galK	rpsL	(StrR)	endA1	nupG	fhuA::IS2	
Proteobacteria	 Thermo	Fisher	
Scientific	
Escherichia	coli	BL21	(DE3)	 F–	ompT	hsdSB	(rB–,	mB–)	gal	dcm	(DE3)	 Proteobacteria	 Thermo	Fisher	
Scientific	
	
7.4.1 E.	coli	
Maintenance	
For	short	term	cultivation	of	E.	coli,	 it	was	streaked	for	single	colonies	on	LB	agar	containing	the	
appropriate	antibiotic	with	a	Drigalski	spatula	and	incubated	at	37	°C	for	12	h.	Plates	were	stored	
for	up	to	1	month	at	4	°C.	3-5	mL	LB	overnight	cultures	were	inoculated	from	plates	or	from	25%	
glycerol	stocks.	Stocks	were	prepared	from	500	µL	overnight	culture	and	500	µL	50%	glycerol	and	
stored	at	-80	°C.	
Transformation	
To	50	µL	of	competent	E.	coli	1-3	µL	vector	DNA	was	added	and	incubated	on	ice	for	up	to	30	min.	
After	a	45	sec	heat	shock	at	42	°C,	the	cells	were	placed	on	ice	for	2	min	and	300	µL	of	SOC	medium	
was	added.	Cells	were	 incubated	at	37	°C,	350	rpm	for	1	h	and	then	collected	by	centrifugation	
(4000	g,	3	min).	300	µL	SOC	was	discarded	and	the	cells	suspended	in	the	remaining	supernatant	
prior	to	plating	out	on	LB	agar	containing	the	appropriate	antibiotic	for	12	h	at	37	°C.	
7.4.2 S.	cerevisiae	
Maintenance	
For	short-term	cultivation	of	S.	cerevisiae,	it	was	streaked	on	YPAD	and	incubated	at	28	°C	for	up	to	
one	week	or	at	4	°C	for	up	to	1	month.	For	stock	preparation	1	mL	of	a	ddH2O	was	used	to	suspend	
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a	single	colony	from	a	YPAD	plate.	Cells	were	collected	with	a	pipette	and	50%	glycerol	was	added	
to	a	final	concentration	of	25%	glycerol.	Stocks	were	stored	at	-80	°C.		
Transformation	
A	young	(3-5d)	single	colony	of	S.	cerevisiae	was	used	to	inoculate	a	10	mL	YPAD	pre-culture	and	
incubated	at	28	°C,	200	rpm.	After	18	h	40	mL	of	YPAD	media	was	added	and	incubated	for	4	h	at	
28	°C,	200	rpm.	Cells	were	collected	by	centrifugation	(3000	g,	5	min),	washed	with	5	mL	ddH2O	
and	centrifuged	(3000	g,	5	min).	Supernatant	was	discarded;	cells	suspended	in	1	mL	ddH2O	and	
transferred	to	a	1.5	mL	microfuge	tube.	The	mixture	was	centrifuged	(14500	rpm,	15	s)	and	cells	
were	 suspended	 in	 400	 µL	 0.1	 M	 lithium	 acetate.	 50	 µL	 aliquots	 were	 prepared,	 centrifuged	
(14500	rpm,	15	s)	and	the	supernatant	discarded.	240	µL	of	a	50%	PEG3350	solution,	36	µL	1	M	
lithium	acetate,	50	µL	carrier	DNA	(denatured	salmon	sperm	DNA,	2	mg/mL	in	TE	buffer)	and	up	to	
34	µL	DNA	were	added	to	the	cell	pellet	 regarding	the	order.	Concentration	of	each	 linear	DNA	
fragment	was	approximately	0.5-1	µg.	 Fragments	 to	be	 joined	contained	at	 least	30	bp	overlap	
sequence	and	were	added	in	a	1:1:1	ratio.	Cells	were	suspended	in	the	transformation	mixture	and	
incubated	 at	 42°C	 for	 50	 min.	 Cells	 were	 collected	 by	 centrifugation	 (6000	 rpm,	 15	 s),	 the	
supernatant	 was	 discarded	 and	 pellet	 was	 suspended	 in	 1	 mL	 ddH2O.	 200	 µL	 were	 spread	 on	
SM-URA	plates	and	 incubated	at	28	 °C	 for	3-4	d.	As	negative	control	ddH2O,	as	positive	control	
circular	plasmid	and	as	background	control	linearized	plasmid	was	used.		
7.4.3 A.	oryzae	
Maintenance	
For	short-term	cultivation	of	A.	oryzae	NSAR1	it	was	streaked	on	DPY	and	incubated	at	28	°C	for	up	
to	one	month	or	at	4	°C	for	up	to	3	months.	For	stock	preparation	10	mL	of	a	ddH2O	was	added	to	
a	sporulating	DPY	plate.	Mycelia	and	spores	were	scraped	of	using	an	inoculation	loop	and	mixed	
vigorously.	 50%	 glycerol	 was	 added	 to	 a	 final	 concentration	 of	 25%	 glycerol	 to	 prepare	 a	
mycelia/spore	mixed	stock.	When	spore	stocks	were	prepared	mixture	was	gravity	 filtered	over	
sterile	miracloth	and	glycerol	to	a	final	concentration	of	25%	added.	Stocks	were	stored	at	-80	°C.		
Transformation	
1	mL	 spore	 suspension	 from	a	 fresh	A.	 oryzae	 NSAR1	DPY	 plate	was	 used	 to	 inoculate	 100	mL	
(500	mL	flask)	of	GN	liquid	culture	and	incubated	for	12	h	at	28	°C,	180	rpm.	Cells	were	collected	by	
filtration	 over	 sterile	miracloth,	washed	with	 0.8	M	NaCl	 (50-100	mL)	 and	 suspended	 in	 10	mL	
filter-sterilised	A.	oryzae	NSAR1	protoplasting	solution	by	inversion.	Suspension	was	incubated	at	
30	°C	and	150	rpm	for	2	h.	Protoplast	formation	was	checked	every	hour	for	completion	using	a	
microscope.	When	majority	of	mycelia	had	been	digested	 into	spherical	protoplasts,	these	were	
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released	 by	 repeated	 pipetting	 with	 a	 cut	 tip	 and	 gravity	 filtration	 through	 sterile	 miracloth	
removed	 remaining	 mycelia.	 Protoplasts	 were	 collected	 by	 centrifugation	 (2000	 g,	 5	 min)	 and	
directly	suspended	in	the	required	amount	of	fungal	transformation	solution	I.	
DNA	(≥	1μg,	in	10	μL	ddH2O)	was	mixed	with	100	μL	protoplasts	and	incubated	on	ice	for	5	min.	
1	mL	of	fungal	transformation	solution	II	was	added	drop	wise	and	the	mixture	incubated	at	25	°C	
for	20	min.	14	mL	molten	CZD+S	0.8%	agar	(~37	°C)	was	added	and	the	mixture	poured	over	two	
plates	containing	CZD+S	1.5%	agar.	Plates	were	incubated	at	28	°C	until	colonies	could	be	observed	
(usually	 6	d),	 these	were	 transferred	 to	 secondary	plates	of	CZD	1.5%	agar.	Vigorously	 growing	
colonies	 were	 transferred	 onto	 third	 plate	 (CZD	 1.5%	 agar).	 Real	 transformants	 were	 used	 to	
inoculate	liquid	cultures	and	to	prepare	25%	glycerol	stocks.	The	supplements	in	all	CDZ	media	were	
adapted	for	each	transformation	in	regard	of	the	added	DNA.	
7.4.4 A.	strictum	
Maintenance	
For	short-term	cultivation	of	A.	strictum	single	colonies	were	streaked	on	ASSA	and	incubated	at	
25	 °C	 for	 up	 to	 one	 month	 or	 at	 4	 °C	 for	 up	 to	 3	 months.	 For	 stock	 preparation	 10	 mL	 of	 a	
0.01%	Tween	80	solution	was	added	to	a	sporulating	ASSA	plate.	Mycelia	and	spores	were	scraped	
of	using	an	inoculation	loop	and	mixed	vigorously.	50%	glycerol	was	added	to	a	final	concentration	
of	25%	glycerol	 to	prepare	a	mycelia/spore	mixed	stock.	When	spore	stocks	were	prepared	the	
mixture	was	 gravity	 filtered	 over	 sterile	miracloth	 and	 glycerol	 to	 a	 final	 concentration	 of	 25%	
added.	Stocks	were	stored	at	-80	°C.	
Transformation	
100	μL	spore	suspension	was	used	to	inoculate	100	mL	(500	mL	flask)	of	ASSM	liquid	culture	and	
incubated	 for	 1.5	 d	 at	 25	 °C,	 200	 rpm.	 Cells	were	 collected	 by	 filtration	 over	 sterile	miracloth,	
washed	 with	 0.8	 M	 NaCl	 (50-100	 mL)	 and	 suspended	 in	 10	 mL	 filter-sterilised	 A.	 strictum	
protoplasting	solution	by	inversion.	Suspension	was	incubated	at	30	°C	and	150	rpm	up	to	1.5	h.	
Protoplast	formation	was	checked	every	hour	for	completion	using	a	microscope.	When	majority	
of	mycelia	had	been	digested	into	spherical	protoplasts,	these	were	released	by	repeated	pipetting	
with	 a	 cut	 tip	 and	 gravity	 filtration	 through	 sterile	 miracloth	 removed	 remaining	 mycelia.	
Protoplasts	were	collected	by	centrifugation	(2000	g,	5	min)	and	washed	twice	with	20	mL	0.8	M	
NaCl	(2000	g,	5	min).	10	mL	fungal	transformation	solution	I	was	used	to	suspend	protoplasts	and	
the	concentration	was	determined	by	microscopic	analysis	using	a	haemocytometer.	Cells	were	
collected	in	a	final	centrifugation	(2000	g,	5	min)	and	suspended	in	solution	I	to	a	concentration	of	
1-9	x	107	protoplasts	per	L.	Protoplasts	were	stored	on	ice	and	used	as	soon	as	possible.	
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DNA	(≥	1μg,	in	10	μL	ddH2O)	was	mixed	with	100	μL	protoplasts	and	incubated	on	ice	for	5	min.	
1	mL	of	fungal	transformation	solution	II	was	added	drop	wise	and	the	mixture	incubated	at	25	°C	
for	20	min.	30	mL	molten	CD+S	0.8%	agar	(~37	°C)	with	100	µg/mL	hygromycin	B	was	added	and	
the	mixture	poured	over	two	plates.	Plates	were	incubated	at	25	°C	until	resistant	colonies	could	
be	 observed	 (usually	 10	 d),	 these	 were	 transferred	 to	 secondary	 plates	 of	 CD+S	 1.5%	 agar	
containing	100	μg/mL	hygromycin	B.	Vigorously	growing	colonies	were	transferred	onto	third	plate	
(CD+S	1.5%	agar,	100	μg/mL	Hygromycin	B)	after	7	d.	Real	transformants	were	used	to	inoculate	
liquid	cultures	for	xenovulene	production	and	prepare	25%	glycerol	stocks.	All	used	CD+S	media	
were	prepared	with	deionised	water,	as	no	colonies	could	be	recovered	with	milipore	water.	
Nuclei	staining	
A.	strictum	was	grown	in	100	mL	ASSM	liquid	media	for	three	days	at	25	°C	and	200	rpm.	A	1	mL	
sample	was	taken	and	washed	twice	with	water	(2	x	1	mL).	Pelleted	cells	(5	min,	maximum	speed)	
were	suspended	in	1	mL	ethanol	(70%)	and	incubated	at	25	°C	for	10	min.	Cells	were	washed	with	
water	(1x	1	mL)	and	DAPI	(stock	solution	1	mg/mL)	added	to	a	final	concentration	of	0.1	µg/mL	in	
water	or	methanol.	After	incubation	for	10	min	at	25	°C	cells	were	washed	once	with	water	(1x	1mL)	
and	 suspended	 in	25%	glycerol.	 Cells	were	 immobilised	 in	1%	agar	 in	between	 two	microscope	
cover	slides.	
7.5 Chemical	Analysis	of	Fungal	cultures	
Fungal	 cultures	 for	extraction	were	 inoculated	either	 from	plate	or	directly	 from	glycerol	 stock.	
When	a	fresh	fungal	plate	was	used,	3	mL	water	was	added,	fungal	material	scraped	off	with	the	
tip	and	transferred	into	the	flasks.	100	mL	A.	oryzae	NSAR1	cultures	were	grown	in	500	mL	baffled	
flasks.	A.	strictum	was	cultivated	in	50	mL	and	100	mL	using	250	mL/500	mL	flasks	respectively.	
Table	7.15	Standard	conditions	for	liquid	fermentation	of	the	cultured	ascomycetes.	
Strain	 Medium	 Cultivation	conditions	
A.	strictum	
A.	oryzae	NSAR1	
ASPM,	PDB,	ME,	YMG,	CM	
CMP,	Starch	M	+	0.15%	methionine,	DPY	
25	°C,	200	rpm,	3-10	d	
28	°C,	110	rpm,	4-6	d,	baffled	flasks	
	
7.5.1 A.	strictum	
100	mL	A.	strictum	cultures	were	centrifuged	(8000	rpm,	10	min),	supernatant	acidified	to	pH	2	
with	HCl	(2M)	and	extracted	twice	with	ethyl	acetate/hexane	(1:1,	2	x	100	mL).	Combined	organic	
layers	were	dried	over	MgSO4	and	solvents	removed	in	vacuo.	Extract	was	dissolved	in	methanol	or	
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acetonitrile:water	(9:1)	to	a	concentration	of	10	mg/mL,	filtered	over	glass	wool	and	analysed	by	
LCMS.	
For	screening	of	multiple	colonies,	a	small	scale	extraction	method	was	used.	1	mL	of	A.	strictum	
liquid	culture	was	centrifuged	(5	min,	maximum	speed),	the	supernatant	was	transferred	to	a	2	mL	
centrifuge	tube	and	extracted	twice	with	1	mL	ethyl	acetate/hexane	(1:1).	Solvents	were	removed	
in	a	vacuum	centrifuge,	samples	were	dissolved	in	200	µL	methanol	and	directly	analysed	by	LCMS.	
7.5.2 A.	oryzae		
100	mL	A.	oryzae	NSAR1	cultures	were	acidified	to	pH	2	with	HCl	(2M)	and	incubated	for	30	min	at	
28	 °C,	 110	 rpm.	 Cells	 were	 disrupted	with	 a	 hand	 blender	 and	 removed	 by	 Büchner	 filtration.	
Supernatant	was	 extracted	 twice	with	 ethyl	 acetate	 or	 ethyl	 acetate/hexane	 (1:1,	 2	 x	 100	mL).	
Combined	 organic	 layers	 were	 dried	 over	 MgSO4	 and	 solvents	 removed	 in	 vacuo.	 Extract	 was	
dissolved	in	methanol	to	a	concentration	of	10	mg/mL,	filtered	over	glass	wool	and	analysed	by	
LCMS.	
When	cells	and	supernatant	were	extracted	separately,	cells	were	removed	by	filtration	and	stirred	
in	acetone	(100	mL	for	100	mL	culture	volume)	for	3	h.	In	a	next	step	cells	were	removed	by	filtration	
and	 the	water/acetone	mixture	 concentrated	 in	 vacuo.	 Resulting	water	 layer	was	 increased	 to	
100	mL	with	deionised	water,	acidified	to	pH	2	with	HCl	(2M)	and	extracted	with	ethyl	acetate	twice	
(2	x	100	mL).	Supernatant	was	acidified	to	pH	2	with	HCl	(2M)	and	extracted	twice	with	ethyl	acetate	
(2	 x	 100	 mL).	 Combined	 organic	 layers	 of	 both	 samples	 were	 dried	 over	 MgSO4	 and	 solvents	
removed	 in	 vacuo.	 Extracts	 were	 dissolved	 in	 methanol	 or	 acetonitrile:water	 (9:1)	 to	 a	
concentration	of	10	mg/mL,	filtered	over	glass	wool	and	analysed	by	LCMS.	
7.5.3 LCMS	
A	Waters	2545	binary	gradient	module	and	a	Waters	515	HPLC	pump	coupled	to	a	Waters	2998	
DAD,	a	Waters	2420	evaporative	light	scattering	detector	(ELSD)	and	a	Waters	single	quadrupole	
mass	detector	2	(SQ	detector	2)	were	used	for	analytical	and	preparative	LCMS	analysis.	Column	
selection	 was	 managed	 by	 the	 Waters	 system	 fluidics	 organizer	 (SFO).	 The	 DAD	 measured	
wavelengths	from	210	to	600	nm	and	the	mass	detector	was	adjusted	depending	on	the	sample	to	
measure	in	a	range	of	100-1000	m/z.	Analytical	and	preparative	LCMS	methods	were	operated	in	
water	and	acetonitrile	with	the	addition	of	0.05%	(v/v)	formic	acid.	LCMS	grade	acetonitrile	was	
purchased	and	water	was	prepared	by	double	distillation	of	millipore	water.	
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7.5.3.1 Analytical	
Samples	were	 dissolved	 in	methanol	 or	 acetonitrile:water	 9:1	 to	 a	 concentration	 of	 10	mg/mL,	
filtered	over	 glass	wool	 and	10	–	20	µL	 injected	onto	 a	Phenomenex	Kinetex	2.6	µm	C18	 100	Å	
column	 (size	100	x	4.6	mm).	The	gradient	was	 selected	depending	on	 the	 sample	and	 run	with	
1	mL/min.	
Table	7.16	Different	programs	used	for	analytical	LCMS.	
Program	 Time/min	 Water-acetonitrile/%	
A1	standard	 0-1	
1-10	
10-12	
12-13	
13-15	
90-10	
10-90	
10-90	
90-10	
90-10	
A2	polar	 0-1	
1-10	
10-12	
12-13	
13-15	
90-10	
60-40	
10-90	
90-10	
90-10	
	
7.5.3.2 Preparative	
Samples	were	 dissolved	 in	methanol	 or	 acetonitrile:water	 9:1	 to	 a	 concentration	 of	 50	mg/mL,	
filtered	over	glass	wool	and	50	–	200	µL	injected	onto	a	Phenomenex	Kinetex	5	µm	C18	100	Å,	AXIA	
column	(size	250	x	21.2	mm).	The	gradient	was	selected	depending	on	the	sample	and	run	with	
20	mL/min.	Fractions	were	collected	with	the	Waters	Sample	Manager	2767	by	either	mass	directed	
or	 time	 dependent	 trigger.	 Combined	 fractions	 were	 dried	 using	 the	 vacuum	 centrifuge	 Christ	
RVC	2-25	CD	plus.		
7.5.4 GCMS	
GCMS	analysis	was	carried	out	on	a	HP	6890	gas	chromatograph	connected	to	an	Agilent	5973	mass	
detector	on	an	OPTIMA	5	MS	capillary	column	(30	m,	0.32	mm	i.d.,	0,25	µm	film).	Chromatography	
was	 achieved	with	 1.5	mL/min	 helium	 flow,	 electron	 energy	 of	 70	 eV	 and	 280	 °C	 transfer	 line.	
Injection	volume	of	5	µL	was	injected	with	a	split	less	method.	GC	program:	0-1	min	/	50	°C,	gradient	
20	°C/min	to	300°C.	
7.5.5 HRMS	
High	 resolution	 mass	 spectrums	 were	 acquired	 on	 a	 Waters	 Acquity	 ultra-performance	 liquid	
chromatography	(UPLC)	coupled	to	a	quadrupole	time-of-flight	mass	spectrometer	(Q-TOF).	
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7.5.6 NMR	spectroscopy	
All	NMR	spectra	were	acquired	on	a	Bruker	Ascend	400	MHz	or	Bruker	DRX	500	MHz	Spectrometer	
respectively.	The	data	is	shown	in	ppm,	referenced	to	the	used	deuterated	solvent	and	coupling	
constant	 J	 are	 quoted	 in	 Hz.	 Coupling	 constants	 and	 multiplets	 are	 described	 as	 observed.	
Deviations	are	caused	by	digitisation.	The	software	MestReNova	10.0	was	used	for	analysis	of	the	
data.	
	
Compound	191:236	1H	NMR	(500	MHz,	CD3OD),	δH:	5.98	(s,	1H,	4-CH),	2.19	(s,	3H,	6-CH3),	1.84	(s,	3H,	
7-CH3).	13C	NMR	(125	MHz,	CD3OD),	δC:	169.2	(C-1),	168.9	(C-3),	161.3	(C-5),	102.0	(C-4),	98.5	(C-2),	
19.5	(C-6),	8.2	(C-7).	
	
	
	
Compound	121:97	1H	NMR	(400MHz,	d6-DMSO),	δH:	8.13	(s,	1H,	7-CHOH),	5.64	(s,	1H,	4-CH),	2.22	
(s,	3H,	8-CH3),	1.30	(s,	3H,	9-CH3).	
	
	
Compound	194:98	1H	NMR	(500	MHz,	CD3OD),	δH:	6.92	(s,	1H,	3-CH),	6.78	(s,	1H,7-CH),	6.69	(s,	1H,	
5-CH),	 2.38	 (s,	 3H,	 8-CH3).	 13C	 NMR	 (125	MHz,	 CD3OD),	 δC:	 174.2	 (1-CO),	 169.5	 (6-COH),	 166.4	
(2-COH),	150.4	(4-CCH3),	122.0	(5-CH),	118.1	(3-CH),	113.7	(7-CH),	27.8	(8-CH3).	
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Compound	125:98	1H	NMR	(500	MHz,	CD3OD),	δH:	8.20	(dd,	1H,	4JHH	=	1.9,	5JHH	=	0.8,	9-CHOCH),	8.01	
(d,	1H,	4JHH	=	1.9,	8-CHOCH),	6.89	(s,	1H,	5JHH	=	0.8,	3-CH).	13C	NMR	(125	MHz,	CD3OD),	δC:	182.0	
(1-CO),	168.4	(6-COH),	150.8	(2-COH),	145.8	(9-CHOCH),	143.6	(8-CHOCH),	121.7	(4-C),	121.6	(4-C),	
107.5-107.3	(7-CD),	103.6	(3-CH).	
	
	
Compound	196:98	1H	NMR	(500	MHz,	CD3OD),	δH:	8.11	(s,	1H,	9-CH),	7.00	(s,	1H,	3-CH),	6.86	(s,	1H,	
3’-CH),	6.60	 (d,	1H,	 JHH	=	2.4,	9’-CHOC),	5.32	 (dd,	1H,	 JHH	=	14.0,	3.6,	8’-CH2OC,	Ha),	5.15	 (d,	1H,	
JHH	 =	 13.8,	 8’-CH2OC,	 Hb).	 13C	 NMR	 (125	 MHz,	 CD3OD),	 δC:	 182.2	 (1-CO),	 173.4	 (1’-CO),	 167.6	
(2’-COH),	167.0	(6’-COH),	165.6	(6-C),	153.0	(8-C),	150.7	(2-COH),	148.9	(4’-C),	144.2	(9-CH),	128.6	
(5’-C),	122.0	(5-C),	118.1	(4-C),	107.0	(3’-CH),	103.5	(3-CH),	80.6	(9’-CHOC),	78.80	(8’-CH2OC).	7-CH	
and	7’-CH	are	most	likely	exchanged	to	7-CD	and	7’-CD.	
7.5.7 Methylation	of	Compound	108	
	
Scheme	7.1	Methylation	of	108	with	TMS-diazomethane	152.	
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To	a	solution	of	0.075	mmol	108	 in	THF/Methanol	 (8.5/1.5	v/v)	0.450	mmol	TMS-diazomethane	
(2	M	in	hexane)	was	added.	The	reaction	mixture	was	stirred	at	25	°C	for	3	h.	Solvents	were	removed	
and	mixture	dissolved	in	methanol	for	LCMS	analysis.120,121	
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9 Appendix	
9.1 Chapter	2	NMR	spectra	
9.1.1 Compound	108	
	
Figure	9.1	1H	NMR	of	compound	108	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	Table	2.2	for	assignment.	
	
Figure	9.2	13C	NMR	of	compound	108	in	CDCl3	(125MHz)	referenced	to	CDCl3.	Table	2.2	for	assignment.	
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Figure	9.3	HSQC	of	compound	108.	
	
Figure	9.4	HMBC	of	compound	108.	
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Figure	9.5	1H,1H	COSY	of	compound	108.	
9.1.2 Compound	153d	
	
Figure	9.6	1H	NMR	of	compound	153d	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	Table	2.3	for	assignment.	
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Figure	9.7	13C	NMR	of	compound	153d	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	Table	2.3	for	assignment.	
	
Figure	9.8	HSQC	of	compound	153d.	
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Figure	9.9	HMBC	of	compound	153d.	
	
Figure	9.10	1H,1H	COSY	of	compound	153d.	
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9.1.3 Compound	107a	
	
Figure	9.11	1H	NMR	of	compound	107a	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	Table	2.4	for	assignment.	
	
Figure	9.12	13C	NMR	of	compound	107a	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	Table	2.4	for	assignment.	
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Figure	9.13	HSQC	of	compound	107a.	
	
Figure	9.14	HMBC	of	compound	107a.	
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Figure	9.15	1H,1H	COSY	of	compound	107a.	
9.1.4 Compound	107b	
	
Figure	9.16	1H	NMR	of	compound	107b	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	Table	2.4	for	assignment.	
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Figure	9.17	13C	NMR	of	compound	107b	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	Table	2.4	for	assignment.	
	
Figure	9.18	HSQC	of	compound	107b.	
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Figure	9.19	HMBC	of	compound	107b.	
	
Figure	9.20	1H,1H	COSY	of	compound	107b.	
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9.1.5 Compound	154	
	
Figure	9.21	1H	NMR	of	compound	154	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	Table	2.5	for	assignment.	
	
Figure	9.22	13C	NMR	of	compound	154	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	Table	2.5	for	assignment.	
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Figure	9.23	HSQC	of	compound	154.	
	
Figure	9.24	HMBC	of	compound	154.	
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Figure	9.25	1H,1H	COSY	of	compound	154.	
9.1.6 Compound	109a	
	
Figure	9.26	1H	NMR	of	compound	109a	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	Table	2.6	for	assignment.	
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Figure	9.27	13C	NMR	of	compound	109a	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	Table	2.6	for	assignment.	
	
Figure	9.28	HSQC	of	compound	109a.	
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Figure	9.29	HMBC	of	compound	109a.	
	
Figure	9.30	1H,1H	COSY	of	compound	109a.	
δ/ppm
δ/ppm
0.51.01.52.02.53.03.54.04.55.05.56.06.5
f2	(ppm)
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
f1
	(p
pm
)
δ/ppm
δ/ppm
0.60.81.01.21.41.61.82.02.22.42.62.83.03.23.43.63.84.04.24.44.64.85.05.2
f2	(ppm)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
f1
	(p
pm
)
Appendix	
	 190	
9.1.7 Compound	156	
	
Figure	9.31	1H	NMR	of	compound	156	in	CD3OD	(500	MHz)	referenced	to	CD3OD.	Table	2.8	for	assignment.	
	
Figure	9.32	13C	NMR	of	compound	156	in	CD3OD	(500	MHz)	referenced	to	CD3OD.	Table	2.8	for	assignment.	
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Figure	9.33	HSQC	of	compound	156.	
	
Figure	9.34	HMBC	of	compound	156.	
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Figure	9.35	1H,1H	COSY	of	compound	156.	
9.1.8 Compound	157	and	158	
	
Figure	9.36	1H	NMR	of	compounds	157	and	158	in	CD3OD	(500	MHz)	referenced	to	CD3OD.	Table	2.9	for	assignment.	
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Figure	9.37	13C	NMR	of	compounds	157	and	158	in	CD3OD	(500	MHz)	referenced	to	CD3OD.	Table	2.9	for	assignment.	
	
Figure	9.38	HSQC	of	compounds	157	and	158.	
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Figure	9.39	HMBC	of	compounds	157	and	158.	
	
Figure	9.40	1H,1H	COSY	of	compounds	157	and	158.	
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9.2 Chapter	3	
9.2.1 aspks1	BGC	
Table	9.1	Exon	and	intron	positions	in	the	aspsk1	BGC.	
#	 gene,	protein	 bp	(mRNA),	aa	 Exons	on	gDNA	
Asg3679	
Asg3678	
Asg3677	
Asg3676	
Asg3676	
Asg3675	
Asg3674	
Asg3673	
Asg3672	
Asg3671	
Asg3670	
Asg3669	
Asg3668	
Asg3667	
Asg3666	
asL7,	AsL7	
asL6,	AsL6	
asL5,	AsL5	
asL4,	AsL4	
asL3,	AsL3	
asL2,	AsL2	
asL1,	AsL1	
aspks1,	MOS	
asR1,	AsR1	
asR2,	AsR2	
asR3,	AsR3	
asR4,	AsR4	
asR5,	AsR5	
asR6,	AsR6	
asR7,	AsR7	
4350,	1449	
1272,	423	
750,	249	
1293,	430	
1023,	340	
348,	115	
1443,	480	
8190,	2729	
1308,	435	
1551,	516	
2565,	854	
1899,	632	
1206,	401	
1293,	430	
2469,	822	
1-626,	697-846,	938-1884,	1944-2841,	2932-4638	
1-1272	
1-750	
1-1293	
1-327,	390-693,	764-1155	
1-348	
1-205,	305-637,	716-1212,	1288-1695	
1-630,	699-6883,	6910-8334	
1-173,	239-826,	891-986,	1062-1349,	1410-1572	
1-305,	387-745,	854-1087,	1173-1628,	1719-1807,	1887-1990	
1-2565	
1-746,	813-1964	
1-1206	
1-1293	
1-2469	
	
9.2.2 Other	BGC	
Table	9.2	Depudecin	162	like	A.	strictum	BGC	with	50%	similarities	(antiSMASH).	
#	 Putative	function	 Homologue	 Identity/similarity	%	 BLASTp	and	CD	
Asg8737	
Asg8738	
Asg8739	
Asg8740	
Asg8741	
Asg8742	
Asg8743	
Asg8744	
Asg8745	
Asg8746	
Asg8747	
Asg8748	
Asg8749	
Asg8750	
Asg8751	
transporter	
hypothetical	
oxidoreductase	
oxidoreductase	
transporter	
oxidoreductase	
oxidoreductase	
HR-PKS	
oxidoreductase	
transporter	
hypothetical	
oxidoreductase	
regulation	
hypothetical	
transporter	
-	
-	
-	
-	
-	
-	
-	
DEP5	
DEP4	
DEP3	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
-	
49.3/65.3	
45.7/64.4	
23.9/32.7	
-	
-	
-	
-	
-	
Mitochondrial	FeII	transporter	
hypothetical	
FAD	dependent	oxidoreductase	
alcohol	dehydrogenase	
MFS	transporter	
NAD	dependent	
epimerase/dehydratase	
FAD	dependent	oxidoreductase	
HR-PKS,	KS-AT-DH-ER-KR	
FMN	dependent	monoxygenase	
MFS	transporter	
b-barrel	
shor-chain	dehydrogenase	
transcription	factor	
hypothetical	
MFS	transporter	
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Table	9.3	Leucinostatin	165	like	A.	strictum	BGC	with	25%	similarities	(antiSMASH).	
#	 Putative	function	 Homologue	 Identity/similarity	%	 BLASTp	and	CD	
Asg2757	
Asg2758	
Asg2759	
Asg2760	
Asg2761	
Asg2762	
Asg2763	
Asg2764	
Asg2765	
Asg2766	
Asg27647	
PKS	
keto	synthase	
hypothetical	
regulation	
hypothetical	
thiolesterase	
hypothetical	
transporter	
transporter	
NRPS	
hypothetical	
-	
-	
-	
-	
-	
VFPBJ_02535	
-	
VFPBJ_02529	
VFPBJ_02522	
-	
-	
-	
-	
-	
-	
-	
25.7/31.9	
-	
48.1/60.4	
55.5/70.6	
-	
-	
PKS,	AT-DH-C-MeT	
keto	synthase	
hypothetical	
transcription	factor	
hypothetical	
thiolesterase	
class	II	aldolase/adducin	
ABC	transporter	
ABC	transporter	
NRPS,	A-A-PCP-C-PCP-TD	
hypothetical	
	
Table	9.4	Aspyridone	164	like	A.	strictum	BGC	with	22%	similarities	(antiSMASH).	
#	 Putative	function	 Homologue	 Identity/similarity	%	 BLASTp	and	CD	
Asg3006	
Asg3007	
Asg3008	
	
Asg3009	
Asg3010	
Asg3011	
Asg3012	
Asg3013	
Asg3014	
Asg3015	
Asg3016	
Asg3017	
Asg3018	
Asg3019	
Asg3020	
Asg3021	
Asg3022	
	
Asg3024	
Asg3025	
Asg3026	
Asg3027	
regulation	
regulation	
PKS-NRPS	
	
enoyl	reductase	
regulation	
oxidoreductase	
methyltransferase	
transport	
oxidoreductase	
regulation	
hypothetical	
oxidoreductase	
oxidoreductase	
hypothetical	
hypothetical	
hypothetical	
PKS-NRPS	
	
enoyl	reductase	
hypothetical	
methyl	transferase	
oxidoreductase	
-	
-	
AN8412	
Asg3222	
AN8409	
-	
-	
-	
-	
-	
-	
-	
AN8411	
-	
-	
-	
-	
AN8412	
Asg3008	
-	
-	
-	
-	
-	
-	
43.7/60.5	
33.5/51.0	
40.5/43.7	
-	
-	
-	
-	
-	
-	
-	
53.4/67.8	
-	
-	
-	
-	
33.1/50.3	
33.5/51.0	
-	
-	
-	
-	
transpcription	factor	
transpcription	factor	
PKS-NRPS,	KS-AT-DH-MeT-KR-ACP-
C-A-PLP-TD	
enoyl	reductase	
transcription	factor	
FAD/NAD(P)	binding	protein	
O-methyltransferase	
MFS	transporter	
cytochrome	P450	
transcription	factor	
hypothetical	
cytochrome	P450	
cytochrome	P450	
hypothetical	
AMP	dependent	synthetase/ligase	
hypothetical	
PKS-NRPS,	KS-AT-DH-MeT-KR-ACP-
C-A-PLP-TD	
enoyl	reductase	
PEP	kinase	
O-methyltransferase	
cytochrome	P450,	FMN,	NAD/FAD	
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Table	9.5	Clapurine	163	like	A.	strictum	BGC	with	27%	similarities	(antiSMASH).	
#	 Putative	function	 Homologue	 Identity/similarity	%	 BLASTp	and	CD	
Asg7689	
Asg7690	
Asg7691	
Asg7692	
	
Asg7693	
Asg7694	
Asg7695	
Asg7696	
Asg7697	
Asg7698	
Asg7699	
Asg7700	
Asg7701	
Asg7702	
Asg7703	
Asg7704	
Asg7705	
hypothetical	
oxidoreductase	
aminotransferase	
prenyltransferase	
oxidoreductase	
hypothetical	
transporter	
hypothetical	
regulation	
NRPS	
hypothetical	
hypothetical	
hypothetical	
hydrolase	
regulation	
hypothetical	
transport	
hypothetical	
-	
CPUR_02681	
CPUR_02679	
CPUR_02678	
CPUR_02677	
CPUR_02676	
-	
-	
-	
CPUR_02680	
-	
-	
-	
-	
-	
-	
-	
-	
-	
51.4/66.3	
37.6/47.5	
36.0/51.4	
29.1/44.5	
51.4/69.7	
-	
-	
-	
30.0/40.5	
-	
-	
-	
-	
-	
-	
-	
-	
hypothetical	
Pyridine	nucleotide-disulphide	
oxidoreductase	
PLP	dependent	transferase	
aromatic	prenyltransferase	(DMATS)	
cytochrome	P450	
glutathione-S-transferase	
MFS	transporter	
hypothetical	
transcription	factor	
NRPS,	A-PCP-C-A-PCP-A	
hypothetical	
hypothetical	
b-glucosidase	
fumarylacetoacetate	hydrolase	
transcription	factor	
peptidase	
MFS	transporter	
hypothetical	
	
9.3 Chapter	4	
Table	9.6	Overview	of	transformants	obtained	by	bipartite	substrate	KO	targeting	aspks1.	
Transformation	 GOI	 Resistance	cassette	 ID	of	transformed	vector	 #transformants	 #transformants	
RSI101/106	 2	
RSI101/106	 4	
RSI101/106	6	
asL4	
asL5	
asL6	
hygR	
RSI95	2	
RSI95	4	
RSI95	6	
25	
16	
12	
11	
5	
8	
	
Table	9.7	Overview	of	transformants	obtained	by	bipartite	substrate	KO	targeting	aspks1.	
Transformation	 GOI	 Resistance	cassette	 Plasmid	ID	for	PCR	 #transformants	
RSI32	
RSI47	
RSI58	
RSI66	
aspks1	
aspks1	
aspks1	
aspks1	
hygR	
hygR	
hygR	
hygR	
RSI21B5	and	RSI21A1	
12	
8	
14	
9	
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9.4 Chapter	5	
9.4.1 Additional	Constructed	Vectors	
	
Figure	9.41	Additional	vectors	constructed	in	this	work.	
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9.4.2 LCMS	Analysis	of	A.	oryzae	Transformations	RSI98	and	RSI113	
	
Figure	 9.42	DAD	 chromatogram	 of	A.	 oryzae	 NSAR1	 transformants	 RSI98	 1-11	 and	 RSI113	measured	with	 analytical	
gradient	A2	on	LCMS.	Extracts	were	obtained	from	cultures	grown	in	DPY	for	5	d.	
9.4.3 NMR	of	novel	Compounds	
9.4.3.1 Compound	193	
	
Figure	9.43	1H	NMR	of	compound	193	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	Table	5.2	for	assignment.	
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Figure	9.44	13C	NMR	of	compound	193	in	CDCl3	(500	MHz)	referenced	to	CDCl3.	Table	5.2	for	assignment.	
	
Figure	9.45	HSQC	of	compound	193.	
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Figure	9.46	HMBC	of	compound	193.	
9.4.3.2 Compound	195a	
	
Figure	9.47	1H	NMR	of	compound	195a	in	d6-DMSO	(500	MHz)	referenced	to	d6-DMSO	Table	5.4	for	assignment.	
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Figure	9.48	13C	NMR	of	compound	195a	in	d6-DMSO	(500	MHz)	referenced	to	d6-DMSO.	Table	5.4	for	assignment.	
	
Figure	9.49	HSQC	of	compound	195a.	
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Figure	9.50	HMBC	of	compound	195a.	
	
Figure	9.51	1H,1H	COSY	of	compound	195a.	
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9.4.3.3 Compound	197	
	
Figure	9.52	1H	NMR	of	compound	197	in	CD3OD	(500	MHz)	referenced	to	CD3OD.	Table	5.5	for	assignment.	
	
Figure	9.53	13C	NMR	of	compound	197	in	CD3OD	(500	MHz)	referenced	to	CD3OD.	Table	5.5	for	assignment.	
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Figure	9.54	HSQC	of	compound	197.	
	
Figure	9.55	HMBC	of	compound	197.	
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Figure	9.56	1H,1H	COSY	of	compound	197.	
9.4.4 MS2	Analysis	of	Xenovulene	A	101	
MS2	of	m/z	=	359	[M]H+	of	xenovulene	A	101	from	A.	strictum	WT	(collision	energy	5-15	eV):	359,	341,	303,	
285,	235,	233,	215,	181,	155,	123,	109,	95.	
MS2	of	m/z	=	359	[M]H+	of	xenovulene	A	101	from	A.	oryzae	NSAR1	RSI107	B7	(collision	energy	5-15	eV):	359,	
341,	303,	285,	235,	233,	215,	181,	155,	123,	109,	95.	
9.4.5 E.	coli	Codon	Optimised	Sequences	and	ESI-Q-TOF-MS	
AsR5:5’-ATGCGTCGTAGCTTTCTGATTAGCGCAGCACTGGGTCTGAGCATGAGCACACCGGCACTGGCAGCAAGCATTCAGAGCGTTCTGGGTTATC
TGCGTCCGACCAGCCATCATCATGCACCGTGTGCCGATGATGTTGTTCTGAAACAGAGCGCAGGTAGCGATAGTGCAGCACCGGATCCGCTGCCGAG
CCGTGTTGTTCATAATTGGCCGAATGGCACCTGGATTGAAAACATTAGCGTTCGTCCGAATGGTAATCTGCTGGTTAGCCAGAGTACACCGCGTGGTC
GTGTTTGGCAGGTTAAAGAACCGTGGCTGGATGAACCGAAAGTTGAACTGGCATATGATTTTGATGAATGGGTTGATCGCATTATTGGTATTGGTGA
AACCACACCGGATAAATATGTTGTTGTTGGTAGCCGTTTTTATAGCCTGGATCCGCAGAGCAGCCAGGTTGAACGTACCTTTTGTGCAATGGAACTGG
ATTTTACCAAAGGTGAAAAACCGAGCGCACGTCTGGTTGCACGTTTTCCGCATGCAAATCTGCTGCAGAGCGTTAGCGCACTGCCGTGGGATCGTAGC
GTGGTTCTGATTTCAGATCAGTACCTGCTGCATCCGCGTGCAGATTGGGAAGATCTGACCCCTGGTCCGGGTCAGATTTGGCGTCTGGATACCAAAAC
CGGTCATCATGAAATTGTGATGACCAACTATGCCGAAATGAACACCACCTATAATCATGGTCTGGATGTGGGTATTAACGGCATTAAAATCCATGGCG
ATCATCTGTATTGGATCAATATGGATACCGGTGGTGCGTATCGTGTTCGCATTGATAAATACGGTTATCCGACACCGCTGAATGCAGTTCCGGAAACA
CTGGGTGTTGCCGAAGATGCACTGTGGGATGATTTTGCAATGCATGGCACCCGCATTGGTGAAGAAAGTGATGATACCACCATGTTTGCAACCAGCA
TTGTTAATCTGATGGCAATTAGTCCGGAAAATGGCACCATTGTTCCGCTGGCAGGCGTTGGCACCAGCGAACCGATGGGTTTTCCGGGTCCGACCTCA
GCACAGTTTGGTCGTACCGAAAAAGATAGCCATATTCTGTATGTGACCGGCAAACTGTTTAATGTTCCGCCTAGCATTCGTGATGTTGTGATTCAAGGT
TGGGTTCGTGCAATTGATACCACGGGTTTTCACTTTTAA-3’	
AsR6:5’-ATGCCGGTTACCACACCGACCAAAATGGCAACCCTGACCACCAAACAAATGTGGCAGACCATCAAAGATTATTTTGGTGATGGTTTTGTTAC
CGGTAGCGCACCGATTAGCTATAACGTTCATACCTGTGATATGCAACTGCAGCCGGATAGCGGTATTCATGCAGCAAGTGATGGTATTCATTATGGTG
TTCAGATTAGCGAAGATAGCATGCCGCTGTTTAGCATTATGGGTGATACCGCAGCACCGCCTTGTACCTGTCATCGTGTTGATGAAATTGTGAAACAC
ATCGACGAATTTCTGGAACGTGCACCGGAAGCACTGCCGGATGATGGTGCAATTACCAGCGGTAAACCGTGTGATACCAATCCGGATCAGGTTAGCC
TGTATGCAATGCGTGATAGCCTGAGTTGGTGGGTTCATTGGGGTGGTAATCTGCGTCCGGAACATTATTGGAAGCAGATTTATATCGGTTTTGCAGCC
ATTCCTGATGATGTGCAGATTAGTCCGCGTGAATTCCTGGATGGCACCTATCGTTATCTGGGTCATACCTGGGATGATTGTCTGAGCGGTCTGGAAGA
AGAGGGCGTTAGTCCGGATGAAATCGAATTTGCCAATATGTGTATGTGGCGTCAGATGCTGACCCAGTGGCTGGAAAAAGCAGATCCTGAACTGCTG
CCGCTGCTGAAAGGTAAAATTAGCCTGATGCTGCAGTATCGTGTTCTGACCGCAAATACCCTGGGTTGTCTGGCACTGTTTATGAATGCAACCGCAGA
δ/ppm
δ/ppm
0.81.01.21.41.61.82.02.22.42.62.83.03.23.43.63.84.04.24.44.64.85.05.25.4
f2 (ppm)
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
f1
 (p
pm
)
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TCCGAAAGATGGTCCGATCCATTATGCAGATAGCAGCTATGAAATGGAAATTGCAAGCGTTGCACAGTGTGTTACCCTGGATATGGCAAAAGAAGCA
ATGGGTATTCTGCAGGGTGAACGTACCGAAGTTGTTGCCGGTGATCGTGCACAGCGTAAACGTGAACTGCGTTGGATTTATGTTCGTTGTATGCAGAT
TCTGGAAAGCCAGCCGCATGCACATATGCTGCGTCGTTATGGTAGCGCAGGTCTGCATTATGTTCCGATGATGGATCGCTATCTGGAACGCGTTAGCG
GTCATACCCGTTTTCCGATTCGTGATGGTGCCGCACGTATCCTGGAACGTTTTATCAATCGTGCAGAACTGCCGAAAGAAAGCGAGGATATTAATCCG
AATGGTCGTAGCCTGAAAGTTAGCGCAAAAATGAATGGTAATGGTCAGCTGCATCATGAAGTTAATGGCAATGCAAAACTGCATCTGGAAGCCGAAC
GTCCGGATGTTACCACCGCAGTTGGTTAA-3’	
AsR5,	ESI-qTOF-MS,	Coverage	70.32%,	identified	peptides:	
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDHPFTMRRSFLISAALGLSMSTPALAASIQSVLGYLRPTSHHHAPCADDVVLKQSAGSDSAAPDPLP
SRVVHNWPNGTWIENISVRPNGNLLVSQSTPRGRVWQVKEPWLDEPKVELAYDFDEWVDRIIGIGETTPDKYVVVGSRFYSLDPQSSQVERTFCAMELDF
TKGEKPSARLVARFPHANLLQSVSALPWDRSVVLISDQYLLHPRADWEDLTPGPGQIWRLDTKTGHHEIVMTNYAEMNTTYNHGLDVGINGIKIHGDHLY
WINMDTGGAYRVRIDKYGYPTPLNAVPETLGVAEDALWDDFAMHGTRIGEESDDTTMFATSIVNLMAISPENGTIVPLAGVGTSEPMGFPGPTSAQFGRT
EKDSHILYVTGKLFNVPPSIRDVVIQGWVRAIDTTGFHF	
AsR6,	ESI-qTOF-MS,	Coverage	65.45%,	identified	peptides:	
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDHPFTMPVTTPTKMATLTTKQMWQTIKDYFGDGFVTGSAPISYNVHTCDMQLQPDSGIHAASD
GIHYGVQISEDSMPLFSIMGDTAAPPCTCHRVDEIVKHIDEFLERAPEALPDDGAITSGKPCDTNPDQVSLYAMRDSLSWWVHWGGNLRPEHYWKQIYIGF
AAIPDDVQISPREFLDGTYRYLGHTWDDCLSGLEEEGVSPDEIEFANMCMWRQMLTQWLEKADPELLPLLKGKISLMLQYRVLTANTLGCLALFMNATAD
PKDGPIHYADSSYEMEIASVAQCVTLDMAKEAMGILQGERTEVVAGDRAQRKRELRWIYVRCMQILESQPHAHMLRRYGSAGLHYVPMMDRYLERVSG
HTRFPIRDGAARILERFINRAELPKESEDINPNGRSLKVSAKMNGNGQLHHEVNGNAKLHLEAERPDVTTAVG	
9.4.6 MS2	Analysis	of	Phenolic	Meroterpenoids	109a	and	109b	
tR	=	9.2	min:	MS2	of	m/z	=	369	[M-H]-	of	109a	from	A.	strictum	WT	(collision	energy	10-20	eV):	369,	341,	165,	
137;	MS2	of	m/z	=	369	[M-H]-	of	109a	from	A.	oryzae	NSAR1	RSI111	2-2	(collision	energy	10-20	eV):	369,	341,	
165,	137.	
tR	=	9.4	min:	MS2	of	m/z	=	369	[M-H]-	of	109b	from	A.	strictum	WT	(collision	energy	5-15	eV):	369,	165.	MS2	
of	m/z	=	369	[M-H]-	of	109b	from	A.	oryzae	NSAR1	RSI111	3-3	(collision	energy	5-15	eV):	369,	165.	
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